Royal Devon University Healthcare NHS Foundation Trust

SACT Cancer report - updates

Reference Number: RDF2048-23
Date of Response: 02/01/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

I am conducting analysis on the usage of medicines in secondary care and kindly request your help.
I would be grateful if you could send me one dataset from your Trust, to inform this analysis:
SACT Cancer report – updates - Date period (December 2022 to the most recent month data is available). Please include the following data fie ds:

Organisation code (code of provider)
Primary diagnosis (ICD-10 3rd or 4th digit)
Morphology (ICD-O)
TNM stage
Adjunctive therapy type
Regimen treatment intent
Drug regimen
Drug regimen acronym
Clinical trial indicator
Drug name
Actual dose
Unit of measure
Route of administration
Cycle number
Number of planned cycles
SACT administration date
Organisation identifier (of SACT administration)

Answer: Please see .csv file attached that contains a refresh of the SACT (Systemic Anti-Cancer Therapy) report. This file runs from 01/12/2022 to our latest available data of 31/08/2023 and contains SACT data for both Eastern and Northern Services.

Please note: Each row is for every instance of administered drug and all accompanying columns relate to this instance instead of patients themselves. No patient identifiable data is included in this report.

Definitions for each of the columns are as stated in the NHS data dictionary.

Adjunctive Therapy Type:
https://www.datadictionary.nhs.uk/attributes/adjunctive_therapy_type.html

Intent of Treatment:
https://www.datadictionary.nhs.uk/data_elements/systemic_anti-cancer_therapy_drug_regimen_treatment_intent.html

Clinical Trial:
https://www.datadictionary.nhs.uk/data_elements/clinical_trial_indicator.html

SACT Administration Route:
https://www.datadictionary.nhs.uk/attributes/systemic_anti-cancer_therapy_drug_route_of_administration.html

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	16	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	01/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CYTARABINE	50	258684004	3	Intrathecal	72607000	01/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	270	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	800	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	550	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CETUXIMAB	1000	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CETUXIMAB	800	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	01/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1450	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	110	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C349	80423			99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	450	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	180	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C349	80423			99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	200	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	93	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	350	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	01/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	4	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	700	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	148	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IDARUBICIN HYDROCHLORIDE	15	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	55	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	220	258684004	1	Intravenous	47625008	01/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3600	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	24	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	98	Other	HYD AML/CML 1DY>	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	4000	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Osimertinib	40	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	75	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PALBOCICLIB	125	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	100	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PALBOCICLIB	125	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	144	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IBRUTINIB	420	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	21	NIRAPARIB	300	258684004	2	Oral	26643006	01/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	18	METFORMIN	850	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IMATINIB	200	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	400	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	47	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	32	BEVACIZUMAB - ALYMSYS	1400	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	POLATUZUMAB VEDOTIN	168	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	01/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISATUX CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PALBOCICLIB	125	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		9				RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	400	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISATUX CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	ISATUXIMAB	580	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C921	98633	9		99	Not known	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BOSUTINIB	400	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	01/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C43		9				PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1400	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	Nivolumab	480	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	400	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	98	Other	BCNU/THIOTEPA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZANUBRUTINIB	80	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	01/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IBRUTINIB	420	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	98	Other	BCNU/THIOTEPA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THIOTEPA	300	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	LENALIDOMIDE	5	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1800	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2000	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DURVALUMAB	1500	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	VTD(28 DAY)5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C900	97323	9		99	Not known	PBDA> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C900	97323	9		99	Not known	PBDA> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Panobinostat	20	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	01/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CABAZITAXEL	36	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	59	RUXOLITINIB	25	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	120	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C900	97323	9		99	Not known	PBDA> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	10	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	10	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	500	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	10	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	148	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IBRUTINIB	420	258684004	2	Oral	26643006	01/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	NILOTINIB	200	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IBRUTINIB	560	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	93	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	93	ERIBULIN	1.67	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THALIDOMIDE	100	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	01/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	01/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	180	258684004	1	Intravenous	47625008	01/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	600	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	350	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	550	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	550	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	90	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	110	258684004	1	Intravenous	47625008	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CETUXIMAB	900	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CETUXIMAB	1100	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CETUXIMAB	800	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CETUXIMAB	900	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CETUXIMAB	900	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	10	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	35	LENALIDOMIDE	15	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	10	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	650	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OXALIPLATIN	135	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	800	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	120	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 150mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	225	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C920	98723	9		98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C920	98723	9		98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	4500	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IDARUBICIN HYDROCHLORIDE	15	258684004	1	Intravenous	47625008	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	55	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3600	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	40	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	HYD AML/CML 1DAY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	500	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PALBOCICLIB	100	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PALBOCICLIB	125	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	100	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	360	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ALECTINIB	600	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	48	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN	250	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	48	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1150	258684004	2	Oral	26643006	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	2000	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	98	Other	VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	44	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	98	Other	VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	100	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	600	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	46	Nivolumab	480	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ALECTINIB	600	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	Nivolumab	480	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	PONATINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PONATINIB	30	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	SACITUZUMAB GOVITECAN	740	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENCORAFENIB	300	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CETUXIMAB	1000	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	Nivolumab	480	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	400	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	400	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	D473	99623			98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	96803	3	Not Applicable (Primary Treatment)	98	Other	BCNU/THIOTEPA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZOLIZUMAB>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	98	Other	BCNU/THIOTEPA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THIOTEPA	300	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PAC ALB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	10	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	25	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	POMALIDOMIDE	4	258684004	2	Oral	26643006	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	25	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ISATUXIMAB	900	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB> +	2	PATIENT is not taking part in a CLINICAL TRIAL	83	AVELUMAB	800	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IXAZOMIB	4	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IXAZOMIB	4	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	IXAZOMIB	4	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	GDP>1 (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABAZITAXEL	40	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	GDP>1 (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1600	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	120	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	GDP>1 (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	113	258684004	1	Intravenous	47625008	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	800	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	375	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	165	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	80	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C787				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	IBRUTINIB	140	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	IBRUTINIB	420	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	26	IBRUTINIB	280	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DASATINIB	100	258684004	2	Oral	26643006	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ERIBULIN	1.23	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	02/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	800	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	700	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	18750	408102007	1	Intravenous	47625008	02/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	180	258684004	1	Intravenous	47625008	02/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Osimertinib	80	258684004	2	Oral	26643006	03/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Osimertinib	40	258684004	2	Oral	26643006	03/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/12/2022	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	03/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IMATINIB	400	258684004	2	Oral	26643006	03/12/2022	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	43	IMATINIB	400	258684004	2	Oral	26643006	03/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	42	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CABOZANTINIB	60	258684004	2	Oral	26643006	04/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CABOZANTINIB	40	258684004	2	Oral	26643006	04/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Osimertinib	40	258684004	2	Oral	26643006	04/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Osimertinib	80	258684004	2	Oral	26643006	04/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/12/2022	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	04/12/2022	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	98	Other	VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	44	258684004	5	Subcutaneous	34206005	04/12/2022	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	98	Other	VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	300	258684004	2	Oral	26643006	04/12/2022	RH8
RH8	C921	98633	1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	60	IMATINIB	100	258684004	2	Oral	26643006	04/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IBRUTINIB	560	258684004	2	Oral	26643006	04/12/2022	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	76	LENALIDOMIDE	5	258684004	2	Oral	26643006	05/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	140	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	700	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1450	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	900	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	180	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	2	Oral	26643006	05/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	700	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	750	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CISPLATIN	79	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	200	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	Osimertinib	80	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	125	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	100	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	55	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C349	80463	9		99	Not known	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ALECTINIB	450	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	360	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C61X		1	Adjuvant Therapy	99	Not known	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	15	METFORMIN	850	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE 90 CYC1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IMATINIB	400	258684004	2	Oral	26643006	05/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	9		99	Not known	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	200	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C189				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRIFLURIDINE/TIPIRACIL	70	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	3.3	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CABOZANTINIB	40	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	725	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	16	GEMCITABINE	1200	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C10X				99	Not known	COMP- CAR WKLY>	1	PATIENT is taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	05/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509				99	Not known	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	400	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	98	Other	VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	44	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	98	Other	VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	100	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	900	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	400	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IBRUTINIB	420	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	23	NIRAPARIB	100	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	SACITUZUMAB GOVITECAN	620	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C916		3	Not Applicable (Primary Treatment)	98	Other	ALEMTUZ T-PLL>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ALEMTUZUMAB	30	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CARFILZOMIB	54	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PATHOS RDE CIS	1	PATIENT is taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	200	258684004	2	Oral	26643006	05/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	400	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IMATINIB	400	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	D473	99623			98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C12X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	56	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	56	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C13X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	63	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C02X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	63	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	65	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	2260	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	7	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	15	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	99	Not known	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	05/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	99	Not known	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	150	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	VTD(28 DAY)5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IXAZOMIB	2.3	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	APIXABAN	2.5	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	120	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	4	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	10	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	10	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMETREXED	900	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PROCARBAZINE	200	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	180	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	NILOTINIB	400	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	SUNITINIB	50	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LOMUSTINE	200	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	10	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	POMALIDOMIDE	3	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APIXABAN	2.5	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	05/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	05/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	135	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DOCETAXEL	80	258684004	1	Intravenous	47625008	05/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	500	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LIPOSOMAL DOXORUBICIN	62	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	600	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1450	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	725	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CETUXIMAB	700	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	113	258684004	1	Intravenous	47625008	06/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9				Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	10	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	9				Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	15	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	GEMCITABINE	1000	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CISPLATIN	24	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2150	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	280	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	220	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	06/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	360	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C900	97323	9		98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	700	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-55Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C900	97323	9		98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINIB RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABOZANTINIB	20	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	5	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	650	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	06/12/2022	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PALBOCICLIB	75	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	125	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-55Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PANITUMUMAB	500	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	Osimertinib	80	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-55Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	15	VENETOCLAX	400	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	9		98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	600	258684004	2	Oral	26643006	06/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C749		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MITOTANE 4.5-9.0	2	PATIENT is not taking part in a CLINICAL TRIAL	12	MITOTANE	500	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C749		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MITOTANE 4.5-9.0	2	PATIENT is not taking part in a CLINICAL TRIAL	12	MITOTANE	1000	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 3W	1	PATIENT is taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB/PLACEBO	200	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C23X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1650	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C23		1	Adjuvant Therapy	99	Not known	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	06/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PALBOCICLIB	75	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	100	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	RIBOCICLIB	200	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	98	Other	VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	44	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	144	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Nivolumab	480	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	1	PATIENT is taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C846	97143	3	Not Applicable (Primary Treatment)	98	Other	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	1.5	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C846	97143	3	Not Applicable (Primary Treatment)	98	Other	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ACALABRUTINIB	100	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	25	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CARFILZOMIB	54	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	06/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	98	Other	BCNU/THIOTEPA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C300		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	70	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			AVELUMAB>4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AVELUMAB	800	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	15	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1450	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DACARBAZINE	450	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ISATUXIMAB	900	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AXITINIB	5	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	APIXABAN	2.5	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IXAZOMIB	4	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	25	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	24	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	RUXOLITINIB	10	258684004	2	Oral	26643006	06/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	120	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TEPOTINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TEPOTINIB	450	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C44		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	93	AVELUMAB	800	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	6	IXAZOMIB	4	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	10	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C179				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	06/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			Ipilimumab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	250	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	5	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	15000	408102007	1	Intravenous	47625008	06/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	180	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NILOTINIB	200	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>	1	PATIENT is taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	10	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>	1	PATIENT is taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	15	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	1.94	258684004	1	Intravenous	47625008	06/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>	1	PATIENT is taking part in a CLINICAL TRIAL	10	IXAZOMIB	3	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINBLASTINE SULFATE	9	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1780	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	10	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PROCARBAZINE	100	258684004	2	Oral	26643006	06/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXRAZOXANE	1160	258684004	1	Intravenous	47625008	06/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	550	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	17	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	07/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CYTARABINE	50	258684004	3	Intrathecal	72607000	07/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	336	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1800	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	65	LENALIDOMIDE	5	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	110	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	320	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	700	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	07/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	100	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	2400	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	CTD (Thalidomide 100mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	198	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	07/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	07/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	07/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	MERCAPTOPURINE	120	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	120	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	METHOTREXATE	40	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C900				98	Other	MYL XI LEN MAIN>	1	PATIENT is taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	5	258684004	2	Oral	26643006	07/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	75	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	BOSUTINIB	500	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/12/2022	RH8
RH8	C259		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	225	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN	180	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C259		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C900	97323	9		98	Other	RADA ISATUX CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C259		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C189				99	Not known	RALT/OXALI-MET>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RALTITREXED	4.5	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C189				99	Not known	RALT/OXALI-MET>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PALBOCICLIB	100	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1600	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	400	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C900	97323	9		98	Other	RADA ISATUX CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	ISATUXIMAB	720	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C539		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ACALABRUTINIB	100	258684004	2	Oral	26643006	07/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	120	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C916		3	Not Applicable (Primary Treatment)	98	Other	ALEMTUZ T-PLL>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ALEMTUZUMAB	30	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	96	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	28	IMATINIB	400	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB - EMTANSINE	260	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	07/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C20X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2500	258684004	2	Oral	26643006	07/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	25	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DACARBAZINE	450	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DURVALUMAB	1500	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Nivolumab	480	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB UC-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IXAZOMIB	4	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C848	97183	9		98	Other	Brentuximab	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BRENTUXIMAB VEDOTIN	100	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C73		3	Not Applicable (Primary Treatment)			CABOZ MTC -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CABOZANTINIB	20	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	15	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABAZITAXEL	40	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	07/12/2022	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	24	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	07/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	19	RUXOLITINIB	10	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	5	IXAZOMIB	4	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PEMBRO CHL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	07/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	180	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	164	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	IBRUTINIB	420	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	93	IBRUTINIB	280	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IBRUTINIB	560	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DASATINIB	20	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ERIBULIN	1.06	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	07/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	07/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	150	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	88	258684004	1	Intravenous	47625008	07/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	360	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	240	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	790	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	216	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	240	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	08/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	540	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C20				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1800	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1650	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DEXAMETHASONE	10	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	20	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	270	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	280	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	725	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	148	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	220	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	180	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	08/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINORELBINE	110	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	08/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	800	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	2400	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	220	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	KADCYLA ADJ ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB - EMTANSINE	280	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	120	258684004	2	Oral	26643006	08/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINIB RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABOZANTINIB	40	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABOZANTINIB	40	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	75	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	49	PALBOCICLIB	125	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	890	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	42	PALBOCICLIB	75	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C911	98233	9		98	Other	VENETOCLAX-R WK1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	20	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	144	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DABRAFENIB	100	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRAMETINIB	2	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	2	ISATUXIMAB	580	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IBRUTINIB	280	258684004	2	Oral	26643006	08/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	164	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IMATINIB	400	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	44	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	336	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	600	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SACITUZUMAB GOVITECAN	590	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	48	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1400	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Olaparib	200	258684004	2	Oral	26643006	08/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZANUBRUTINIB	160	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	D473	99623	9		98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DEXAMETHASONE	10	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	POMALIDOMIDE	2	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	60	LENALIDOMIDE	15	258684004	2	Oral	26643006	08/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	1500	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1150	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	110	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ISATUXIMAB	650	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ISATUXIMAB	1100	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	VTD(28 DAY)5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	APIXABAN	2.5	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	60	IXAZOMIB	4	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	81	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	650	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABAZITAXEL	34	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABAZITAXEL	48	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	24	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	08/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	9		99	Not known	PBDA> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	BEXAROTENE	300	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			LORLATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LORLATINIB	100	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	128	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	3.3	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	47	PAZOPANIB	400	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	180	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	IBRUTINIB	280	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ERIBULIN	2.02	258684004	1	Intravenous	47625008	08/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	08/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	08/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	180	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	108	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	08/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	216	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	450	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	09/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	FLUOROURACIL	700	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	700	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	240	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CETUXIMAB	900	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	CETUXIMAB	800	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CETUXIMAB	900	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	450	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	25	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	128	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	09/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	550	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	550	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	360	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINORELBINE	80	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	09/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	96	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	2400	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TEMOZOLOMIDE	180	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	17	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	630	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	09/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	120	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	100	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C61		9				ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	100	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	80	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABOZANTINIB	40	258684004	2	Oral	26643006	09/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ABEMACICLIB	150	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Osimertinib	80	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C509		9				ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ABEMACICLIB	100	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DABRAFENIB	75	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	TRAMETINIB	1	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C900	97323	9		98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	51	ALECTINIB	600	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	34	NIRAPARIB	100	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	108	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	360	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	20	METFORMIN	850	258684004	2	Oral	26643006	09/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		99	Not known	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C61X		9				ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	2000	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	378	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	300	258684004	1	Intravenous	47625008	09/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	400	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	37	IBRUTINIB	420	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AVELUMAB	800	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AXITINIB	7	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C916		3	Not Applicable (Primary Treatment)	98	Other	ALEMTUZ T-PLL>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ALEMTUZUMAB	30	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ACALABRUTINIB	100	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1150	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	225	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO RESECTED	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C259		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	80	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C259		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	15	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2150	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	650	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CAPECITABINE	1200	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	25	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C259		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	OXALIPLATIN	110	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	135	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IXAZOMIB	3	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IXAZOMIB	3	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C61		9				Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	09/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	GDP>1 (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1600	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	24	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	RUXOLITINIB	15	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RUXOLITINIB	5	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C172				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	72	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	SUNITINIB	50	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	180	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IBRUTINIB	420	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	65	DASATINIB	100	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C921	98633	9		98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	108	NILOTINIB	150	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CABOZANTINIB	20	258684004	2	Oral	26643006	10/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Osimertinib	80	258684004	2	Oral	26643006	10/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	400	258684004	2	Oral	26643006	10/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/12/2022	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NINTEDANIB	200	258684004	2	Oral	26643006	10/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PAZOPANIB	600	258684004	2	Oral	26643006	10/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRAMETINIB	2	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DABRAFENIB	150	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IMATINIB	400	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CABOZANTINIB	20	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NIRAPARIB	100	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ACALABRUTINIB	100	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Crizotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	32	CRIZOTINIB	250	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Erlotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	67	ERLOTINIB	50	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PAZOPANIB	400	258684004	2	Oral	26643006	11/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	10	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	15	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	5	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	12/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	800	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	500	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	800	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1650	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	225	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C509				99	Not known	Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	12/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	12/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	12/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	12/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C900	97323	9		98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MELPHALAN	195	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C719				99	Not known	Temozolomide 150mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	235	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 150mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TEMOZOLOMIDE	285	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	140	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	2000	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	300	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1500	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	330	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA(60)3 + 10 + GO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA(60)3 + 10 + GO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAUNORUBICIN	135	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	200	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	12/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA(60)3 + 10 + GO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	220	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	HYD AML/CML 1DAY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CABOZANTINIB	20	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Osimertinib	80	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	12/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	Osimertinib	40	258684004	2	Oral	26643006	12/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	Osimertinib	80	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C349	80463	9				OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	Osimertinib	80	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	49	VENETOCLAX	200	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	225	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	12/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRAMETINIB	2	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DABRAFENIB	150	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	46	BOSUTINIB	400	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	80	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C300		3	Not Applicable (Primary Treatment)			NIVOLUMAB H + N>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Nivolumab	240	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ALECTINIB	600	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	12/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	12/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	12/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C924	98663	9		1	Curative – aiming to permanently eradicate the disease	ATRA/ATO CON C4	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ARSENIC TRIOXIDE	15	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C259		2	Neoadjuvant Therapy	99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1500	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PALBOCICLIB	100	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C10X				99	Not known	COMP- CAR WKLY>	1	PATIENT is taking part in a CLINICAL TRIAL	5	CARBOPLATIN	180	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	270	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	336	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C924	98663	9		1	Curative – aiming to permanently eradicate the disease	ATRA/ATO CON C4	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRETINOIN	70	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIVO - MESO C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	12/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	SACITUZUMAB GOVITECAN	620	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IMATINIB	400	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C921	98633	1	Adjuvant Therapy	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IMATINIB	100	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DEXAMETHASONE	10	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	10	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C12X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	56	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C02X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	63	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C13X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	63	258684004	1	Intravenous	47625008	12/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NIRAPARIB	100	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	APIXABAN	2.5	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	79	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	15	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	80	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2650	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	98	Other	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DURVALUMAB	1500	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C189				99	Not known	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	Nivolumab	480	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	18000		1	Intravenous	47625008	12/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	9				DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IXAZOMIB	3	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	12/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	69	RUXOLITINIB	10	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	10	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APIXABAN	2.5	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C227		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sorafenib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SORAFENIB	200	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DASATINIB	20	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IBRUTINIB	420	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C921	98633			99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	65	NILOTINIB	400	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C169		9				Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	SUNITINIB	50	258684004	2	Oral	26643006	12/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	12/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DOXORUBICIN HYDROCHLORIDE	65	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CYCLOPHOSPHAMIDE	2260	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	135	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	80	258684004	1	Intravenous	47625008	12/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	790	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	240	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	116	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	128	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C20X				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C20X				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	280	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB-ONTRUZANT	378	258684004	1	Intravenous	47625008	13/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C66		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C66		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2200	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-55Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	10	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61		9				ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	125	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-55Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PALBOCICLIB	125	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PALBOCICLIB	100	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-55Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	VENETOCLAX	400	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C900	97323	9		98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	13/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	600	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP500 AD(3DAYS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	13/12/2022	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	APIXABAN	2.5	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRIFLURIDINE/TIPIRACIL	40	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C924	98663	9		1	Curative – aiming to permanently eradicate the disease	ATRA/ATO CON C4	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ARSENIC TRIOXIDE	15	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C01X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C23		1	Adjuvant Therapy	99	Not known	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1650	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	125	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	144	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	1	PATIENT is taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	13/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	1000	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Nivolumab	480	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	400	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			AVELUMAB UC +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	25	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C300		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	70	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IBRUTINIB	560	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	10	258684004	2	Oral	26643006	13/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	49	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	60	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	56	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	25	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	80	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	725	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	55	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	336	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	120	258684004	1	Intravenous	47625008	13/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	160	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IXAZOMIB	4	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	75	RUXOLITINIB	15	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	83	AVELUMAB	800	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	700	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	150	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	15000	408102007	1	Intravenous	47625008	13/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NILOTINIB	150	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	37	NILOTINIB	300	258684004	2	Oral	26643006	13/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TALIMOGENE LAHERPAREPVEC 10*8	4	74964007	5	Subcutaneous	34206005	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DOXORUBICIN HYDROCHLORIDE	65	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	630	258684004	1	Intravenous	47625008	13/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	16500	408102007	1	Intravenous	47625008	13/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	18	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	14/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CYTARABINE	50	258684004	3	Intrathecal	72607000	14/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	110	258684004	1	Intravenous	47625008	14/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	130	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	800	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	29	TRASTUZUMAB-ONTRUZANT	651	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	CTD (Thalidomide 100mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	14/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	198	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	180	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB SC>9	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	MERCAPTOPURINE	120	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	120	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CABOZANTINIB	40	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	METHOTREXATE	40	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	45	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	45	FLUOROURACIL	650	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	45	PALBOCICLIB	75	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PALBOCICLIB	75	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	125	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	45	PANITUMUMAB	500	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Osimertinib	80	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PALBOCICLIB	100	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PALBOCICLIB	100	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PALBOCICLIB	100	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	14	VENETOCLAX	400	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	85	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	96	258684004	1	Intravenous	47625008	14/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	23	Nivolumab	480	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	360	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	22	NIRAPARIB	200	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IMATINIB	200	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/12/2022	RH8
RH8	C259		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	225	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/12/2022	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRIFLURIDINE/TIPIRACIL	45	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C924	98663	9		1	Curative – aiming to permanently eradicate the disease	ATRA/ATO CON C4	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ARSENIC TRIOXIDE	15	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C259		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C10		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C900	97323	9		98	Other	RADA ISATUX CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C259		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	14/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1600	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RIBOCICLIB	200	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	9		98	Other	RADA ISATUX CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	ISATUXIMAB	720	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C539		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IBRUTINIB	280	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AVELUMAB	800	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AXITINIB	8	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ACALABRUTINIB	100	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CHLORAMBUCIL	20	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	MITHRI RUXOL >	1	PATIENT is taking part in a CLINICAL TRIAL	19	RUXOLITINIB	15	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	Nivolumab	480	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	14/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IMATINIB	400	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Olaparib	100	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	POMALIDOMIDE	2	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB DERUXTECAN	400	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	10	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	25	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	POMALIDOMIDE	2	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	22	CAPECITABINE	2000	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	150	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ISATUXIMAB	800	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ISATUXIMAB	440	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ISATUXIMAB	900	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IXAZOMIB	4	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	14/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	9		98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	21	RUXOLITINIB	15	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	280	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	750	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	800	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	120	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OXALIPLATIN	135	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C183				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	14/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB DERUXTECAN	320	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	THALIDOMIDE	100	258684004	2	Oral	26643006	14/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	14/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	164	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ERIBULIN	1.06	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	900	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	14/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	14/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	88	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	108	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	630	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	16250	408102007	1	Intravenous	47625008	14/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	14/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	500	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	330	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	270	258684004	1	Intravenous	47625008	15/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	5	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C259				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C259				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	260	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	68	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	15/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	EMBARK-EN/PL + LE	1	PATIENT is taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE/PLACEBO	160	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENCORAFENIB	450	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENCORAFENIB	200	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BINIMETINIB	45	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	BINIMETINIB	30	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA(60)3 + 10 + GO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	220	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	EMBARK-EN/PL + LE	1	PATIENT is taking part in a CLINICAL TRIAL	22	LEUPROLIDE	22.5	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	57	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	57	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	40	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	51	LENALIDOMIDE	5	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	23	CAPECITABINE	1000	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	125	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	54	PALBOCICLIB	75	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PALBOCICLIB	125	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BINIMETINIB	45	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENCORAFENIB	450	258684004	2	Oral	26643006	15/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PALBOCICLIB	125	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	61	TRAMETINIB	1.5	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	61	DABRAFENIB	100	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C911	98233	9		98	Other	VENETOCLAX-R WK2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	50	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	600	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	600	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C06		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	15/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	800	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C20		9		99	Not known	RALT/OXALI-MET>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	110	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C20		9		99	Not known	RALT/OXALI-MET>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RALTITREXED	3.5	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	100	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	336	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	10	NINTEDANIB	150	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NIRAPARIB	200	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SACITUZUMAB GOVITECAN	590	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	16	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	890	258684004	1	Intravenous	47625008	15/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	378	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	30	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	0.86	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	148	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	80	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	15	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CAPECITABINE	2150	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	25	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	Osimertinib	40	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IXAZOMIB	4	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	5	IXAZOMIB	4	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABAZITAXEL	40	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			TEPOTINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TEPOTINIB	450	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C64		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AVELUMAB	800	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C64		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AXITINIB	5	258684004	2	Oral	26643006	15/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	7	IXAZOMIB	4	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C259				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	15/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IBRUTINIB	420	258684004	2	Oral	26643006	15/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C86X	97193	3	Not Applicable (Primary Treatment)	98	Other	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	700	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C86X	97193	3	Not Applicable (Primary Treatment)	98	Other	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARMUSTINE	620	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	18750	408102007	1	Intravenous	47625008	15/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	15/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	270	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	240	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	350	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	550	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	90	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	CETUXIMAB	1100	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CETUXIMAB	800	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CETUXIMAB	900	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DEXAMETHASONE	10	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	650	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	25	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C68X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1300	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	OXALIPLATIN	135	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C68X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	56	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	APIXABAN	2.5	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1250	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	220	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	164	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TCH (21 day Trastuzumab) Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TCH (21 day Trastuzumab) Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TCH (21 day Trastuzumab) Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	120	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	164	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	120	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DOCETAXEL	148	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C719		1	Adjuvant Therapy	99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 150mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BEVACIZUMAB - ALYMSYS	600	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Vinorelbine (oral)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINORELBINE	120	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENCORAFENIB	450	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BINIMETINIB	45	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRAST UZUMAB	1200	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	63	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	63	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABOZANTINIB	20	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	500	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PANITUMUMAB	260	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	50	VENETOCLAX	300	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C900	97323	9		98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	250	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	TRAMETINIB	2	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DABRAFENIB	150	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	38	IBRUTINIB	140	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	90	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NIRAPARIB	300	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	22	METFORMIN	850	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C924	98663	9		1	Curative – aiming to permanently eradicate the disease	ATRA/ATO CON C4	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ARSENIC TRIOXIDE	15	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C349	80463			99	Not known	LAROTRECTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Larotrectinib	100	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C259				99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	2000	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PALBOCICLIB	125	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	600	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IBRUTINIB	420	258684004	2	Oral	26643006	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SACITUZUMAB GOVITECAN	740	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ACALABRUTINIB	100	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CETUXIMAB	1000	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	43	RIBOCICLIB	400	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMETREXED	1000	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BUSULFAN	50	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	143	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	10	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CAPECITABINE	1300	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	27	CAPECITABINE	1300	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	120	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C20X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	25	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CAPECITABINE	1300	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1000	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CAPECITABINE	1300	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ISATUXIMAB	900	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	Nivolumab	480	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IXAZOMIB	3	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APIXABAN	2.5	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABAZITAXEL	36	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	37	RUXOLITINIB	10	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RUXOLITINIB	15	258684004	2	Oral	26643006	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C44		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	84	AVELUMAB	800	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	800	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	375	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	10	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	165	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	80	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	200	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	164	258684004	1	Intravenous	47625008	16/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NILOTINIB	400	258684004	2	Oral	26643006	16/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	85	NILOTINIB	200	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	NILOTINIB	400	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C880	97613	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IBRUTINIB	420	258684004	2	Oral	26643006	16/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	17/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	17/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	24	NIRAPARIB	100	258684004	2	Oral	26643006	17/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	IBRUTINIB	420	258684004	2	Oral	26643006	17/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	EXEMESTANE	25	258684004	2	Oral	26643006	18/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	EVEROLIMUS	5	258684004	2	Oral	26643006	18/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ALECTINIB	600	258684004	2	Oral	26643006	18/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IMATINIB	400	258684004	2	Oral	26643006	18/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IBRUTINIB	560	258684004	2	Oral	26643006	18/12/2022	RH8
RH8	C86X	97193	3	Not Applicable (Primary Treatment)	98	Other	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/12/2022	RH8
RH8	C86X	97193	3	Not Applicable (Primary Treatment)	98	Other	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	400	258684004	1	Intravenous	47625008	18/12/2022	RH8
RH8	C86X	97193	3	Not Applicable (Primary Treatment)	98	Other	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	400	258684004	1	Intravenous	47625008	18/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB - EMTANSINE	200	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1000	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	700	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	270	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	113	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	15	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	19/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	750	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	650	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1650	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	700	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	800	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2150	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	900	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	225	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	19/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	120	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C459		9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	4	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C459		9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C459		9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	1000	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C831	96733	1	Adjuvant Therapy	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CARBOPLATIN	700	258684004	1	Intravenous	47625008	19/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TEMOZOLOMIDE	380	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	140	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1500	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2400	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Vinorelbine (oral)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINORELBINE	120	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C911	98233	9		98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	19/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	25	CABOZANTINIB	20	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	19/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	400	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	48	BOSUTINIB	500	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRIFLURIDINE/TIPIRACIL	50	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C924	98663	9		1	Curative – aiming to permanently eradicate the disease	ATRA/ATO CON C4	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ARSENIC TRIOXIDE	13	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2300	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	17	GEMCITABINE	1200	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	125	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C10X				99	Not known	COMP- CAR WKLY>	1	PATIENT is taking part in a CLINICAL TRIAL	6	CARBOPLATIN	180	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	600	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	600	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ECT - BLEOMYCIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	27500	408102007	1	Intravenous	47625008	19/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ACALABRUTINIB	100	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	25	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CARFILZOMIB	54	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	180	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	110	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	320	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IMATINIB	400	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	19/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IMATINIB	400	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C12X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	56	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C13X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	63	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C02X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	63	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NIRAPARIB	100	258684004	2	Oral	26643006	19/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	200	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2300	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL (C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DURVALUMAB	1500	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DURVALUMAB	1500	258684004	1	Intravenous	47625008	19/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	800	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C829	96953	9		98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RUXOLITINIB	15	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	5	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Dabrafenib	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DABRAFENIB	50	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	9		98	Other	PBD - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	400	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	180	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	NILOTINIB	400	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	SUNITINIB	25	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - KISPLYX	20	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	THALIDOMIDE	100	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	19/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	19/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	164	258684004	1	Intravenous	47625008	19/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1000	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	164	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	5	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	20/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	900	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	150	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	20/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	80	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	128	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	20/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	MERCAPTOPURINE	100	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-55Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	METHOTREXATE	37.5	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C917	98311	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ORAL MTX -RDE C1	2	PATIENT is not taking part in a CLINICAL TRIAL	59	METHOTREXATE	10	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	47	PALBOCICLIB	100	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-55Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	Osimertinib	80	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PALBOCICLIB	75	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-55Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	20/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VENETOCLAX	200	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DABRAFENIB	150	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRAMETINIB	2	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	600	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BOSUTINIB	300	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IMATINIB	400	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C539		9		1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	144	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	600	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	1	PATIENT is taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	20/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AVELUMAB	800	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AXITINIB	5	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	6	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ACALABRUTINIB	100	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			GILTERITINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	GILTERITINIB	120	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	800	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	20/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Etoposide oral	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	50	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	400	258684004	2	Oral	26643006	20/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	14	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	10	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	80	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	120	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	25	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DURVALUMAB	1500	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IXAZOMIB	3	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APIXABAN	2.5	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	30	RUXOLITINIB	5	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RUXOLITINIB	15	258684004	2	Oral	26643006	20/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	5	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	5	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C259				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	20/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	20/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	400	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NILOTINIB	300	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IBRUTINIB	420	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SUNITINIB	50	258684004	2	Oral	26643006	20/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TALIMOGENE LAHERPAREPVEC 10*8	3	74964007	5	Subcutaneous	34206005	20/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	164	258684004	1	Intravenous	47625008	20/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	19	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	21/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CYTARABINE	50	258684004	3	Intrathecal	72607000	21/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	270	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	540	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	69	LENALIDOMIDE	10	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	10	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	130	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	50	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	320	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1800	258684004	2	Oral	26643006	21/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	700	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	250	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	240	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	240	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	CTD (Thalidomide 100mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	CTD (Thalidomide 100mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	400	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C541		9				Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	790	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	21/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	21/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	21/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	MERCAPTOPURINE	120	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	39	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	METHOTREXATE	40	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	790	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PALBOCICLIB	125	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ANASTROZOLE	1	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PALBOCICLIB	100	258684004	2	Oral	26643006	21/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	100	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	18	VENETOCLAX	400	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	96	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	600	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	200	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IPILIMUMAB	75	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	30	RIBOCICLIB	400	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	2	ISATUXIMAB	720	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ALECTINIB	600	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	Nivolumab	360	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE 90 CYC1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IMATINIB	400	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	36	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	21/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	21/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		3	Not Applicable (Primary Treatment)			TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C349	80463	9				PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C259		2	Neoadjuvant Therapy	99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TEMOZOLOMIDE	430	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	400	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C32X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO H + N C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C539		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	17	AVELUMAB	800	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	17	AXITINIB	5	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	800	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	120	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	120	258684004	1	Intravenous	47625008	21/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	21/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AXITINIB	5	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	5	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	49	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2500	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	47	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829	96953	9		98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	1.5	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C829	96953	9		98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	37	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	47	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	650	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C829	96953	9		98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	109	RUXOLITINIB	15	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RUXOLITINIB	10	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	400	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	21/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	NILOTINIB	400	258684004	2	Oral	26643006	21/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DASATINIB	40	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IBRUTINIB	420	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	21/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	THALIDOMIDE	100	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	21/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	21/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	21/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	164	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C86X	97193	3	Not Applicable (Primary Treatment)	98	Other	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	550	258684004	1	Intravenous	47625008	22/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CETUXIMAB	800	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C189		9				Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C189		9				Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1450	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cytarabine low (10to20mg/m2) IV/SC	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CYTARABINE	20	258684004	5	Subcutaneous	34206005	22/12/2022	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1450	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C679				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	180	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C679				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	94	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	22/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	22/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	22/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	22/12/2022	RH8
RH8	C66		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C66		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	360	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	65	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	200	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	4500	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	22/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABOZANTINIB	40	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Osimertinib	80	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ABEMACICLIB	100	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PALBOCICLIB	100	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	22/12/2022	RH8
RH8	C911	98233	9		99	Not known	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	22	VENETOCLAX	300	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C911	98233	9		98	Other	VENETOCLAX-RWK3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	100	258684004	2	Oral	26643006	22/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	144	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	TRAMETINIB	2	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DABRAFENIB	150	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRAMETINIB	2	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DABRAFENIB	150	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	600	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	600	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	2	ISATUXIMAB	580	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	22/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	22/12/2022	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	33	BEVACIZUMAB - ALYMSYS	1400	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C924	98663	9		1	Curative – aiming to permanently eradicate the disease	ATRA/ATO CON C4	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ARSENIC TRIOXIDE	13	258684004	1	Intravenous	47625008	22/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	100	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PALBOCICLIB	125	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	29	BOSUTINIB	500	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NIRAPARIB	200	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ACALABRUTINIB	100	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C61X				99	Not known	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ABEM & LETROZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	22/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX WK1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	20	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	82	Nivolumab	480	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	22/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	48	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	POMALIDOMIDE	4	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	15	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	22/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2000	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ISATUXIMAB	1000	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ISATUXIMAB	650	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZ MTC -	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CABOZANTINIB	100	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABAZITAXEL	36	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	86	RUXOLITINIB	5	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RUXOLITINIB	10	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AVELUMAB	800	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	56	PAZOPANIB	600	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C21X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SCCA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	200	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IBRUTINIB	420	258684004	2	Oral	26643006	22/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IBRUTINIB	420	258684004	2	Oral	26643006	22/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	94	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	94	ERIBULIN	1.67	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	164	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	22/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	216	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		9		99	Not known	Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB - EMTANSINE	180	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	600	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	890	258684004	1	Intravenous	47625008	23/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	336	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CETUXIMAB	900	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C68X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1300	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C300		3	Not Applicable (Primary Treatment)			CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C300		3	Not Applicable (Primary Treatment)			CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C300		3	Not Applicable (Primary Treatment)			CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C300		3	Not Applicable (Primary Treatment)			CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	128	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAUNORUBICIN	112.5	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	180	258684004	1	Intravenous	47625008	23/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C66		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2200	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EPIRUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	225	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	68	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	23/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C931	99803	3	Not Applicable (Primary Treatment)			HYD AML/CML 3/4>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	80	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q 28D>1	2	PATIENT is not taking part in a CLINICAL TRIAL	75	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	20	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PALBOCICLIB	75	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	46	PALBOCICLIB	100	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	100	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ABEMACICLIB	50	258684004	2	Oral	26643006	23/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	100	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PALBOCICLIB	75	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	400	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	250	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	80	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	IXAZOMIB	2.3	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZOLIZUMAB >>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	100	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	336	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	144	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	600	258684004	2	Oral	26643006	23/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AVELUMAB	800	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C920	98733	9		98	Other	VEN/LD CYT19>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CYTARABINE	36	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C920	98733	9		98	Other	VEN/LD CYT19>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VENETOCLAX	100	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ACALABRUTINIB	100	258684004	2	Oral	26643006	23/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PAC ALB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	40	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	91	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	15	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	2000	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	Nivolumab	480	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IXAZOMIB	3	258684004	2	Oral	26643006	23/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	99	Not known	PEMBRO CHL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	37	RUXOLITINIB	5	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	108	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB DERUXTECAN	600	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ERIBULIN	1.23	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	800	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	164	258684004	1	Intravenous	47625008	23/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	180	258684004	1	Intravenous	47625008	24/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	65	258684004	1	Intravenous	47625008	24/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	24/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	4500	258684004	1	Intravenous	47625008	24/12/2022	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	PONATINIB - C3>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PONATINIB	15	258684004	2	Oral	26643006	24/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ACALABRUTINIB	100	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ACALABRUTINIB	100	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PAZOPANIB	400	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IBRUTINIB	420	258684004	2	Oral	26643006	24/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	24/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	2000	258684004	1	Intravenous	47625008	24/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/12/2022	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXRAZOXANE	1200	258684004	1	Intravenous	47625008	24/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	25/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAUNORUBICIN	112.5	258684004	1	Intravenous	47625008	25/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	180	258684004	1	Intravenous	47625008	25/12/2022	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	25/12/2022	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CABOZANTINIB	20	258684004	2	Oral	26643006	25/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Osimertinib	80	258684004	2	Oral	26643006	25/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	400	258684004	2	Oral	26643006	25/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IMATINIB	400	258684004	2	Oral	26643006	25/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/12/2022	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABOZANTINIB	20	258684004	2	Oral	26643006	25/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	IBRUTINIB	420	258684004	2	Oral	26643006	25/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	IBRUTINIB	140	258684004	2	Oral	26643006	25/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	10	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	15	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	26/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	180	258684004	1	Intravenous	47625008	26/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C931	99803	3	Not Applicable (Primary Treatment)			HYD AML/CML 3/4>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	80	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	80	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	125	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	100	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	AML Mainten MIDO	1	PATIENT is taking part in a CLINICAL TRIAL	9	MIDOSTAURIN	50	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	26/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DABRAFENIB	150	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	TRAMETINIB	2	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C61X		9				ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C61X		9				ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	400	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NIRAPARIB	200	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IMATINIB	400	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IMATINIB	400	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	D473	99623			99	Not known	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	40	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	35	IBRUTINIB	420	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	49	NILOTINIB	300	258684004	2	Oral	26643006	26/12/2022	RH8
RH8	C900		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	110	LENALIDOMIDE	10	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	74	LENALIDOMIDE	15	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	27/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAUNORUBICIN	112.5	258684004	1	Intravenous	47625008	27/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	180	258684004	1	Intravenous	47625008	27/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	73	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	MERCAPTOPURINE	100	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	27/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	40	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	METHOTREXATE	37.5	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	Osimertinib	80	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/12/2022	RH8
RH8	C924	98663	9		1	Curative – aiming to permanently eradicate the disease	ATRA/ATO CON C4	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ARSENIC TRIOXIDE	13	258684004	1	Intravenous	47625008	27/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C23X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1650	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C252				99	Not known	EVEROLIMUS NET>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EVEROLIMUS	5	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	D473	99623	9		98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	120	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	120	258684004	2	Oral	26643006	27/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	116	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RUXOLITINIB	15	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	RUXOLITINIB	20	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C880	97613	9				Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IBRUTINIB	140	258684004	2	Oral	26643006	27/12/2022	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	20	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	28/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CYTARABINE	50	258684004	3	Intrathecal	72607000	28/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1450	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	28/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C169		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	113	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cytarabine low (10to20mg/m2) IV/SC	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CYTARABINE	20	258684004	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	140	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	78	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	220	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	28/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	4	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	2400	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	1000	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	CTD (Thalidomide 100mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	140	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	180	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	28/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	25	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CABOZANTINIB	20	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	100	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	75	258684004	2	Oral	26643006	28/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	Osimertinib	80	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PATHOS RDE CARBO	1	PATIENT is taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	360	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	20	METFORMIN	850	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C900	97323	9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C23		1	Adjuvant Therapy	99	Not known	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C189				99	Not known	RALT/OXALI-MET>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	150	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C189				99	Not known	RALT/OXALI-MET>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RALTITREXED	4.5	258684004	1	Intravenous	47625008	28/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	725	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C10X				99	Not known	COMP- CAR WKLY>	1	PATIENT is taking part in a CLINICAL TRIAL	7	CARBOPLATIN	180	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	336	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	900	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C539		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	70	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	1	PATIENT is taking part in a CLINICAL TRIAL	4	CISPLATIN	70	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AVELUMAB	800	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C846	97143	3	Not Applicable (Primary Treatment)	98	Other	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	1.5	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C846	97143	3	Not Applicable (Primary Treatment)	98	Other	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	25	258684004	2	Oral	26643006	28/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	25	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	120	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CARFILZOMIB	54	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	75	Olaparib	250	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C13X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	63	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NIRAPARIB	100	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C349	80463	9				CERITINIB SUB	2	PATIENT is not taking part in a CLINICAL TRIAL	25	CERITINIB	300	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			AVELUMAB UC 5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AVELUMAB	800	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	10	258684004	2	Oral	26643006	28/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	120	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	74	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C20X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2500	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	5	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	99	Not known	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	POMALIDOMIDE	3	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	99	Not known	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	110	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ISATUXIMAB	440	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ISATUXIMAB	900	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	APIXABAN	2.5	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IXAZOMIB	2.3	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C848	97183	9		98	Other	Brentuximab	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BRENTUXIMAB VEDOTIN	100	258684004	1	Intravenous	47625008	28/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C829	96913	9		98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	BEXAROTENE	225	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C259		9				Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	148	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	4	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C259		9				Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	325	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C259		9				Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C44X		9		98	Other	Vismodegib	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VISMONDEGIB	150	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C259		9				Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	70	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMETREXED	900	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	APIXABAN	2.5	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	28/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	28/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	180	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DASATINIB	100	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C831	96733	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IBRUTINIB	560	258684004	2	Oral	26643006	28/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ERIBULIN	1.94	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TALIMOGENE LAHERPAREPVEC 10*8	4	74964007	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	28/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	630	258684004	1	Intravenous	47625008	28/12/2022	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	16250	408102007	1	Intravenous	47625008	28/12/2022	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	29/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	270	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	800	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1450	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	330	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	225	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	135	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	148	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	180	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	29/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	500	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	110	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FCR Oral - Cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUDARABINE PHOSPHATE	90	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FCR Oral - Cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	1000	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FCR Oral - Cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	550	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	4	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	800	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	2400	258684004	1	Intravenous	47625008	29/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMTUZUMAB OZOGAMCIN	5.5	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	180	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C66		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB SC>9	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMG>4	1	PATIENT is taking part in a CLINICAL TRIAL	25	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	HYD AML/CML 1DAY	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Osimertinib	40	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	700	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PALBOCICLIB	100	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	75	258684004	2	Oral	26643006	29/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PALBOCICLIB	125	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	75	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C911	98233	9		98	Other	VENETOCLAX-R WK4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	200	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	96	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	144	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		9				RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	400	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	120	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	120	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C921	98633	9		99	Not known	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BOSUTINIB	400	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C61X		1	Adjuvant Therapy	99	Not known	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	18	METFORMIN	850	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IMATINIB	400	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	48	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2500	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	15	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Osimertinib	80	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PALBOCICLIB	125	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	RIBOCICLIB	200	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	10	IXAZOMIB	4	258684004	2	Oral	26643006	29/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	INOTUZUMAB ALL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	INOTUZUMAB OZOGAMICIN	1.5	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ACALABRUTINIB	100	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ACALABRUTINIB	100	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CARFILZOMIB	54	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	300	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1400	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PALBOCICLIB	125	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX WK2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	50	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C920	98733	9		98	Other	VEN/LD CYT19>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CYTARABINE	36	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EXEMESTANE	25	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IBRUTINIB	560	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	5	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	LENALIDOMIDE	5	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	650	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	25	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DURVALUMAB	1500	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	29/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C44X		9				Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	4	IXAZOMIB	4	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	60	RUXOLITINIB	25	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C64		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AVELUMAB	800	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	10	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	10	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	10	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	D015				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	37	SUNITINIB	50	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	15000	408102007	1	Intravenous	47625008	29/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	180	258684004	1	Intravenous	47625008	29/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	164	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IBRUTINIB	560	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	94	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	94	ERIBULIN	1.67	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ERIBULIN	2.02	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/12/2022	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	29/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	100	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DOCETAXEL	80	258684004	1	Intravenous	47625008	29/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	360	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	216	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	240	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	240	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	CETUXIMAB	1100	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	10	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	36	LENALIDOMIDE	15	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	10	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	800	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	650	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	200	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	250	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Liposomal Doxorubicin 50mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LIPOSOMAL DOXORUBICIN	90	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	2	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	2400	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CISPLATIN	79	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	18	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	180	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Bevacizumab 15mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	101	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2400	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	100	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	108	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BINIMETINIB	30	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENCORAFENIB	250	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	198	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	41	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Osimertinib	80	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PALBOCICLIB	125	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PALBOCICLIB	100	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	100	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PALBOCICLIB	125	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ALECTINIB	600	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C924	98663	9		1	Curative – aiming to permanently eradicate the disease	ATRA/ATO CON C4	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ARSENIC TRIOXIDE	13	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	300	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	Nivolumab	480	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	9		98	Other	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	SACITUZUMAB GOVITECAN	620	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	SACITUZUMAB GOVITECAN	590	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	9		98	Other	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C911	98233	1	Adjuvant Therapy			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	360	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	9		98	Other	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	700	258684004	1	Intravenous	47625008	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1150	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENCORAFENIB	300	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	225	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CETUXIMAB	1000	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	40	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	10	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DEXAMETHASONE	40	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	25	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	POMALIDOMIDE	4	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	55	LENALIDOMIDE	15	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2150	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	15	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1450	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CAPECITABINE	1200	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	25	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	150	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	630	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	336	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ISATUXIMAB	900	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C44X		9				Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IXAZOMIB	4	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	55	IXAZOMIB	3	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IXAZOMIB	4	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IXAZOMIB	4	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IXAZOMIB	4	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	49	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	49	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABAZITAXEL	30	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	280	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	750	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	800	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	800	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	120	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	165	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	OXALIPLATIN	110	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C787				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	72	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	180	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IBRUTINIB	280	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	79	NILOTINIB	150	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	IBRUTINIB	420	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LOMUSTINE	160	258684004	2	Oral	26643006	30/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ERIBULIN	1.23	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ERIBULIN	1.06	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	THALIDOMIDE	100	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/12/2022	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	30/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	31/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	31/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	180	258684004	1	Intravenous	47625008	31/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Osimertinib	40	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	31/12/2022	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	31/12/2022	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NINTEDANIB	200	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	400	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZANUBRUTINIB	80	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	D473	99623			99	Not known	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	43	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	C509		9		99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CAPECITABINE	2300	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NINTEDANIB	200	258684004	2	Oral	26643006	31/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	31/12/2022	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	180	258684004	1	Intravenous	47625008	31/12/2022	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GOWBC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	180	258684004	1	Intravenous	47625008	01/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	01/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	PONATINIB - C2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PONATINIB	30	258684004	2	Oral	26643006	01/01/2023	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	400	258684004	2	Oral	26643006	01/01/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IMATINIB	400	258684004	2	Oral	26643006	01/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	01/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	180	258684004	1	Intravenous	47625008	01/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	40	IBRUTINIB	140	258684004	2	Oral	26643006	01/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DASATINIB	100	258684004	2	Oral	26643006	01/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	NILOTINIB	200	258684004	2	Oral	26643006	01/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IBRUTINIB	560	258684004	2	Oral	26643006	01/01/2023	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	77	LENALIDOMIDE	5	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	02/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	750	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	800	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEMOZOLOMIDE	330	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	MYL XI LEN MAIN>	1	PATIENT is taking part in a CLINICAL TRIAL	77	LENALIDOMIDE	10	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	125	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IBRUTINIB	420	258684004	2	Oral	26643006	02/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	9		99	Not known	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ALECTINIB	450	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IMATINIB	400	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C509				99	Not known	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	400	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RIBOCICLIB	400	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	24	NIRAPARIB	100	258684004	2	Oral	26643006	02/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IMATINIB	400	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	44	IMATINIB	400	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	15	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	APIXABAN	2.5	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IXAZOMIB	2.3	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	62	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	10	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	10	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	NILOTINIB	400	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	10	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	POMALIDOMIDE	3	258684004	2	Oral	26643006	02/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB	14	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APIXABAN	2.5	258684004	2	Oral	26643006	02/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	650	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	700	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CETUXIMAB	900	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CETUXIMAB	900	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	128	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	500	258684004	1	Intravenous	47625008	03/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C20X				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C20X				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	280	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C509				99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	320	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	500	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CETUXIMAB	800	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	96	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	03/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	MERCAPTOPURINE	100	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	5.5	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CABOZANTINIB	40	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CABOZANTINIB	60	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	METHOTREXATE	37.5	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	5	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	125	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Osimertinib	40	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Osimertinib	80	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Osimertinib	40	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	100	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	50	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	120	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	100	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	16	VENETOCLAX	400	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	225	258684004	1	Intravenous	47625008	03/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	132	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	360	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	80	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	80	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C300		3	Not Applicable (Primary Treatment)			NIVOLUMAB H + N>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	Nivolumab	240	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	COMP- ARM 1 WKLY	1	PATIENT is taking part in a CLINICAL TRIAL	1	CISPLATIN	80	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C924	98663	9		1	Curative – aiming to permanently eradicate the disease	ATRA/ATO CON C4	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ARSENIC TRIOXIDE	13	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	03/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C23		1	Adjuvant Therapy	99	Not known	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1650	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	2000	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	RIBOCICLIB	200	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	1000	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	240	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Nivolumab	480	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	1	PATIENT is taking part in a CLINICAL TRIAL	5	CISPLATIN	70	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AVELUMAB	800	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C900	97323	9		98	Other	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	Nivolumab	480	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AXITINIB	5	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	61	IMATINIB	100	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	8	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	15	258684004	2	Oral	26643006	03/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C349	80463	9				DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IXAZOMIB	4	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	APIXABAN	2.5	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1780	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C829	96913	1	Adjuvant Therapy	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXRAZOXANE	1160	258684004	1	Intravenous	47625008	03/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	40	RUXOLITINIB	10	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	120	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	7	IXAZOMIB	4	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	700	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	375	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	150	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	80	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C179				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	5	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	03/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	NILOTINIB	200	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TALIMOGENE LAHERPAREPVEC 10*8	3	74964007	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	03/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	9	258684004	1	Intravenous	47625008	03/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CHLORAMBUCIL	10	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PROCARBAZINE	150	258684004	2	Oral	26643006	03/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	21	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	04/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	21	CYTARABINE	50	258684004	3	Intrathecal	72607000	04/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	336	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	66	LENALIDOMIDE	5	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	04/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	50	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	320	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	700	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	700	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1650	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	550	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	240	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	30	TRASTUZUMAB-ONTRUZANT	651	258684004	1	Intravenous	47625008	04/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	04/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	96	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	9	METHOTREXATE	12	258684004	3	Intrathecal	72607000	04/01/2023	RH8
RH8	C00X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C00X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)2 + 4 + GEMD1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMTUZUMAB OZOGAMCIN	5	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)2 + 4 + GEMD1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DAUNORUBICIN	110	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)2 + 4 + GEMD1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYTARABINE	1800	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	04/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	180	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	KADCYLA ADJ ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB - EMTANSINE	360	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	25	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	MERCAPTOPURINE	120	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	10	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	120	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	650	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/01/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PALBOCICLIB	75	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	Osimertinib	80	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PANITUMUMAB	500	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PALBOCICLIB	75	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	04/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	2	ISATUXIMAB	720	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	360	258684004	1	Intravenous	47625008	04/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	04/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	POLATUZUMAB VEDOTIN	152	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CABOZANTINIB	40	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	17	GEMCITABINE	1200	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1600	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NINTEDANIB	200	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	400	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C539		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	70	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	17	AVELUMAB	800	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	30	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	0.85	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	148	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IMATINIB	400	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	400	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	65	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	2260	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C13X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	63	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB DERUXTECAN	320	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	21	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C159		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	POMALIDOMIDE	4	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	25	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	23	CAPECITABINE	2000	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	10	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C159		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ISATUXIMAB	900	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Nivolumab	480	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IXAZOMIB	4	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	15	258684004	2	Oral	26643006	04/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	04/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	120	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	20	RUXOLITINIB	10	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	120	258684004	5	Subcutaneous	34206005	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	6	IXAZOMIB	4	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB DERUXTECAN	400	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	2	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	20	SUNITINIB	25	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	04/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	IBRUTINIB	420	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IBRUTINIB	560	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	NILOTINIB	300	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>	1	PATIENT is taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	10	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>	1	PATIENT is taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	15	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>	1	PATIENT is taking part in a CLINICAL TRIAL	11	IXAZOMIB	3	258684004	2	Oral	26643006	04/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	900	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	04/01/2023	RH8
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	04/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	330	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	300	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	550	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	05/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CETUXIMAB	800	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C20				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	540	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1650	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C20				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1800	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	10	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	33	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	110	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	69	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)2 + 4 + GEMD1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DAUNORUBICIN	110	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	400	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)2 + 4 + GEMD1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYTARABINE	1800	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	05/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	100	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	200	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	700	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1800	258684004	2	Oral	26643006	05/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	120	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABOZANTINIB	20	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CAPECITABINE	1000	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	50	PALBOCICLIB	125	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	43	PALBOCICLIB	125	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	46	PALBOCICLIB	75	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX-R WK1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	20	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C911	98233	9		98	Other	VENETOCLAX-R WK5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	65	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRAMETINIB	2	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DABRAFENIB	100	258684004	2	Oral	26643006	05/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)			VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	400	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	3	ISATUXIMAB	580	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TUCATINIB	250	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	360	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	45	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	05/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	350	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1150	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PALBOCICLIB	75	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C20		9		99	Not known	RALT/OXALI-MET>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	80	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C20		9		99	Not known	RALT/OXALI-MET>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RALTITREXED	3.5	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	150	258684004	1	Intravenous	47625008	05/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PANITUMUMAB	180	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OXALIPLATIN	90	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	13	VENETOCLAX	100	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	336	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	144	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	30	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	49	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	0.85	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1400	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX WK3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	100	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	148	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IMATINIB	200	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C911	98233	9		99	Not known	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	450	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NIRAPARIB	100	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DEXAMETHASONE	10	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	POMALIDOMIDE	2	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	61	LENALIDOMIDE	15	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CAPECITABINE	2150	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DURVALUMAB	1500	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ISATUXIMAB	650	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	61	IXAZOMIB	4	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	APIXABAN	2.5	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	82	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABAZITAXEL	40	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	99	Not known	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	05/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TEPOTINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TEPOTINIB	450	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C21X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SCCA >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	200	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)			LENVATINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - LENVIMA	24	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	SUNITINIB	25	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	05/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	10	NILOTINIB	300	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	IBRUTINIB	280	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NILOTINIB	400	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ERIBULIN	1.94	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ERIBULIN	2.02	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C349	80463	9				PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	THALIDOMIDE	100	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	05/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	05/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	05/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	700	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	05/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	600	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	270	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	600	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	450	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	FLUOROURACIL	700	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CETUXIMAB	900	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CETUXIMAB	900	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	CETUXIMAB	800	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	450	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	650	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	25	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	OXALIPLATIN	135	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2000	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	600	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	550	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	250	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	240	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TCH (21 day Trastuzumab) Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	400	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TCH (21 day Trastuzumab) Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TCH (21 day Trastuzumab) Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINORELBINE	100	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINORELBINE	120	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	128	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	164	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	120	258684004	1	Intravenous	47625008	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DOCETAXEL	120	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BEVACIZUMAB - ALYMSYS	600	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)2 + 4 + GEMD1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYTARABINE	1800	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	200	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	198	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	650	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ERLOTINIB 2MTH +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ERLOTINIB	150	258684004	2	Oral	26643006	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AVELUMAB	800	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AXITINIB	7	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61		9				ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM CAR TAXOL +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	15	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ABEMACICLIB	150	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM CAR TAXOL +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		9				ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ABEMACICLIB	100	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DABRAFENIB	75	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	TRAMETINIB	1	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM CAR TAXOL +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	378	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	70	DABRAFENIB	150	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	70	TRAMETINIB	2	258684004	2	Oral	26643006	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ALECTINIB	600	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	52	ALECTINIB	600	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	35	NIRAPARIB	100	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	38	IBRUTINIB	420	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL.	2	PATIENT is not taking part in a CLINICAL TRIAL	28	IBRUTINIB	140	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	96	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	27	METFORMIN	850	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IXAZOMIB	3	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	9		99	Not known	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C189				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRIFLURIDINE/TIPIRACIL	70	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C189				99	Not known	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C924	98663	9		1	Curative – aiming to permanently eradicate the disease	ATRA/ATO CON C4	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ARSENIC TRIOXIDE	13	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1150	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1400	258684004	1	Intravenous	47625008	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	336	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	400	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	47	Nivolumab	480	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO RESECTED >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	30	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	SACITUZUMAB GOVITECAN	620	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	INOTUZUMAB ALL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	INOTUZUMAB OZOGAMICIN	1	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	SACITUZUMAB GOVITECAN	630	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	SACITUZUMAB GOVITECAN	590	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	0.85	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80463	9				PEMBRO 428 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMETREXED	1000	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	148	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Etoposide oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	50	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IMATINIB	400	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ACALABRUTINIB	100	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	450	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	650	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IBRUTINIB	560	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	144	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	28	CAPECITABINE	1300	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	80	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2300	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CAPECITABINE	1300	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	25	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IXAZOMIB	3	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61		9				Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABAZITAXEL	36	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	RUXOLITINIB	15	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	99	Not known	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RUXOLITINIB	5	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	120	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C172				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	THALIDOMIDE	100	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NILOTINIB	300	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	164	258684004	1	Intravenous	47625008	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	200	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IBRUTINIB	420	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	94	IBRUTINIB	280	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	66	DASATINIB	100	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DASATINIB	20	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C921	98633	9		98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	109	NILOTINIB	150	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			TEPOTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEPOTINIB	450	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	POMALIDOMIDE	2	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	06/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ERIBULIN	1.06	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	800	258684004	1	Intravenous	47625008	06/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	108	258684004	1	Intravenous	47625008	06/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABOZANTINIB	40	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABOZANTINIB	40	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IBRUTINIB	280	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ACALABRUTINIB	100	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZANUBRUTINIB	160	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			LORLATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LORLATINIB	100	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	48	PAZOPANIB	400	258684004	2	Oral	26643006	07/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CABOZANTINIB	40	258684004	2	Oral	26643006	08/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Osimertinib	80	258684004	2	Oral	26643006	08/01/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRAMETINIB	2	258684004	2	Oral	26643006	08/01/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DABRAFENIB	150	258684004	2	Oral	26643006	08/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NIRAPARIB	100	258684004	2	Oral	26643006	08/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ACALABRUTINIB	100	258684004	2	Oral	26643006	08/01/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ACALABRUTINIB	100	258684004	2	Oral	26643006	08/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Erlotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	68	ERLOTINIB	50	258684004	2	Oral	26643006	08/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	26	IBRUTINIB	420	258684004	2	Oral	26643006	08/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB - EMTANSINE	200	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DEXAMETHASONE	10	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	34	LENALIDOMIDE	15	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	550	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	110	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	120	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C459		9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	4	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C459		9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	630	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C459		9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMETREXED	1000	258684004	1	Intravenous	47625008	09/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEMOZOLOMIDE	240	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CARBOPLATIN	630	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DOCETAXEL	120	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	Osimertinib	80	258684004	2	Oral	26643006	09/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	65	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DABRAFENIB	150	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRAMETINIB	2	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	100	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	120	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	360	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ALECTINIB	600	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	ENRICH-RITUX + I	1	PATIENT is taking part in a CLINICAL TRIAL	9	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	ENRICH-RITUX + I	1	PATIENT is taking part in a CLINICAL TRIAL	9	IBRUTINIB	420	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	200	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	09/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	750	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMETREX LUNG 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	750	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2300	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1400	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	Osimertinib	80	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	1000	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMETREX LUNG 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	650	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIVO - MESO C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C911	98233	9		1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ACALABRUTINIB	100	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	110	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	320	258684004	1	Intravenous	47625008	09/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	Nivolumab	480	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB - EMTANSINE	160	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DEXAMETHASONE	10	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	10	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	APIXABAN	2.5	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP> C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	800	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	80	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2000	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	15	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2300	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP> C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C189				99	Not known	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	Nivolumab	480	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IXAZOMIB	3	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	70	RUXOLITINIB	10	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	99	Not known	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	10	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APIXABAN	2.5	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	180	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C921	98633			99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	66	NILOTINIB	400	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	60	SUNITINIB	25	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	09/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	09/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	09/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LIPOSOMAL DOXORUBICIN	58	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	600	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	725	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	270	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CETUXIMAB	700	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	10	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	15	258684004	2	Oral	26643006	10/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	900	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1450	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	150	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	180	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	100	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	10/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2500	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	100	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	10	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61		9				ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	125	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	100	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PALBOCICLIB	125	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	120	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	VENETOCLAX	400	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	132	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	600	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	BOSUTINIB	500	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	APIXABAN	2.5	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRIFLURIDINE/TIPIRACIL	60	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CABOZANTINIB	20	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	2000	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	125	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	800	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Nivolumab	480	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	25	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	800	258684004	1	Intravenous	47625008	10/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	84	AVELUMAB	800	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	4	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	50	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	61	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	120	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	57	LENALIDOMIDE	10	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	25	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	80	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C44X		9				Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	10/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IXAZOMIB	4	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PAC ALB C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	500	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABAZITAXEL	30	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	25	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	76	RUXOLITINIB	15	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	99	Not known	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Crizotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	33	CRIZOTINIB	250	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PAZOPANIB	200	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	400	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	100	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	320	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	NILOTINIB	150	258684004	2	Oral	26643006	10/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	200	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	NILOTINIB	300	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TALIMOGENE LAHERPAREPVEC 10*8	1	74964007	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TALIMOGENE LAHERPAREPVEC 10*8	4	74964007	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	10/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TALIMOGENE LAHERPAREPVEC 10*6	2	74964007	5	Subcutaneous	34206005	10/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	10/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	22	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	11/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine + Methotrexate Intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	22	CYTARABINE	50	258684004	3	Intrathecal	72607000	11/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	117	LENALIDOMIDE	10	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	600	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	135	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1450	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	200	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	240	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	800	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	11/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	400	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C541		9				Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AVELUMAB	800	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AXITINIB	8	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB SC>9	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	120	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	11/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CABOZANTINIB	20	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	900	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	46	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	46	FLUOROURACIL	650	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	Osimertinib	80	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	46	PALBOCICLIB	75	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	AML MAINT MIDOST	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MIDOSTAURIN	50	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	890	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	46	PANITUMUMAB	500	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Osimertinib	40	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PALBOCICLIB	100	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PALBOCICLIB	100	258684004	2	Oral	26643006	11/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	9				OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	Osimertinib	80	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	15	VENETOCLAX	400	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	24	Nivolumab	480	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IBRUTINIB	280	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C921	98633	9		98	Other	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	83	BOSUTINIB	200	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	23	NIRAPARIB	200	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	Nivolumab	360	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IMATINIB	100	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C189				99	Not known	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C01X				99	Not known	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	800	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	120	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1400	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	Osimertinib	80	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1600	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	RIBOCICLIB	200	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	11/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CHLORAMBUCIL	20	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	MITHRI RUXOL >	1	PATIENT is taking part in a CLINICAL TRIAL	20	RUXOLITINIB	15	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	Nivolumab	480	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Nivolumab	480	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	400	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Olaparib	100	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	POMALIDOMIDE	2	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1150	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	225	258684004	1	Intravenous	47625008	11/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	18000		1	Intravenous	47625008	11/01/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			AVELUMAB UC5-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AVELUMAB	800	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	10	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	80	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	650	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	20	258684004	2	Oral	26643006	11/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2500	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	POMALIDOMIDE	2	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	20	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ISATUXIMAB	440	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ISATUXIMAB	900	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IXAZOMIB	4	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IXAZOMIB	4	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	11/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	25	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	99	Not known	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	D45X	99503	9		98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	22	RUXOLITINIB	15	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	120	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Vismodegib	2	PATIENT is not taking part in a CLINICAL TRIAL	84	VISMONDEGIB	150	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C183				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SCCA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	180	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	11/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	400	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	100	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	11/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	320	258684004	1	Intravenous	47625008	11/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DASATINIB	20	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SUNITINIB	25	258684004	2	Oral	26643006	11/01/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	11/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	164	258684004	1	Intravenous	47625008	11/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DEXAMETHASONE	10	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	20	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C679				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C679				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	100	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	12/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	800	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CETUXIMAB	1000	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	96	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	12/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	300	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENCORAFENIB	450	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BINIMETINIB	45	258684004	2	Oral	26643006	12/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENCORAFENIB	450	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENCORAFENIB	200	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BINIMETINIB	45	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	BINIMETINIB	30	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	12/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	58	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	58	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	40	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	51	LENALIDOMIDE	5	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	125	258684004	2	Oral	26643006	12/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	62	DABRAFENIB	100	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	62	TRAMETINIB	1.5	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	12/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	96	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	144	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	600	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	600	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C10X				99	Not known	COMPARE-ARM 5ECG	1	PATIENT is taking part in a CLINICAL TRIAL	1	DURVALUMAB	1500	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	120	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NIRAPARIB	200	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	12/01/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	34	BEVACIZUMAB - ALYMSYS	1400	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PALBOCICLIB	100	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	11	NINTEDANIB	150	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	600	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	600	258684004	2	Oral	26643006	12/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	INOTUZUMAB ALL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	INOTUZUMAB OZOGAMICIN	1	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX WK4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	200	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	400	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	12/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2300	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	80	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	80	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	2000	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	25	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DURVALUMAB	1500	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	6	IXAZOMIB	4	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO*	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	12/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO*	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	10	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CABAZITAXEL	36	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	25	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	12/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	8	IXAZOMIB	4	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	700	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	110	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	95	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	95	ERIBULIN	1.67	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	12/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	12/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	12/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	12/01/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	120	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	72	258684004	1	Intravenous	47625008	12/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	216	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		9		99	Not known	Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB - EMTANSINE	180	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	890	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	CETUXIMAB	1100	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DEXAMETHASONE	10	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	25	258684004	2	Oral	26643006	13/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C68X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1000	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C68X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	56	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	APIXABAN	2.5	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	650	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1450	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	180	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C679				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	100	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	220	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	95	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C300		3	Not Applicable (Primary Treatment)			CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C300		3	Not Applicable (Primary Treatment)			CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C300		3	Not Applicable (Primary Treatment)			CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C300		3	Not Applicable (Primary Treatment)			CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	128	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C10		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C10		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CARBOPLATIN	560	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C719		1	Adjuvant Therapy	99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	200	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BINIMETINIB	45	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENCORAFENIB	450	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CABOZANTINIB	20	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	500	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	45	ABEMACICLIB	100	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	AML MAINT MIDOST	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MIDOSTAURIN	50	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PANITUMUMAB	260	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	13/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Osimertinib	80	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	51	VENETOCLAX	300	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	13/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	250	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	TRAMETINIB	2	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DABRAFENIB	150	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IBRUTINIB	420	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	80	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NIRAPARIB	300	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	24	METFORMIN	850	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IMATINIB	300	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C349	80463			99	Not known	LAROTRECTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Larotrectinib	100	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			LAROTRECTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Larotrectinib	100	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C259				99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	44	RIBOCICLIB	400	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	600	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NIRAPARIB	200	258684004	2	Oral	26643006	13/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	39	IBRUTINIB	140	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NIRAPARIB	200	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	SACITUZUMAB GOVITECAN	630	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	13/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	9		98	Other	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	13/01/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IMATINIB	400	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZOLIZUMAB>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PAC ALB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	10	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	10	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CAPECITABINE	1300	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	80	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	120	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	25	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	5	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	15	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	20	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	1500	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1950	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	110	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ISATUXIMAB	900	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IXAZOMIB	4	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APIXABAN	2.5	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IXAZOMIB	3	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IXAZOMIB	4	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IXAZOMIB	3	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	25	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	13/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RUXOLITINIB	15	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	85	AVELUMAB	800	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	800	258684004	1	Intravenous	47625008	13/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OXALIPLATIN	165	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB DERUXTECAN	600	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	13/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	164	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	86	NILOTINIB	200	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	NILOTINIB	400	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	NILOTINIB	400	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C880	97613	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IBRUTINIB	420	258684004	2	Oral	26643006	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ERIBULIN	1.23	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	13/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	14/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	25	NIRAPARIB	100	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	Osimertinib	40	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			TEPOTINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TEPOTINIB	450	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IBRUTINIB	420	258684004	2	Oral	26643006	14/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	IBRUTINIB	420	258684004	2	Oral	26643006	14/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	14/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	164	258684004	1	Intravenous	47625008	14/01/2023	RH8
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Idarubicin + Tretinoin Spanish Crse4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IDARUBICIN HYDROCHLORIDE	12	258684004	1	Intravenous	47625008	15/01/2023	RH8
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Idarubicin + Tretinoin Spanish Crse4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	15/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABOZANTINIB	20	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ALECTINIB	600	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	49	IBRUTINIB	560	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	C831	96733	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IBRUTINIB	560	258684004	2	Oral	26643006	15/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	15/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	164	258684004	1	Intravenous	47625008	15/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	216	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LIPOSOMAL DOXORUBICIN	54	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	270	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	16/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	700	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	900	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	500	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CETUXIMAB	800	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CARBOPLATIN	700	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	16/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C911	98233	9		98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	400	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	180	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	198	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PALBOCICLIB	125	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	600	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	16/01/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	16/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IPILIMUMAB	55	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	49	BOSUTINIB	500	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	360	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	16/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRIFLURIDINE/TIPIRACIL	50	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1400	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1400	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	125	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PALBOCICLIB	75	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	600	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PANITUMUMAB	400	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	180	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	200	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CETUXIMAB	1000	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	63	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	79	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C20X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1800	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	99	Not known	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C880	97613	9		98	Other	ZANUBRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZANUBRUTINIB	160	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	99	Not known	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	110	258684004	1	Intravenous	47625008	16/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DURVALUMAB	1500	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DURVALUMAB	1500	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	RUXOLITINIB	15	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	2.5	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C679		9		1	Curative – aiming to permanently eradicate the disease	GEM100 RAD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	170	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	R - GemOx	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PROCARBAZINE	200	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	R - GemOx	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	900	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	180	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	36	258684004	1	Intravenous	47625008	16/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	10	NILOTINIB	400	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C921	98633	9		5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NILOTINIB	400	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	R - GemOx	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB	700	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	SUNITINIB	50	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LOMUSTINE	200	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	164	258684004	1	Intravenous	47625008	16/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	16/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	16/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	240	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Idarubicin + Tretinoin Spanish Crse4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IDARUBICIN HYDROCHLORIDE	12	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Idarubicin + Tretinoin Spanish Crse4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	17/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	320	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	500	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	650	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CETUXIMAB	800	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CETUXIMAB	900	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	25	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	GEMCITABINE	1000	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CISPLATIN	24	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	17/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	800	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	80	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	17/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	128	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	17/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C66		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2200	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUDARABINE PHOSPHATE	50	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	3300	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	43	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	MERCAPTOPURINE	100	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	METHOTREXATE	37.5	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	48	PALBOCICLIB	100	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PALBOCICLIB	75	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PALBOCICLIB	75	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	120	258684004	1	Intravenous	47625008	17/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VENETOCLAX	200	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	250	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	132	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BOSUTINIB	300	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	80	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C300		3	Not Applicable (Primary Treatment)			NIVOLUMAB H + N>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	Nivolumab	240	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IMATINIB	400	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C921	98633			99	Not known	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IMATINIB	400	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	37	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	17/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	700	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	2000	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PANITUMUMAB	400	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	240	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	600	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	600	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	17/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AVELUMAB	800	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AXITINIB	5	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C917	98311	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ORAL MTX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	60	METHOTREXATE	10	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	25	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	17/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SACITUZUMAB GOVITECAN	730	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	15	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	10	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	80	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	120	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	25	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	21	CAPECITABINE	1000	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	10	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL (C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DURVALUMAB	1500	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DURVALUMAB	1500	258684004	1	Intravenous	47625008	17/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APIXABAN	2.5	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IXAZOMIB	3	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	31	RUXOLITINIB	5	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	5	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	375	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	80	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C259				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	17/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	17/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IBRUTINIB	420	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NILOTINIB	300	258684004	2	Oral	26643006	17/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	66	IBRUTINIB	140	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	300	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA 3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA 3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAUNORUBICIN	105	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA 3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	200	258684004	1	Intravenous	47625008	17/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TALIMOGENE LAHERPAREPVEC 10*8	3	74964007	5	Subcutaneous	34206005	17/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	17/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	17/01/2023	RH8
RBZ	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	18/01/2023	RH8
RBZ	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	18/01/2023	RH8
RBZ	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	600	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1450	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	300	258684004	1	Intravenous	47625008	18/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CETUXIMAB	900	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	113	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	40	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	LENALIDOMIDE	15	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	70	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1800	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	50	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	45	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	18/01/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	18/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	18/01/2023	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	18/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IFOSFAMIDE	2400	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	330	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TEMOZOLOMIDE	380	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUDARABINE PHOSPHATE	50	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	3300	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AXITINIB	5	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	101	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	MERCAPTOPURINE	120	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	101	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	26	CABOZANTINIB	20	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	METHOTREXATE	40	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	100	258684004	1	Intravenous	47625008	18/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	80	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	125	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	Osimertinib	80	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PALBOCICLIB	125	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ANASTROZOLE	1	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	100	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PALBOCICLIB	100	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	19	VENETOCLAX	400	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	31	RIBOCICLIB	400	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	3	ISATUXIMAB	720	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ALECTINIB	600	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	18/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	18/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	18/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	18/01/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 3W	1	PATIENT is taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB/PLACEBO	200	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	18/01/2023	RH8
RBZ	C32X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO H + N C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C846	97143	3	Not Applicable (Primary Treatment)	98	Other	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	18/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C846	97143	3	Not Applicable (Primary Treatment)	98	Other	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	300	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ACALABRUTINIB	100	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	120	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IMATINIB	400	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	5	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	18/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	50	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C20X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2500	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ISATUXIMAB	900	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	48	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C848	97183	9		98	Other	Brentuximab	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BRENTUXIMAB VEDOTIN	100	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	48	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	38	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	110	RUXOLITINIB	15	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RUXOLITINIB	15	258684004	2	Oral	26643006	18/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		9				Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	148	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C259		9				Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	325	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C259		9				Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C259		9				Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	70	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	180	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	18/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	36	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	18/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	NILOTINIB	400	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IBRUTINIB	420	258684004	2	Oral	26643006	18/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA 3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	200	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ERIBULIN	1.06	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	18/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	220	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	164	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	630	258684004	1	Intravenous	47625008	18/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	270	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Idarubicin + Tretinoin Spanish Crse4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IDARUBICIN HYDROCHLORIDE	12	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Idarubicin + Tretinoin Spanish Crse4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	LENALIDOMIDE	5	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2200	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	240	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	108	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	70	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	350	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IFOSFAMIDE	2400	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C66		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Vinorelbine (oral)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINORELBINE	100	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	120	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IDARUBICIN HYDROCHLORIDE	14	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUDARABINE PHOSPHATE	50	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	350	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	3300	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C931	99803	3	Not Applicable (Primary Treatment)			HYD AML/CML 3/4>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	100	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	900	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	40	ABEMACICLIB	100	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	43	PALBOCICLIB	75	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PALBOCICLIB	100	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX-R WK3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	100	258684004	2	Oral	26643006	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C911	98233	9		99	Not known	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	23	VENETOCLAX	300	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	96	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	144	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DABRAFENIB	150	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DABRAFENIB	150	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRAMETINIB	2	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	TRAMETINIB	2	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	600	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	400	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	3	ISATUXIMAB	580	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	120	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	BOSUTINIB	500	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	350	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PANITUMUMAB	180	258684004	1	Intravenous	47625008	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ABEM & LETROZ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	150	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	100	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PALBOCICLIB	100	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PALBOCICLIB	125	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	50	VENETOCLAX	200	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	336	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ACALABRUTINIB	100	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ACALABRUTINIB	100	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	16	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1400	258684004	1	Intravenous	47625008	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	300	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX WK5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	83	Nivolumab	480	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	18	BUSULFAN	30	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	49	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	650	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ISATUXIMAB	650	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	VTD(28 DAY)>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZ MTC -	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CABOZANTINIB	100	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	87	RUXOLITINIB	5	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	RUXOLITINIB	10	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RUXOLITINIB	15	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C21X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SCCA >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	180	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	180	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	36	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	NILOTINIB	400	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IBRUTINIB	420	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IBRUTINIB	420	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	95	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA 3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA 3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAUNORUBICIN	105	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA 3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	200	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	95	ERIBULIN	1.67	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	800	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	11600	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	220	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	164	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	19/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	19/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	19/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	700	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	150	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	165	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	108	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	96	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DOCETAXEL	80	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	88	258684004	1	Intravenous	47625008	19/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	360	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	216	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	240	258684004	1	Intravenous	47625008	20/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	600	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	350	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	31	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	31	FLUOROURACIL	700	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	500	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	700	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	90	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	20/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	630	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	300	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CETUXIMAB	900	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CETUXIMAB	800	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	31	CETUXIMAB	800	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CETUXIMAB	800	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CETUXIMAB	900	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	25	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	15	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	550	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	20/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	200	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	20/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	96	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	120	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	148	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	2	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IFOSFAMIDE	2400	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CISPLATIN	79	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	200	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AVELUMAB	800	258684004	1	Intravenous	47625008	20/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	80	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q 28D>1	2	PATIENT is not taking part in a CLINICAL TRIAL	76	LENALIDOMIDE	5	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	900	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CABOZANTINIB	40	258684004	2	Oral	26643006	20/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CABOZANTINIB	20	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	20	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	47	PALBOCICLIB	100	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PALBOCICLIB	75	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	100	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ABEMACICLIB	50	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	100	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	600	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BOSUTINIB	200	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	IXAZOMIB	2.3	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C20				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRIFLURIDINE/TIPIRACIL	55	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PALBOCICLIB	125	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	400	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	300	258684004	1	Intravenous	47625008	20/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SACITUZUMAB GOVITECAN	590	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Etoposide oral	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	50	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1150	258684004	2	Oral	26643006	20/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	D475		3	Not Applicable (Primary Treatment)	98	Other	IMAT CEL/HES>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	100	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			AVELUMAB>4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AVELUMAB	800	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C21		3	Not Applicable (Primary Treatment)			Off Protocol	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Off Protocol drug	1	408102007	1	Intravenous	47625008	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	92	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CAPECITABINE	1200	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	120	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	Nivolumab	480	258684004	1	Intravenous	47625008	20/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	Nivolumab	480	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABAZITAXEL	30	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	RUXOLITINIB	5	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	750	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	600	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	90	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	98	Other	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	OXALIPLATIN	110	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	72	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APIXABAN	2.5	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	SUNITINIB	50	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	36	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	180	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DASATINIB	40	258684004	2	Oral	26643006	20/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ERIBULIN	1.23	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	20/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	164	258684004	1	Intravenous	47625008	20/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DEXAMETHASONE	10	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	83	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	21/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	10	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	Osimertinib	80	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IMATINIB	400	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	C509		9		99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CAPECITABINE	2300	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NINTEDANIB	200	258684004	2	Oral	26643006	21/01/2023	RH8
RH8	C931	99803	3	Not Applicable (Primary Treatment)			HYD AML/CML 3/4>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/01/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/01/2023	RH8
RH8	C259				99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	375	258684004	2	Oral	26643006	22/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ACALABRUTINIB	100	258684004	2	Oral	26643006	22/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	99	Not known	ASCIMINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ASCIMINIB	80	258684004	2	Oral	26643006	22/01/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	40	IBRUTINIB	420	258684004	2	Oral	26643006	22/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	600	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	240	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1450	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	4	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	800	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	13	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	23/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	198	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	23/01/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	80	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	80	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	790	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	23/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	100	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	125	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	TRAMETINIB	2	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DABRAFENIB	150	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EXEMESTANE	25	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	600	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EVEROLIMUS	7.5	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1400	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	400	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	270	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	23/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	PONATINIB - C3>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PONATINIB	15	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NIRAPARIB	200	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	D693		9		98	Other	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ACALABRUTINIB	100	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	25	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CARFILZOMIB	54	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO + FULVEST	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO + FULVEST	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	23/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IMATINIB	400	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	63	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	79	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BUSULFAN	2	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	40	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABAZITAXEL	40	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABAZITAXEL	54	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	38	RUXOLITINIB	10	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C679		9		1	Curative – aiming to permanently eradicate the disease	GEM100 RAD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	170	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	30	NILOTINIB	200	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	36	IBRUTINIB	420	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	50	NILOTINIB	300	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IBRUTINIB	420	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C169		9				Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	SUNITINIB	50	258684004	2	Oral	26643006	23/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	600	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	CETUXIMAB	700	258684004	1	Intravenous	47625008	24/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	111	LENALIDOMIDE	10	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	75	LENALIDOMIDE	15	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	500	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	800	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	120	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	24/01/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	96	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	164	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cytarabine intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	70	258684004	3	Intrathecal	72607000	24/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	24/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	100	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	300	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	74	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	24/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	650	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	MERCAPTOPURINE	100	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	40	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CABOZANTINIB	20	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 C MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	METHOTREXATE	37.5	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	75	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	Osimertinib	40	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	120	258684004	1	Intravenous	47625008	24/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	200	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IMATINIB	400	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	24/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C01X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C189				99	Not known	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	900	258684004	1	Intravenous	47625008	24/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	1000	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C252				99	Not known	EVEROLIMUS NET>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EVEROLIMUS	5	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	30	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	D693		3	Not Applicable (Primary Treatment)	99	Not known	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	0.85	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	120	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	120	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CARFILZOMIB	54	258684004	1	Intravenous	47625008	24/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	55	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	24/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	160	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	148	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SACITUZUMAB GOVITECAN	730	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	75	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABAZITAXEL	44	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	RUXOLITINIB	15	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	RUXOLITINIB	20	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	85	AVELUMAB	800	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	24/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	24/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	IBRUTINIB	140	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	30	NILOTINIB	200	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NILOTINIB	300	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	DA 3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	200	258684004	1	Intravenous	47625008	24/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	24/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TALIMOGENE LAHERPAREPVEC 10*8	4	74964007	5	Subcutaneous	34206005	24/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	24/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	24/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	24/01/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	550	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	25/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	240	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	450	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CETUXIMAB	900	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C900	97323	9				Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	10	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	5	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	650	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	600	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C900	97323	9				Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	25	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	25/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	50	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1650	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	225	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	180	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C609		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (2 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	8200	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C609		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (2 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	164	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	31	TRASTUZUMAB-ONTRUZANT	651	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	25/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	500	258684004	1	Intravenous	47625008	25/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AVELUMAB	800	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB SC>9	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	MERCAPTOPURINE	120	258684004	2	Oral	26643006	25/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	METHOTREXATE	40	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	47	FLUOROURACIL	650	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	47	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	100	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	47	PANITUMUMAB	500	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	400	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	85	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BOSUTINIB	100	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	360	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IMATINIB	400	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	25/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C10		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1400	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	30	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	0.85	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ACALABRUTINIB	100	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	120	258684004	2	Oral	26643006	25/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	120	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	DA-EPOCH R C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	148	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	76	Olaparib	250	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IMATINIB	400	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IMATINIB	400	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	400	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB - EMTANSINE	360	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C159		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C159		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	25/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IBRUTINIB	420	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	10	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	117	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	120	258684004	2	Oral	26643006	25/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	80	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	5	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CAPECITABINE	2000	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	POMALIDOMIDE	3	258684004	2	Oral	26643006	25/01/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	98	Other	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DURVALUMAB	1500	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ISATUXIMAB	440	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ISATUXIMAB	900	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	APIXABAN	2.5	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IXAZOMIB	2.3	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	BEXAROTENE	225	258684004	2	Oral	26643006	25/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C21X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SCCA >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	180	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	10	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C44X		9		98	Other	Vismodegib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VISMONDEGIB	150	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	APIXABAN	2.5	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R CODOX M	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	36	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB DERUXTECAN	240	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB DERUXTECAN	400	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R CODOX M	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R CODOX M	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R CODOX M	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R CODOX M	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	25/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	25/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	180	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ERIBULIN	1.06	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	25/01/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	360	258684004	1	Intravenous	47625008	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	216	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	800	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	550	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CETUXIMAB	1000	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CETUXIMAB	800	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1300	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	110	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	225	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	70	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	70	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FCR Oral - Cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUDARABINE PHOSPHATE	90	258684004	2	Oral	26643006	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FCR Oral - Cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	1000	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FCR Oral - Cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	550	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	120	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	180	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	400	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	INOTUX >1 CR/CRI	2	PATIENT is not taking part in a CLINICAL TRIAL	2	INOTUZUMAB OZOGAMICIN	1	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	700	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	CAPECITABINE	1000	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	140	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PALBOCICLIB	100	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PALBOCICLIB	125	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX-R WK4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	200	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX-R WK1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	20	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	96	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	144	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	200	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		9				RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	400	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	96	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IBRUTINIB	420	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C921	98633	9		99	Not known	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BOSUTINIB	400	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	360	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	49	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1150	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	150	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	Osimertinib	80	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PALBOCICLIB	125	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	336	258684004	1	Intravenous	47625008	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	400	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	120	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	RIBOCICLIB	200	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C349	80463	9				NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NINTEDANIB	200	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ERLOTINIB 2MNTH	2	PATIENT is not taking part in a CLINICAL TRIAL	71	ERLOTINIB	50	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ECT - BLEOMYCIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	32500	408102007	1	Intravenous	47625008	26/01/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	50	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	46	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1400	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	40	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	LENALIDOMIDE	5	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	5	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Panobinostat	15	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	15	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1450	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CAPECITABINE	2150	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	25	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DURVALUMAB	1500	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	128	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C64		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IXAZOMIB	3	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	5	IXAZOMIB	4	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT - 6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	2000	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXRAZOXANE	1200	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	61	RUXOLITINIB	25	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT - 6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IBRUTINIB	560	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	700	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	110	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	D015				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R CODOX M	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	360	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R CODOX M	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ERIBULIN	2.02	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ERIBULIN	1.94	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	26/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	26/01/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	120	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	68	258684004	1	Intravenous	47625008	26/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	26/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	240	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	400	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CETUXIMAB	1100	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	10	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	37	LENALIDOMIDE	15	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	10	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	25	258684004	2	Oral	26643006	27/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	2000	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	250	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	166	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Liposomal Doxorubicin 50mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LIPOSOMAL DOXORUBICIN	90	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINORELBINE	100	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	27/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	128	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	13	BEVACIZUMAB - ALYMSYS	600	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	450	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAZOPANIB - RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	57	PAZOPANIB	600	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	96	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BINIMETINIB	30	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENCORAFENIB	250	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	200	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	27/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	42	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABOZANTINIB	20	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	27/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	38	PALBOCICLIB	100	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	100	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	Osimertinib	80	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	125	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PALBOCICLIB	75	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PALBOCICLIB	75	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PALBOCICLIB	125	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	100	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PALBOCICLIB	125	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C911	98233			98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DABRAFENIB	150	258684004	2	Oral	26643006	27/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	TRAMETINIB	2	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	40	NIRAPARIB	100	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ALECTINIB	600	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM MAIN 200 +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	CABOZANTINIB	20	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	CABOZANTINIB	40	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	Nivolumab	480	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NIRAPARIB	200	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	SACITUZUMAB GOVITECAN	630	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SACITUZUMAB GOVITECAN	590	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ACALABRUTINIB	100	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C920	98733	9		98	Other	VEN/LD CYT19>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CYTARABINE	36	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C920	98733	9		98	Other	VEN/LD CYT19>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VENETOCLAX	100	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Olaparib	100	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	27/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	86	AVELUMAB	800	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	145	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB-ONTRUZANT	378	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	40	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	10	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	29	CAPECITABINE	1300	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	25	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	POMALIDOMIDE	4	258684004	2	Oral	26643006	27/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	56	LENALIDOMIDE	15	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2150	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	15	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2650	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1650	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CAPECITABINE	1300	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PALBOCICLIB	125	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ISATUXIMAB	900	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IXAZOMIB	4	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	56	IXAZOMIB	3	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IXAZOMIB	4	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	27/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	50	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	50	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CABAZITAXEL	36	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			LORLATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LORLATINIB	75	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Panobinostat	20	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C787				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Treosulfan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TREOSULFAN	500	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PACHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PACHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	27/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PACHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DASATINIB	100	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	164	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	IBRUTINIB	420	258684004	2	Oral	26643006	27/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	80	NILOTINIB	150	258684004	2	Oral	26643006	27/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	800	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	108	258684004	1	Intravenous	47625008	27/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Osimertinib	40	258684004	2	Oral	26643006	28/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Osimertinib	80	258684004	2	Oral	26643006	28/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NINTEDANIB	200	258684004	2	Oral	26643006	28/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	28/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	44	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PAZOPANIB	600	258684004	2	Oral	26643006	28/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Osimertinib	80	258684004	2	Oral	26643006	29/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	86	IMATINIB	300	258684004	2	Oral	26643006	29/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	103	IMATINIB	400	258684004	2	Oral	26643006	29/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/01/2023	RH8
RH8	C911	98233	1	Adjuvant Therapy			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	29/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	29/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	40	NILOTINIB	200	258684004	2	Oral	26643006	29/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	IBRUTINIB	140	258684004	2	Oral	26643006	29/01/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Fluorouracil + Mitomycin + RT (Bladder)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	30/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Fluorouracil + Mitomycin + RT (Bladder)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	500	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	216	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CETUXIMAB	800	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	800	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	900	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	30/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C459		9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	4	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C459		9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C459		9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMETREXED	1000	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cytarabine intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYTARABINE	70	258684004	3	Intrathecal	72607000	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MELPHALAN	340	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	330	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	30/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	80	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	Osimertinib	40	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	125	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/01/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/01/2023	RH8
RH8	C349	80463	9		99	Not known	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ALECTINIB	450	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	15	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	110	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509				99	Not known	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	400	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	RIBOCICLIB	400	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	320	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IBRUTINIB	420	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	25	NIRAPARIB	100	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	11	IXAZOMIB	4	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	D693		9		98	Other	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	30/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENCORAFENIB	300	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CARFILZOMIB	54	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PEMETREXED	1000	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CETUXIMAB	1000	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	400	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	79	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	63	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	9	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	15	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	APIXABAN	2.5	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IXAZOMIB	2.3	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	63	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	10	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	10	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	10	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C679		9		1	Curative – aiming to permanently eradicate the disease	GEM100 RAD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	170	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	30/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - KISPLYX	14	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	400	258684004	1	Intravenous	47625008	30/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	SUNITINIB	25	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>	1	PATIENT is taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	10	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>	1	PATIENT is taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	15	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>	1	PATIENT is taking part in a CLINICAL TRIAL	12	IXAZOMIB	3	258684004	2	Oral	26643006	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	750	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	750	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	96	258684004	1	Intravenous	47625008	30/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	600	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CETUXIMAB	900	258684004	1	Intravenous	47625008	31/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	10	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	78	LENALIDOMIDE	5	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	20	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	800	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C20X				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2000	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C20X				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	225	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	180	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	31/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	100	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C66		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	2200	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C66		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	400	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C300		3	Not Applicable (Primary Treatment)			NIVOLUMAB H + N> +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	Nivolumab	240	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	79	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	89	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	300	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	225	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	80	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	31/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AXITINIB	7	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CAPECITABINE	1800	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	5	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	31/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	500	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	125	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PANITUMUMAB	260	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	100	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	120	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	17	VENETOCLAX	400	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	336	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	360	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TUCATINIB	250	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C539		9		1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C349	80463	9				PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	22	RIBOCICLIB	200	258684004	2	Oral	26643006	31/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	700	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	Nivolumab	480	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AVELUMAB	800	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	AVELUMAB	800	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	D693		3	Not Applicable (Primary Treatment)	99	Not known	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CARFILZOMIB	54	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	Nivolumab	480	258684004	1	Intravenous	47625008	31/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IMATINIB	400	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IMATINIB	400	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMETREXED	800	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	900	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PAC ALB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	15	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	31/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23		3	Not Applicable (Primary Treatment)	99	Not known	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2000	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	99	Not known	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OXALIPLATIN	110	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	Nivolumab	480	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IXAZOMIB	4	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IXAZOMIB	4	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1780	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	31/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXRAZOXANE	1140	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	RUXOLITINIB	10	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	8	IXAZOMIB	4	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	375	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	80	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C179				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BLEOMYCIN	15000	408102007	1	Intravenous	47625008	31/01/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	200	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DASATINIB	100	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NILOTINIB	200	258684004	2	Oral	26643006	31/01/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633			99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	68	NILOTINIB	300	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	9	258684004	1	Intravenous	47625008	31/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PROCARBAZINE	150	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CHLORAMBUCIL	10	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	31/01/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	31/01/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	550	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	790	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	01/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	600	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CETUXIMAB	900	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1450	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	800	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	240	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	01/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	01/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	108	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C00X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C00X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	400	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	360	258684004	1	Intravenous	47625008	01/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/02/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	120	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C900				98	Other	MYL XI LEN MAIN>	1	PATIENT is taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	5	258684004	2	Oral	26643006	01/02/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PALBOCICLIB	75	258684004	2	Oral	26643006	01/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	75	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	890	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IPILIMUMAB	75	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	3	ISATUXIMAB	780	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	Nivolumab	360	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IMATINIB	200	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IMATINIB	400	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1150	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NINTEDANIB	200	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	400	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ACALABRUTINIB	100	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	120	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO + FULVEST	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	45	IMATINIB	400	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	22	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	80	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	80	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	650	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PLATO - ACT5	1	PATIENT is taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	10	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PLATO - ACT5	1	PATIENT is taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	15	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	7	IXAZOMIB	4	258684004	2	Oral	26643006	01/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/EVEROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - KISPLYX	14	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	800	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OXALIPLATIN	165	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/EVEROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EVEROLIMUS	5	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	40	IBRUTINIB	420	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IBRUTINIB	560	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	NILOTINIB	300	258684004	2	Oral	26643006	01/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3600	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	630	258684004	1	Intravenous	47625008	01/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	10	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1650	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	225	258684004	1	Intravenous	47625008	02/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	890	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	300	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	02/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	INOTUX >1 CR/CRI	2	PATIENT is not taking part in a CLINICAL TRIAL	2	INOTUZUMAB OZOGAMICIN	1	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	120	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	Osimertinib	40	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	48	PALBOCICLIB	100	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	51	PALBOCICLIB	125	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	44	PALBOCICLIB	125	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1100	258684004	1	Intravenous	47625008	02/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	140	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Osimertinib	40	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Osimertinib	80	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	100	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PALBOCICLIB	100	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX-R WK5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX-R WK2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	50	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	144	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRAMETINIB	2	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DABRAFENIB	100	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EXEMESTANE	25	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VENETOCLAX	400	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	4	ISATUXIMAB	590	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	120	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	46	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	35	BEVACIZUMAB - ALYMSYS	1400	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	02/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PALBOCICLIB	75	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	800	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	120	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	02/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	62	IMATINIB	100	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ACALABRUTINIB	100	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DEXAMETHASONE	10	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	62	LENALIDOMIDE	15	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	POMALIDOMIDE	2	258684004	2	Oral	26643006	02/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2300	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	25	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	2000	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DURVALUMAB	1500	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ISATUXIMAB	650	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	APIXABAN	2.5	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	62	IXAZOMIB	4	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IXAZOMIB	4	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	83	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	BEXAROTENE	300	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	700	258684004	1	Intravenous	47625008	02/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	NILOTINIB	300	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	40	IBRUTINIB	280	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	95	IBRUTINIB	280	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NILOTINIB	200	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	96	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	96	ERIBULIN	1.67	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ERIBULIN	2.02	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	THALIDOMIDE	100	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	02/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3600	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	700	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	02/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	600	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	350	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	03/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	FLUOROURACIL	700	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	700	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	90	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	890	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	336	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CETUXIMAB	900	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CETUXIMAB	800	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	CETUXIMAB	800	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CETUXIMAB	900	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	25	258684004	2	Oral	26643006	03/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C68X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1000	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C68X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	56	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	550	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	500	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ZOLEDRONIC ACID ADJ	3	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	96	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	13	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	4	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	15	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Osimertinib	80	258684004	2	Oral	26643006	03/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	Osimertinib	80	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ABEMACICLIB	150	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	165	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PANITUMUMAB	400	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	100	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PALBOCICLIB	75	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	TRAMETINIB	1	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	DABRAFENIB	75	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	71	DABRAFENIB	150	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	71	TRAMETINIB	2	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ALECTINIB	600	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	53	ALECTINIB	600	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	36	NIRAPARIB	100	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IBRUTINIB	140	258684004	2	Oral	26643006	03/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IXAZOMIB	3	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	9		99	Not known	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZOLIZUMAB >>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	350	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABOZANTINIB	40	258684004	2	Oral	26643006	03/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PANITUMUMAB	180	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	400	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	48	Nivolumab	480	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IMATINIB	400	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	400	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IMATINIB	400	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	80	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	25	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	120	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IXAZOMIB	3	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C61		9				Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	99	Not known	PEMBRO CHL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	RUXOLITINIB	15	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	OSIMERT ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Osimertinib	80	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RUXOLITINIB	5	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	750	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	90	258684004	1	Intravenous	47625008	03/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB DERUXTECAN	600	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PACHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PACHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NILOTINIB	300	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	POMALIDOMIDE	1	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	03/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THIOTEPA	54	258684004	1	Intravenous	47625008	03/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABOZANTINIB	20	258684004	2	Oral	26643006	04/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	40	PALBOCICLIB	100	258684004	2	Oral	26643006	04/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IBRUTINIB	280	258684004	2	Oral	26643006	04/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	200	258684004	2	Oral	26643006	04/02/2023	RH8
RH8	C189				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRIFLURIDINE/TIPIRACIL	70	258684004	2	Oral	26643006	04/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/02/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/02/2023	RH8
RH8	C911	98233	9		99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ACALABRUTINIB	100	258684004	2	Oral	26643006	04/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	04/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IMATINIB	200	258684004	2	Oral	26643006	04/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRAMETINIB	2	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DABRAFENIB	150	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	NIRAPARIB	100	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IMATINIB	400	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			TEPOTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEPOTINIB	450	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Erlotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	69	ERLOTINIB	50	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IBRUTINIB	420	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DASATINIB	20	258684004	2	Oral	26643006	05/02/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Fluorouracil + Mitomycin + RT (Bladder)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Fluorouracil + Mitomycin + RT (Bladder)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	24	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	890	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	216	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	67	LENALIDOMIDE	5	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	06/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	110	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	06/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	200	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	198	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	06/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABOZANTINIB	20	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABOZANTINIB	40	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	06/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/02/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	VENETOCLAX	100	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	100	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	100	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	48	BOSUTINIB	400	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	360	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ALECTINIB	600	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	13	METFORMIN	850	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIVO - MESO C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	D693		9		98	Other	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	D45	99503	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ACALABRUTINIB	100	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	06/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	Nivolumab	480	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZANUBRUTINIB	160	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ANASTROZOLE	1	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	63	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	79	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C02X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	56	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	81	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	15	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IXAZOMIB	3	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	06/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	71	RUXOLITINIB	10	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	26	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			LORLATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LORLATINIB	100	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C679		9		1	Curative – aiming to permanently eradicate the disease	GEM100 RAD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	170	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	06/02/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APIXABAN	2.5	258684004	2	Oral	26643006	06/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	49	PAZOPANIB	400	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C921	98633			99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	67	NILOTINIB	400	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C921	98633	9		98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	110	NILOTINIB	150	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	POMALIDOMIDE	4	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	06/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	06/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	65	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	06/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	240	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LIPOSOMAL DOXORUBICIN	58	258684004	1	Intravenous	47625008	07/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	FLUOROURACIL	600	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	725	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	CETUXIMAB	700	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	10	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	15	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	07/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	164	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C66		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	07/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C66		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	330	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	EMBARK-EN/PL + LE>	1	PATIENT is taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE/PLACEBO	160	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	180	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	300	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	200	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	10	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CABOZANTINIB	40	258684004	2	Oral	26643006	07/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		9				ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	07/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	125	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	07/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Osimertinib	80	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	100	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	100	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PALBOCICLIB	125	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	120	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	20	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	BOSUTINIB	500	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	APIXABAN	2.5	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2300	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	2000	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	07/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	240	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	07/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	95	IBRUTINIB	280	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	INOTUZUMAB ALL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	INOTUZUMAB OZOGAMICIN	1.7	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	D693		3	Not Applicable (Primary Treatment)	99	Not known	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	07/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ACALABRUTINIB	100	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	25	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	07/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Nivolumab	480	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C509				99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C509				99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C509				99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C509				99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	2	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	25	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	4	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	40	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	120	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	58	LENALIDOMIDE	10	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	25	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IXAZOMIB	4	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	77	RUXOLITINIB	15	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	86	AVELUMAB	800	258684004	1	Intravenous	47625008	07/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	5	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	300	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	07/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	10	NILOTINIB	150	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	07/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	67	DASATINIB	100	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	NILOTINIB	300	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IBRUTINIB	420	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	07/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TALIMOGENE LAHERPAREPVEC 10*8	4	74964007	5	Subcutaneous	34206005	07/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	9	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	07/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	630	258684004	1	Intravenous	47625008	07/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	16500	408102007	1	Intravenous	47625008	07/02/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	700	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	118	LENALIDOMIDE	10	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1400	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	36	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	128	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	260	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	100	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	4	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	08/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C49X		2	Neoadjuvant Therapy	99	Not known	Doxorubicin + Ifosfamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	2400	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	650	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	800	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	330	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C509		1	Adjuvant Therapy			Vinorelbine (oral)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	120	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB SC>9	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	120	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	47	PALBOCICLIB	75	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Osimertinib	80	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	Osimertinib	80	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PALBOCICLIB	100	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	100	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	16	VENETOCLAX	400	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	25	Nivolumab	480	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	24	NIRAPARIB	200	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 3W	1	PATIENT is taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB/PLACEBO	200	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	800	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	120	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1400	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	19	GEMCITABINE	1200	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	MITHRI RUXOL >>	1	PATIENT is taking part in a CLINICAL TRIAL	21	RUXOLITINIB	15	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	43	RIBOCICLIB	200	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AVELUMAB	800	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AXITINIB	8	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	Nivolumab	480	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Nivolumab	480	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Olaparib	100	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ACALABRUTINIB	100	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	POMALIDOMIDE	2	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	10	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	80	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C20X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2500	258684004	2	Oral	26643006	08/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1800	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	POMALIDOMIDE	2	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ISATUXIMAB	440	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ISATUXIMAB	900	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	08/02/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	26	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	08/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SCCA >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	200	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	2	Oral	26643006	08/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	650	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBROLIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ERIBULIN	1.06	258684004	1	Intravenous	47625008	08/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	800	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	450	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	550	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CETUXIMAB	900	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	CETUXIMAB	1000	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CETUXIMAB	800	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CAPECITABINE	1650	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	09/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	20	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	500	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1450	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C679				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	400	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C679				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C911	98233	9		98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	900	258684004	1	Intravenous	47625008	09/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C911	98233	9		98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAZOPANIB - RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PAZOPANIB	200	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENCORAFENIB	450	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	BINIMETINIB	30	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BINIMETINIB	45	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENCORAFENIB	200	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	59	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	59	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	40	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	52	LENALIDOMIDE	5	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PALBOCICLIB	125	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1100	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	140	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX-R WK3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	100	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	96	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	144	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	600	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C10X				99	Not known	COMPARE - ARM 5>	1	PATIENT is taking part in a CLINICAL TRIAL	2	DURVALUMAB	1500	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NIRAPARIB	200	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	222.5	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CHLORAMBUCIL	46	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABOZANTINIB	20	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	100	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	336	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	120	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	12	NINTEDANIB	150	258684004	2	Oral	26643006	09/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	600	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	600	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C844	97023	9		1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	SACITUZUMAB GOVITECAN	590	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C844	97023	9		1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C844	97023	9		1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		9				SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	300	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1400	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	09/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503			99	Not known	Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	14	BUSULFAN	40	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-DHAP/RCHOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-DHAP/RCHOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	80	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	80	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	25	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DURVALUMAB	1500	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C44X		9				Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-DHAP/RCHOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	185	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	7	IXAZOMIB	4	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	10	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABAZITAXEL	30	258684004	1	Intravenous	47625008	09/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CABAZITAXEL	36	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	26	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	9	IXAZOMIB	4	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Crizotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	34	CRIZOTINIB	250	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	SUNITINIB	50	258684004	2	Oral	26643006	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	96	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	96	ERIBULIN	1.67	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	800	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	09/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	164	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	135	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	80	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	09/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	450	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	10/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CETUXIMAB	900	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DEXAMETHASONE	10	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	LENALIDOMIDE	25	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	APIXABAN	2.5	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	700	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509				99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	96	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	120	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CISPLATIN	79	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C10		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C10		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CARBOPLATIN	560	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Bevacizumab 15mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	102	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	10/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BINIMETINIB	45	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENCORAFENIB	450	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	1.5	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	CABOZANTINIB	20	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	22	CABOZANTINIB	20	258684004	2	Oral	26643006	10/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	Osimertinib	80	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	Osimertinib	40	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	Osimertinib	40	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	45	RIBOCICLIB	400	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	52	VENETOCLAX	300	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	250	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DABRAFENIB	150	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	TRAMETINIB	2	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	40	IBRUTINIB	140	258684004	2	Oral	26643006	10/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	80	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NIRAPARIB	300	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IMATINIB	200	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C259		2	Neoadjuvant Therapy			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN	225	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C349	80463			99	Not known	LAROTRECTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	Larotrectinib	100	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			LAROTRECTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Larotrectinib	100	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C7AX				99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C259		2	Neoadjuvant Therapy			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO RESECTED >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	10/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1000	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	225	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABRAXANE C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN	450	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	10	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	80	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	120	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	51	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	20	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	5	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	25	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CAPECITABINE	2000	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	22	CAPECITABINE	1000	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-DHAP/RCHOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	3600	258684004	1	Intravenous	47625008	10/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ISATUXIMAB	900	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IXAZOMIB	4	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IXAZOMIB	3	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IXAZOMIB	3	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APIXABAN	2.5	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C829	96953	9		98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABAZITAXEL	30	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RUXOLITINIB	15	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	87	AVELUMAB	800	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	108	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	10/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	87	NILOTINIB	200	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DASATINIB	20	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NILOTINIB	400	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NILOTINIB	400	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	NILOTINIB	400	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C880	97613	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IBRUTINIB	420	258684004	2	Oral	26643006	10/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ERIBULIN	0.97	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	400	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	11/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	26	NIRAPARIB	100	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IMATINIB	400	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	IBRUTINIB	420	258684004	2	Oral	26643006	11/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	11/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	11/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	11/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	164	258684004	1	Intravenous	47625008	11/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CABOZANTINIB	20	258684004	2	Oral	26643006	12/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Osimertinib	80	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ALECTINIB	600	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IMATINIB	400	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ACALABRUTINIB	100	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IMATINIB	400	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	50	IBRUTINIB	560	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	C831	96733	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IBRUTINIB	560	258684004	2	Oral	26643006	12/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	12/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	12/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	700	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	216	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	900	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1450	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	128	258684004	1	Intravenous	47625008	13/02/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	13/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	148	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	13/02/2023	RH8
RH8	C831	96733	1	Adjuvant Therapy	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	13/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C629	90613	1	Adjuvant Therapy	99	Not known	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	1080	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CARBOPLATIN	700	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	180	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	200	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	14	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C911	98233	9		98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VENETOCLAX	400	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	13/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	AML MAINT MIDOST	2	PATIENT is not taking part in a CLINICAL TRIAL	2	MIDOSTAURIN	50	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	790	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	600	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	400	258684004	2	Oral	26643006	13/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NIRAPARIB	200	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRIFLURIDINE/TIPIRACIL	50	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PALBOCICLIB	75	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	378	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	600	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	50	BOSUTINIB	500	258684004	2	Oral	26643006	13/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D693		9		98	Other	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CARFILZOMIB	54	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	180	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CETUXIMAB	1000	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENCORAFENIB	300	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CETUXIMAB	900	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	63	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	79	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	63	258684004	1	Intravenous	47625008	13/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C02X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	56	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	80	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	Osimertinib	40	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DURVALUMAB	1500	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABAZITAXEL	40	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABAZITAXEL	54	258684004	1	Intravenous	47625008	13/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RUXOLITINIB	15	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IBRUTINIB	420	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	NILOTINIB	400	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C921	98633	9		5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NILOTINIB	400	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	13/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	13/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	164	258684004	1	Intravenous	47625008	13/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	13/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	13/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	600	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	240	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CETUXIMAB	900	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	4	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	25	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	25	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	GEMCITABINE	1000	258684004	1	Intravenous	47625008	14/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CISPLATIN	24	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	800	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Liposomal Doxorubicin 50mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LIPOSOMAL DOXORUBICIN	70	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	96	258684004	1	Intravenous	47625008	14/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	164	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C66		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C349	80423	9				ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C349	80423	9				ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C349	80423	9				ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	500	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C349	80423	9				ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	148	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AVELUMAB	800	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AXITINIB	5	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AVELUMAB	800	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AXITINIB	5	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	14/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	44	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	650	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	500	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	14/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PANITUMUMAB	260	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PALBOCICLIB	75	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	VENETOCLAX	200	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	50	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIMRDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	300	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIMRDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	90	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	38	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	14/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	3	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PALBOCICLIB	125	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	55	258684004	1	Intravenous	47625008	14/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	600	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO/IPI RCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	160	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	63	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	D693		3	Not Applicable (Primary Treatment)	99	Not known	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C917	98311	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ORAL MTX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	61	METHOTREXATE	10	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			GILTERITINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	GILTERITINIB	120	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	37	PALBOCICLIB	75	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 4>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CARFILZOMIB	54	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	14/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	2260	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	650	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	150	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DURVALUMAB	1500	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DURVALUMAB	1500	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	Brentuximab	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BRENTUXIMAB VEDOTIN	180	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABAZITAXEL	44	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	32	RUXOLITINIB	5	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - KISPLYX	14	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	375	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OXALIPLATIN	80	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C259				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EVEROLIMUS	5	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PROCARBAZINE	200	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	14/02/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	14/02/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	14/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	67	IBRUTINIB	140	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IBRUTINIB	420	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NILOTINIB	150	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LOMUSTINE	200	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	61	SUNITINIB	50	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	2	Oral	26643006	14/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	900	258684004	1	Intravenous	47625008	14/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	550	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	240	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	15/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1500	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1000	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	600	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	164	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CETUXIMAB	900	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	29	LENALIDOMIDE	15	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	41	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	71	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1400	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	50	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	36	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	15/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	800	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	450	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	500	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	180	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	240	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	32	TRASTUZUMAB-ONTRUZANT	651	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	15/02/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	180	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	5600	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C349	80423	9				ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	100	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IDARUBICIN HYDROCHLORIDE	12	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	42.5	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE-Cyc 2 + 3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	1000	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3000	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE-Cyc 2 + 3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	102	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	49	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	MERCAPTOPURINE	120	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	49	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	102	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	METHOTREXATE	40	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PALBOCICLIB	75	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	100	258684004	2	Oral	26643006	15/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ANASTROZOLE	1	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PALBOCICLIB	100	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	20	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	600	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	32	RIBOCICLIB	400	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	4	ISATUXIMAB	780	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	360	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ALECTINIB	600	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	16	METFORMIN	850	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID -Cyc1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	15/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID -Cyc1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	20	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Osimertinib	80	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1400	258684004	1	Intravenous	47625008	15/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	19	GEMCITABINE	1200	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	39	IBRUTINIB	420	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AVELUMAB	800	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AXITINIB	5	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID -Cyc1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	120	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB - EMTANSINE	360	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	5	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	450	258684004	1	Intravenous	47625008	15/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	51	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	41	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	25	CAPECITABINE	2000	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ISATUXIMAB	800	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Nivolumab	480	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IXAZOMIB	4	258684004	2	Oral	26643006	15/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OSIMERT ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Osimertinib	80	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	111	RUXOLITINIB	15	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RUXOLITINIB	15	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB DERUXTECAN	240	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	5	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	21	SUNITINIB	25	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	180	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IBRUTINIB	420	258684004	2	Oral	26643006	15/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	1.67	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ERIBULIN	1.06	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	15/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	630	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	15/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	600	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	700	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	240	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	41	LENALIDOMIDE	5	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	16/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	89	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	145	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	725	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	200	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	100	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	240	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	71	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	120	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	16/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	180	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IDARUBICIN HYDROCHLORIDE	12	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	42.5	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE-Cyc 2 + 3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE-Cyc 2 + 3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE-Cyc 2 + 3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	11600	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3000	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE-Cyc 2 + 3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	40	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	16/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	26	CAPECITABINE	1000	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	49	PALBOCICLIB	100	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	140	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	44	PALBOCICLIB	75	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PALBOCICLIB	100	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C911	98233	9		99	Not known	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	24	VENETOCLAX	300	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX-R WK4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	200	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	144	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	96	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRAMETINIB	2	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DABRAFENIB	150	258684004	2	Oral	26643006	16/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	TRAMETINIB	2	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DABRAFENIB	150	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	600	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	400	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	4	ISATUXIMAB	590	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	BOSUTINIB	500	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	200	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	800	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	100	258684004	2	Oral	26643006	16/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	100	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PALBOCICLIB	125	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	51	VENETOCLAX	200	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	51	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ACALABRUTINIB	100	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ACALABRUTINIB	100	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1400	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	84	Nivolumab	480	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	450	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NIRAPARIB	200	258684004	2	Oral	26643006	16/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	50	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Panobinostat	15	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1450	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CAPECITABINE	2150	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ISATUXIMAB	650	258684004	1	Intravenous	47625008	16/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	128	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZ MTC -	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CABOZANTINIB	100	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	88	RUXOLITINIB	5	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CARBO BR CA	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RUXOLITINIB	15	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	700	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	128	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	26	SUNITINIB	25	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	26	NILOTINIB	400	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IBRUTINIB	420	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IBRUTINIB	420	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ERIBULIN	2.02	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C349	80463	9				PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THALIDOMIDE	100	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	16/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	16/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	700	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	200	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	120	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	68	258684004	1	Intravenous	47625008	16/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	360	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	198	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LIPOSOMAL DOXORUBICIN	62	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	350	258684004	1	Intravenous	47625008	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	600	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	700	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OXALIPLATIN	90	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CETUXIMAB	900	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CETUXIMAB	800	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CETUXIMAB	900	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	25	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	550	258684004	1	Intravenous	47625008	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	800	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	500	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	167	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	FLUOROURACIL	700	258684004	1	Intravenous	47625008	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	CETUXIMAB	800	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C719		1	Adjuvant Therapy	99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	5600	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	100	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IDARUBICIN HYDROCHLORIDE	12	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	42.5	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3000	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE-Cyc 2 + 3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	4	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DEXAMETHASONE	4	258684004	2	Oral	26643006	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	80	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	27	CABOZANTINIB	20	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q 28D>1	2	PATIENT is not taking part in a CLINICAL TRIAL	77	LENALIDOMIDE	5	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	20	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	37	PALBOCICLIB	75	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	48	PALBOCICLIB	100	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PANITUMUMAB	400	258684004	1	Intravenous	47625008	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABEMACICLIB	100	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	Osimertinib	80	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	100	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	400	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BOSUTINIB	200	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IXAZOMIB	2.3	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C20				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRIFLURIDINE/TIPIRACIL	55	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C259		2	Neoadjuvant Therapy			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN	225	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100 X 3 - 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	900	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	350	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PANITUMUMAB	180	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PALBOCICLIB	125	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C259		2	Neoadjuvant Therapy			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	400	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	216	258684004	1	Intravenous	47625008	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	SACITUZUMAB GOVITECAN	630	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM MAIN 200 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C7AX		9		99	Not known	CAPE + TEMOZOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1000	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IMATINIB	400	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB-ONTRUZANT	378	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Olaparib - PS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	300	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	146	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	93	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2150	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1650	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	120	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	Nivolumab	480	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	Nivolumab	480	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CABAZITAXEL	36	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	RUXOLITINIB	5	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	RUXOLITINIB	10	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			TEPOTINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TEPOTINIB	450	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	650	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	750	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	800	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	10	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C259		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	110	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	90	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	OXALIPLATIN	165	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			Ipilimumab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	250	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APIXABAN	2.5	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	THALIDOMIDE	100	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	17/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	164	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	17/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ERIBULIN	0.97	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	17/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DEXAMETHASONE	10	258684004	2	Oral	26643006	18/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	84	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	18/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	15	258684004	2	Oral	26643006	18/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/02/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/02/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	18/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE 90 CYC1	2	PATIENT is not taking part in a CLINICAL TRIAL	52	IMATINIB	400	258684004	2	Oral	26643006	18/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ACALABRUTINIB	100	258684004	2	Oral	26643006	18/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CABOZANTINIB	40	258684004	2	Oral	26643006	19/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/02/2023	RH8
RH8	C7AX				99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TEMOZOLOMIDE	375	258684004	2	Oral	26643006	19/02/2023	RH8
RH8	D475		3	Not Applicable (Primary Treatment)	98	Other	IMAT CEL/HES>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	100	258684004	2	Oral	26643006	19/02/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	IBRUTINIB	420	258684004	2	Oral	26643006	19/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Fluorouracil + Mitomycin + RT (Bladder)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	20	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	5	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	5	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	20/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	180	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	200	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C49X		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	180	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	96	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	20/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	80	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	80	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	Osimertinib	80	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	125	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	100	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	125	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	63	TRAMETINIB	1.5	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	63	DABRAFENIB	100	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	100	258684004	2	Oral	26643006	20/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	TRAMETINIB	2	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DABRAFENIB	150	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NIRAPARIB	100	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C921	98633	9		98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IMATINIB	400	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	20/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	400	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NIRAPARIB	200	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	INOTUZUMAB ALL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	INOTUZUMAB OZOGAMICIN	1.1	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Melphalan oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MELPHALAN	16	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	400	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	9		98	Other	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZANUBRUTINIB	80	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	63	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	63	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	79	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C02X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	56	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	GILTERITINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GILTERITINIB	120	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1950	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	20/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAUNORUBICIN	110	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	21	RUXOLITINIB	10	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	D45X	99503	9		98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	23	RUXOLITINIB	15	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	180	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	5	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Panobinostat	20	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	36	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	20/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	37	IBRUTINIB	420	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	31	NILOTINIB	200	258684004	2	Oral	26643006	20/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ETOPOSIDE	180	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	750	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	750	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	164	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	20/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	20/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	96	258684004	1	Intravenous	47625008	20/02/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	790	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C900		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	112	LENALIDOMIDE	10	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	76	LENALIDOMIDE	15	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C20X				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2000	258684004	2	Oral	26643006	21/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	225	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	180	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	100	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TEMOZOLOMIDE	380	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	21/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	89	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	79	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	21/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	75	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	21/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C931	99803	3	Not Applicable (Primary Treatment)			HYD AML/CML 3/4>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	40	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	21/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	75	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	100	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	336	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	108	258684004	1	Intravenous	47625008	21/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	21	METFORMIN	850	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	14	METFORMIN	850	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	2000	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	130	258684004	5	Subcutaneous	34206005	21/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	240	258684004	1	Intravenous	47625008	21/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C252				99	Not known	EVEROLIMUS NET>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EVEROLIMUS	5	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	100	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	600	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	63	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BOSUTINIB	400	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ACALABRUTINIB	100	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	120	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	87	AVELUMAB	800	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PAC ALB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	21/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	16	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	76	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	2000	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C44X		9				Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RUXOLITINIB	15	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	RUXOLITINIB	20	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	180	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		9				MET PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	21/02/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	750	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	99	Not known	ASCIMINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ASCIMINIB	80	258684004	2	Oral	26643006	21/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PAZOPANIB	600	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	21/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	36	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	164	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	21/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	31	NILOTINIB	200	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ETOPOSIDE	180	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	21/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TALIMOGENE LAHERPAREPVEC 10*8	4	74964007	5	Subcutaneous	34206005	21/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	21/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THALIDOMIDE	100	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	21/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	164	258684004	1	Intravenous	47625008	21/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	2	Oral	26643006	21/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	550	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	790	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C900	97323	9				Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	10	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	650	258684004	1	Intravenous	47625008	22/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	600	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	15	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	9				Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	25	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	135	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	110	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	50	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	50	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	45	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	22/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	550	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	650	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	100	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	22/02/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C21		3	Not Applicable (Primary Treatment)			Capecitabine + Cisplatin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C21		3	Not Applicable (Primary Treatment)			Capecitabine + Cisplatin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	22/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	25	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	22/02/2023	RH8
RH8	C32		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVOLUMAB - H + N	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB SC>9	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	22/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	22/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	49	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	49	FLUOROURACIL	650	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	22/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	Osimertinib	40	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	61	PALBOCICLIB	100	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	890	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	49	PANITUMUMAB	500	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VENETOCLAX	400	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	50	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EVEROLIMUS	7.5	258684004	2	Oral	26643006	22/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EXEMESTANE	25	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	200	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	BOSUTINIB	100	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	24	NIRAPARIB	300	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	Nivolumab	360	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	22/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID -Cyc1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	22/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C189				99	Not known	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C01X				99	Not known	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1150	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	130	258684004	5	Subcutaneous	34206005	22/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	19	GEMCITABINE	1200	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	200	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	PONATINIB - C3>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PONATINIB	15	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ACALABRUTINIB	100	258684004	2	Oral	26643006	22/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	120	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	120	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	3600	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	77	Olaparib	200	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	400	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Olaparib	200	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IBRUTINIB	280	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	D473	99623			99	Not known	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	10	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	120	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	118	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	80	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	41	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	5	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2500	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2750	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	POMALIDOMIDE	3	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ISATUXIMAB	1000	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ISATUXIMAB	440	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ISATUXIMAB	900	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	APIXABAN	2.5	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IXAZOMIB	2.3	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAUNORUBICIN	110	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	180	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	BEXAROTENE	225	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB UC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AVELUMAB	800	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AVELUMAB	800	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	10	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C44X		9		98	Other	Vismodegib	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VISMONDEGIB	150	258684004	2	Oral	26643006	22/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	APIXABAN	2.5	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	36	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	51	NILOTINIB	300	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SUNITINIB	25	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IBRUTINIB	420	258684004	2	Oral	26643006	22/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ETOPOSIDE	180	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	1.06	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	164	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	22/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DACARBAZINE	630	258684004	1	Intravenous	47625008	22/02/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	17500	408102007	1	Intravenous	47625008	22/02/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	FLUOROURACIL	800	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	550	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2000	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	CETUXIMAB	1000	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	21	CETUXIMAB	800	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	113	258684004	1	Intravenous	47625008	23/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	10	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	29	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1650	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	350	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	890	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	300	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	23/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CABOZANTINIB	20	258684004	2	Oral	26643006	23/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	140	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	50	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX-R WK5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	96	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	600	258684004	2	Oral	26643006	23/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	400	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	96	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C921	98633	9		99	Not known	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BOSUTINIB	200	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	19	METFORMIN	850	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IMATINIB	400	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	400	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	50	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C900	97323	9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	36	BEVACIZUMAB - ALYMSYS	1400	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	POLATUZUMAB VEDOTIN	140	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CHLORAMBUCIL	46	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1150	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	150	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1500	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	300	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IBRUTINIB	420	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AVELUMAB	800	258684004	1	Intravenous	47625008	23/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	120	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C349	80463	9				CERITINIB SUB>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	CERITINIB	300	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PEMETREXED	1000	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	19	RIBOCICLIB	200	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IBRUTINIB	560	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	40	258684004	2	Oral	26643006	23/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2300	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CAPECITABINE	2000	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	25	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	6	IXAZOMIB	4	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	2000	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXRAZOXANE	1240	258684004	1	Intravenous	47625008	23/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	62	RUXOLITINIB	25	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	39	RUXOLITINIB	10	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	D015				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	36	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	40	IBRUTINIB	140	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IBRUTINIB	420	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	97	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ETOPOSIDE	180	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	97	ERIBULIN	1.67	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ERIBULIN	2.02	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL ALBUMIN BOUND	500	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	23/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	23/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	164	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	23/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	96	258684004	1	Intravenous	47625008	23/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	450	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CETUXIMAB	900	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	10	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	38	LENALIDOMIDE	15	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	700	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	24/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	800	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	700	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	97	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1800	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FCR Oral - Cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUDARABINE PHOSPHATE	90	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FCR Oral - Cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	1000	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	FCR Oral - Cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	550	258684004	2	Oral	26643006	24/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	14	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENCORAFENIB	250	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BINIMETINIB	30	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	43	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C931	99803	3	Not Applicable (Primary Treatment)			HYD AML/CML 3/4>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C349	80463	9				PEMBRO428 6WK C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	100	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	125	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	100	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PALBOCICLIB	125	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C911	98233			98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	TRAMETINIB	2	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DABRAFENIB	150	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	13	NIRAPARIB	100	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL.	2	PATIENT is not taking part in a CLINICAL TRIAL	45	IBRUTINIB	420	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ALECTINIB	600	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NIRAPARIB	200	258684004	2	Oral	26643006	24/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	200	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	24/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	130	258684004	5	Subcutaneous	34206005	24/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	100	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRAMETINIB	2	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C349	80463	9				NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NINTEDANIB	200	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C259		9				GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	225	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ACALABRUTINIB	100	258684004	2	Oral	26643006	24/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C259		9				GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	39	PALBOCICLIB	100	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C259		9				GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THIOTEPA	54	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IMATINIB	400	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IMATINIB	400	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IMATINIB	400	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZOLIZUMAB>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	24/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	40	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C06X		3	Not Applicable (Primary Treatment)			PEMBRO H + N	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DEXAMETHASONE	40	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	25	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	57	LENALIDOMIDE	15	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	15	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	15	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	24/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	LENALIDOMIDE	25	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IXAZOMIB	4	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	57	IXAZOMIB	3	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IXAZOMIB	3	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IXAZOMIB	4	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IXAZOMIB	4	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	51	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	51	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAUNORUBICIN	110	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	180	258684004	1	Intravenous	47625008	24/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	88	AVELUMAB	800	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/02/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C680				99	Not known	XELOX UROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C680				99	Not known	XELOX UROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	260	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Treosulfan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TREOSULFAN	500	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	24/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	58	PAZOPANIB	600	258684004	2	Oral	26643006	24/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	36	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ETOPOSIDE	180	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	164	258684004	1	Intravenous	47625008	24/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	Osimertinib	80	258684004	2	Oral	26643006	25/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	25/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	CABOZANTINIB	20	258684004	2	Oral	26643006	25/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	CABOZANTINIB	40	258684004	2	Oral	26643006	25/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	45	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/02/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP (RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	2	Oral	26643006	25/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/02/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CABOZANTINIB	20	258684004	2	Oral	26643006	26/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	Osimertinib	80	258684004	2	Oral	26643006	26/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IMATINIB	300	258684004	2	Oral	26643006	26/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Osimertinib	80	258684004	2	Oral	26643006	26/02/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DASATINIB	100	258684004	2	Oral	26643006	26/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	IBRUTINIB	140	258684004	2	Oral	26643006	26/02/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Fluorouracil + Mitomycin + RT (Bladder)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	890	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	216	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	500	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	216	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CETUXIMAB	800	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	27/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	40	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	500	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	900	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	70	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MELPHALAN	220	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	195	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TEMOZOLOMIDE	330	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C09X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	200	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	180	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	220	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	96	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	198	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	550	258684004	1	Intravenous	47625008	27/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/02/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	125	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	Osimertinib	40	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	125	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PANITUMUMAB	340	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Osimertinib	80	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	100	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	27/02/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	27/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IBRUTINIB	420	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C349	80463	9		99	Not known	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ALECTINIB	450	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IMATINIB	400	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IMATINIB	400	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	25	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	15	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	130	258684004	5	Subcutaneous	34206005	27/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CARFILZOMIB	54	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	27/02/2023	RH8
RH8	C509				99	Not known	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RIBOCICLIB	400	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	27/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	800	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	27/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NINTEDANIB	200	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RIBOCICLIB	400	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	70	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	26	NIRAPARIB	100	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS UNFIT >	1	PATIENT is taking part in a CLINICAL TRIAL	12	IXAZOMIB	4	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	INOTUZUMAB ALL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	INOTUZUMAB OZOGAMICIN	1.1	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENCORAFENIB	300	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	27/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	900	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CETUXIMAB	1000	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	400	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CETUXIMAB	900	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	63	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	79	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C02X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	56	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	D473	99623			99	Not known	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	D473	99623			98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	10	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	30	CAPECITABINE	1300	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	15	258684004	2	Oral	26643006	27/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	APIXABAN	2.5	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IXAZOMIB	2.3	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	64	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	120	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	180	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AVELUMAB	800	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	10	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PROCARBAZINE	200	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LOMUSTINE	200	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	10	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	POMALIDOMIDE	3	258684004	2	Oral	26643006	27/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	APIXABAN	2.5	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/02/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THALIDOMIDE	100	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	1440	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3600	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	27/02/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	108	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	27/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	65	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	27/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	28/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	FLUOROURACIL	600	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	600	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	CETUXIMAB	700	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CETUXIMAB	900	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	10	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	79	LENALIDOMIDE	5	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	15	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	28/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	36	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	800	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	180	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	164	258684004	1	Intravenous	47625008	28/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	330	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	180	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	600	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AVELUMAB	800	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AVELUMAB	800	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	5	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	500	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PANITUMUMAB	260	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Osimertinib	80	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	100	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	200	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	28/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	400	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IMATINIB	200	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C900	97323	9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	130	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CARFILZOMIB	54	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	336	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	200	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	63	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	Nivolumab	480	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AVELUMAB	800	258684004	1	Intravenous	47625008	28/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AXITINIB	5	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C911	98233	1	Adjuvant Therapy			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SACITUZUMAB GOVITECAN	880	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	15	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL (C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DURVALUMAB	1500	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IXAZOMIB	4	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IXAZOMIB	4	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C829	96913	1	Adjuvant Therapy	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	RUXOLITINIB	10	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Olaparib	300	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	9	IXAZOMIB	4	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ADJ PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	375	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OXALIPLATIN	80	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C179				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	3.3	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PROCARBAZINE	200	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	THALIDOMIDE	50	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	28/02/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NILOTINIB	200	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LOMUSTINE	200	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	9	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CHLORAMBUCIL	10	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PROCARBAZINE	150	258684004	2	Oral	26643006	28/02/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3600	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	1440	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	108	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/02/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	28/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	99	Not known	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	99	Not known	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	99	Not known	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	96	258684004	1	Intravenous	47625008	28/02/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	500	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	600	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	01/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CETUXIMAB	900	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CETUXIMAB	900	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	480	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DEXAMETHASONE	20	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	5	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900				98	Other	Lenalidomide 10mg (Cycle 1 to 25)	1	PATIENT is taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	5	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1400	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	45	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	01/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1650	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2200	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	550	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	240	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	01/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	260	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	128	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	100	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	01/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C00X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C00X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	330	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	55	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3600	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	01/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC CATCH UP RIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	350	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	MERCAPTOPURINE	120	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	10	258684004	2	Oral	26643006	01/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	40	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	120	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	METHOTREXATE	40	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	Osimertinib	40	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	75	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	45	PALBOCICLIB	125	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	100	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	600	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	4	ISATUXIMAB	780	258684004	1	Intravenous	47625008	01/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IMATINIB	400	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	01/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID -Cyc1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	01/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C159		9				PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	800	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C159		9				PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	130	258684004	5	Subcutaneous	34206005	01/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	120	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C159		9				PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NINTEDANIB	200	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	39	RIBOCICLIB	400	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AVELUMAB	800	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO*	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ACALABRUTINIB	100	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	120	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IMATINIB	400	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	900	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/03/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	23	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	80	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	80	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	POMALIDOMIDE	3	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1450	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	10	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ISATUXIMAB	800	258684004	1	Intravenous	47625008	01/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NINTEDANIB	200	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	Nivolumab	480	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C848	97183	9		98	Other	Brentuximab	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BRENTUXIMAB VEDOTIN	100	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PEMBRO CHL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	15	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	01/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	8	IXAZOMIB	4	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	4	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	4	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMETREXED	900	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	650	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C921	98633			99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	69	NILOTINIB	300	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IBRUTINIB	560	258684004	2	Oral	26643006	01/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	1	Adjuvant Therapy	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	26	NILOTINIB	300	258684004	2	Oral	26643006	01/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ERIBULIN	1.06	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IFOSFAMIDE	1440	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R IVAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	108	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	630	258684004	1	Intravenous	47625008	01/03/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1650	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	10	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	128	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1450	258684004	2	Oral	26643006	02/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C679				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C679				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	55	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3600	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	400	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC CATCH UP RIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	350	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	02/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMG>4	1	PATIENT is taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	700	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	120	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	49	PALBOCICLIB	100	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	52	PALBOCICLIB	125	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	140	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PALBOCICLIB	100	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PALBOCICLIB	100	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PALBOCICLIB	75	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	100	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRAMETINIB	2	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DABRAFENIB	100	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EXEMESTANE	25	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VENETOCLAX	400	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	5	ISATUXIMAB	580	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	96	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	FLAIR - IBRUT MA	1	PATIENT is taking part in a CLINICAL TRIAL	19	IBRUTINIB	420	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	POLATUZUMAB VEDOTIN	152	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C23		1	Adjuvant Therapy	99	Not known	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1500	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	02/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	350	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PALBOCICLIB	75	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PANITUMUMAB	180	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO and FULV 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	600	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	PONATINIB - C3>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PONATINIB	30	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ACALABRUTINIB	100	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	800	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	02/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	400	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IMATINIB	400	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DEXAMETHASONE	10	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	120	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	POMALIDOMIDE	2	258684004	2	Oral	26643006	02/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	63	LENALIDOMIDE	15	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	25	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DURVALUMAB	1500	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ISATUXIMAB	650	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	63	IXAZOMIB	4	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	APIXABAN	2.5	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IXAZOMIB	4	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	84	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	700	258684004	1	Intravenous	47625008	02/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	209	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	NILOTINIB	300	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	IBRUTINIB	280	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NILOTINIB	200	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	800	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	02/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DACARBAZINE	700	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	02/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	34	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	600	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	350	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	34	FLUOROURACIL	700	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	34	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	700	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OXALIPLATIN	90	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CETUXIMAB	800	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CETUXIMAB	900	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	34	CETUXIMAB	800	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C20X		9				Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CETUXIMAB	900	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CAPECITABINE	1650	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	25	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	36	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	2000	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	550	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	500	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	250	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1800	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	120	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	2	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C10X		9				CISPLATIN + FLUOROURACIL	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CISPLATIN	79	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	4	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	120	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2500	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	15	258684004	2	Oral	26643006	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PANITUMUMAB	400	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	165	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PALBOCICLIB	75	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	100	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	TRAMETINIB	1	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	DABRAFENIB	75	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	250	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ALECTINIB	600	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	54	ALECTINIB	600	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	37	NIRAPARIB	100	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL.	2	PATIENT is not taking part in a CLINICAL TRIAL	41	IBRUTINIB	420	258684004	2	Oral	26643006	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	80	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IXAZOMIB	2.3	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	47	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C900	97323	9		99	Not known	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1500	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PALBOCICLIB	100	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	23	RIBOCICLIB	200	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	216	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NINTEDANIB	200	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	400	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	49	Nivolumab	480	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C259		9				GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	225	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C259		9				GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		9				GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C920	98733	9		98	Other	VEN/LD CYT19>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CYTARABINE	36	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C920	98733	9		98	Other	VEN/LD CYT19>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VENETOCLAX	100	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	Nivolumab	480	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	46	IMATINIB	400	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN	180	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C349	80463	9				PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C349	80463	9				PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C349	80463	9				PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IBRUTINIB	560	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABRAXANE>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL ALBUMIN	450	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	80	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CAPECITABINE	2000	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	25	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2000	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	23	CAPECITABINE	1000	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OXALIPLATIN	120	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IXAZOMIB	3	258684004	2	Oral	26643006	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - KISPLYX	14	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	RUXOLITINIB	15	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RUXOLITINIB	5	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EVEROLIMUS	5	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	800	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	OXALIPLATIN	165	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C172X				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	03/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	SUNITINIB	50	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NILOTINIB	300	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	03/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IBRUTINIB	420	258684004	2	Oral	26643006	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	97	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	97	ERIBULIN	1.67	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	Osimertinib	40	258684004	2	Oral	26643006	04/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Osimertinib	80	258684004	2	Oral	26643006	04/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ACALABRUTINIB	100	258684004	2	Oral	26643006	04/03/2023	RH8
RH8	C911	98233	9		99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	04/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	04/03/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	63	IMATINIB	100	258684004	2	Oral	26643006	04/03/2023	RH8
RH8	D473	99623			98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Osimertinib	80	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DABRAFENIB	150	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRAMETINIB	2	258684004	2	Oral	26643006	05/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IMATINIB	400	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C921	98633	9		99	Not known	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	200	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CABOZANTINIB	40	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IBRUTINIB	280	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	NIRAPARIB	100	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IMATINIB	400	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IMATINIB	400	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	400	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C911	98233	9		1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	OSIMERT ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Osimertinib	80	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	28	IBRUTINIB	420	258684004	2	Oral	26643006	05/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LIPOSOMAL DOXORUBICIN	58	258684004	1	Intravenous	47625008	06/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	68	LENALIDOMIDE	5	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	800	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1450	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	80	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	198	258684004	1	Intravenous	47625008	06/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C837	96873	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	4	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	06/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	180	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	15	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	220	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RAD MELPH HD RDE	1	PATIENT is taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	790	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	790	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	VENETOCLAX	100	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C459		9		99	Not known	NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	75	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	225	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	100	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	06/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C459		9		99	Not known	NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	80	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ALECTINIB	600	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RAD MELPH HD RDE	1	PATIENT is taking part in a CLINICAL TRIAL	5	MELPHALAN	335	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	ENRICH-RITUX + I	1	PATIENT is taking part in a CLINICAL TRIAL	10	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	ENRICH-RITUX + I	1	PATIENT is taking part in a CLINICAL TRIAL	10	IBRUTINIB	420	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C749		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MITOTANE 4.5-9.0	2	PATIENT is not taking part in a CLINICAL TRIAL	13	MITOTANE	500	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C749		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MITOTANE 4.5-9.0	2	PATIENT is not taking part in a CLINICAL TRIAL	13	MITOTANE	1000	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C509				99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1400	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IBRUTINIB	280	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIVO - MESO C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	Nivolumab	480	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	63	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	06/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	2560	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	82	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	15	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	440	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IXAZOMIB	3	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	06/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	72	RUXOLITINIB	10	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABAZITAXEL	54	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	27	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	10	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APIXABAN	2.5	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C921	98633	9		98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	111	NILOTINIB	150	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C169		9				Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	SUNITINIB	50	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/03/2023	RH8
RH8	C900	97323	9		98	Other	POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	06/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POMALIDOMIDE	4	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C900	97323	9		98	Other	POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	06/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	06/03/2023	RH8
RH8	C509		9		99	Not known	Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB - EMTANSINE	180	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LIPOSOMAL DOXORUBICIN	58	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	725	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	10	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	600	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	15	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	120	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	07/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	36	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C051				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C051				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	240	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	180	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	164	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEMOZOLOMIDE	150	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ERLOTINIB 2MTH +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ERLOTINIB	150	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	07/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	650	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RAD MELPH HD RDE	1	PATIENT is taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	10	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C61		9				ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	50	PALBOCICLIB	75	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	125	258684004	2	Oral	26643006	07/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	100	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PALBOCICLIB	125	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	BOSUTINIB	500	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	APIXABAN	2.5	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C509				99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509				99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C01X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C509				99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509				99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	378	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	600	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	63	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	13	BOSUTINIB	200	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PALBOCICLIB	125	258684004	2	Oral	26643006	07/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Nivolumab	480	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Etoposide oral	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	50	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IMATINIB	400	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	50	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	10	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	4	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	120	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	15	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	59	LENALIDOMIDE	10	258684004	2	Oral	26643006	07/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	25	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C509		9		99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CAPECITABINE	2000	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	120	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DACARBAZINE	560	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	440	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IXAZOMIB	4	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IXAZOMIB	4	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)			LENVATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - LENVIMA	24	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABAZITAXEL	44	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABAZITAXEL	40	258684004	1	Intravenous	47625008	07/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	27	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	78	RUXOLITINIB	15	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			TEPOTINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEPOTINIB	450	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	88	AVELUMAB	800	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	750	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	5	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Erlotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	70	ERLOTINIB	50	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	07/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	07/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	NILOTINIB	150	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	07/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	40	NILOTINIB	300	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DASATINIB	20	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TALIMOGENE LAHERPAREPVEC 10*8	4	74964007	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	900	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	9	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	07/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	07/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	108	258684004	1	Intravenous	47625008	07/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	550	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	240	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	240	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	08/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	72	LENALIDOMIDE	10	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	119	LENALIDOMIDE	10	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	650	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	600	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	135	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	120	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	320	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	700	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	240	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	08/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	33	TRASTUZUMAB-ONTRUZANT	651	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	08/03/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	180	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	4	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	1000	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	08/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	6300	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	100	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	08/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	08/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	35	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABOZANTINIB	20	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CABOZANTINIB	40	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	120	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	80	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	08/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	48	PALBOCICLIB	75	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Osimertinib	80	258684004	2	Oral	26643006	08/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PALBOCICLIB	100	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	125	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	100	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	200	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	17	VENETOCLAX	400	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IPILIMUMAB	85	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	26	Nivolumab	480	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	360	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	25	NIRAPARIB	200	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IMATINIB	400	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID -Cyc1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	08/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C189				99	Not known	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C10		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	44	RIBOCICLIB	200	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	MITHRI RUXOL >	1	PATIENT is taking part in a CLINICAL TRIAL	22	RUXOLITINIB	15	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Nivolumab	480	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Nivolumab	480	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Olaparib	100	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	08/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	2260	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZANUBRUTINIB	160	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	POMALIDOMIDE	2	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	360	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	10	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	10	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	40	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	80	258684004	2	Oral	26643006	08/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POMALIDOMIDE	4	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	POMALIDOMIDE	2	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	26	CAPECITABINE	2000	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DACARBAZINE	560	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ISATUXIMAB	1000	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ISATUXIMAB	440	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ISATUXIMAB	900	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	440	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C189				99	Not known	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	Nivolumab	480	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB UC-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	08/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AXITINIB	5	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	27	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	08/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			LORLATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LORLATINIB	100	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Dabrafenib	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DABRAFENIB	50	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C183X				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	08/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL ALBUMIN	400	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	50	PAZOPANIB	400	258684004	2	Oral	26643006	08/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	180	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	300	258684004	2	Oral	26643006	08/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509				99	Not known	THP (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	08/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509				99	Not known	THP (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ERIBULIN	1.67	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ERIBULIN	1.06	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	135	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DACARBAZINE	630	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	96	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	80	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	17500	408102007	1	Intravenous	47625008	08/03/2023	RH8
RH8	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	08/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	08/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	240	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	FLUOROURACIL	800	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	FLUOROURACIL	550	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	CETUXIMAB	1000	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	22	CETUXIMAB	800	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	09/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	89	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	72	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	09/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	120	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C911	98233	9		98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	900	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C911	98233	9		98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide + RT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	150	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BINIMETINIB	45	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENCORAFENIB	450	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	BINIMETINIB	30	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENCORAFENIB	200	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C64		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C64		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AXITINIB	5	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	09/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	60	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	60	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	40	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	53	LENALIDOMIDE	5	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	27	CAPECITABINE	1000	258684004	2	Oral	26643006	09/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CABOZANTINIB	40	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PALBOCICLIB	125	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	100	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	790	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	140	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Osimertinib	80	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	200	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	100	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C10X				99	Not known	COMPARE - ARM 5>	1	PATIENT is taking part in a CLINICAL TRIAL	3	DURVALUMAB	1500	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	49	BOSUTINIB	400	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	96	IBRUTINIB	280	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	88	258684004	1	Intravenous	47625008	09/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	NIRAPARIB	200	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	222.5	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	70	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PALBOCICLIB	100	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	13	NINTEDANIB	150	258684004	2	Oral	26643006	09/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AVELUMAB	800	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AXITINIB	8	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	52	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	400	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	450	258684004	1	Intravenous	47625008	09/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BINIMETINIB	45	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENCORAFENIB	450	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	360	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	80	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Panobinostat	15	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1500	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CAPECITABINE	2150	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	25	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	09/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	8	IXAZOMIB	4	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	1780	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	10	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABAZITAXEL	30	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXRAZOXANE	1140	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	27	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	10	IXAZOMIB	4	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C254X				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	68	DASATINIB	100	258684004	2	Oral	26643006	09/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	88	NILOTINIB	200	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PROCARBAZINE	200	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	10	258684004	2	Oral	26643006	09/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	09/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	164	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	96	258684004	1	Intravenous	47625008	09/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	360	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	198	258684004	1	Intravenous	47625008	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	450	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CETUXIMAB	900	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DEXAMETHASONE	20	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	700	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	29	LENALIDOMIDE	25	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	36	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	29	APIXABAN	2.5	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	800	258684004	1	Intravenous	47625008	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	168	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1800	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C10		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C10		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CARBOPLATIN	560	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	6300	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BINIMETINIB	45	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENCORAFENIB	450	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C349	80463	9				ERLOTINIB 2MTH +	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ERLOTINIB	50	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	55	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	80	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Osimertinib	80	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	Osimertinib	80	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	46	RIBOCICLIB	400	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C459		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	65	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	53	VENETOCLAX	300	258684004	2	Oral	26643006	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	96	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	72	TRAMETINIB	2	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	72	DABRAFENIB	150	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	TRAMETINIB	2	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DABRAFENIB	150	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C459		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	NIRAPARIB	300	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	23	METFORMIN	850	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	222.5	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C259				99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1500	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	600	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	600	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO RESECTED >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IBRUTINIB	140	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	SACITUZUMAB GOVITECAN	630	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB-ONTRUZANT	378	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN	180	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	450	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	400	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	360	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	147	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	52	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	120	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	80	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	25	258684004	2	Oral	26643006	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	5	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	25	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	2150	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CAPECITABINE	1300	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1800	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IXAZOMIB	4	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IXAZOMIB	3	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APIXABAN	2.5	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IXAZOMIB	4	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CABAZITAXEL	36	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	120	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	27	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RUXOLITINIB	15	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			Ipilimumab	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	250	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	180	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NILOTINIB	400	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NILOTINIB	400	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	NILOTINIB	200	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	19	NILOTINIB	400	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C880	97613	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IBRUTINIB	420	258684004	2	Oral	26643006	10/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ERIBULIN	2.02	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	900	258684004	1	Intravenous	47625008	10/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	800	258684004	1	Intravenous	47625008	10/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	400	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CABOZANTINIB	20	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	27	NIRAPARIB	100	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Crizotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	35	CRIZOTINIB	250	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PAZOPANIB	200	258684004	2	Oral	26643006	11/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	46	IBRUTINIB	420	258684004	2	Oral	26643006	11/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	23	CABOZANTINIB	20	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	Osimertinib	40	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	Osimertinib	80	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Osimertinib	40	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ALECTINIB	600	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	51	IBRUTINIB	560	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DASATINIB	40	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DASATINIB	20	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	C831	96733	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IBRUTINIB	560	258684004	2	Oral	26643006	12/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	13/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	216	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	21	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	500	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CETUXIMAB	800	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1400	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	33	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C20		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C20		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	500	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C20		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	900	258684004	1	Intravenous	47625008	13/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	360	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	700	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	180	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	6300	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C66		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1400	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C66		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	300	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	13/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C911	98233	9		98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VENETOCLAX	400	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	220	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB - EMTANSINE	160	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	INOTUZUMAB CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	INOTUZUMAB OZOGAMICIN	1.7	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	13/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	48	PALBOCICLIB	75	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	AML MAINT MIDOST	2	PATIENT is not taking part in a CLINICAL TRIAL	3	MIDOSTAURIN	50	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	790	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	600	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	400	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	13/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	96	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	51	BOSUTINIB	500	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1400	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CARFILZOMIB	54	258684004	1	Intravenous	47625008	13/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PALBOCICLIB	75	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	125	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENCORAFENIB	300	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	13/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CETUXIMAB	1000	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CETUXIMAB	900	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IMATINIB	400	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	2560	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PROCARBAZINE	200	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	63	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	50	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	440	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	19	BUSULFAN	30	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			AVELUMAB>4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AVELUMAB	800	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	80	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	2000	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1950	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1000	258684004	2	Oral	26643006	13/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	120	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61X		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	80	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DURVALUMAB	1500	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL (C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DURVALUMAB	1500	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DURVALUMAB	1500	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	21250		1	Intravenous	47625008	13/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	128	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	RUXOLITINIB	15	258684004	2	Oral	26643006	13/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	336	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	2	ACALABRUTINIB	100	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	33	IBRUTINIB	420	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	NILOTINIB	400	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	13/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	13/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	13/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	164	258684004	1	Intravenous	47625008	13/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	FLUOROURACIL	600	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	600	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CETUXIMAB	700	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CETUXIMAB	900	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	30	LENALIDOMIDE	15	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	25	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	14/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	145	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	800	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Liposomal Doxorubicin 50mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LIPOSOMAL DOXORUBICIN	70	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	180	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	70	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	100	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C349	80423	9				ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C349	80423	9				ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C349	80423	9				ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C349	80423	9				ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	148	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	45	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	14/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CAPECITABINE	1800	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C917	98311	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ORAL MTX -RDE C1	2	PATIENT is not taking part in a CLINICAL TRIAL	62	METHOTREXATE	10	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	500	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	38	PALBOCICLIB	75	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PANITUMUMAB	260	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	14/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Osimertinib	80	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	VENETOCLAX	200	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	175	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	336	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TUCATINIB	250	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	58	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IMATINIB	200	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	39	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	14/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	4	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C349	80463	9				PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1500	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Osimertinib	80	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CARFILZOMIB	54	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	125	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	144	258684004	1	Intravenous	47625008	14/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	336	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	600	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	63	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AVELUMAB	800	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	14/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	900	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	440	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	10	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	POMALIDOMIDE	3	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	650	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	14/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	150	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	270	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ISATUXIMAB	900	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	POMALIDOMIDE	4	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ISATUXIMAB	800	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	375	258684004	1	Intravenous	47625008	14/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	OXALIPLATIN	80	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	14/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	68	IBRUTINIB	140	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	14/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	14/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	96	258684004	1	Intravenous	47625008	14/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	790	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	500	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	600	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CETUXIMAB	900	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CETUXIMAB	900	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	42	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	5	258684004	2	Oral	26643006	15/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	2000	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	GEMCITABINE	1400	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	50	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	63	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1450	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	550	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	450	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	165	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	180	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	15/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	100	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	15/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	145	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	15/03/2023	RH8
RH8	C49X		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	890	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE-Cyc 2 + 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	15/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	(R) ICE-Cyc 2 + 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	220	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	HYD AML/CML 1DY>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	MERCAPTOPURINE	120	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	40	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	METHOTREXATE	40	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	550	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C911	98233	9		98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	100	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	15/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	15/03/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PANITUMUMAB	340	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	Osimertinib	80	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	100	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ANASTROZOLE	1	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PALBOCICLIB	100	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IPILIMUMAB	75	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	33	RIBOCICLIB	400	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	5	ISATUXIMAB	780	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	40	IBRUTINIB	420	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ALECTINIB	600	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	Nivolumab	360	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IMATINIB	400	258684004	2	Oral	26643006	15/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	15/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/03/2023	RH8
RH8	C189				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRIFLURIDINE/TIPIRACIL	70	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	50	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	50	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	20	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	20	GEMCITABINE	1200	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	378	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AVELUMAB	800	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AXITINIB	5	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	15/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	2000	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	120	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB - EMTANSINE	360	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	440	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BLEOMYCIN	18000		1	Intravenous	47625008	15/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	52	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	42	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2500	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2750	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	Osimertinib	40	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	336	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ISATUXIMAB	800	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Nivolumab	480	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	15/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	112	RUXOLITINIB	15	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CARBO BR CA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RUXOLITINIB	15	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	800	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	5	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C252X				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	15/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB DERUXTECAN	400	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	2	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IBRUTINIB	420	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IBRUTINIB	420	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ERIBULIN	1.67	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	2	Oral	26643006	15/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DACARBAZINE	630	258684004	1	Intravenous	47625008	15/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	600	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	216	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	240	258684004	1	Intravenous	47625008	16/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C541		9				Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C541		9				Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	42	LENALIDOMIDE	5	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	25	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1450	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	725	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	240	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	16/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	700	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CETUXIMAB	1000	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	890	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1300	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	41	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	57	PALBOCICLIB	75	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	50	PALBOCICLIB	100	258684004	2	Oral	26643006	16/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	200	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PALBOCICLIB	100	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C911	98233	9		99	Not known	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	25	VENETOCLAX	300	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRAMETINIB	2	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DABRAFENIB	150	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	600	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	600	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	400	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	5	ISATUXIMAB	580	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	BOSUTINIB	500	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	96	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	25	NIRAPARIB	300	258684004	2	Oral	26643006	16/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	16	METFORMIN	850	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	37	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POLATUZUMAB VEDOTIN	140	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C23		1	Adjuvant Therapy	99	Not known	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1150	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CHLORAMBUCIL	46	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	16/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	100	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PALBOCICLIB	100	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PALBOCICLIB	125	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	52	VENETOCLAX	200	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DABRAFENIB	150	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	28	TRAMETINIB	2	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	18	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	85	Nivolumab	480	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ACALABRUTINIB	100	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PEMETREXED	1000	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	FIANLIMAB/CEMIPLIMAB	1950	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	FIANLIMAB/CEMIPLIMAB	750	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	51	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CAPECITABINE	2000	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DURVALUMAB	1500	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ISATUXIMAB	650	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IXAZOMIB	4	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	16/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	89	RUXOLITINIB	5	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RUXOLITINIB	15	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EVEROLIMUS	5	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Panobinostat	10	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	700	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	150	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C97X				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	10	258684004	2	Oral	26643006	16/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	27	NILOTINIB	400	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IBRUTINIB	420	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IBRUTINIB	420	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PACLITAXEL ALBUMIN BOUND	500	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	98	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	98	ERIBULIN	1.67	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	THALIDOMIDE	100	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	16/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	16/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DACARBAZINE	700	258684004	1	Intravenous	47625008	16/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	216	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	216	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LIPOSOMAL DOXORUBICIN	62	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	600	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CETUXIMAB	900	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (1st cycle)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB - EMTANSINE	300	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	25	258684004	2	Oral	26643006	17/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	550	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1450	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C20		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	180	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	98	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	180	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	17/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C719		1	Adjuvant Therapy	99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	15	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	160	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	96	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	17/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	4	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	80	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C911	98233	9		98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	900	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Osimertinib	80	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	38	PALBOCICLIB	75	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	49	PALBOCICLIB	100	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	165	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PANITUMUMAB	400	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ABEMACICLIB	50	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	75	258684004	2	Oral	26643006	17/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PALBOCICLIB	75	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	96	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	400	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	40	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZOLIZUMAB >>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	17/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D489		9		99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1150	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PALBOCICLIB	125	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	400	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	270	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	216	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Olaparib - PS>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	300	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	SACITUZUMAB GOVITECAN	630	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABOZANTINIB	20	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMETREXED	750	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Melphalan oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MELPHALAN	8	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN	180	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BINIMETINIB	45	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENCORAFENIB	450	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C01X				99	Not known	PEMBRO H + N	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	94	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1950	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CAPECITABINE	1200	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	Nivolumab	480	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	Nivolumab	480	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	3	Not Applicable (Primary Treatment)	99	Not known	PEMBRO CHL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C680				99	Not known	XELOX UROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C680				99	Not known	XELOX UROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	260	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	19	RUXOLITINIB	10	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CARBO BR CA	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	450	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EVEROLIMUS	2.5	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APIXABAN	2.5	258684004	2	Oral	26643006	17/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ERIBULIN	2.02	258684004	1	Intravenous	47625008	17/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DEXAMETHASONE	10	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	85	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	IMATINIB	400	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ACALABRUTINIB	100	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ACALABRUTINIB	100	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	2	Oral	26643006	18/03/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	19/03/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	28	CABOZANTINIB	20	258684004	2	Oral	26643006	19/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/03/2023	RH8
RH8	C259				99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TEMOZOLOMIDE	375	258684004	2	Oral	26643006	19/03/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IMATINIB	400	258684004	2	Oral	26643006	19/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	IBRUTINIB	420	258684004	2	Oral	26643006	19/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	125	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	240	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	5	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	40	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	500	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	20/03/2023	RH8
RH8	C509				99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	20/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509				99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	20/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	70	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CARBOPLATIN	700	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MELPHALAN	380	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TEMOZOLOMIDE	380	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	140	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C10X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CARBOPLATIN	180	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C66		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1400	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	240	258684004	1	Intravenous	47625008	20/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	800	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	INOTUZUMAB CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	INOTUZUMAB OZOGAMICIN	1.1	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	HYD AML/CML 1DAY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	GILTERITINIB Cy2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GILTERITINIB	120	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PALBOCICLIB	125	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	100	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	64	DABRAFENIB	100	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	64	TRAMETINIB	1.5	258684004	2	Oral	26643006	20/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	20/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	400	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	NIRAPARIB	100	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IMATINIB	400	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/03/2023	RH8
RH8	C189				99	Not known	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1400	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	75	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	40	RIBOCICLIB	400	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	20/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	600	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	NIRAPARIB	200	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ACALABRUTINIB	100	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	20/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Melphalan oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	MELPHALAN	16	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	20/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZANUBRUTINIB	80	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	63	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	50	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	21250		1	Intravenous	47625008	20/03/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	80	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	113	RUXOLITINIB	10	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	22	RUXOLITINIB	10	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	D45X	99503	9		98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	24	RUXOLITINIB	15	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	BEXAROTENE	300	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	20/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	IBRUTINIB	420	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	32	NILOTINIB	200	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	SUNITINIB	25	258684004	2	Oral	26643006	20/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	20/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	20/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	20/03/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	600	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	790	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	336	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	600	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	77	LENALIDOMIDE	15	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	21/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	800	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	164	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	330	258684004	1	Intravenous	47625008	21/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	76	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	40	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CABOZANTINIB	40	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	Osimertinib	80	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	75	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABEMACICLIB	100	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	BOSUTINIB	400	258684004	2	Oral	26643006	21/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	144	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	378	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	D175X				99	Not known	EVEROLIMUS NET>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EVEROLIMUS	5	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	600	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AVELUMAB	800	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AXITINIB	5	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SACITUZUMAB GOVITECAN	700	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	21/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ACALABRUTINIB	100	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	120	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	1000	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	17	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	21/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	77	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	80	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1150	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	10	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	RUXOLITINIB	15	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	26	RUXOLITINIB	20	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ISATUXIMAB	800	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	89	AVELUMAB	800	258684004	1	Intravenous	47625008	21/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Olaparib	300	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C179X				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			SOTORASIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SOTORASIB	240	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	D591		9		99	Not known	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	21/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	21/03/2023	RH8
RH8	C629	90803	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	21/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	32	NILOTINIB	200	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NILOTINIB	300	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	21/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	21/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	21/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	360	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	15	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	5	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1400	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	2000	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	GEMCITABINE	1400	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	50	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	33	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	45	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	320	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	22/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	700	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2150	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	225	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	280	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	240	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	128	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	260	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	100	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	120	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	22/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	164	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	22/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	400	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R(IVF)-IBRU MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	MERCAPTOPURINE	120	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C159		9				PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABOZANTINIB	20	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	80	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	METHOTREXATE	40	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	50	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	50	FLUOROURACIL	650	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C159		9				PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	62	PALBOCICLIB	100	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	125	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	50	PANITUMUMAB	500	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C159		9				PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VENETOCLAX	400	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX-R WK1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	20	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	22/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	200	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BOSUTINIB	100	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R(IVF)-IBRU MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IBRUTINIB	560	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	22/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	20	GEMCITABINE	1200	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	200	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C64		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	22/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	120	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	120	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYTARABINE	3600	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	900	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	78	Olaparib	250	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IMATINIB	400	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	Olaparib	200	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	22/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	5	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C880	97613	9		98	Other	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZANUBRUTINIB	80	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	22/03/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	22/03/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	10	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	10	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C04X		3	Not Applicable (Primary Treatment)			PEMBRO H + N	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	42	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	48	LENALIDOMIDE	5	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	POMALIDOMIDE	4	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ISATUXIMAB	1000	258684004	1	Intravenous	47625008	22/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ISATUXIMAB	440	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ISATUXIMAB	900	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	48	APIXABAN	2.5	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	48	IXAZOMIB	2.3	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C848	97183	9		98	Other	Brentuximab	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BRENTUXIMAB VEDOTIN	100	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	BEXAROTENE	225	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	4	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	4	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C44X		9		98	Other	Vismodegib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VISMONDEGIB	150	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PEMETREXED	900	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	650	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	52	NILOTINIB	300	258684004	2	Oral	26643006	22/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	NILOTINIB	400	258684004	2	Oral	26643006	22/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ERIBULIN	1.06	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	630	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	96	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	80	258684004	1	Intravenous	47625008	22/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	17500	408102007	1	Intravenous	47625008	22/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	270	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	FLUOROURACIL	800	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	FLUOROURACIL	550	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CETUXIMAB	1000	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	23	CETUXIMAB	800	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	23/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1650	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CAPECITABINE	1650	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cytarabine low (10to20mg/m2) IV/SC	2	PATIENT is not taking part in a CLINICAL TRIAL	23	CYTARABINE	20	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	10	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	900	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	15	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	700	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1450	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	23/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	800	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CETUXIMAB	900	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C629	90613	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	1220	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1300	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	23/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAZOPANIB - RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PAZOPANIB	600	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	96	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	25	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C64		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMG>4	1	PATIENT is taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	100	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	600	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		9				RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	400	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IBRUTINIB	420	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	51	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C900	97323	9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	23/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	6	POLATUZUMAB VEDOTIN	152	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C23		1	Adjuvant Therapy	99	Not known	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1500	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	350	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PANITUMUMAB	180	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1500	258684004	1	Intravenous	47625008	23/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRAMETINIB	2	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	RIBOCICLIB	200	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AVELUMAB	800	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ACALABRUTINIB	100	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	120	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	580	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYTARABINE	3600	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C509		9				RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	23/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-DHAP/RCHOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-DHAP/RCHOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	40	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	40	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	25	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C44X		9				Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	23/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-DHAP/RCHOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	185	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	7	IXAZOMIB	4	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	40	RUXOLITINIB	10	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	63	RUXOLITINIB	25	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Trabectedin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRABECTEDIN	3	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	99	Not known	ASCIMINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ASCIMINIB	80	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	APIXABAN	2.5	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	SUNITINIB	50	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - KISPLYX	20	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	98	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	98	ERIBULIN	1.67	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	POMALIDOMIDE	4	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	23/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	23/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IFOSFAMIDE	2640	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	148	258684004	1	Intravenous	47625008	23/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	99	Not known	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	135	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	165	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	99	Not known	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	96	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	80	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	99	Not known	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	23/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	350	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	450	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	11	OXALIPLATIN	90	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	400	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	300	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CETUXIMAB	800	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CETUXIMAB	900	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	2	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	5	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	550	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	39	LENALIDOMIDE	15	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	550	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		1	Adjuvant Therapy	99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	110	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	800	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	500	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1800	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Bevacizumab 15mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	103	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	220	258684004	1	Intravenous	47625008	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	96	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BINIMETINIB	30	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENCORAFENIB	250	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	44	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	Osimertinib	40	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	40	PALBOCICLIB	100	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	75	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	100	258684004	2	Oral	26643006	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	125	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	100	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PALBOCICLIB	125	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C911	98233			98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	250	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	96	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	180	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRAMETINIB	2	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DABRAFENIB	150	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EVEROLIMUS	7.5	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EXEMESTANE	25	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	108	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	46	IBRUTINIB	420	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	80	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ALECTINIB	600	258684004	2	Oral	26643006	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NIRAPARIB	200	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	400	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C20				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRIFLURIDINE/TIPIRACIL	45	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2500	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FOXTROT 2 OxCap	1	PATIENT is taking part in a CLINICAL TRIAL	1	CAPECITABINE	2150	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PALBOCICLIB	125	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FOXTROT 2 OxCap	1	PATIENT is taking part in a CLINICAL TRIAL	1	OXALIPLATIN	280	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	PONATINIB - C3>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PONATINIB	15	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PALBOCICLIB	125	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		9				RIBO + FULVEST	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Nivolumab	480	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IMATINIB	400	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ACALABRUTINIB	100	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IBRUTINIB	420	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	40	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	40	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	31	CAPECITABINE	1300	258684004	2	Oral	26643006	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	25	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	58	LENALIDOMIDE	15	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2300	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2450	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	15	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	15	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1450	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CAPECITABINE	2000	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	25	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CAPECITABINE	1000	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-DHAP/RCHOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYTARABINE	3600	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APIXABAN	2.5	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IXAZOMIB	4	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	58	IXAZOMIB	3	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IXAZOMIB	3	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IXAZOMIB	4	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IXAZOMIB	4	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	52	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	52	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABAZITAXEL	44	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LENVATINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - LENVIMA	24	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	5	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C800X				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	24/03/2023	RH8
RH8	C900	97323	9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	24/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IBRUTINIB	420	258684004	2	Oral	26643006	24/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ERIBULIN	0.97	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IFOSFAMIDE	2640	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	148	258684004	1	Intravenous	47625008	24/03/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CABOZANTINIB	20	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	120	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IMATINIB	400	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	C349	80463	9				CERITINIB SUB>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	CERITINIB	300	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	46	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	IBRUTINIB	140	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	IBRUTINIB	420	258684004	2	Oral	26643006	25/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IFOSFAMIDE	2640	258684004	1	Intravenous	47625008	25/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	148	258684004	1	Intravenous	47625008	25/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	26/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/03/2023	RH8
RH8	D489		9		99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEMOZOLOMIDE	245	258684004	2	Oral	26643006	26/03/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IMATINIB	400	258684004	2	Oral	26643006	26/03/2023	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IMATINIB	400	258684004	2	Oral	26643006	26/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IMATINIB	400	258684004	2	Oral	26643006	26/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IFOSFAMIDE	2640	258684004	1	Intravenous	47625008	26/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	148	258684004	1	Intravenous	47625008	26/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	500	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CETUXIMAB	800	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	5	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	40	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	900	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	27/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		1	Adjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	240	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	100	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	70	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	330	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	140	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	13	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	27/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	16	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX> +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENCORAFENIB	300	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	240	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	250	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX> +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CETUXIMAB	1000	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ERLOTINIB 2MTH +	2	PATIENT is not taking part in a CLINICAL TRIAL	72	ERLOTINIB	50	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	80	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	INOTUZUMAB CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	INOTUZUMAB OZOGAMICIN	1.1	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2250	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	790	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	Osimertinib	80	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	100	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	225	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	120	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C459		9		99	Not known	NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C349	80463	9		99	Not known	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ALECTINIB	450	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	80	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	CABOZANTINIB	20	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	CABOZANTINIB	40	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	25	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CARFILZOMIB	54	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509				99	Not known	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	RIBOCICLIB	400	258684004	2	Oral	26643006	27/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	700	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	9	NINTEDANIB	200	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	RIBOCICLIB	400	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IBRUTINIB	420	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	27	NIRAPARIB	100	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APIXABAN	2.5	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CETUXIMAB	900	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	27/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	2560	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			ENCOR + CETUX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENCORAFENIB	300	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	50	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	63	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	440	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			ENCOR + CETUX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CETUXIMAB	1000	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	11	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2000	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	27/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	65	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABAZITAXEL	54	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AVELUMAB	800	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	10	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	40	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NILOTINIB	200	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	10	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	POMALIDOMIDE	3	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	APIXABAN	2.5	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	THALIDOMIDE	100	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	27/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	27/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IFOSFAMIDE	2640	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	148	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	98	Other	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	98	Other	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	98	Other	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	27/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	600	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	270	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CETUXIMAB	900	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	10	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	80	LENALIDOMIDE	5	258684004	2	Oral	26643006	28/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	15	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C051				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	360	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C051				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	240	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	164	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	164	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	270	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	180	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CABOZANTINIB	20	258684004	2	Oral	26643006	28/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	5	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	500	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	150	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PANITUMUMAB	260	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	Osimertinib	80	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	100	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	21	METFORMIN	850	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	400	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/03/2023	RH8
RH8	C900	97323	9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	28/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509				99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509				99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509				99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509				99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	144	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	336	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	270	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	28/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	200	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	Nivolumab	480	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	AVELUMAB	800	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AVELUMAB	800	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AXITINIB	5	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	DARATUMUMAB SC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	1100	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1000	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	560	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	225	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		9				RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	440	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	15	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C509		9		99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CAPECITABINE	2000	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IXAZOMIB	4	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IXAZOMIB	4	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DC	1	PATIENT is taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DC	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABAZITAXEL	44	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABAZITAXEL	40	258684004	1	Intravenous	47625008	28/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	RUXOLITINIB	10	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ISATUXIMAB	800	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	10	IXAZOMIB	4	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	28/03/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	750	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	375	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	OXALIPLATIN	80	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	28/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	40	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DASATINIB	100	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	180	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	IBRUTINIB	140	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NILOTINIB	200	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	62	SUNITINIB	25	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINBLASTINE SULFATE	9	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CHLORAMBUCIL	10	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PROCARBAZINE	150	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THALIDOMIDE	100	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	28/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	28/03/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	28/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	108	258684004	1	Intravenous	47625008	28/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	500	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CETUXIMAB	900	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	29/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (1st cycle)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB - EMTANSINE	200	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	45	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C20		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C20		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C20		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	500	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	550	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	240	258684004	1	Intravenous	47625008	29/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	34	TRASTUZUMAB-ONTRUZANT	651	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	29/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	120	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	180	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C66X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	100	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	29/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	40	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	120	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	550	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C900				98	Other	MYL XI LEN MAIN>	1	PATIENT is taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	5	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	Osimertinib	40	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	46	PALBOCICLIB	125	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	75	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PANITUMUMAB	340	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Osimertinib	80	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX-R WK2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	50	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	5	ISATUXIMAB	780	258684004	1	Intravenous	47625008	29/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	360	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	29/03/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	20	GEMCITABINE	1200	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NINTEDANIB	200	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	40	RIBOCICLIB	400	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	378	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AVELUMAB	800	258684004	1	Intravenous	47625008	29/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	120	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	400	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ACALABRUTINIB	100	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	560	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	440	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	80	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	80	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2750	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C169		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO MSI C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	29/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	Nivolumab	480	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C66		3	Not Applicable (Primary Treatment)			AVELUMAB UC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AVELUMAB	800	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	9	IXAZOMIB	4	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C509				99	Not known	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C44X		9		98	Other	Cemiplimab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C509				99	Not known	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	80	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	300	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	1.6	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PROCARBAZINE	150	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	22	SUNITINIB	25	258684004	2	Oral	26643006	29/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	40	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C921	98633			99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	70	NILOTINIB	300	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LOMUSTINE	200	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IBRUTINIB	560	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	27	NILOTINIB	300	258684004	2	Oral	26643006	29/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ERIBULIN	1.67	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ERIBULIN	1.06	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	500	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	29/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	700	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	30/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1300	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CETUXIMAB	1000	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	100	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	10	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	89	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1500	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	200	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	30/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	73	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	108	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	120	258684004	1	Intravenous	47625008	30/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C830	96993	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	360	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	2000	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	30/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	D57		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 1 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	40	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	28	CAPECITABINE	1000	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	50	PALBOCICLIB	100	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	53	PALBOCICLIB	125	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	100	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	130	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	120	258684004	1	Intravenous	47625008	30/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Osimertinib	80	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PALBOCICLIB	100	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PALBOCICLIB	75	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PALBOCICLIB	100	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRAMETINIB	2	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DABRAFENIB	100	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EXEMESTANE	25	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VENETOCLAX	400	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	6	ISATUXIMAB	580	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	30/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	3.3	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	POLATUZUMAB VEDOTIN	152	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CHLORAMBUCIL	46	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PALBOCICLIB	75	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1500	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	30/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	53	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ACALABRUTINIB	100	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C911	98233	1	Adjuvant Therapy			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ACALABRUTINIB	100	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	400	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	37	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	DEXAMETHASONE	10	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	120	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	POMALIDOMIDE	2	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Panobinostat	15	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CAPECITABINE	1500	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	21	CAPECITABINE	2150	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DURVALUMAB	1500	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ISATUXIMAB	650	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	APIXABAN	2.5	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	85	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	209	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	D591		3	Not Applicable (Primary Treatment)	98	Other	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	30/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	27	SUNITINIB	25	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	40	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	IBRUTINIB	280	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DASATINIB	100	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	NILOTINIB	200	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C509				99	Not known	EC - CY1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C509				99	Not known	EC - CY1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/03/2023	RH8
RH8	C349	80463	9				PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	30/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	30/03/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DACARBAZINE	700	258684004	1	Intravenous	47625008	30/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	35	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	35	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	35	FLUOROURACIL	700	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	35	CETUXIMAB	800	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	800	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	25	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	180	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	375	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	31/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	550	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	148	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	31/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1800	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	31/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	31/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	600	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CETUXIMAB	900	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	120	258684004	1	Intravenous	47625008	31/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	160	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	96	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	31/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	120	258684004	2	Oral	26643006	31/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	Osimertinib	40	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PALBOCICLIB	125	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Osimertinib	80	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	790	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	45	PALBOCICLIB	75	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	100	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PALBOCICLIB	75	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	TRAMETINIB	1	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	DABRAFENIB	75	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	180	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ALECTINIB	600	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	55	ALECTINIB	600	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	38	NIRAPARIB	100	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	42	IBRUTINIB	420	258684004	2	Oral	26643006	31/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	88	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	28	METFORMIN	850	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	48	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/03/2023	RH8
RH8	C900	97323	9		99	Not known	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PALBOCICLIB	100	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	300	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RIBOCICLIB	400	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	50	Nivolumab	480	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BOSUTINIB	200	258684004	2	Oral	26643006	31/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	HYDROXYCARBAMIDE	300	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	400	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BUSULFAN	50	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	148	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	31/03/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	31/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	80	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CAPECITABINE	1300	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1800	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	25	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IXAZOMIB	3	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA	2	PATIENT is not taking part in a CLINICAL TRIAL	64	LENALIDOMIDE	15	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABAZITAXEL	36	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RUXOLITINIB	5	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA	2	PATIENT is not taking part in a CLINICAL TRIAL	64	IXAZOMIB	4	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	800	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	31/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	4000	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			Ipilimumab	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	250	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Treosulfan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TREOSULFAN	500	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB DERUXTECAN	440	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	NILOTINIB	300	258684004	2	Oral	26643006	31/03/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ERIBULIN	0.97	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	800	258684004	1	Intravenous	47625008	31/03/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FEC 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	900	258684004	1	Intravenous	47625008	31/03/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	01/04/2023	RBZ
RH8	C900		9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	10	258684004	2	Oral	26643006	01/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	25	258684004	2	Oral	26643006	01/04/2023	RBZ
RH8	C900		9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	01/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	01/04/2023	RBZ
RH8	C900		9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	01/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	01/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/04/2023	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	300	258684004	2	Oral	26643006	01/04/2023	RH8
RH8	C921		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IMATINIB	400	258684004	2	Oral	26643006	01/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IMATINIB	400	258684004	2	Oral	26643006	01/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	80	258684004	2	Oral	26643006	01/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	15	258684004	2	Oral	26643006	01/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	APIXABAN	2.5	258684004	2	Oral	26643006	01/04/2023	RH8
RH8	D471		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	RUXOLITINIB	15	258684004	2	Oral	26643006	01/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	4	258684004	2	Oral	26643006	01/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/04/2023	RH8
RBZ	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DABRAFENIB	150	258684004	2	Oral	26643006	02/04/2023	RBZ
RBZ	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRAMETINIB	2	258684004	2	Oral	26643006	02/04/2023	RBZ
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	400	258684004	2	Oral	26643006	02/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	02/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	NIRAPARIB	100	258684004	2	Oral	26643006	02/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ACALABRUTINIB	100	258684004	2	Oral	26643006	02/04/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	47	IMATINIB	400	258684004	2	Oral	26643006	02/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	02/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	02/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IBRUTINIB	420	258684004	2	Oral	26643006	02/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	03/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	216	258684004	1	Intravenous	47625008	03/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LIPOSOMAL DOXORUBICIN	58	258684004	1	Intravenous	47625008	03/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	03/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	69	LENALIDOMIDE	5	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	36	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	550	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	70	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	03/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	700	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	195	258684004	2	Oral	26643006	03/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	150	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C349				99	Not known	DABRAF + TRAM(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C349				99	Not known	DABRAF + TRAM(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRAMETINIB	2	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	240	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CYTARA 12H 3g/m?	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	Osimertinib	40	258684004	2	Oral	26643006	03/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	125	258684004	2	Oral	26643006	03/04/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	03/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Osimertinib	80	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CYTARA 12H 3g/m?	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYTARABINE	5600	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	03/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	03/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	300	258684004	1	Intravenous	47625008	03/04/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	100	258684004	2	Oral	26643006	03/04/2023	RBZ
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IBRUTINIB	280	258684004	2	Oral	26643006	03/04/2023	RBZ
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	47	BOSUTINIB	400	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	90	258684004	1	Intravenous	47625008	03/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ALECTINIB	600	258684004	2	Oral	26643006	03/04/2023	RBZ
RH8	C900		9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829		3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	03/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	03/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	03/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	2560	258684004	1	Intravenous	47625008	03/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/04/2023	RBZ
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PROCARBAZINE	200	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	03/04/2023	RH8
RBZ	C921	98633	1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	64	IMATINIB	100	258684004	2	Oral	26643006	03/04/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB - EMTANSINE	160	258684004	1	Intravenous	47625008	03/04/2023	RBZ
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	03/04/2023	RBZ
RH8	C911		3	Not Applicable (Primary Treatment)			ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	03/04/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	420	258684004	1	Intravenous	47625008	03/04/2023	RBZ
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	56	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	50	258684004	1	Intravenous	47625008	03/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	21250		1	Intravenous	47625008	03/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C900		9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	83	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	60	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C900		9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	15	258684004	2	Oral	26643006	03/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	03/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/04/2023	RBZ
RH8	C900		9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IXAZOMIB	3	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C900		9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)			HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1000	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	D471		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	73	RUXOLITINIB	10	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	336	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	03/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C900		9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C900		9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	APIXABAN	2.5	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	03/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	03/04/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IBRUTINIB	420	258684004	2	Oral	26643006	03/04/2023	RBZ
RH8	C921		9		98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	112	NILOTINIB	150	258684004	2	Oral	26643006	03/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	03/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LIPOSOMAL DOXORUBICIN	58	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	725	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	37	DEXAMETHASONE	6	258684004	2	Oral	26643006	04/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	04/04/2023	RBZ
RBZ	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	10	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	600	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	37	LENALIDOMIDE	15	258684004	2	Oral	26643006	04/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	04/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	15	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	135	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	128	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	145	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	800	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	240	258684004	1	Intravenous	47625008	04/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	04/04/2023	RBZ
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	150	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C349		9				ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C349		9				ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C349		9				ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C349		9				ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	148	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	270	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	EMBARK-EN/PL + LE	1	PATIENT is taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE/PLACEBO	160	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	EMBARK-EN/PL + LE	1	PATIENT is taking part in a CLINICAL TRIAL	10	LEUPROLIDE	22.5	258684004	5	Subcutaneous	34206005	04/04/2023	RH8
RH8	C900		2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	04/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	04/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CAPECITABINE	1800	258684004	2	Oral	26643006	04/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C349		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	15	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C900		2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	10	258684004	2	Oral	26643006	04/04/2023	RH8
RBZ	C61		9				ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	04/04/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Osimertinib	80	258684004	2	Oral	26643006	04/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	51	PALBOCICLIB	75	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	Osimertinib	80	258684004	2	Oral	26643006	04/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	130	258684004	5	Subcutaneous	34206005	04/04/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	04/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PALBOCICLIB	125	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	100	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	175	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TUCATINIB	250	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	BOSUTINIB	400	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	58	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IXAZOMIB	2.3	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C900		2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	22	APIXABAN	2.5	258684004	2	Oral	26643006	04/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/04/2023	RBZ
RH8	C829		3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	04/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	04/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	04/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	04/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	04/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/04/2023	RBZ
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/04/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1500	258684004	2	Oral	26643006	04/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		3	Not Applicable (Primary Treatment)			ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CABOZANTINIB	40	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	378	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	DARATUMUMAB SC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C349		9				PEMBRO 428 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	Nivolumab	480	258684004	1	Intravenous	47625008	04/04/2023	RBZ
RH8	C921		3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IMATINIB	400	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IMATINIB	400	258684004	2	Oral	26643006	04/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	04/04/2023	RBZ
RBZ	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	2	258684004	2	Oral	26643006	04/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	25	258684004	2	Oral	26643006	04/04/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMETREXED	900	258684004	1	Intravenous	47625008	04/04/2023	RBZ
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	90	AVELUMAB	800	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BUSULFAN	46	258684004	2	Oral	26643006	04/04/2023	RH8
RBZ	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	37	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	04/04/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	10	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C900		9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	4	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	120	258684004	2	Oral	26643006	04/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	15	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C900		9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	25	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	120	258684004	2	Oral	26643006	04/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	650	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C349		1	Adjuvant Therapy	99	Not known	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Osimertinib	80	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	150	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	216	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C44X		9				Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	04/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	04/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IXAZOMIB	4	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C900		9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IXAZOMIB	4	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C900		9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C900		9		99	Not known	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C829		9		98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	04/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	79	RUXOLITINIB	15	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C900		9		99	Not known	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ISATUXIMAB	800	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	5	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C900		9		98	Other	PBD> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	04/04/2023	RH8
RBZ	C44		3	Not Applicable (Primary Treatment)			Cemiplimab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	04/04/2023	RBZ
RH8	D591		9		99	Not known	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	04/04/2023	RBZ
RH8	C900		9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	04/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	04/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	NILOTINIB	150	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	NILOTINIB	300	258684004	2	Oral	26643006	04/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TALIMOGENE LAHERPAREPVEC 10*8	3	74964007	5	Subcutaneous	34206005	04/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	04/04/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/04/2023	RBZ
RH8	C812		3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINBLASTINE SULFATE	9	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	04/04/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/04/2023	RBZ
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IFOSFAMIDE	2880	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	04/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	04/04/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	04/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	04/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	96	258684004	1	Intravenous	47625008	04/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	05/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C831		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C509		9		99	Not known	Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB - EMTANSINE	180	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	22	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	600	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CETUXIMAB	900	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	120	LENALIDOMIDE	10	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	73	LENALIDOMIDE	10	258684004	2	Oral	26643006	05/04/2023	RH8
RBZ	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RBZ	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	550	258684004	1	Intravenous	47625008	05/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	25	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	2000	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	110	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	50	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	128	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	79	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	700	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2150	258684004	2	Oral	26643006	05/04/2023	RBZ
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1300	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1450	258684004	2	Oral	26643006	05/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	280	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/04/2023	RH8
RH8	C349		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINORELBINE	100	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	05/04/2023	RH8
RH8	C349		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	145	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C49X		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1600	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	360	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C910		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	MERCAPTOPURINE	120	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	36	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CYTARA 12H 3g/m?	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	120	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C910		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	METHOTREXATE	40	258684004	2	Oral	26643006	05/04/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	51	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	51	FLUOROURACIL	650	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	49	PALBOCICLIB	75	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	130	258684004	5	Subcutaneous	34206005	05/04/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	51	PANITUMUMAB	500	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	05/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	125	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	100	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PALBOCICLIB	125	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PALBOCICLIB	100	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CYTARA 12H 3g/m?	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYTARABINE	5600	258684004	1	Intravenous	47625008	05/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	18	VENETOCLAX	400	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	27	Nivolumab	480	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	26	NIRAPARIB	200	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	Nivolumab	360	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/04/2023	RBZ
RH8	C829		3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	222.5	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	D45X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/04/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189				99	Not known	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C01X				99	Not known	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	45	RIBOCICLIB	200	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C921		9		98	Other	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	84	BOSUTINIB	200	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	Nivolumab	480	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Nivolumab	480	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	05/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IMATINIB	200	258684004	2	Oral	26643006	05/04/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AXITINIB	5	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Olaparib	100	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SACITUZUMAB GOVITECAN	830	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	POMALIDOMIDE	2	258684004	2	Oral	26643006	05/04/2023	RH8
RBZ	D45	99503	9		99	Not known	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	24	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	6	258684004	2	Oral	26643006	05/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	10	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	C900		9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	10	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C900		1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	80	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	40	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	POMALIDOMIDE	4	258684004	2	Oral	26643006	05/04/2023	RBZ
RBZ	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	2500	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2150	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2750	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	POMALIDOMIDE	2	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	10	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ISATUXIMAB	1000	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C900		9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ISATUXIMAB	440	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C900		1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ISATUXIMAB	900	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C189				99	Not known	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	Nivolumab	480	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	C900		9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)			LENVATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENVATINIB - LENVIMA	20	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/04/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/04/2023	RBZ
RBZ	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/04/2023	RBZ
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C946		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	28	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	05/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	05/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Dabrafenib	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DABRAFENIB	50	258684004	2	Oral	26643006	05/04/2023	RH8
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	05/04/2023	RBZ
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C349		9		99	Not known	TEPOTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEPOTINIB	225	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ERIBULIN	1.67	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C859		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VC-RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VC-RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CYCLOPHOSPHAMIDE	2000	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	700	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	200	258684004	2	Oral	26643006	05/04/2023	RH8
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	05/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	165	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	135	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	630	258684004	1	Intravenous	47625008	05/04/2023	RH8
RBZ	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	96	258684004	1	Intravenous	47625008	05/04/2023	RBZ
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	80	258684004	1	Intravenous	47625008	05/04/2023	RH8
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	17500	408102007	1	Intravenous	47625008	05/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	216	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	06/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	600	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	FLUOROURACIL	550	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	06/04/2023	RH8
RBZ	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	06/04/2023	RBZ
RH8	C541		9				Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	06/04/2023	RH8
RBZ	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	06/04/2023	RBZ
RH8	C541		9				Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	240	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CETUXIMAB	900	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CETUXIMAB	800	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	900	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	06/04/2023	RH8
RBZ	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	06/04/2023	RBZ
RBZ	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	06/04/2023	RBZ
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	06/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	700	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	500	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	06/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	06/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	06/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	06/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	06/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	06/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	06/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	06/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	06/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	06/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	108	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1300	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RH8	C911		9		98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	900	258684004	1	Intravenous	47625008	06/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	450	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C911		9		98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	80	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	270	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	BINIMETINIB	30	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	BINIMETINIB	45	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENCORAFENIB	200	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENCORAFENIB	450	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			RADA VCD + LEN C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AVELUMAB	800	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AXITINIB	8	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	06/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	61	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	61	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	40	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C946		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	54	LENALIDOMIDE	5	258684004	2	Oral	26643006	06/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	06/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PALBOCICLIB	125	258684004	2	Oral	26643006	06/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	100	258684004	2	Oral	26643006	06/04/2023	RBZ
RH8	C920		3	Not Applicable (Primary Treatment)	98	Other	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	130	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	120	258684004	1	Intravenous	47625008	06/04/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENCORAFENIB	450	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BINIMETINIB	45	258684004	2	Oral	26643006	06/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	06/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	96	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	400	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C10X				99	Not known	COMPARE - ARM 5>	1	PATIENT is taking part in a CLINICAL TRIAL	4	DURVALUMAB	1500	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NIRAPARIB	200	258684004	2	Oral	26643006	06/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829		3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	222.5	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	38	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/04/2023	RH8
RBZ	C23		1	Adjuvant Therapy	99	Not known	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	800	258684004	2	Oral	26643006	06/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	350	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PANITUMUMAB	180	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PALBOCICLIB	100	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PALBOCICLIB	75	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	06/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	06/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	06/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	14	NINTEDANIB	150	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	2	FIANLIMAB/CEMIPLIMAB	750	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	2	FIANLIMAB/CEMIPLIMAB	1950	258684004	1	Intravenous	47625008	06/04/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	06/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PEMETREXED	1000	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	2	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	06/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RBZ	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	2150	258684004	2	Oral	26643006	06/04/2023	RH8
RBZ	C159				99	Not known	OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	06/04/2023	RBZ
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	80	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	80	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CAPECITABINE	2000	258684004	2	Oral	26643006	06/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	25	258684004	2	Oral	26643006	06/04/2023	RH8
RBZ	C159				99	Not known	OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	06/04/2023	RBZ
RH8	C900		9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	9	IXAZOMIB	4	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C946		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	28	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	700	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	120	258684004	1	Intravenous	47625008	06/04/2023	RH8
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	06/04/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	06/04/2023	RH8
RBZ	D591		3	Not Applicable (Primary Treatment)	98	Other	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	06/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	89	NILOTINIB	200	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	98	Other	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DASATINIB	20	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			SOTORASIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SOTORASIB	960	258684004	2	Oral	26643006	06/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	99	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	99	ERIBULIN	1.67	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ERIBULIN	2.02	258684004	1	Intravenous	47625008	06/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	06/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	06/04/2023	RH8
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	06/04/2023	RBZ
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	06/04/2023	RBZ
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CHLORAMBUCIL	10	258684004	2	Oral	26643006	06/04/2023	RBZ
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PROCARBAZINE	150	258684004	2	Oral	26643006	06/04/2023	RBZ
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	06/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	96	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	80	258684004	1	Intravenous	47625008	06/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	450	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CETUXIMAB	900	258684004	1	Intravenous	47625008	07/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DEXAMETHASONE	20	258684004	2	Oral	26643006	07/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	30	LENALIDOMIDE	25	258684004	2	Oral	26643006	07/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	30	APIXABAN	2.5	258684004	2	Oral	26643006	07/04/2023	RBZ
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	800	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	99	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1800	258684004	1	Intravenous	47625008	07/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	160	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	96	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAZOPANIB - RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	51	PAZOPANIB	400	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENCORAFENIB	450	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BINIMETINIB	45	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	07/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CYTARA 12H 3g/m?	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CABOZANTINIB	40	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CABOZANTINIB	20	258684004	2	Oral	26643006	07/04/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Osimertinib	80	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	47	RIBOCICLIB	400	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CYTARA 12H 3g/m?	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYTARABINE	5600	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	54	VENETOCLAX	300	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	180	258684004	1	Intravenous	47625008	07/04/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	73	DABRAFENIB	150	258684004	2	Oral	26643006	07/04/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	73	TRAMETINIB	2	258684004	2	Oral	26643006	07/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DABRAFENIB	150	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	TRAMETINIB	2	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IBRUTINIB	140	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE 90 CYC1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	IMATINIB	400	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	336	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	07/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	600	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C911		9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ACALABRUTINIB	100	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C349		9				PEMBRO 428 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	07/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	07/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	120	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1400	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C509		9				PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PALBOCICLIB	125	258684004	2	Oral	26643006	07/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	132	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C880		9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZANUBRUTINIB	160	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	07/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	120	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	53	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CAPECITABINE	1200	258684004	2	Oral	26643006	07/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/04/2023	RBZ
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C680				99	Not known	XELOX UROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C680				99	Not known	XELOX UROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	260	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	D471		3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RUXOLITINIB	15	258684004	2	Oral	26643006	07/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			LORLATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LORLATINIB	100	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	07/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	07/04/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NILOTINIB	400	258684004	2	Oral	26643006	07/04/2023	RBZ
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NILOTINIB	400	258684004	2	Oral	26643006	07/04/2023	RBZ
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	NILOTINIB	200	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	20	NILOTINIB	400	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C880		9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IBRUTINIB	420	258684004	2	Oral	26643006	07/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CABOZANTINIB	40	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	08/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	28	NIRAPARIB	100	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/04/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ACALABRUTINIB	100	258684004	2	Oral	26643006	08/04/2023	RBZ
RH8	C921		3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	400	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	4	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	47	IBRUTINIB	420	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	69	DASATINIB	100	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	97	IBRUTINIB	280	258684004	2	Oral	26643006	08/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	Osimertinib	80	258684004	2	Oral	26643006	09/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	Osimertinib	80	258684004	2	Oral	26643006	09/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ALECTINIB	600	258684004	2	Oral	26643006	09/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IMATINIB	200	258684004	2	Oral	26643006	09/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	09/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	09/04/2023	RH8
RH8	D45X		1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	52	IBRUTINIB	560	258684004	2	Oral	26643006	09/04/2023	RH8
RH8	C831		9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IBRUTINIB	560	258684004	2	Oral	26643006	09/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	31	LENALIDOMIDE	15	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	400	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C911		9		98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VENETOCLAX	400	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C900		9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	10/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C900		9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	10/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CABOZANTINIB	20	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	AML MAINT MIDOST	2	PATIENT is not taking part in a CLINICAL TRIAL	4	MIDOSTAURIN	50	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C900		9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	10/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	52	BOSUTINIB	500	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/04/2023	RBZ
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	10/04/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CABOZANTINIB	20	258684004	2	Oral	26643006	10/04/2023	RBZ
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	10/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	10/04/2023	RBZ
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	10/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	10/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	180	258684004	2	Oral	26643006	10/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	180	258684004	2	Oral	26643006	10/04/2023	RBZ
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	21250		1	Intravenous	47625008	10/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	80	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	10/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	120	258684004	2	Oral	26643006	10/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/04/2023	RBZ
RH8	C61X		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	80	258684004	2	Oral	26643006	10/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/04/2023	RBZ
RBZ	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	19	RUXOLITINIB	15	258684004	2	Oral	26643006	10/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Crizotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	36	CRIZOTINIB	250	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	34	IBRUTINIB	420	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C900		9		98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C900		9		98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	POMALIDOMIDE	4	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C900		9		98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	10/04/2023	RH8
RH8	C859		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	10/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	216	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	216	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB - EMTANSINE	300	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RBZ	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	10	258684004	2	Oral	26643006	11/04/2023	RBZ
RBZ	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	25	258684004	2	Oral	26643006	11/04/2023	RBZ
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	11/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	180	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	60	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	11/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	11/04/2023	RH8
RBZ	C509				99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RBZ	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	132	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RH8	C829		3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	11/04/2023	RH8
RH8	C900		9		98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		2	Neoadjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C900		9		98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MELPHALAN	170	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	11/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	46	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	11/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/04/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CABOZANTINIB	20	258684004	2	Oral	26643006	11/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	500	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/04/2023	RBZ
RBZ	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PANITUMUMAB	260	258684004	1	Intravenous	47625008	11/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	Osimertinib	80	258684004	2	Oral	26643006	11/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Osimertinib	40	258684004	2	Oral	26643006	11/04/2023	RH8
RBZ	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	VENETOCLAX	100	258684004	2	Oral	26643006	11/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	VENETOCLAX	200	258684004	2	Oral	26643006	11/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	216	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	200	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C921		1	Adjuvant Therapy	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IMATINIB	100	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	40	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/04/2023	RH8
RH8	C900		1	Adjuvant Therapy			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	D45X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	11/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C25.9				99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1500	258684004	2	Oral	26643006	11/04/2023	RH8
RBZ	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1400	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	125	258684004	2	Oral	26643006	11/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PALBOCICLIB	75	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	144	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRAMETINIB	2	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	270	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NINTEDANIB	200	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	600	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	600	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AVELUMAB	800	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AXITINIB	5	258684004	2	Oral	26643006	11/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	SACITUZUMAB GOVITECAN	630	258684004	1	Intravenous	47625008	11/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C917		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ORAL MTX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	63	METHOTREXATE	10	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENCORAFENIB	300	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CETUXIMAB	900	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	2000	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	11/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ACALABRUTINIB	100	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	1000	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	800	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	56	258684004	1	Intravenous	47625008	11/04/2023	RH8
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	320	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	80	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1600	258684004	2	Oral	26643006	11/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DURVALUMAB	1500	258684004	1	Intravenous	47625008	11/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DURVALUMAB	1500	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C349		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DURVALUMAB	1500	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C349		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DURVALUMAB	1500	258684004	1	Intravenous	47625008	11/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Olaparib	300	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	750	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	150	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PROCARBAZINE	200	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	11/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	69	IBRUTINIB	140	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	DASATINIB	40	258684004	2	Oral	26643006	11/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DASATINIB	20	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LOMUSTINE	200	258684004	2	Oral	26643006	11/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			SOTORASIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SOTORASIB	960	258684004	2	Oral	26643006	11/04/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	300	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	11/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	11/04/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	11/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	11/04/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	360	258684004	1	Intravenous	47625008	12/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	600	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CETUXIMAB	900	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	5	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	5	258684004	2	Oral	26643006	12/04/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1400	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	2000	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	12/04/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	33	258684004	1	Intravenous	47625008	12/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	50	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	45	258684004	1	Intravenous	47625008	12/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	12/04/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	800	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	12/04/2023	RH8
RBZ	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	12/04/2023	RBZ
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2150	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	165	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RH8	C169		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	12/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	128	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	260	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	100	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C349		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINORELBINE	100	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C900		9		98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1600	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	270	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX> +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CETUXIMAB	1000	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AVELUMAB	800	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AXITINIB	5	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	12/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C910		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	HYD AML/CML 1DY>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	12/04/2023	RBZ
RH8	C910		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	MERCAPTOPURINE	120	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C159		9				PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	35	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C900		9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	40	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C61X		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C910		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	METHOTREXATE	40	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	10	258684004	2	Oral	26643006	12/04/2023	RBZ
RH8	C946		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q 28D>1	2	PATIENT is not taking part in a CLINICAL TRIAL	78	LENALIDOMIDE	5	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	550	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RH8	C159		9				PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	12/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	150	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	12/04/2023	RH8
RBZ	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PANITUMUMAB	340	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RH8	C159		9				PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	200	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PALBOCICLIB	100	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	100	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ANASTROZOLE	1	258684004	2	Oral	26643006	12/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	34	RIBOCICLIB	400	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C900		9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	6	ISATUXIMAB	800	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ALECTINIB	600	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	5	METFORMIN	850	258684004	2	Oral	26643006	12/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IXAZOMIB	4	258684004	2	Oral	26643006	12/04/2023	RBZ
RBZ	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	12/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	12/04/2023	RH8
RH8	C189				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRIFLURIDINE/TIPIRACIL	70	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	51	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	51	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/04/2023	RH8
RBZ	C509				99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RH8	C06X		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	20	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C900		1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CARFILZOMIB	54	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	378	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	216	258684004	1	Intravenous	47625008	12/04/2023	RH8
RBZ	C509				99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	12/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AVELUMAB	800	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Olaparib - PS>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Olaparib	300	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C43		9				PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	500	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	100	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PANITUMUMAB	340	258684004	1	Intravenous	47625008	12/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	12/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EXEMESTANE	25	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EVEROLIMUS	5	258684004	2	Oral	26643006	12/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	12/04/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IMATINIB	400	258684004	2	Oral	26643006	12/04/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DACARBAZINE	450	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	900	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	320	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	12/04/2023	RBZ
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	12/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB-ONTRUZANT	651	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	43	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	53	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	80	258684004	2	Oral	26643006	12/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RBZ
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RBZ
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	80	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	280	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ISATUXIMAB	800	258684004	1	Intravenous	47625008	12/04/2023	RH8
RBZ	C66		3	Not Applicable (Primary Treatment)			AVELUMAB UC-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PEMBRO CHL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RUXOLITINIB	15	258684004	2	Oral	26643006	12/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	4	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C900		1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	5	258684004	2	Oral	26643006	12/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	12/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMETREXED	650	258684004	1	Intravenous	47625008	12/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	IBRUTINIB	420	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IBRUTINIB	420	258684004	2	Oral	26643006	12/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/04/2023	RH8
RBZ	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C159		2	Neoadjuvant Therapy	99	Not known	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C159		2	Neoadjuvant Therapy	99	Not known	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RBZ	C159		2	Neoadjuvant Therapy	99	Not known	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	12/04/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	500	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	700	258684004	1	Intravenous	47625008	13/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CETUXIMAB	800	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CETUXIMAB	1000	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C189		9		99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CAPECITABINE	1650	258684004	2	Oral	26643006	13/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	43	LENALIDOMIDE	5	258684004	2	Oral	26643006	13/04/2023	RBZ
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	360	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	148	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C349		1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	90	258684004	2	Oral	26643006	13/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C349		1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	128	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	700	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	400	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TEMOZOLOMIDE	330	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	16	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	400	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	270	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	42	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	13/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	40	258684004	2	Oral	26643006	13/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	80	258684004	2	Oral	26643006	13/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	13/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	58	PALBOCICLIB	75	258684004	2	Oral	26643006	13/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Osimertinib	80	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	51	PALBOCICLIB	100	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Osimertinib	80	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PALBOCICLIB	100	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C900		9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	13/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911		9		99	Not known	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	26	VENETOCLAX	300	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX-R WK3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	50	258684004	2	Oral	26643006	13/04/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DABRAFENIB	150	258684004	2	Oral	26643006	13/04/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRAMETINIB	2	258684004	2	Oral	26643006	13/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DABRAFENIB	150	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	TRAMETINIB	2	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	FLAIR - IBR/VEN*	1	PATIENT is taking part in a CLINICAL TRIAL	24	VENETOCLAX	400	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	6	ISATUXIMAB	580	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	FLAIR - IBR/VEN*	1	PATIENT is taking part in a CLINICAL TRIAL	24	IBRUTINIB	140	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IMATINIB	300	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	13/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	POLATUZUMAB VEDOTIN	140	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CHLORAMBUCIL	46	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PALBOCICLIB	100	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PALBOCICLIB	100	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PALBOCICLIB	125	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	53	VENETOCLAX	200	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	600	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	600	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	33	BOSUTINIB	500	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C859		3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	13/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/04/2023	RH8
RBZ	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ACALABRUTINIB	100	258684004	2	Oral	26643006	13/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ACALABRUTINIB	100	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C859		3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CHLORAMBUCIL	18	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	25	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	580	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	86	Nivolumab	480	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	13/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C831		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ/BEVA HCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SACITUZUMAB GOVITECAN	580	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SACITUZUMAB GOVITECAN	830	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-CHOP/RDHAP>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ/BEVA HCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	13/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	120	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	52	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/04/2023	RH8
RBZ	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DURVALUMAB	1500	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ISATUXIMAB	650	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	13/04/2023	RH8
RBZ	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IXAZOMIB	4	258684004	2	Oral	26643006	13/04/2023	RBZ
RBZ	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	13/04/2023	RBZ
RH8	C920		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	D471		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	90	RUXOLITINIB	5	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Trabectedin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRABECTEDIN	3	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	D471		3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RUXOLITINIB	15	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	900	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C921		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	28	NILOTINIB	400	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IBRUTINIB	420	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IBRUTINIB	420	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	99	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	99	ERIBULIN	1.67	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ERIBULIN	2.02	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ERIBULIN	1.06	258684004	1	Intravenous	47625008	13/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	THALIDOMIDE	100	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	13/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	13/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	13/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DACARBAZINE	700	258684004	1	Intravenous	47625008	13/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LIPOSOMAL DOXORUBICIN	62	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	14/04/2023	RH8
RBZ	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RBZ	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	630	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RBZ	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	14/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C56		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	14/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	10	258684004	2	Oral	26643006	14/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	25	258684004	2	Oral	26643006	14/04/2023	RBZ
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	800	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	375	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	550	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	100	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	14/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RBZ	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	128	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RBZ	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	260	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RBZ	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	100	258684004	2	Oral	26643006	14/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	14/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Bevacizumab 15mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	104	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	160	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	96	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	14/04/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	55	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	14/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/04/2023	RBZ
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	14/04/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	14/04/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1800	258684004	1	Intravenous	47625008	14/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C911		9		98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FOXTROT2 OxCap>1	1	PATIENT is taking part in a CLINICAL TRIAL	2	CAPECITABINE	2150	258684004	2	Oral	26643006	14/04/2023	RH8
RBZ	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	14/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	39	PALBOCICLIB	75	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Osimertinib	80	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENCORAFENIB	450	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BINIMETINIB	45	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	75	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FOXTROT2 OxCap>1	1	PATIENT is taking part in a CLINICAL TRIAL	2	OXALIPLATIN	280	258684004	1	Intravenous	47625008	14/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	14/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	250	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	180	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	270	258684004	1	Intravenous	47625008	14/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	14/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	80	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C900		9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	350	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRIFLURIDINE/TIPIRACIL	40	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	14/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			LAROTRECTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	Larotrectinib	100	258684004	2	Oral	26643006	14/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2500	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	D48.9		9		99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1150	258684004	2	Oral	26643006	14/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PALBOCICLIB	125	258684004	2	Oral	26643006	14/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PALBOCICLIB	125	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	400	258684004	2	Oral	26643006	14/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	336	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	216	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ALECTINIB	600	258684004	2	Oral	26643006	14/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RBZ	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ACALABRUTINIB	100	258684004	2	Oral	26643006	14/04/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	14/04/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	14/04/2023	RBZ
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1400	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	132	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	400	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZOLIZUMAB>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	14/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	32	CAPECITABINE	1300	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	95	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2450	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	2300	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1950	258684004	2	Oral	26643006	14/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1450	258684004	2	Oral	26643006	14/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CAPECITABINE	2000	258684004	2	Oral	26643006	14/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	25	CAPECITABINE	1000	258684004	2	Oral	26643006	14/04/2023	RH8
RBZ	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	14/04/2023	RBZ
RH8	C349		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	Osimertinib	40	258684004	2	Oral	26643006	14/04/2023	RH8
RBZ	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	240	258684004	1	Intravenous	47625008	14/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	Nivolumab	480	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	Nivolumab	480	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABAZITAXEL	44	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RH8	D471		3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	20	RUXOLITINIB	10	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/04/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	800	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C900		9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	10	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	135	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EVEROLIMUS	5	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C900		9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APIXABAN	2.5	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Erlotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	71	ERLOTINIB	50	258684004	2	Oral	26643006	14/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	SUNITINIB	50	258684004	2	Oral	26643006	14/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	14/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ERIBULIN	0.97	258684004	1	Intravenous	47625008	14/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DEXAMETHASONE	10	258684004	2	Oral	26643006	15/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	86	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	15/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	29	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/04/2023	RBZ
RH8	C61X		9				ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/04/2023	RH8
RH8	C61X		9				ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ACALABRUTINIB	100	258684004	2	Oral	26643006	15/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/04/2023	RH8
RH8	D473		1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	15/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Osimertinib	80	258684004	2	Oral	26643006	16/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABOZANTINIB	20	258684004	2	Oral	26643006	16/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	59	PAZOPANIB	400	258684004	2	Oral	26643006	16/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	IBRUTINIB	420	258684004	2	Oral	26643006	16/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	630	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	216	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	240	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	17/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	5	258684004	2	Oral	26643006	17/04/2023	RBZ
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	17/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	17/04/2023	RBZ
RH8	C189		1	Adjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C189		1	Adjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	250	258684004	1	Intravenous	47625008	17/04/2023	RH8
RBZ	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (2 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	7250	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (2 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CARBOPLATIN	700	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MELPHALAN	380	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	6300	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	17/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	17/04/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	17/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	17/04/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	17/04/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	17/04/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	17/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/04/2023	RH8
RBZ	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	17/04/2023	RBZ
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	125	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	790	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	17/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ANASTROZOLE	1	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	17/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	75	258684004	2	Oral	26643006	17/04/2023	RBZ
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	100	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C900		9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	17/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	120	258684004	1	Intravenous	47625008	17/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	17/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	26	NIRAPARIB	300	258684004	2	Oral	26643006	17/04/2023	RBZ
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE 90 CYC1	2	PATIENT is not taking part in a CLINICAL TRIAL	76	IMATINIB	200	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IMATINIB	400	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C921				99	Not known	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IMATINIB	400	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/04/2023	RH8
RH8	C900		1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/04/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C189				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	17/04/2023	RH8
RBZ	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	1400	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POLATUZUMAB VEDOTIN	128	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/04/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/04/2023	RH8
RBZ	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM MAIN 200 +	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	17/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	10	258684004	2	Oral	26643006	17/04/2023	RH8
RBZ	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	725	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	41	RIBOCICLIB	400	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C900		1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	17/04/2023	RH8
RBZ	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RIBOCICLIB	600	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	NIRAPARIB	200	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/04/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	17/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	17/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	2560	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	99	Not known	GILTERITINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GILTERITINIB	120	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	440	258684004	1	Intravenous	47625008	17/04/2023	RH8
RBZ	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	80	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	17/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	2000	258684004	2	Oral	26643006	17/04/2023	RH8
RBZ	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	135	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	315	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	17/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CABAZITAXEL	54	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	D471		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	34	RUXOLITINIB	5	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	D471		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	114	RUXOLITINIB	10	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	23	RUXOLITINIB	10	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	D45X		9		98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	25	RUXOLITINIB	15	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	10	258684004	2	Oral	26643006	17/04/2023	RH8
RBZ	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	10	258684004	2	Oral	26643006	17/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	10	258684004	2	Oral	26643006	17/04/2023	RH8
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	17/04/2023	RBZ
RBZ	D591		3	Not Applicable (Primary Treatment)			Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	17/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	40	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	98	IBRUTINIB	280	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	IBRUTINIB	140	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	33	NILOTINIB	200	258684004	2	Oral	26643006	17/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	IBRUTINIB	420	258684004	2	Oral	26643006	17/04/2023	RH8
RBZ	C169		9				Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	SUNITINIB	50	258684004	2	Oral	26643006	17/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - CY1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	17/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - CY1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	17/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C859		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C859		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	198	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	600	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	78	LENALIDOMIDE	15	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1400	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	135	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	800	258684004	1	Intravenous	47625008	18/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C05.1				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	18/04/2023	RH8
RBZ	C44		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	360	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RH8	C05.1				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	240	258684004	1	Intravenous	47625008	18/04/2023	RH8
RBZ	C44		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	200	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	18/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RBZ	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	132	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	18/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	18/04/2023	RH8
RBZ	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	164	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	17	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	18/04/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	18/04/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	77	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/04/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	18/04/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	40	258684004	2	Oral	26643006	18/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/04/2023	RBZ
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	CABOZANTINIB	20	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	100	258684004	1	Intravenous	47625008	18/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/04/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			CABOZANTINIB RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABOZANTINIB	20	258684004	2	Oral	26643006	18/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	75	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	39	PALBOCICLIB	75	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ANASTROZOLE	1	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	150	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABEMACICLIB	100	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	65	TRAMETINIB	1.5	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	65	DABRAFENIB	100	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	600	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	18/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C459		9		99	Not known	NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	75	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	132	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	18/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	400	258684004	2	Oral	26643006	18/04/2023	RBZ
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	BOSUTINIB	400	258684004	2	Oral	26643006	18/04/2023	RBZ
RBZ	C459		9		99	Not known	NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	360	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	18/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C509				99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	18/04/2023	RH8
RBZ	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C01X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	18/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	18/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	18/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1650	258684004	2	Oral	26643006	18/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2300	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	18/04/2023	RH8
RBZ	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1400	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	144	258684004	1	Intravenous	47625008	18/04/2023	RH8
RBZ	C7A				99	Not known	EVEROLIMUS NET>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EVEROLIMUS	5	258684004	2	Oral	26643006	18/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	18/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	1100	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C519		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	18/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D693		9		98	Other	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	D45X		1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ACALABRUTINIB	100	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	120	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	400	258684004	2	Oral	26643006	18/04/2023	RH8
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1000	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	560	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	225	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	56	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	440	258684004	1	Intravenous	47625008	18/04/2023	RH8
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BLEOMYCIN	18000		1	Intravenous	47625008	18/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473		1	Adjuvant Therapy			Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BUSULFAN	30	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	18	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	18/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	6	258684004	2	Oral	26643006	18/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	10	258684004	2	Oral	26643006	18/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	78	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	25	258684004	2	Oral	26643006	18/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	POMALIDOMIDE	3	258684004	2	Oral	26643006	18/04/2023	RBZ
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	80	258684004	2	Oral	26643006	18/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/04/2023	RBZ
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ISATUXIMAB	900	258684004	1	Intravenous	47625008	18/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	18/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	APIXABAN	2.5	258684004	2	Oral	26643006	18/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IXAZOMIB	3	258684004	2	Oral	26643006	18/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	5	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CABAZITAXEL	40	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	18/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABAZITAXEL	40	258684004	1	Intravenous	47625008	18/04/2023	RH8
RBZ	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	RUXOLITINIB	15	258684004	2	Oral	26643006	18/04/2023	RBZ
RH8	D471		3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	RUXOLITINIB	25	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	18/04/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	91	AVELUMAB	800	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	18/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	18/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	40	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	18/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	180	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	33	NILOTINIB	200	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)			Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	NILOTINIB	150	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	300	258684004	2	Oral	26643006	18/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ETOPOSIDE	180	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	18/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TALIMOGENE LAHERPAREPVEC 10*8	3	74964007	5	Subcutaneous	34206005	18/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	18/04/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	18/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	18/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THALIDOMIDE	50	258684004	2	Oral	26643006	18/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	18/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	18/04/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	18/04/2023	RBZ
RH8	C833		9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	18/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833		9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C833		9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C833		9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	108	258684004	1	Intravenous	47625008	18/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	600	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CETUXIMAB	900	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1650	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DEXAMETHASONE	2	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	550	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	30	LENALIDOMIDE	5	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	15	258684004	2	Oral	26643006	19/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	5	258684004	2	Oral	26643006	19/04/2023	RH8
RBZ	C900	97323	9				Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	25	258684004	2	Oral	26643006	19/04/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	45	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C900		9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	320	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	500	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	700	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	19/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	19/04/2023	RBZ
RBZ	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C05.1				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	100	258684004	2	Oral	26643006	19/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	19/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	19/04/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	180	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	2	MELPHALAN	400	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C920		3	Not Applicable (Primary Treatment)	98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920		3	Not Applicable (Primary Treatment)	98	Other	Cytarabine High Dose	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	6300	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VENETOCLAX	400	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C833		9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C833		9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C880		9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C833		9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C833		9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C880		9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	19/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C880		9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CABOZANTINIB	20	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/04/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	52	FLUOROURACIL	650	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	52	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	63	PALBOCICLIB	100	258684004	2	Oral	26643006	19/04/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	52	PANITUMUMAB	500	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	19/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IPILIMUMAB	75	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	200	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BOSUTINIB	100	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	360	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	25	METFORMIN	850	258684004	2	Oral	26643006	19/04/2023	RH8
RBZ	C20				99	Not known	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	70	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	19/04/2023	RH8
RBZ	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	21	GEMCITABINE	1200	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	19/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349		3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	270	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Regorafenib CRC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	REGORAFENIB	120	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/04/2023	RH8
RBZ	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	19/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	120	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	120	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	79	Olaparib	250	258684004	2	Oral	26643006	19/04/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	Olaparib	200	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C880		9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZANUBRUTINIB	80	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	5	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	19/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IBRUTINIB	280	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO - AD OES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	10	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C900		9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	10	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	49	LENALIDOMIDE	5	258684004	2	Oral	26643006	19/04/2023	RBZ
RBZ	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1000	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2750	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/04/2023	RH8
RBZ	C880	97613	3	Not Applicable (Primary Treatment)			ZANUBRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZANUBRUTINIB	160	258684004	2	Oral	26643006	19/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ISATUXIMAB	1000	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C900		9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ISATUXIMAB	440	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	49	IXAZOMIB	2.3	258684004	2	Oral	26643006	19/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	49	APIXABAN	2.5	258684004	2	Oral	26643006	19/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB - EMTANSINE	240	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	19/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473		9		98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C848		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	BEXAROTENE	225	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C44X		9		98	Other	Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Olaparib	300	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C44X		9		98	Other	Vismodegib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	VISMONDEGIB	150	258684004	2	Oral	26643006	19/04/2023	RH8
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	19/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	40	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	NILOTINIB	400	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	53	NILOTINIB	300	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	81	NILOTINIB	150	258684004	2	Oral	26643006	19/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ETOPOSIDE	180	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ERIBULIN	1.67	258684004	1	Intravenous	47625008	19/04/2023	RH8
RH8	C859		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3600	258684004	1	Intravenous	47625008	19/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	110	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	96	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C169		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	64	258684004	1	Intravenous	47625008	19/04/2023	RH8
RBZ	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RBZ	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RBZ	C349	80423	9				CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	19/04/2023	RBZ
RH8	C880		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C859		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C859		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	20/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	600	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CETUXIMAB	900	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cytarabine low (10to20mg/m2) IV/SC	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CYTARABINE	20	258684004	5	Subcutaneous	34206005	20/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	10	258684004	2	Oral	26643006	20/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	40	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	20/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	700	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1500	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	500	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2150	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	200	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	250	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	225	258684004	1	Intravenous	47625008	20/04/2023	RBZ
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	280	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	20/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	20/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	20/04/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	FLUOROURACIL	550	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	20/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	120	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	20/04/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	CETUXIMAB	800	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TEMOZOLOMIDE	380	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	20/04/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	20/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880		3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	270	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AVELUMAB	800	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	1.5	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C829		3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	20/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	80	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	29	CAPECITABINE	1000	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	Osimertinib	80	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	890	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	125	258684004	2	Oral	26643006	20/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	100	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C900		9		99	Not known	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX-R WK4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	100	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	600	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRAMETINIB	2	258684004	2	Oral	26643006	20/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DABRAFENIB	150	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	21	RIBOCICLIB	200	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	200	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	600	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	42	NIRAPARIB	100	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	NIRAPARIB	300	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	35	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RH8	C900		9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POLATUZUMAB VEDOTIN	152	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	20/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/04/2023	RBZ
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C25.9				99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TEMOZOLOMIDE	375	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	50	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			ABEM & LETROZ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABEMACICLIB	100	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C509		9				RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	400	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C509		9				RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	200	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IBRUTINIB	420	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			ECT - BLEOMYCIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	28750	408102007	1	Intravenous	47625008	20/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	28	NIRAPARIB	100	258684004	2	Oral	26643006	20/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	54	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	D473		1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	120	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IBRUTINIB	560	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	D475		3	Not Applicable (Primary Treatment)	98	Other	IMAT CEL/HES>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	100	258684004	2	Oral	26643006	20/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	38	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	20/04/2023	RBZ
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C900		9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	43	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/04/2023	RBZ
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	5	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C900		9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Panobinostat	15	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CAPECITABINE	1500	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	22	CAPECITABINE	2150	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	25	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C900		9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB UC-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	8	IXAZOMIB	4	258684004	2	Oral	26643006	20/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C920		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RBZ	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	64	RUXOLITINIB	25	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	D45X		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	41	RUXOLITINIB	10	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CARBO BR CA	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	400	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C900		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	700	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	120	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	20/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	APIXABAN	2.5	258684004	2	Oral	26643006	20/04/2023	RH8
RBZ	D591		3	Not Applicable (Primary Treatment)	98	Other	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	20/04/2023	RBZ
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	40	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NILOTINIB	300	258684004	2	Oral	26643006	20/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POMALIDOMIDE	4	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ETOPOSIDE	180	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ERIBULIN	1.06	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	POMALIDOMIDE	4	258684004	2	Oral	26643006	20/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	20/04/2023	RH8
RH8	C859		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	3600	258684004	1	Intravenous	47625008	20/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	110	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	630	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	80	258684004	1	Intravenous	47625008	20/04/2023	RH8
RBZ	C349	80423	3	Not Applicable (Primary Treatment)	98	Other	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	20/04/2023	RBZ
RBZ	C349	80423	3	Not Applicable (Primary Treatment)	98	Other	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	20/04/2023	RBZ
RBZ	C349	80423	3	Not Applicable (Primary Treatment)	98	Other	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	20/04/2023	RBZ
RH8	C509				99	Not known	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C509				99	Not known	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	20/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C880		3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	450	258684004	1	Intravenous	47625008	21/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	400	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CETUXIMAB	900	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	5	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	40	LENALIDOMIDE	15	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1500	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	40	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	650	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	21/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349		3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	180	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	148	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		9				Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/04/2023	RH8
RBZ	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	35	TRASTUZUMAB-ONTRUZANT	651	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	169	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1300	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	21/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	120	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C719		1	Adjuvant Therapy	99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	21/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RBZ	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C719				99	Not known	Temozolomide + RT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	140	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide + RT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	150	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BINIMETINIB	30	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENCORAFENIB	250	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	160	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	200	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	21/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	96	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	21/04/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	21/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	21/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	45	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	80	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	80	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C911		9		98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	80	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	51	PALBOCICLIB	75	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	41	PALBOCICLIB	100	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	150	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	790	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABEMACICLIB	100	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	125	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	100	258684004	2	Oral	26643006	21/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PALBOCICLIB	75	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PALBOCICLIB	100	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C459		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	65	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C911				98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	180	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	21/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	400	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C459		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	360	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RBZ	C921	98633	9		99	Not known	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BOSUTINIB	100	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ALECTINIB	600	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	NIRAPARIB	200	258684004	2	Oral	26643006	21/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833		3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	60	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C10		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C349		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	21/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PALBOCICLIB	125	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	336	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	21/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	21/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C509		9				RIBO and FULV 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	400	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Nivolumab	480	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	47	IBRUTINIB	420	258684004	2	Oral	26643006	21/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C844		3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C844		3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C844		3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ACALABRUTINIB	100	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	21/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	132	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Nivolumab	480	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IMATINIB	400	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SACITUZUMAB GOVITECAN	580	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		9				RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	21/04/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	21/04/2023	RH8
RH8	D45X		1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	25	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	80	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C900		9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POMALIDOMIDE	4	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	15	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	15	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	25	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1800	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ISATUXIMAB	800	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APIXABAN	2.5	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IXAZOMIB	4	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IXAZOMIB	3	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IXAZOMIB	4	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C900		9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IXAZOMIB	4	258684004	2	Oral	26643006	21/04/2023	RBZ
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	21/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	149	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	21/04/2023	RH8
RH8	C900		9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	5	258684004	2	Oral	26643006	21/04/2023	RH8
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	21/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			Ipilimumab	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	225	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB DERUXTECAN	440	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	21/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	21/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	40	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	164	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ETOPOSIDE	180	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ERIBULIN	0.97	258684004	1	Intravenous	47625008	21/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	120	258684004	2	Oral	26643006	22/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	47	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/04/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	99	Not known	ASCIMINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ASCIMINIB	80	258684004	2	Oral	26643006	22/04/2023	RBZ
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	EP500(5)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	4	258684004	2	Oral	26643006	22/04/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PAZOPANIB	600	258684004	2	Oral	26643006	22/04/2023	RBZ
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	26	IBRUTINIB	420	258684004	2	Oral	26643006	22/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	22/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ETOPOSIDE	180	258684004	1	Intravenous	47625008	22/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	Osimertinib	40	258684004	2	Oral	26643006	23/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EXEMESTANE	25	258684004	2	Oral	26643006	23/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EVEROLIMUS	7.5	258684004	2	Oral	26643006	23/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/04/2023	RH8
RH8	D48.9		9		99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	325	258684004	2	Oral	26643006	23/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	PONATINIB - C3>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PONATINIB	15	258684004	2	Oral	26643006	23/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ACALABRUTINIB	100	258684004	2	Oral	26643006	23/04/2023	RH8
RBZ	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IMATINIB	400	258684004	2	Oral	26643006	23/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	23/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/04/2023	RH8
RBZ	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IBRUTINIB	420	258684004	2	Oral	26643006	23/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	24/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	24/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	216	258684004	1	Intravenous	47625008	24/04/2023	RBZ
RH8	C900		9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C900		9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	5	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	15	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	36	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	24/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	280	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	4	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	700	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Melphalan IV High dose	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MELPHALAN	180	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	14	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	132	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	50	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	1.4	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	750	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CABOZANTINIB	20	258684004	2	Oral	26643006	24/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	24/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	300	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	225	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	24/04/2023	RBZ
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IBRUTINIB	420	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C349		9		99	Not known	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ALECTINIB	450	258684004	2	Oral	26643006	24/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	90	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	80	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IMATINIB	400	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	2560	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/04/2023	RBZ
RBZ	C189				99	Not known	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PROCARBAZINE	200	258684004	2	Oral	26643006	24/04/2023	RH8
RBZ	C23		1	Adjuvant Therapy	99	Not known	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1500	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C509				99	Not known	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RIBOCICLIB	400	258684004	2	Oral	26643006	24/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	10	NINTEDANIB	200	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	RIBOCICLIB	400	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	220	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	24/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ECT - BLEOMYCIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	20000	408102007	1	Intravenous	47625008	24/04/2023	RH8
RBZ	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	24/04/2023	RBZ
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	D471		3	Not Applicable (Primary Treatment)			HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ACALABRUTINIB	100	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENCORAFENIB	300	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CETUXIMAB	900	258684004	1	Intravenous	47625008	24/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189		3	Not Applicable (Primary Treatment)			ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CETUXIMAB	1000	258684004	1	Intravenous	47625008	24/04/2023	RBZ
RBZ	C349	80463	9				CERITINIB SUB>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	CERITINIB	300	258684004	2	Oral	26643006	24/04/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB - EMTANSINE	160	258684004	1	Intravenous	47625008	24/04/2023	RBZ
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C812		9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	23750		1	Intravenous	47625008	24/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	12	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	24/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1600	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1000	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	10	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	24/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	66	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CYCLOPHOSPHAMIDE	1780	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXRAZOXANE	1140	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C900		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	10	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	24/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C900		9		98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	24/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	180	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DEXAMETHASONE	10	258684004	2	Oral	26643006	24/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	POMALIDOMIDE	3	258684004	2	Oral	26643006	24/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	APIXABAN	2.5	258684004	2	Oral	26643006	24/04/2023	RBZ
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IFOSFAMIDE	1440	258684004	1	Intravenous	47625008	24/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	164	258684004	1	Intravenous	47625008	24/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	790	258684004	1	Intravenous	47625008	25/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CARBOPLATIN	560	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	300	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	600	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	240	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CETUXIMAB	900	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C900		9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	10	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	600	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C900		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	81	LENALIDOMIDE	5	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	15	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C900		9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	15	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	120	258684004	1	Intravenous	47625008	25/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	145	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C900		9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB-ONTRUZANT	651	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	132	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	25/04/2023	RBZ
RBZ	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RBZ	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	400	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	370	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	25/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349		9				ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C349		9				ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C349		9				ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C349		9				ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	148	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AVELUMAB	800	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AXITINIB	5	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CAPECITABINE	1800	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	5	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	500	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CABOZANTINIB	40	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	330	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PANITUMUMAB	260	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PALBOCICLIB	125	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	175	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	25/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TUCATINIB	250	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	68	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	58	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IMATINIB	400	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	25/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	C349	80463	9				PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1500	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	25	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1400	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CARFILZOMIB	54	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	144	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	270	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	25/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	600	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	200	258684004	2	Oral	26643006	25/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C519		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	220	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	PONATINIB - C3>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PONATINIB	15	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	Nivolumab	480	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AVELUMAB	800	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C900		1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APIXABAN	2.5	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	D693		9		98	Other	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMETREXED	800	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	33	IMATINIB	400	258684004	2	Oral	26643006	25/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	3280	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	56	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	164	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	38	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	D473				98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	15	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	41	LENALIDOMIDE	5	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CAPECITABINE	1450	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	400	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	216	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IXAZOMIB	4	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	IXAZOMIB	4	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VDC<25 Cy>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CABAZITAXEL	44	258684004	1	Intravenous	47625008	25/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	RUXOLITINIB	10	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	C44		3	Not Applicable (Primary Treatment)			Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	25/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	25/04/2023	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	11	IXAZOMIB	4	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	750	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	10	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	150	258684004	1	Intravenous	47625008	25/04/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NILOTINIB	200	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	2.2	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	THALIDOMIDE	100	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	25/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/04/2023	RBZ
RH8	C900		9		98	Other	Z-Dex.	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IDARUBICIN HYDROCHLORIDE	20	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINBLASTINE SULFATE	9	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/04/2023	RBZ
RH8	C900		9		98	Other	Z-Dex.	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PROCARBAZINE	150	258684004	2	Oral	26643006	25/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CHLORAMBUCIL	10	258684004	2	Oral	26643006	25/04/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	25/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	96	258684004	1	Intravenous	47625008	25/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cytarabine low (10to20mg/m2) IV/SC	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CYTARABINE	20	258684004	5	Subcutaneous	34206005	26/04/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1400	258684004	1	Intravenous	47625008	26/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	2000	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	78	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	50	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	79	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	700	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	800	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	26/04/2023	RBZ
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	280	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RBZ	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	26/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	240	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	180	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	26/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	19	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	26/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C349		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINORELBINE	100	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	26/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	26/04/2023	RH8
RH8	C349		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	145	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C49X		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	270	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	26/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AVELUMAB	800	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C910		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	MERCAPTOPURINE	120	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	26/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C900		9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	40	258684004	2	Oral	26643006	26/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	120	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C910		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	METHOTREXATE	40	258684004	2	Oral	26643006	26/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911		3	Not Applicable (Primary Treatment)			Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	100	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	75	258684004	2	Oral	26643006	26/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABEMACICLIB	150	258684004	2	Oral	26643006	26/04/2023	RBZ
RBZ	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PANITUMUMAB	340	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	Osimertinib	80	258684004	2	Oral	26643006	26/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C900		9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	6	ISATUXIMAB	800	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/04/2023	RH8
RBZ	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C509				99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)			PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CARFILZOMIB	54	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	21	GEMCITABINE	1200	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	9	NINTEDANIB	200	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	41	RIBOCICLIB	400	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	216	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	378	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C509				99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	336	258684004	1	Intravenous	47625008	26/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	600	258684004	2	Oral	26643006	26/04/2023	RBZ
RH8	C812		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	220	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	120	258684004	2	Oral	26643006	26/04/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB - EMTANSINE	360	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	164	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C44		3	Not Applicable (Primary Treatment)			AVELUMAB>4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AVELUMAB	800	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB DERUXTECAN	280	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	D45X		1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	2	258684004	2	Oral	26643006	26/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/04/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	80	258684004	2	Oral	26643006	26/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	POMALIDOMIDE	3	258684004	2	Oral	26643006	26/04/2023	RH8
RBZ	C189		1	Adjuvant Therapy	99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	2500	258684004	2	Oral	26643006	26/04/2023	RBZ
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1950	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C900		1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	POMALIDOMIDE	4	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ISATUXIMAB	800	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C900		1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ISATUXIMAB	900	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C169		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C159		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	Nivolumab	480	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RBZ	C66		3	Not Applicable (Primary Treatment)			AVELUMAB UC-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C900		1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	26/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C509		9				CARBO BR CA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	10	IXAZOMIB	4	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C509				99	Not known	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/04/2023	RBZ
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	180	258684004	1	Intravenous	47625008	26/04/2023	RH8
RBZ	C509				99	Not known	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	80	258684004	1	Intravenous	47625008	26/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C921				99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	71	NILOTINIB	300	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	IBRUTINIB	560	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C921		1	Adjuvant Therapy	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	28	NILOTINIB	300	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ERIBULIN	1.67	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	THALIDOMIDE	100	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	26/04/2023	RH8
RH8	C900		9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	26/04/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			DOSTAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOSTARLIMAB	500	258684004	1	Intravenous	47625008	26/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	200	258684004	2	Oral	26643006	26/04/2023	RH8
RBZ	C159		2	Neoadjuvant Therapy	99	Not known	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RBZ	C159		2	Neoadjuvant Therapy	99	Not known	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	26/04/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	27/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	216	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	500	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	600	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CETUXIMAB	800	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CETUXIMAB	1000	258684004	1	Intravenous	47625008	27/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	LENALIDOMIDE	10	258684004	2	Oral	26643006	27/04/2023	RBZ
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	40	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1650	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	165	258684004	1	Intravenous	47625008	27/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	74	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	27/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	27/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CABOZANTINIB	20	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)			Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	900	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	54	PALBOCICLIB	125	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	100	258684004	2	Oral	26643006	27/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PALBOCICLIB	100	258684004	2	Oral	26643006	27/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PALBOCICLIB	75	258684004	2	Oral	26643006	27/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Osimertinib	80	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PALBOCICLIB	100	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX-R WK5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	200	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PACLITAXEL	72	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DABRAFENIB	100	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRAMETINIB	2	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)			VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	12	VENETOCLAX	400	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	52	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	49	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	39	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	27/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	D473		1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	OBIN + CHLORAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CHLORAMBUCIL	46	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	350	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PALBOCICLIB	75	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PANITUMUMAB	180	258684004	1	Intravenous	47625008	27/04/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BOSUTINIB	300	258684004	2	Oral	26643006	27/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SACITUZUMAB GOVITECAN	830	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C830		3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	3	FIANLIMAB/CEMIPLIMAB	750	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	3	FIANLIMAB/CEMIPLIMAB	1950	258684004	1	Intravenous	47625008	27/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/04/2023	RBZ
RH8	C911		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ACALABRUTINIB	100	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C830		3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	16	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	3	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	27/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ACALABRUTINIB	100	258684004	2	Oral	26643006	27/04/2023	RBZ
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	164	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IBRUTINIB	560	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RH8	D45X		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/04/2023	RH8
RBZ	D473	99623	9		98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	DEXAMETHASONE	10	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C900		9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	40	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/04/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/04/2023	RBZ
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	120	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	POMALIDOMIDE	1	258684004	2	Oral	26643006	27/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C900		9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	15	258684004	2	Oral	26643006	27/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CAPECITABINE	2000	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C349		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DURVALUMAB	1500	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ISATUXIMAB	650	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C900		9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	APIXABAN	2.5	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C900		9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IXAZOMIB	4	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C900		9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	27/04/2023	RH8
RBZ	C259				98	Other	mFOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	27/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO*	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	86	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	27/04/2023	RBZ
RBZ	C259				98	Other	mFOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	27/04/2023	RBZ
RBZ	C259				98	Other	mFOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	135	258684004	1	Intravenous	47625008	27/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DASATINIB	100	258684004	2	Oral	26643006	27/04/2023	RBZ
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	IBRUTINIB	140	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C831		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	IBRUTINIB	280	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NILOTINIB	200	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - CY1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - CY1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	100	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	100	ERIBULIN	1.67	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ERIBULIN	2.02	258684004	1	Intravenous	47625008	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	27/04/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	790	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	28/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	36	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	350	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	36	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	36	FLUOROURACIL	700	258684004	1	Intravenous	47625008	28/04/2023	RH8
RBZ	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RBZ	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CETUXIMAB	800	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	36	CETUXIMAB	800	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C900		1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	800	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C900		1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	25	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	28/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	180	258684004	1	Intravenous	47625008	28/04/2023	RH8
RBZ	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	164	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	375	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	550	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	550	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	100	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	28/04/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	200	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	160	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	96	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	28/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/04/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/04/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	120	258684004	2	Oral	26643006	28/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	42	ABEMACICLIB	150	258684004	2	Oral	26643006	28/04/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PALBOCICLIB	125	258684004	2	Oral	26643006	28/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	Osimertinib	40	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C349		3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Osimertinib	80	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PALBOCICLIB	75	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	100	258684004	2	Oral	26643006	28/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	100	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	46	PALBOCICLIB	75	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	DABRAFENIB	75	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	TRAMETINIB	1	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VENETOCLAX	400	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	300	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	180	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DABRAFENIB	150	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRAMETINIB	2	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ALECTINIB	600	258684004	2	Oral	26643006	28/04/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	21	NIRAPARIB	100	258684004	2	Oral	26643006	28/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	56	ALECTINIB	600	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BOSUTINIB	200	258684004	2	Oral	26643006	28/04/2023	RBZ
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IBRUTINIB	280	258684004	2	Oral	26643006	28/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	100	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	28/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	99	Not known	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RH8	D473				99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	D473		1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RH8	C01X				99	Not known	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	C23		1	Adjuvant Therapy	99	Not known	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	800	258684004	2	Oral	26643006	28/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	500	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PANITUMUMAB	340	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	100	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PALBOCICLIB	100	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	216	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	28/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	RIBOCICLIB	400	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	51	Nivolumab	480	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	43	IBRUTINIB	420	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RH8	C911		3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ACALABRUTINIB	100	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1400	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	28/04/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	Nivolumab	480	258684004	1	Intravenous	47625008	28/04/2023	RBZ
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	400	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB-ONTRUZANT	378	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1800	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	400	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ETOPOSIDE	164	258684004	1	Intravenous	47625008	28/04/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	28/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	28/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	80	258684004	2	Oral	26643006	28/04/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/04/2023	RBZ
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	65	LENALIDOMIDE	15	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	25	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	65	IXAZOMIB	4	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IXAZOMIB	3	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C812		3	Not Applicable (Primary Treatment)	99	Not known	PEMBRO CHL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C680				99	Not known	XELOX UROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C680				99	Not known	XELOX UROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	260	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	D471		3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RUXOLITINIB	5	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	28/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	28/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	800	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	135	258684004	1	Intravenous	47625008	28/04/2023	RH8
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	28/04/2023	RBZ
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PROCARBAZINE	200	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C629		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	28/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NILOTINIB	300	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LOMUSTINE	200	258684004	2	Oral	26643006	28/04/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	375	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	28/04/2023	RH8
RH8	C833		3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	700	258684004	1	Intravenous	47625008	28/04/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	10	258684004	2	Oral	26643006	29/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	25	258684004	2	Oral	26643006	29/04/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	29/04/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/04/2023	RBZ
RH8	C349		3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Osimertinib	80	258684004	2	Oral	26643006	29/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	87	IMATINIB	300	258684004	2	Oral	26643006	29/04/2023	RH8
RH8	D473				99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/04/2023	RH8
RH8	D473		1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/04/2023	RH8
RH8	C911		1	Adjuvant Therapy			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ACALABRUTINIB	100	258684004	2	Oral	26643006	29/04/2023	RH8
RH8	C921		3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	400	258684004	2	Oral	26643006	29/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	80	258684004	2	Oral	26643006	29/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	15	258684004	2	Oral	26643006	29/04/2023	RH8
RH8	C900		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	APIXABAN	2.5	258684004	2	Oral	26643006	29/04/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/04/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Osimertinib	40	258684004	2	Oral	26643006	30/04/2023	RBZ
RH8	D473				99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/04/2023	RH8
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/04/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473		1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/04/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	NIRAPARIB	100	258684004	2	Oral	26643006	30/04/2023	RH8
RBZ	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	400	258684004	2	Oral	26643006	30/04/2023	RBZ
RH8	D473		3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/04/2023	RH8
RH8	D473				98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/04/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LENVATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - LENVIMA	16	258684004	2	Oral	26643006	30/04/2023	RH8
RH8	C911		3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IBRUTINIB	420	258684004	2	Oral	26643006	30/04/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	70	LENALIDOMIDE	5	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	48	BOSUTINIB	400	258684004	2	Oral	26643006	01/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ALECTINIB	600	258684004	2	Oral	26643006	01/05/2023	RBZ
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	14	METFORMIN	850	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	D473	99623			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/05/2023	RBZ
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Melphalan oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	MELPHALAN	8	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IMATINIB	300	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IMATINIB	400	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	84	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	61	LENALIDOMIDE	10	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	15	258684004	2	Oral	26643006	01/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/05/2023	RBZ
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	01/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IXAZOMIB	3	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	74	RUXOLITINIB	10	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	46	RUXOLITINIB	15	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	10	258684004	2	Oral	26643006	01/05/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IBRUTINIB	420	258684004	2	Oral	26643006	01/05/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	SUNITINIB	25	258684004	2	Oral	26643006	01/05/2023	RBZ
RH8	C900	97323	9		98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	19	APIXABAN	2.5	258684004	2	Oral	26643006	01/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	25	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB - EMTANSINE	300	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LIPOSOMAL DOXORUBICIN	42	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LIPOSOMAL DOXORUBICIN	62	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	25	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	25	FLUOROURACIL	800	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	330	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	02/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	725	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	270	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	25	CETUXIMAB	1000	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DEXAMETHASONE	6	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	10	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	600	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	15	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	10	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	15	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	135	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	02/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	600	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	550	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	165	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	180	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	240	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/05/2023	RH8
RBZ	C509				99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1800	258684004	1	Intravenous	47625008	02/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	132	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C01		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TEMOZOLOMIDE	150	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	360	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1600	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRASTAD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	02/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	15	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	02/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PALBOCICLIB	125	258684004	2	Oral	26643006	02/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	216	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DABRAFENIB	150	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	TRAMETINIB	2	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	100	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	BOSUTINIB	400	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	84	IMATINIB	200	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IXAZOMIB	2.3	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IMATINIB	400	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	02/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	D473	99623			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	CABOZANTINIB	40	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	CABOZANTINIB	20	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	02/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C519		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ACALABRUTINIB	100	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ACALABRUTINIB	100	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RH8	C679		3	Not Applicable (Primary Treatment)			ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PALBOCICLIB	125	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	750	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	Nivolumab	480	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	48	IMATINIB	400	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	60	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	2000	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	25	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	800	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	50	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	320	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	D473	99623	9		98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	10	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	4	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	120	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	15	258684004	2	Oral	26643006	02/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	25	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	80	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	120	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C880	97613	9		98	Other	Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	6	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			GILTERITINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GILTERITINIB	120	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1500	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	135	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	96	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IXAZOMIB	4	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IXAZOMIB	4	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	02/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	80	RUXOLITINIB	15	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Olaparib	300	258684004	2	Oral	26643006	02/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	02/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	5	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	300	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	D591		3	Not Applicable (Primary Treatment)			Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	02/05/2023	RBZ
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	NILOTINIB	150	258684004	2	Oral	26643006	02/05/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	NILOTINIB	300	258684004	2	Oral	26643006	02/05/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/05/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TALIMOGENE LAHERPAREPVEC 10*8	3	74964007	5	Subcutaneous	34206005	02/05/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/05/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/05/2023	RBZ
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VC-RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	13	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	02/05/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VC-RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CYCLOPHOSPHAMIDE	2000	258684004	1	Intravenous	47625008	02/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/05/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/05/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	500	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	600	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CETUXIMAB	900	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CETUXIMAB	900	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1450	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DEXAMETHASONE	2	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	10	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	03/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	550	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	121	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	74	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	500	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	15	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1200	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1400	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	2000	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	110	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	30	258684004	1	Intravenous	47625008	03/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	50	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	45	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	320	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1300	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	700	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2150	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	100	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	03/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	03/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	03/05/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	220	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	270	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AXITINIB	5	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	03/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	37	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RH8	C159		9				PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	120	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	40	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	53	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	53	FLUOROURACIL	650	258684004	1	Intravenous	47625008	03/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C159		9				PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	Osimertinib	40	258684004	2	Oral	26643006	03/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	52	PALBOCICLIB	75	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	50	PALBOCICLIB	75	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	53	PANITUMUMAB	500	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	03/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Osimertinib	80	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	125	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PALBOCICLIB	125	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	75	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PALBOCICLIB	100	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C159		9				PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	150	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	03/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	28	Nivolumab	480	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	27	NIRAPARIB	200	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	18	METFORMIN	850	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	23	APIXABAN	2.5	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/05/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/05/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	D473	99623			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C04X		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	46	RIBOCICLIB	200	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C911	98233	9		98	Other	VENETOCLAX MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	03/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	21250		1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C64		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Nivolumab	480	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	03/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	200	258684004	2	Oral	26643006	03/05/2023	RBZ
RBZ	C921	98633	1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	65	IMATINIB	100	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Olaparib	100	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BCNU/THIOTEPA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	POMALIDOMIDE	2	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	03/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DACARBAZINE	450	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	400	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	280	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	320	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/05/2023	RBZ
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/05/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	6	258684004	2	Oral	26643006	03/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	10	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	10	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	40	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	80	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	POMALIDOMIDE	4	258684004	2	Oral	26643006	03/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2150	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	POMALIDOMIDE	2	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	21	CAPECITABINE	1200	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ISATUXIMAB	1000	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ISATUXIMAB	440	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C189				99	Not known	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	Nivolumab	480	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APIXABAN	2.5	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	28	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	03/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	98	Other	APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	24	RUXOLITINIB	10	258684004	2	Oral	26643006	03/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	92	AVELUMAB	800	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	4	258684004	2	Oral	26643006	03/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	4	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	03/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PEMETREXED	900	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	03/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMETREXED	650	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	800	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C921	98633	9		5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	NILOTINIB	400	258684004	2	Oral	26643006	03/05/2023	RH8
RBZ	C831	96733	1	Adjuvant Therapy			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IBRUTINIB	560	258684004	2	Oral	26643006	03/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	200	258684004	2	Oral	26643006	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ERIBULIN	1.06	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	03/05/2023	RH8
RBZ	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RBZ	C830	96993	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	03/05/2023	RBZ
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DACARBAZINE	630	258684004	1	Intravenous	47625008	03/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C541		9				Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C541		9				Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	240	258684004	1	Intravenous	47625008	04/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	04/05/2023	RBZ
RBZ	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1650	258684004	2	Oral	26643006	04/05/2023	RBZ
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	145	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	145	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	500	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	04/05/2023	RH8
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	04/05/2023	RBZ
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	04/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	04/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	400	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	17	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1000	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	400	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C911	98233	9		98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	900	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	04/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	9		98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUDARABINE PHOSPHATE	55	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BINIMETINIB	45	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENCORAFENIB	450	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENCORAFENIB	200	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BINIMETINIB	45	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENCORAFENIB	450	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	BINIMETINIB	30	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	3600	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRAST UZUMAB	1800	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	62	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	62	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	40	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	04/05/2023	RBZ
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	55	LENALIDOMIDE	5	258684004	2	Oral	26643006	04/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/05/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2000	258684004	2	Oral	26643006	04/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	50	PALBOCICLIB	75	258684004	2	Oral	26643006	04/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Osimertinib	80	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PALBOCICLIB	125	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	04/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	200	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C10X				99	Not known	COMPARE - ARM 5>	1	PATIENT is taking part in a CLINICAL TRIAL	5	DURVALUMAB	1500	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	7	ISATUXIMAB	590	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NIRAPARIB	200	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	04/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/05/2023	RBZ
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	D473	99623			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	04/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	04/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CABOZANTINIB	40	258684004	2	Oral	26643006	04/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	04/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	270	258684004	1	Intravenous	47625008	04/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	378	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EXEMESTANE	25	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	15	NINTEDANIB	150	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	400	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C509		9				RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	400	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SACITUZUMAB GOVITECAN	830	258684004	1	Intravenous	47625008	04/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	25	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX WK5	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IMATINIB	400	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IMATINIB	400	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	04/05/2023	RH8
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DACARBAZINE	450	258684004	1	Intravenous	47625008	04/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PEMETREXED	1000	258684004	1	Intravenous	47625008	04/05/2023	RH8
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	320	258684004	1	Intravenous	47625008	04/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	04/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	25	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Osimertinib	80	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	10	IXAZOMIB	4	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	28	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	04/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	700	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	120	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	40	SUNITINIB	50	258684004	2	Oral	26643006	04/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	04/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	90	NILOTINIB	200	258684004	2	Oral	26643006	04/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NILOTINIB	400	258684004	2	Oral	26643006	04/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	100	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	100	ERIBULIN	1.67	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ERIBULIN	2.02	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	04/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	04/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	630	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	88	258684004	1	Intravenous	47625008	04/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	650	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	750	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CETUXIMAB	900	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	10	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Bevacizumab 15mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	105	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	05/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUDARABINE PHOSPHATE	55	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	200	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	3600	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	325	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	05/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	05/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYD AML/CML 1DY>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1800	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	05/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	80	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	05/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	55	VENETOCLAX	300	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	180	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	270	258684004	1	Intravenous	47625008	05/05/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	74	TRAMETINIB	2	258684004	2	Oral	26643006	05/05/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	74	DABRAFENIB	150	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DABRAFENIB	150	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	TRAMETINIB	2	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	120	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IMATINIB	200	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZOLIZUMAB >>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	600	258684004	2	Oral	26643006	05/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IBRUTINIB	140	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	PONATINIB - C3>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PONATINIB	15	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ/BEVA HCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SACITUZUMAB GOVITECAN	580	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/05/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ/BEVA HCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	05/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	120	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	05/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1400	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	05/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IMATINIB	200	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	121	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	120	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	80	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	54	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	5	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	2300	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2450	258684004	2	Oral	26643006	05/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/05/2023	RH8
RBZ	C61		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	26	CAPECITABINE	1000	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ISATUXIMAB	700	258684004	1	Intravenous	47625008	05/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IXAZOMIB	4	258684004	2	Oral	26643006	05/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	28	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	05/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RUXOLITINIB	15	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C349	80463	9		99	Not known	TEPOTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEPOTINIB	225	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	185	258684004	1	Intravenous	47625008	05/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			SOTORASIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SOTORASIB	960	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	05/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	NILOTINIB	400	258684004	2	Oral	26643006	05/05/2023	RBZ
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NILOTINIB	400	258684004	2	Oral	26643006	05/05/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	NILOTINIB	200	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	21	NILOTINIB	400	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C880	97613	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	IBRUTINIB	420	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ERIBULIN	0.97	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINBLASTINE SULFATE	9	258684004	1	Intravenous	47625008	05/05/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	98	Other	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	05/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IDARUBICIN HYDROCHLORIDE	15	258684004	1	Intravenous	47625008	06/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUDARABINE PHOSPHATE	55	258684004	1	Intravenous	47625008	06/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	06/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	3600	258684004	1	Intravenous	47625008	06/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ERLOTINIB 2MTH +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ERLOTINIB	150	258684004	2	Oral	26643006	06/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	NIRAPARIB	100	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/05/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ACALABRUTINIB	100	258684004	2	Oral	26643006	06/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Dabrafenib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYTARABINE	4000	258684004	1	Intravenous	47625008	06/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			SOTORASIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SOTORASIB	960	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	48	IBRUTINIB	420	258684004	2	Oral	26643006	06/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DASATINIB	20	258684004	2	Oral	26643006	06/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IDARUBICIN HYDROCHLORIDE	15	258684004	1	Intravenous	47625008	07/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUDARABINE PHOSPHATE	55	258684004	1	Intravenous	47625008	07/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	07/05/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	3600	258684004	1	Intravenous	47625008	07/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CABOZANTINIB	40	258684004	2	Oral	26643006	07/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CABOZANTINIB	20	258684004	2	Oral	26643006	07/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Osimertinib	80	258684004	2	Oral	26643006	07/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ALECTINIB	600	258684004	2	Oral	26643006	07/05/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/05/2023	RBZ
RH8	C911	98233	9		98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ACALABRUTINIB	100	258684004	2	Oral	26643006	07/05/2023	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ZANUBRUTINIB	160	258684004	2	Oral	26643006	07/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	07/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			LORLATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LORLATINIB	100	258684004	2	Oral	26643006	07/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	52	PAZOPANIB	400	258684004	2	Oral	26643006	07/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	32	LENALIDOMIDE	15	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1200	258684004	1	Intravenous	47625008	08/05/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	30	258684004	1	Intravenous	47625008	08/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	08/05/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VENETOCLAX	400	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	C911	98233	9		98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	12	VENETOCLAX	400	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/05/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/05/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CABOZANTINIB	40	258684004	2	Oral	26643006	08/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	AML MAINT MIDOST	2	PATIENT is not taking part in a CLINICAL TRIAL	5	MIDOSTAURIN	50	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	08/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	120	258684004	1	Intravenous	47625008	08/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	53	BOSUTINIB	500	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	C921	98633	9		98	Other	IMAT RDE 90 CYC1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	200	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	08/05/2023	RBZ
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	08/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	180	258684004	2	Oral	26643006	08/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	08/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	08/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	180	258684004	2	Oral	26643006	08/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	400	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	08/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	2900	258684004	1	Intravenous	47625008	08/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/05/2023	RBZ
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	480	258684004	1	Intravenous	47625008	08/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	08/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	120	258684004	2	Oral	26643006	08/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/05/2023	RBZ
RH8	C61X		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	80	258684004	2	Oral	26643006	08/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	08/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CABAZITAXEL	54	258684004	1	Intravenous	47625008	08/05/2023	RH8
RBZ	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	20	RUXOLITINIB	15	258684004	2	Oral	26643006	08/05/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	70	DASATINIB	100	258684004	2	Oral	26643006	08/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	53	IBRUTINIB	560	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	35	IBRUTINIB	420	258684004	2	Oral	26643006	08/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	600	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	198	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CETUXIMAB	800	258684004	1	Intravenous	47625008	09/05/2023	RH8
RBZ	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DEXAMETHASONE	10	258684004	2	Oral	26643006	09/05/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	600	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	09/05/2023	RH8
RBZ	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	25	258684004	2	Oral	26643006	09/05/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	120	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	140	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	09/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	09/05/2023	RH8
RBZ	C44		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	360	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C44		3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	200	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	132	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	09/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C56X		2	Neoadjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	790	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1600	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	890	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	09/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	180	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AVELUMAB	800	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AXITINIB	5	258684004	2	Oral	26643006	09/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RBZ	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	1400	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	47	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/05/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	09/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMG>4	1	PATIENT is taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/05/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	120	258684004	2	Oral	26643006	09/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/05/2023	RBZ
RBZ	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	100	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	725	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	Osimertinib	80	258684004	2	Oral	26643006	09/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	Osimertinib	80	258684004	2	Oral	26643006	09/05/2023	RH8
RBZ	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	100	258684004	2	Oral	26643006	09/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DABRAFENIB	150	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRAMETINIB	2	258684004	2	Oral	26643006	09/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	100	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	20	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	VENETOCLAX	200	258684004	2	Oral	26643006	09/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	132	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	336	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	09/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C459		9		99	Not known	NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	360	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	25	METFORMIN	850	258684004	2	Oral	26643006	09/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	41	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RH8	C900	97323	1	Adjuvant Therapy			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	09/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	09/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	09/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2300	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CARFILZOMIB	54	258684004	1	Intravenous	47625008	09/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	300	258684004	1	Intravenous	47625008	09/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	1100	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NINTEDANIB	200	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	600	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	600	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C519		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	70	258684004	1	Intravenous	47625008	09/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BOSUTINIB	100	258684004	2	Oral	26643006	09/05/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C917	98311	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ORAL MTX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	64	METHOTREXATE	10	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	560	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	315	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	50	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	480	258684004	1	Intravenous	47625008	09/05/2023	RH8
RBZ	C812	96523	9		99	Not known	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BLEOMYCIN	18000		1	Intravenous	47625008	09/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BUSULFAN	46	258684004	2	Oral	26643006	09/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	25	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	80	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	5	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DURVALUMAB	1500	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DURVALUMAB	1500	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DURVALUMAB	1500	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	09/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	5	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C829	96913	1	Adjuvant Therapy	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABAZITAXEL	40	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	28	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	336	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	36	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	800	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	09/05/2023	RH8
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			SOTORASIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	SOTORASIB	240	258684004	2	Oral	26643006	09/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	300	258684004	2	Oral	26643006	09/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	300	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RBZ	D591		3	Not Applicable (Primary Treatment)			Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	09/05/2023	RBZ
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	1.6	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PROCARBAZINE	150	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	THALIDOMIDE	100	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	180	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	70	IBRUTINIB	140	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LOMUSTINE	200	258684004	2	Oral	26643006	09/05/2023	RH8
RBZ	C169		3	Not Applicable (Primary Treatment)			Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	63	SUNITINIB	25	258684004	2	Oral	26643006	09/05/2023	RBZ
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	09/05/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	09/05/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/05/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	09/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	550	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	450	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	10/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	10	258684004	2	Oral	26643006	10/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	5	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	10/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	10/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	900	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	165	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	10/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	180	258684004	1	Intravenous	47625008	10/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	18	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	10/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	270	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	270	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AVELUMAB	800	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	52	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	10/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	MERCAPTOPURINE	120	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	52	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	36	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	40	258684004	2	Oral	26643006	10/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABOZANTINIB	20	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	METHOTREXATE	40	258684004	2	Oral	26643006	10/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	10	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q 28D>1	2	PATIENT is not taking part in a CLINICAL TRIAL	79	LENALIDOMIDE	5	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABEMACICLIB	150	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	10/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	100	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PALBOCICLIB	100	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	100	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ANASTROZOLE	1	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	MITHRI RUXOLI >1	1	PATIENT is taking part in a CLINICAL TRIAL	24	RUXOLITINIB	15	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C911	98233	9		98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	20	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	400	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	35	RIBOCICLIB	400	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	7	ISATUXIMAB	800	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ALECTINIB	600	258684004	2	Oral	26643006	10/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IXAZOMIB	4	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	10/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRIFLURIDINE/TIPIRACIL	70	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	POLATUZUMAB VEDOTIN	128	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	3.3	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	10/05/2023	RH8
RBZ	C509				99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	10/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CABOZANTINIB	20	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CARFILZOMIB	54	258684004	1	Intravenous	47625008	10/05/2023	RH8
RBZ	C509				99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	336	258684004	1	Intravenous	47625008	10/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	10/05/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IBRUTINIB	280	258684004	2	Oral	26643006	10/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AVELUMAB	800	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AXITINIB	5	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	10/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYTARABINE	3600	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	10/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	10/05/2023	RBZ
RH8	C509		9				ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	80	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB - EMTANSINE	240	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		9				ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	10/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	560	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-DHAP/RCHOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYTARABINE	3600	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	480	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	44	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	80	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	54	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RBZ
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2750	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	80	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DURVALUMAB	1500	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	10/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CABAZITAXEL	40	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	28	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/05/2023	RH8
RBZ	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	37	RUXOLITINIB	15	258684004	2	Oral	26643006	10/05/2023	RBZ
RBZ	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RUXOLITINIB	15	258684004	2	Oral	26643006	10/05/2023	RBZ
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	36	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Olaparib	300	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	10/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	700	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	5	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	800	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	150	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			Ipilimumab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	250	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	SUNITINIB	25	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	IBRUTINIB	420	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IBRUTINIB	420	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ERIBULIN	1.06	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	2.38	258684004	1	Intravenous	47625008	10/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ERIBULIN	1.06	258684004	1	Intravenous	47625008	10/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	10/05/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	10/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	2	Oral	26643006	10/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	26	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	500	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	700	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	26	FLUOROURACIL	550	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	26	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CETUXIMAB	800	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CETUXIMAB	1000	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	26	CETUXIMAB	800	258684004	1	Intravenous	47625008	11/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	44	LENALIDOMIDE	5	258684004	2	Oral	26643006	11/05/2023	RBZ
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1600	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	45	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1500	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2150	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	200	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	280	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	148	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	11/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	11/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	2	Oral	26643006	11/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	500	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DOCETAXEL	120	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CETUXIMAB	900	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	11/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C800		9				GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1000	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	11/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VENETOCLAX	400	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	400	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	11/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	43	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CYTARA 12H 3g/m?	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CABOZANTINIB	20	258684004	2	Oral	26643006	11/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	52	PALBOCICLIB	100	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	890	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	11/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	Osimertinib	80	258684004	2	Oral	26643006	11/05/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	Osimertinib	40	258684004	2	Oral	26643006	11/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	Osimertinib	40	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CYTARA 12H 3g/m?	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYTARABINE	5600	258684004	1	Intravenous	47625008	11/05/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DABRAFENIB	150	258684004	2	Oral	26643006	11/05/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRAMETINIB	2	258684004	2	Oral	26643006	11/05/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DABRAFENIB	150	258684004	2	Oral	26643006	11/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	TRAMETINIB	2	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	BOSUTINIB	500	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	200	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IMATINIB	200	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189				99	Not known	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509				99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	350	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	20	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PANITUMUMAB	180	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PALBOCICLIB	100	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	100	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PALBOCICLIB	100	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	37	PALBOCICLIB	125	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	54	VENETOCLAX	400	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	600	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	55	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ACALABRUTINIB	100	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ACALABRUTINIB	100	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CHLORAMBUCIL	12	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYTARABINE	3600	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	1000	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO + FULVEST	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	11/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	87	Nivolumab	480	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	11/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	11/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	30	CAPECITABINE	1000	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	D45X	99503			99	Not known	Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	15	BUSULFAN	40	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	53	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Panobinostat	15	258684004	2	Oral	26643006	11/05/2023	RH8
RBZ	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	11/05/2023	RBZ
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	23	CAPECITABINE	2150	258684004	2	Oral	26643006	11/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ISATUXIMAB	650	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ISATUXIMAB	800	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	11/05/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	11/05/2023	RH8
RBZ	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IXAZOMIB	4	258684004	2	Oral	26643006	11/05/2023	RBZ
RBZ	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	11/05/2023	RBZ
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/05/2023	RH8
RBZ	C73		3	Not Applicable (Primary Treatment)			CABOZ MTC -	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CABOZANTINIB	20	258684004	2	Oral	26643006	11/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABAZITAXEL	44	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	91	RUXOLITINIB	5	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Trabectedin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRABECTEDIN	2.4	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RUXOLITINIB	15	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	36	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	10	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	11/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - KISPLYX	20	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	28	SUNITINIB	25	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	11/05/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	29	NILOTINIB	400	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	IBRUTINIB	420	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	DASATINIB	40	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DASATINIB	20	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IBRUTINIB	420	258684004	2	Oral	26643006	11/05/2023	RH8
RH8	C349	80463	9				PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	100	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	88	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	80	258684004	1	Intravenous	47625008	11/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509				99	Not known	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C509				99	Not known	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	11/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	37	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	37	FLUOROURACIL	700	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	37	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	37	CETUXIMAB	800	258684004	1	Intravenous	47625008	12/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	10	258684004	2	Oral	26643006	12/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	25	258684004	2	Oral	26643006	12/05/2023	RBZ
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	800	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	550	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	180	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	120	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	12/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	450	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	550	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	550	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	170	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	C509		9				Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	12/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C01X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	10	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	240	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	300	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	12/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	80	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	51	PALBOCICLIB	100	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	40	PALBOCICLIB	75	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	180	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	75	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C509		9				PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PALBOCICLIB	100	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	48	RIBOCICLIB	400	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	12/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	180	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C459		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	360	258684004	1	Intravenous	47625008	12/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ALECTINIB	600	258684004	2	Oral	26643006	12/05/2023	RBZ
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IMATINIB	400	258684004	2	Oral	26643006	12/05/2023	RBZ
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	D761		3	Not Applicable (Primary Treatment)	98	Other	HLH-94 + R D1-7	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	D761		3	Not Applicable (Primary Treatment)	98	Other	HLH-94 + R D1-7	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	16.5	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	500	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	100	258684004	1	Intravenous	47625008	12/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PANITUMUMAB	340	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PALBOCICLIB	125	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	400	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	336	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	D761		3	Not Applicable (Primary Treatment)	98	Other	HLH-94 + R D1-7	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	240	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Olaparib - PS>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Olaparib	300	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SACITUZUMAB GOVITECAN	580	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C911	98233	9		99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	12/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	12/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	THIOTEPA	54	258684004	1	Intravenous	47625008	12/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IMATINIB	400	258684004	2	Oral	26643006	12/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	150	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	96	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1800	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C44X		9		98	Other	Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Nivolumab	480	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	21	RUXOLITINIB	10	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	12/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	36	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	10	258684004	2	Oral	26643006	12/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	APIXABAN	2.5	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB DERUXTECAN	440	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IBRUTINIB	560	258684004	2	Oral	26643006	12/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DEXAMETHASONE	10	258684004	2	Oral	26643006	13/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	87	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	13/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	30	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/05/2023	RBZ
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CYTARA 12H 3g/m?	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Osimertinib	80	258684004	2	Oral	26643006	13/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CYTARA 12H 3g/m?	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYTARABINE	5600	258684004	1	Intravenous	47625008	13/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IMATINIB	400	258684004	2	Oral	26643006	13/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	400	258684004	2	Oral	26643006	13/05/2023	RH8
RH8	C61X		9				ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/05/2023	RH8
RH8	C61X		9				ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	13/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ACALABRUTINIB	100	258684004	2	Oral	26643006	13/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	1920	258684004	1	Intravenous	47625008	13/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	36	258684004	1	Intravenous	47625008	13/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	Osimertinib	80	258684004	2	Oral	26643006	14/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/05/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	400	258684004	2	Oral	26643006	14/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/05/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	Osimertinib	40	258684004	2	Oral	26643006	14/05/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	TIP >1(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	4	258684004	2	Oral	26643006	14/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Erlotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	72	ERLOTINIB	50	258684004	2	Oral	26643006	14/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	IBRUTINIB	420	258684004	2	Oral	26643006	14/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	790	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	330	258684004	1	Intravenous	47625008	15/05/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	216	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	15/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	15/05/2023	RBZ
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1200	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C23X		9				Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	30	258684004	1	Intravenous	47625008	15/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	15/05/2023	RBZ
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	15/05/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	330	258684004	1	Intravenous	47625008	15/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	148	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	15/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	50	258684004	2	Oral	26643006	15/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	15/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	4	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	360	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	700	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CARBOPLATIN	700	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	15	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	225	258684004	1	Intravenous	47625008	15/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	80	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	50	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	15/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/05/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	1.4	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	750	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	15/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RAD MELPH HD RDE	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/05/2023	RH8
RBZ	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	15/05/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ANASTROZOLE	1	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	150	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	15/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	100	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	300	258684004	1	Intravenous	47625008	15/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	88	258684004	1	Intravenous	47625008	15/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	90	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RAD MELPH HD RDE	1	PATIENT is taking part in a CLINICAL TRIAL	1	MELPHALAN	355	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IMATINIB	200	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C921	98633	9		99	Not known	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IMATINIB	400	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	15/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RBZ	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	15/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RBZ	C23		1	Adjuvant Therapy	99	Not known	CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1500	258684004	2	Oral	26643006	15/05/2023	RBZ
RBZ	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1400	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	42	RIBOCICLIB	400	258684004	2	Oral	26643006	15/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	15/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	RIBOCICLIB	600	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	D761		3	Not Applicable (Primary Treatment)	98	Other	HLH-94 + R D1-7	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	240	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	NIRAPARIB	200	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	2560	258684004	1	Intravenous	47625008	15/05/2023	RH8
RBZ	D473	99623			99	Not known	HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/05/2023	RBZ
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/05/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ACALABRUTINIB	100	258684004	2	Oral	26643006	15/05/2023	RBZ
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PROCARBAZINE	200	258684004	2	Oral	26643006	15/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	15/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	15/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	15/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	15/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	440	258684004	1	Intravenous	47625008	15/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB - EMTANSINE	160	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/05/2023	RH8
RBZ	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	378	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BLEOMYCIN	23750		1	Intravenous	47625008	15/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	80	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1300	258684004	2	Oral	26643006	15/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1000	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	200	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	50	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP	1	PATIENT is taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	17	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	15/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	115	RUXOLITINIB	10	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	35	RUXOLITINIB	5	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	D45X	99503	9		98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	26	RUXOLITINIB	15	258684004	2	Oral	26643006	15/05/2023	RH8
RBZ	C44		3	Not Applicable (Primary Treatment)			AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	17	AVELUMAB	800	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	15/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/05/2023	RH8
RBZ	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/05/2023	RBZ
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVALUMAB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DURVALUMAB	1000	258684004	1	Intravenous	47625008	15/05/2023	RBZ
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	15/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	180	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	99	IBRUTINIB	280	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	34	NILOTINIB	200	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	40	IBRUTINIB	420	258684004	2	Oral	26643006	15/05/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	180	258684004	1	Intravenous	47625008	15/05/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	16/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	790	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	26	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	26	FLUOROURACIL	800	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	26	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	240	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	16/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	26	CETUXIMAB	1000	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	79	LENALIDOMIDE	15	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	128	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	600	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	550	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	250	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	16/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	16/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	132	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINORELBINE	90	258684004	2	Oral	26643006	16/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	16/05/2023	RBZ
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	128	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RBZ	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	400	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	16/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	180	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/05/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	16/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	78	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/05/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	16/05/2023	RH8
RBZ	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C920	98723	1	Adjuvant Therapy	98	Other	HYD AML/CML 1DAY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	40	258684004	2	Oral	26643006	16/05/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/05/2023	RBZ
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Osimertinib	80	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	40	PALBOCICLIB	75	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	330	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	630	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABEMACICLIB	150	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ANASTROZOLE	1	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABEMACICLIB	100	258684004	2	Oral	26643006	16/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PALBOCICLIB	125	258684004	2	Oral	26643006	16/05/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	66	TRAMETINIB	1.5	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	66	DABRAFENIB	100	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	16/05/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	50	258684004	2	Oral	26643006	16/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	132	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	250	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	16/05/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	68	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	88	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	BOSUTINIB	400	258684004	2	Oral	26643006	16/05/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	80	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	16/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	16/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABOZANTINIB	20	258684004	2	Oral	26643006	16/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1500	258684004	2	Oral	26643006	16/05/2023	RBZ
RH8	C349	80423	9				ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C189				99	Not known	Regorafenib CRC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	REGORAFENIB	120	258684004	2	Oral	26643006	16/05/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NINTEDANIB	200	258684004	2	Oral	26643006	16/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	600	258684004	2	Oral	26643006	16/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	270	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	378	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RBZ	C7A				99	Not known	EVEROLIMUS NET>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EVEROLIMUS	5	258684004	2	Oral	26643006	16/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	16/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	400	258684004	2	Oral	26643006	16/05/2023	RBZ
RH8	C519		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	70	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C349	80463	9				PEMBRO 428 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	75	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	120	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	16/05/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C06X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	50	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	39	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/05/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	79	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CAPECITABINE	1450	258684004	2	Oral	26643006	16/05/2023	RBZ
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	400	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	216	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C44		3	Not Applicable (Primary Treatment)			Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C44X		9				Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	RUXOLITINIB	25	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EVEROLIMUS	5	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	16/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	16/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	34	NILOTINIB	200	258684004	2	Oral	26643006	16/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - KISPLYX	14	258684004	2	Oral	26643006	16/05/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/05/2023	RBZ
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	180	258684004	1	Intravenous	47625008	16/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ERIBULIN	2.38	258684004	1	Intravenous	47625008	16/05/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	16/05/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	16/05/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/05/2023	RBZ
RBZ	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	THALIDOMIDE	50	258684004	2	Oral	26643006	16/05/2023	RBZ
RH8	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	16/05/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	16/05/2023	RBZ
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	500	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	600	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CETUXIMAB	900	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CETUXIMAB	900	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	164	258684004	1	Intravenous	47625008	17/05/2023	RH8
RBZ	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C189				99	Not known	Cetuximab + Oxaliplatin + MdG Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	600	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + Oxaliplatin + MdG Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	17/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1450	258684004	2	Oral	26643006	17/05/2023	RBZ
RH8	C189				99	Not known	Cetuximab + Oxaliplatin + MdG Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	120	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + Oxaliplatin + MdG Load	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CETUXIMAB	700	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	550	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	82	LENALIDOMIDE	5	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	5	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	15	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1200	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1400	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	17/05/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	30	258684004	1	Intravenous	47625008	17/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	320	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	700	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	17/05/2023	RH8
RBZ	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	17/05/2023	RBZ
RH8	C189		2	Neoadjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2200	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C189		2	Neoadjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	315	258684004	1	Intravenous	47625008	17/05/2023	RH8
RBZ	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RBZ	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1800	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1150	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	16	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C49X		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	240	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C679				99	Not known	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	17/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679				99	Not known	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	330	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	360	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	330	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VENETOCLAX	400	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	132	258684004	1	Intravenous	47625008	17/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R(IVF)-IBRU MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	MERCAPTOPURINE	120	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CAPECITABINE	1800	258684004	2	Oral	26643006	17/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	40	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	METHOTREXATE	40	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)	98	Other	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABOZANTINIB	20	258684004	2	Oral	26643006	17/05/2023	RBZ
RH8	C911	98233	9		98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	17/05/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	54	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	54	FLUOROURACIL	650	258684004	1	Intravenous	47625008	17/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	17/05/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	54	PANITUMUMAB	500	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C911	98233	9		98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	50	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	200	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	20	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Nivolumab	480	258684004	1	Intravenous	47625008	17/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TUCATINIB	250	258684004	2	Oral	26643006	17/05/2023	RBZ
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R(IVF)-IBRU MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IBRUTINIB	560	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	17/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	POLATUZUMAB VEDOTIN	128	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C189				99	Not known	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C01X				99	Not known	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PALBOCICLIB	75	258684004	2	Oral	26643006	17/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/05/2023	RH8
RBZ	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/05/2023	RBZ
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	120	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PALBOCICLIB	75	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	3600	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	440	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	80	Olaparib	250	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C509		9				ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	80	258684004	1	Intravenous	47625008	17/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB - EMTANSINE	360	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	93	AVELUMAB	800	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	D473	99623			99	Not known	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	1	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	10	258684004	2	Oral	26643006	17/05/2023	RBZ
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	10	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	50	LENALIDOMIDE	5	258684004	2	Oral	26643006	17/05/2023	RBZ
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1950	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	17/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ISATUXIMAB	1000	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ISATUXIMAB	440	258684004	1	Intravenous	47625008	17/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	50	APIXABAN	2.5	258684004	2	Oral	26643006	17/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	50	IXAZOMIB	2.3	258684004	2	Oral	26643006	17/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB - EMTANSINE	280	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 3/4	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	600	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	17	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	17/05/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	BEXAROTENE	225	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	17/05/2023	RH8
RBZ	C509				99	Not known	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	17/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C44X		9		98	Other	Vismodegib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	VISMONDEGIB	150	258684004	2	Oral	26643006	17/05/2023	RH8
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	17/05/2023	RBZ
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	17/05/2023	RBZ
RBZ	C509				99	Not known	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	80	258684004	1	Intravenous	47625008	17/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/05/2023	RH8
RH8	D479		3	Not Applicable (Primary Treatment)	98	Other	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	THALIDOMIDE	100	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	17/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	17/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	17/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	NILOTINIB	400	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	82	NILOTINIB	150	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	54	NILOTINIB	300	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NILOTINIB	400	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C831	96733	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IBRUTINIB	560	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	17/05/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	180	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ERIBULIN	1.06	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	17/05/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			DOSTAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOSTARLIMAB	500	258684004	1	Intravenous	47625008	17/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cytarabine low (10to20mg/m2) IV/SC	2	PATIENT is not taking part in a CLINICAL TRIAL	25	CYTARABINE	20	258684004	5	Subcutaneous	34206005	18/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	10	258684004	2	Oral	26643006	18/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	5	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1200	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1600	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	45	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1650	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1300	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	500	258684004	1	Intravenous	47625008	18/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1450	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C189		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	180	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	75	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	18/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TEMOZOLOMIDE	380	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	18/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC>9	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	55	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	65	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	18/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	30	CABOZANTINIB	20	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/05/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABOZANTINIB	40	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	50	258684004	2	Oral	26643006	18/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	125	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	200	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	22	RIBOCICLIB	200	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		9				RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	400	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	7	ISATUXIMAB	590	258684004	1	Intravenous	47625008	18/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C56		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	43	NIRAPARIB	100	258684004	2	Oral	26643006	18/05/2023	RBZ
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IBRUTINIB	420	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	36	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RH8	C900	97323	9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C20		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRIFLURIDINE/TIPIRACIL	70	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	40	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	POLATUZUMAB VEDOTIN	152	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	18/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	40	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ABEM & LETROZ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABEMACICLIB	100	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRAMETINIB	2	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	18/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	378	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		9				RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	200	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SACITUZUMAB GOVITECAN	830	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	4	FIANLIMAB/CEMIPLIMAB	750	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	4	FIANLIMAB/CEMIPLIMAB	1950	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	D473	99623			99	Not known	HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ACALABRUTINIB	100	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C64		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ACALABRUTINIB	100	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ACALABRUTINIB	100	258684004	2	Oral	26643006	18/05/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	120	258684004	2	Oral	26643006	18/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	4	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	Olaparib	200	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C159				99	Not known	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	18/05/2023	RBZ
RBZ	C159				99	Not known	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IBRUTINIB	420	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	18/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	18/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	44	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/05/2023	RBZ
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1150	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CAPECITABINE	2000	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	25	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C900	97323	9		99	Not known	PBDA>2 - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	9	IXAZOMIB	4	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	18/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829	96983	3	Not Applicable (Primary Treatment)			OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	17	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABAZITAXEL	40	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RBZ	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	65	RUXOLITINIB	25	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	42	RUXOLITINIB	10	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	18/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			TEPOTINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TEPOTINIB	225	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	18/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	700	258684004	1	Intravenous	47625008	18/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	700	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	120	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	APIXABAN	2.5	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	800	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	18/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NILOTINIB	300	258684004	2	Oral	26643006	18/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	300	258684004	2	Oral	26643006	18/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	350	258684004	1	Intravenous	47625008	18/05/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENVATINIB - KISPLYX	14	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	101	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	POMALIDOMIDE	4	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	180	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	101	ERIBULIN	1.67	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	18/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	700	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	120	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	630	258684004	1	Intravenous	47625008	18/05/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	68	258684004	1	Intravenous	47625008	18/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	750	258684004	1	Intravenous	47625008	19/05/2023	RH8
RBZ	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RBZ	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CETUXIMAB	900	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	41	LENALIDOMIDE	15	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RBZ	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	800	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	19/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	180	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	101	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	19/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1300	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	19/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C719		1	Adjuvant Therapy	99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 150mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	19/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	300	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	28	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	19/05/2023	RH8
RBZ	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	19/05/2023	RH8
RBZ	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	46	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	19/05/2023	RH8
RBZ	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	600	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	19/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C833	96803	9		99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	650	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CABOZANTINIB	20	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINIB RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABOZANTINIB	20	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	42	PALBOCICLIB	100	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	125	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	19/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABEMACICLIB	150	258684004	2	Oral	26643006	19/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	150	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABEMACICLIB	100	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			WKLY CARBOPLATIN	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	180	258684004	1	Intravenous	47625008	19/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	125	258684004	2	Oral	26643006	19/05/2023	RBZ
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	100	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PALBOCICLIB	100	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	19/05/2023	RBZ
RH8	C911	98233			98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	400	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	180	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	400	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	600	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	400	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	48	IBRUTINIB	420	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C921	98633	9		99	Not known	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BOSUTINIB	100	258684004	2	Oral	26643006	19/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ALECTINIB	600	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NIRAPARIB	200	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	53	IMATINIB	400	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	19/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	60	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRIFLURIDINE/TIPIRACIL	60	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	19/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	19/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	19/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	270	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	19/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	19/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	240	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	300	258684004	1	Intravenous	47625008	19/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C509		9				RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	400	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	Nivolumab	480	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	SACITUZUMAB GOVITECAN	610	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	19/05/2023	RH8
RBZ	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/05/2023	RH8
RBZ	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ACALABRUTINIB	100	258684004	2	Oral	26643006	19/05/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	2	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	19/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	360	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1400	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	800	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Nivolumab	480	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ZANUBRUTINIB	80	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	GILTERITINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GILTERITINIB	160	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C880	97613	3	Not Applicable (Primary Treatment)			ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZANUBRUTINIB	160	258684004	2	Oral	26643006	19/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	19/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	40	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	10	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	25	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/05/2023	RBZ
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	POMALIDOMIDE	4	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	15	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	15	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C911	98233	1	Adjuvant Therapy			Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	16	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ISATUXIMAB	700	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IXAZOMIB	4	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APIXABAN	2.5	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IXAZOMIB	3	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IXAZOMIB	4	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APIXABAN	2.5	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	87	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	5	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C680				99	Not known	XELOX UROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2000	258684004	2	Oral	26643006	19/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CABAZITAXEL	36	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	17	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	19/05/2023	RH8
RH8	C680				99	Not known	XELOX UROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	260	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	19/05/2023	RH8
RH8	C509		9				CARBO BR CA	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	19/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	800	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	5	258684004	2	Oral	26643006	19/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	135	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Crizotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	37	CRIZOTINIB	250	258684004	2	Oral	26643006	19/05/2023	RH8
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	19/05/2023	RBZ
RBZ	D591		3	Not Applicable (Primary Treatment)			Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	19/05/2023	RBZ
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IFOSFAMIDE	3200	258684004	1	Intravenous	47625008	19/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	180	258684004	1	Intravenous	47625008	19/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	120	258684004	2	Oral	26643006	20/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	Osimertinib	80	258684004	2	Oral	26643006	20/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	20/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	20/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/05/2023	RH8
RBZ	D475		3	Not Applicable (Primary Treatment)	98	Other	IMAT CEL/HES>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	100	258684004	2	Oral	26643006	20/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	48	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/05/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IBRUTINIB	420	258684004	2	Oral	26643006	20/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/05/2023	RH8
RH8	C921	98633	9		98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IMATINIB	400	258684004	2	Oral	26643006	21/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ACALABRUTINIB	100	258684004	2	Oral	26643006	21/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/05/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	22/05/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	22/05/2023	RBZ
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	5	258684004	2	Oral	26643006	22/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	5	258684004	2	Oral	26643006	22/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	15	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1300	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	22/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	22/05/2023	RBZ
RH8	C719				99	Not known	Temozolomide + RT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	140	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	80	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	80	258684004	2	Oral	26643006	22/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	75	258684004	2	Oral	26643006	22/05/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	200	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRAMETINIB	2	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DABRAFENIB	150	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	58	258684004	1	Intravenous	47625008	22/05/2023	RH8
RBZ	C189				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRIFLURIDINE/TIPIRACIL	45	258684004	2	Oral	26643006	22/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/05/2023	RBZ
RBZ	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	22/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	25	258684004	2	Oral	26643006	22/05/2023	RH8
RBZ	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1400	258684004	1	Intravenous	47625008	22/05/2023	RBZ
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CARFILZOMIB	54	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Osimertinib	80	258684004	2	Oral	26643006	22/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	22/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	11	NINTEDANIB	200	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	RIBOCICLIB	400	258684004	2	Oral	26643006	22/05/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IBRUTINIB	420	258684004	2	Oral	26643006	22/05/2023	RBZ
RH8	C349	80463	9		99	Not known	ALECTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ALECTINIB	450	258684004	2	Oral	26643006	22/05/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	22/05/2023	RBZ
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APIXABAN	2.5	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ACALABRUTINIB	100	258684004	2	Oral	26643006	22/05/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENCORAFENIB	225	258684004	2	Oral	26643006	22/05/2023	RBZ
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BLEOMYCIN	21250		1	Intravenous	47625008	22/05/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CETUXIMAB	800	258684004	1	Intravenous	47625008	22/05/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	400	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	63	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	D473	99623			99	Not known	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	22/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	22/05/2023	RBZ
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1600	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	128	258684004	1	Intravenous	47625008	22/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	67	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	22/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	22/05/2023	RBZ
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	22/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AVELUMAB	800	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AXITINIB	5	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	10	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	22/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	99	Not known	ASCIMINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ASCIMINIB	80	258684004	2	Oral	26643006	22/05/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PAZOPANIB	600	258684004	2	Oral	26643006	22/05/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	60	PAZOPANIB	400	258684004	2	Oral	26643006	22/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DEXAMETHASONE	10	258684004	2	Oral	26643006	22/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	POMALIDOMIDE	3	258684004	2	Oral	26643006	22/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	APIXABAN	2.5	258684004	2	Oral	26643006	22/05/2023	RBZ
RH8	C900	97323	9		98	Other	Z-DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IDARUBICIN HYDROCHLORIDE	20	258684004	2	Oral	26643006	22/05/2023	RH8
RH8	C900	97323	9		98	Other	Z-DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	22/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	700	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	22/05/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	600	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	330	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	270	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CETUXIMAB	900	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	240	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEMOZOLOMIDE	370	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	180	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	AVELUMAB	800	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	80	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/05/2023	RH8
RBZ	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	Osimertinib	40	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	23/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	23/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PALBOCICLIB	125	258684004	2	Oral	26643006	23/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	216	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	20	METFORMIN	850	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CARFILZOMIB	54	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	300	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C509				99	Not known	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	RIBOCICLIB	400	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	23/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	200	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	NIRAPARIB	100	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	800	258684004	1	Intravenous	47625008	23/05/2023	RH8
RBZ	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IMATINIB	400	258684004	2	Oral	26643006	23/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	23/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	13	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	19	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	42	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	15	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	5	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	96	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IXAZOMIB	4	258684004	2	Oral	26643006	23/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	IXAZOMIB	4	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	RUXOLITINIB	10	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Olaparib	300	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Olaparib	300	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	12	IXAZOMIB	4	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/05/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	23/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PROCARBAZINE	200	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	23/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	NILOTINIB	200	258684004	2	Oral	26643006	23/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LOMUSTINE	200	258684004	2	Oral	26643006	23/05/2023	RH8
RBZ	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IBRUTINIB	420	258684004	2	Oral	26643006	23/05/2023	RBZ
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	23/05/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	THALIDOMIDE	100	258684004	2	Oral	26643006	23/05/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	23/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	31	LENALIDOMIDE	5	258684004	2	Oral	26643006	24/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	43	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	24/05/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1400	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1500	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	45	258684004	1	Intravenous	47625008	24/05/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	24/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	750	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	900	258684004	1	Intravenous	47625008	24/05/2023	RH8
RBZ	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RBZ	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	240	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RH8	C169		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	24/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/05/2023	RBZ
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C679				99	Not known	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	240	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	24/05/2023	RH8
RBZ	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	MERCAPTOPURINE	120	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	24/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CABOZANTINIB	20	258684004	2	Oral	26643006	24/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	120	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL2019 B MAI>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	METHOTREXATE	40	258684004	2	Oral	26643006	24/05/2023	RH8
RBZ	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	550	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RBZ	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CABOZANTINIB	40	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABEMACICLIB	100	258684004	2	Oral	26643006	24/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABEMACICLIB	150	258684004	2	Oral	26643006	24/05/2023	RBZ
RBZ	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PANITUMUMAB	340	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C911	98233	9		98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	100	258684004	2	Oral	26643006	24/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	50	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IMATINIB	400	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IMATINIB	400	258684004	2	Oral	26643006	24/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/05/2023	RH8
RBZ	C20				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRIFLURIDINE/TIPIRACIL	70	258684004	2	Oral	26643006	24/05/2023	RBZ
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	24/05/2023	RH8
RBZ	C509				99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	10	NINTEDANIB	200	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	42	RIBOCICLIB	400	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	24/05/2023	RH8
RBZ	C509				99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	336	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AVELUMAB	800	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENCORAFENIB	300	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	120	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CETUXIMAB	1000	258684004	1	Intravenous	47625008	24/05/2023	RH8
RBZ	C349	80463	9				CERITINIB SUB>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	CERITINIB	300	258684004	2	Oral	26643006	24/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C509		9				ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	80	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/05/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ACALABRUTINIB	100	258684004	2	Oral	26643006	24/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	24/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C509		9				ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	400	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	280	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENCORAFENIB	450	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BINIMETINIB	45	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	24/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/05/2023	RBZ
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/05/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	POMALIDOMIDE	3	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2150	258684004	2	Oral	26643006	24/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2500	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	POMALIDOMIDE	4	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	180	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ISATUXIMAB	800	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NINTEDANIB	200	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ISATUXIMAB	900	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C169		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	24/05/2023	RH8
RBZ	C159		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	Nivolumab	480	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	24/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	11	IXAZOMIB	4	258684004	2	Oral	26643006	24/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	4	258684004	2	Oral	26643006	24/05/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PEMETREXED	900	258684004	1	Intravenous	47625008	24/05/2023	RBZ
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	24/05/2023	RBZ
RBZ	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	24/05/2023	RBZ
RH8	D479		3	Not Applicable (Primary Treatment)	98	Other	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	24/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	24/05/2023	RH8
RH8	C921	98633			99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	72	NILOTINIB	300	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	26	IBRUTINIB	560	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	29	NILOTINIB	300	258684004	2	Oral	26643006	24/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ERIBULIN	1.06	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ERIBULIN	2.38	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C859	95913	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	95913	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	24/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	500	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	27	FLUOROURACIL	550	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	27	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	360	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C541		9				Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C541		9				Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	240	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	27	CETUXIMAB	800	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	29	LENALIDOMIDE	10	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	25/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	145	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	25/05/2023	RH8
RBZ	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	100	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	25/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	25/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	25/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	25/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C830	96993	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	25/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	400	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	18	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	DA(60) 3 + 7 + MIDO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	DA(60) 3 + 7 + MIDO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAUNORUBICIN	135	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	DA(60) 3 + 7 + MIDO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	440	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Vinorelbine (oral)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	110	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	160	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/05/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	1.5	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	99	Not known	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	120	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2000	258684004	2	Oral	26643006	25/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	52	PALBOCICLIB	100	258684004	2	Oral	26643006	25/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	54	PALBOCICLIB	75	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	55	PALBOCICLIB	125	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	25/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	200	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PALBOCICLIB	75	258684004	2	Oral	26643006	25/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	100	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PALBOCICLIB	100	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PALBOCICLIB	100	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	225	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRAMETINIB	2	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DABRAFENIB	100	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EXEMESTANE	25	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	13	VENETOCLAX	400	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	40	NIRAPARIB	100	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	68	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	22	METFORMIN	850	258684004	2	Oral	26643006	25/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	50	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	53	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	25/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PALBOCICLIB	75	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SACITUZUMAB GOVITECAN	830	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CHLORAMBUCIL	16	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	25	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	25/05/2023	RH8
RBZ	C920	98733	9		98	Other	VEN/LD CYT19>>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CYTARABINE	36	258684004	5	Subcutaneous	34206005	25/05/2023	RBZ
RBZ	C920	98733	9		98	Other	VEN/LD CYT19>>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	VENETOCLAX	100	258684004	2	Oral	26643006	25/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	25/05/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C269		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IMATINIB	400	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	34	IMATINIB	400	258684004	2	Oral	26643006	25/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IMATINIB	200	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PEMETREXED	1000	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C66		3	Not Applicable (Primary Treatment)			AVELUMAB UC 5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AVELUMAB	800	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	37	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	40	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/05/2023	RH8
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	20	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	66	LENALIDOMIDE	15	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	15	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DURVALUMAB	1500	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	25/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IXAZOMIB	3	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	66	IXAZOMIB	4	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	25/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IXAZOMIB	4	258684004	2	Oral	26643006	25/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	25/05/2023	RBZ
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	25/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	600	258684004	2	Oral	26643006	25/05/2023	RBZ
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	600	258684004	2	Oral	26643006	25/05/2023	RBZ
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	25/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	25/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	25/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	IBRUTINIB	280	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NILOTINIB	200	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			CYCLO PO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	50	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	101	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POMALIDOMIDE	2	258684004	2	Oral	26643006	25/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	101	ERIBULIN	1.67	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C900	97323	9		98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	25/05/2023	RBZ
RBZ	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RBZ	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	630	258684004	1	Intravenous	47625008	25/05/2023	RBZ
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	25/05/2023	RH8
RBZ	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	18000	408102007	1	Intravenous	47625008	25/05/2023	RBZ
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	88	258684004	1	Intravenous	47625008	25/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	38	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	350	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	500	258684004	1	Intravenous	47625008	26/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	38	FLUOROURACIL	700	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	38	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CETUXIMAB	900	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	38	CETUXIMAB	800	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	800	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	25	258684004	2	Oral	26643006	26/05/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1500	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RBZ	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	180	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	36	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	26/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	450	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	550	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	550	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	180	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	26/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	26/05/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	26/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	26/05/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1300	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	26/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	26/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	26/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	26/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	26/05/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Bevacizumab 15mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	106	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C300		3	Not Applicable (Primary Treatment)			NIVOLUMAB H + N> +	2	PATIENT is not taking part in a CLINICAL TRIAL	20	Nivolumab	240	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENCORAFENIB	250	258684004	2	Oral	26643006	26/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BINIMETINIB	30	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	180	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	300	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	300	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			CAPE + PHESGO >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/05/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/05/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	26/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1800	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	26/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	40	258684004	2	Oral	26643006	26/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	120	258684004	2	Oral	26643006	26/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	26/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABEM & FULVEST>>	2	PATIENT is not taking part in a CLINICAL TRIAL	43	ABEMACICLIB	150	258684004	2	Oral	26643006	26/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PALBOCICLIB	125	258684004	2	Oral	26643006	26/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Osimertinib	80	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	100	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	100	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PALBOCICLIB	75	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PALBOCICLIB	75	258684004	2	Oral	26643006	26/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	TRAMETINIB	1	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	DABRAFENIB	75	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	12	VENETOCLAX	400	258684004	2	Oral	26643006	26/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	270	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DABRAFENIB	150	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRAMETINIB	2	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	7	ISATUXIMAB	800	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ALECTINIB	600	258684004	2	Oral	26643006	26/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	57	ALECTINIB	600	258684004	2	Oral	26643006	26/05/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BOSUTINIB	200	258684004	2	Oral	26643006	26/05/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	44	IBRUTINIB	420	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C900	97323	9		99	Not known	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/05/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRIFLURIDINE/TIPIRACIL	40	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ/BEVA HCC>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	3.3	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	26/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/05/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	26/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C227		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ/BEVA HCC>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1650	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	500	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PANITUMUMAB	340	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	100	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PALBOCICLIB	100	258684004	2	Oral	26643006	26/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	26/05/2023	RBZ
RH8	C900	97323	1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	26/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RIBOCICLIB	400	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	52	Nivolumab	480	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IBRUTINIB	280	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SACITUZUMAB GOVITECAN	580	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ACALABRUTINIB	100	258684004	2	Oral	26643006	26/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Refine L 6W C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		9				RIBO + FULVEST	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Olaparib - PS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	300	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/05/2023	RH8
RH8	C06X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	10	258684004	2	Oral	26643006	26/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	80	258684004	2	Oral	26643006	26/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/05/2023	RBZ
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2450	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CAPECITABINE	1450	258684004	2	Oral	26643006	26/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CAPECITABINE	1800	258684004	2	Oral	26643006	26/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	25	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	27	CAPECITABINE	1000	258684004	2	Oral	26643006	26/05/2023	RH8
RBZ	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RBZ	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	240	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ISATUXIMAB	900	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IXAZOMIB	3	258684004	2	Oral	26643006	26/05/2023	RH8
RBZ	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	RUXOLITINIB	5	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	26/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	SUNITINIB	50	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NILOTINIB	300	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C921	98633	9		98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	113	NILOTINIB	150	258684004	2	Oral	26643006	26/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	600	258684004	1	Intravenous	47625008	26/05/2023	RBZ
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	88	258684004	1	Intravenous	47625008	26/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	10	258684004	2	Oral	26643006	27/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	25	258684004	2	Oral	26643006	27/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	27/05/2023	RBZ
RBZ	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/05/2023	RBZ
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CABOZANTINIB	20	258684004	2	Oral	26643006	27/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	Osimertinib	80	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IMATINIB	300	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	15	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	APIXABAN	2.5	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	IBRUTINIB	140	258684004	2	Oral	26643006	27/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	Osimertinib	40	258684004	2	Oral	26643006	28/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Osimertinib	80	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IMATINIB	400	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	NIRAPARIB	100	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ACALABRUTINIB	100	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IMATINIB	400	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	80	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IBRUTINIB	420	258684004	2	Oral	26643006	28/05/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	10	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	71	LENALIDOMIDE	5	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	15	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	550	258684004	1	Intravenous	47625008	29/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	120	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	29/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ERLOTINIB 2MTH +	2	PATIENT is not taking part in a CLINICAL TRIAL	73	ERLOTINIB	50	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	700	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	Osimertinib	80	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	120	258684004	1	Intravenous	47625008	29/05/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ALECTINIB	600	258684004	2	Oral	26643006	29/05/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IMATINIB	200	258684004	2	Oral	26643006	29/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	60	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	C911	98233	1	Adjuvant Therapy			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ACALABRUTINIB	100	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Melphalan oral	2	PATIENT is not taking part in a CLINICAL TRIAL	3	MELPHALAN	8	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	400	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	85	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	62	LENALIDOMIDE	10	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	15	258684004	2	Oral	26643006	29/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/05/2023	RBZ
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IXAZOMIB	3	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	50	RUXOLITINIB	10	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CABAZITAXEL	54	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	47	RUXOLITINIB	15	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	10	258684004	2	Oral	26643006	29/05/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	APIXABAN	2.5	258684004	2	Oral	26643006	29/05/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IBRUTINIB	420	258684004	2	Oral	26643006	29/05/2023	RBZ
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DASATINIB	100	258684004	2	Oral	26643006	29/05/2023	RBZ
RBZ	C169		9				Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	SUNITINIB	50	258684004	2	Oral	26643006	29/05/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LIPOSOMAL DOXORUBICIN	36	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	27	FLUOROURACIL	800	258684004	1	Intravenous	47625008	30/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	27	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	198	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	27	CETUXIMAB	1000	258684004	1	Intravenous	47625008	30/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DEXAMETHASONE	6	258684004	2	Oral	26643006	30/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/05/2023	RBZ
RBZ	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	10	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	600	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	30/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	LENALIDOMIDE	15	258684004	2	Oral	26643006	30/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	10	258684004	2	Oral	26643006	30/05/2023	RBZ
RBZ	C900	97323	9				Lenalidomide 15mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	15	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	120	258684004	1	Intravenous	47625008	30/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	30/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	600	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	500	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C20X				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	30/05/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	120	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	164	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C56X		2	Neoadjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TEMOZOLOMIDE	150	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	30/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	180	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	1100	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	15	258684004	2	Oral	26643006	30/05/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			GILTERITINIB Cy2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GILTERITINIB	120	258684004	2	Oral	26643006	30/05/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	Osimertinib	40	258684004	2	Oral	26643006	30/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	125	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PALBOCICLIB	125	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PALBOCICLIB	125	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	30/05/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DABRAFENIB	150	258684004	2	Oral	26643006	30/05/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	TRAMETINIB	2	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	BOSUTINIB	400	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IXAZOMIB	2.3	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C01X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	30/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		3	Not Applicable (Primary Treatment)			ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	300	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	30/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ACALABRUTINIB	100	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/05/2023	RH8
RBZ	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ACALABRUTINIB	100	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	30/05/2023	RH8
RBZ	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IMATINIB	400	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	30/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	2900	258684004	1	Intravenous	47625008	30/05/2023	RH8
RBZ	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	2	258684004	2	Oral	26643006	30/05/2023	RBZ
RBZ	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	25	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1000	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	315	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	225	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	63	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C06X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	480	258684004	1	Intravenous	47625008	30/05/2023	RH8
RBZ	C900	97323	9		98	Other	LENALID (19)>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	10	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	4	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	80	258684004	2	Oral	26643006	30/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	15	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	25	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	120	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	80	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1600	258684004	1	Intravenous	47625008	30/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APIXABAN	2.5	258684004	2	Oral	26643006	30/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IXAZOMIB	4	258684004	2	Oral	26643006	30/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IXAZOMIB	4	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LENVATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENVATINIB - LENVIMA	14	258684004	2	Oral	26643006	30/05/2023	RH8
RBZ	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	5	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Olaparib	300	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/05/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	700	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	30/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	5	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	150	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	30/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	30/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	NILOTINIB	150	258684004	2	Oral	26643006	30/05/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	NILOTINIB	300	258684004	2	Oral	26643006	30/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	30/05/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	30/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	500	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	198	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CETUXIMAB	900	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	145	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	10	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	550	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	122	LENALIDOMIDE	10	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	75	LENALIDOMIDE	10	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	500	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	15	258684004	2	Oral	26643006	31/05/2023	RBZ
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	110	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1500	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	45	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	31/05/2023	RBZ
RBZ	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	31/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1300	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	31/05/2023	RH8
RBZ	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	31/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	31/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1650	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1400	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	148	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	31/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	RT + CISP >CAR/PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	240	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	31/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	41	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	10	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	55	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	55	FLUOROURACIL	650	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	51	PALBOCICLIB	75	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	55	PANITUMUMAB	500	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	75	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	37	PALBOCICLIB	100	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	125	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	31/05/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	400	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	100	258684004	2	Oral	26643006	31/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	29	Nivolumab	480	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	28	NIRAPARIB	200	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	24	APIXABAN	2.5	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	31/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	POLATUZUMAB VEDOTIN	128	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	31/05/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	31/05/2023	RBZ
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/05/2023	RH8
RBZ	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	31/05/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1100	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	47	RIBOCICLIB	200	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	31/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AVELUMAB	800	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AXITINIB	5	258684004	2	Oral	26643006	31/05/2023	RBZ
RBZ	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/05/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C189				99	Not known	PAN/FOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C189				99	Not known	PAN/FOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	31/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C189				99	Not known	PAN/FOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	53	PALBOCICLIB	75	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	31/05/2023	RBZ
RBZ	C189				99	Not known	PAN/FOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PANITUMUMAB	340	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C189				99	Not known	PAN/FOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	135	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)	98	Other	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	31/05/2023	RBZ
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Nivolumab	480	258684004	1	Intravenous	47625008	31/05/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IMATINIB	300	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	400	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Olaparib	100	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB - EMTANSINE	240	258684004	1	Intravenous	47625008	31/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	POMALIDOMIDE	2	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DACARBAZINE	630	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	480	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	10	258684004	2	Oral	26643006	31/05/2023	RBZ
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	10	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	40	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	80	258684004	2	Oral	26643006	31/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	POMALIDOMIDE	4	258684004	2	Oral	26643006	31/05/2023	RBZ
RBZ	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1000	258684004	2	Oral	26643006	31/05/2023	RBZ
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2750	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	POMALIDOMIDE	2	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ISATUXIMAB	1000	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ISATUXIMAB	440	258684004	1	Intravenous	47625008	31/05/2023	RH8
RBZ	C189				99	Not known	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	Nivolumab	480	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	31/05/2023	RBZ
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APIXABAN	2.5	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CABAZITAXEL	40	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	25	RUXOLITINIB	10	258684004	2	Oral	26643006	31/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	94	AVELUMAB	800	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	31/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	800	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			Ipilimumab	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	250	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	200	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/05/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	D479		3	Not Applicable (Primary Treatment)	98	Other	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	31/05/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	31/05/2023	RH8
RH8	C921	98633	9		5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NILOTINIB	400	258684004	2	Oral	26643006	31/05/2023	RH8
RBZ	C831	96733	1	Adjuvant Therapy			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IBRUTINIB	560	258684004	2	Oral	26643006	31/05/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	300	258684004	2	Oral	26643006	31/05/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/05/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ERIBULIN	1.06	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ERIBULIN	1.06	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	31/05/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	108	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	31/05/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	31/05/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	96	258684004	1	Intravenous	47625008	31/05/2023	RH8
RBZ	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RBZ	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	31/05/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	31/05/2023	RBZ
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C31X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Fluorouracil 4 or 5 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C31X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Fluorouracil 4 or 5 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C31X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Fluorouracil 4 or 5 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	6400	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C31X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Fluorouracil 4 or 5 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	270	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LIPOSOMAL DOXORUBICIN	28	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	600	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	01/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	600	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	400	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CETUXIMAB	800	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CETUXIMAB	900	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1000	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1450	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1200	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1600	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	89	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	145	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	45	258684004	1	Intravenous	47625008	01/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1500	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	500	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	200	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C05.1				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	700	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	400	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	220	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C05.1				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	240	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	148	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C509				99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	01/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	148	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DOCETAXEL	120	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	164	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	01/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	9		98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	900	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C911	98233	9		98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	D761		3	Not Applicable (Primary Treatment)	98	Other	HLH-94 + R D8-28	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	63	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	63	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	D761		3	Not Applicable (Primary Treatment)	98	Other	HLH-94 + R D8-28	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	01/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	40	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	56	LENALIDOMIDE	5	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	80	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	100	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	75	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PALBOCICLIB	100	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	890	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABEMACICLIB	50	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EXEMESTANE	25	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	600	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VENETOCLAX	100	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	01/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	400	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	D761		3	Not Applicable (Primary Treatment)	98	Other	HLH-94 + R D8-28	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	240	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NIRAPARIB	200	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	378	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	1000	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	600	258684004	2	Oral	26643006	01/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	400	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	AVELUMAB	800	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	AXITINIB	8	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEOADJ TPH(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	56	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ACALABRUTINIB	100	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C43		9				PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEOADJ TPH(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	120	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	49	IMATINIB	400	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DACARBAZINE	630	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	480	258684004	1	Intravenous	47625008	01/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	80	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	80	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	25	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	11	IXAZOMIB	4	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABAZITAXEL	44	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	81	RUXOLITINIB	15	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB UC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AVELUMAB	800	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	650	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	700	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	135	258684004	1	Intravenous	47625008	01/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	01/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	91	NILOTINIB	200	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NILOTINIB	400	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CHLORAMBUCIL	10	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PROCARBAZINE	200	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	200	258684004	2	Oral	26643006	01/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	120	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	630	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	68	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	01/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	01/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	750	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CETUXIMAB	900	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	800	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	100	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C05.1				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	100	258684004	2	Oral	26643006	02/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	100	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	37	TRASTUZUMAB-ONTRUZANT	651	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	171	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C509		9				Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	02/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	120	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CABOZANTINIB	20	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	900	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	Osimertinib	40	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	400	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	790	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	100	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	02/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Osimertinib	80	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	56	VENETOCLAX	300	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	225	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DABRAFENIB	150	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	TRAMETINIB	2	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	400	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	96	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IBRUTINIB	140	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	80	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ALPELIS & FULVES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ALPELISIB	300	258684004	2	Oral	26643006	02/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)			OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C10		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	49	RIBOCICLIB	400	258684004	2	Oral	26643006	02/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	270	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	378	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EXEMESTANE	25	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	180	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	1.3	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	144	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	600	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIVO - MESO C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Nivolumab	480	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			AVELUMAB UC5 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AVELUMAB	800	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	99	Not known	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	02/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ACALABRUTINIB	100	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ACALABRUTINIB	100	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APALUTAMIDE	240	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	120	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	500	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	800	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	900	258684004	1	Intravenous	47625008	02/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	151	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	80	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	120	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	122	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	5	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CAPECITABINE	1800	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CAPECITABINE	1500	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ISATUXIMAB	700	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IXAZOMIB	4	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RUXOLITINIB	15	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C44X		9		98	Other	Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	800	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	02/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	135	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	02/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			SOTORASIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SOTORASIB	960	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB DERUXTECAN	320	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PROCARBAZINE	200	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	NILOTINIB	200	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	NILOTINIB	400	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NILOTINIB	400	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	22	NILOTINIB	400	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C880	97613	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	26	IBRUTINIB	420	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LOMUSTINE	200	258684004	2	Oral	26643006	02/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	02/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Osimertinib	80	258684004	2	Oral	26643006	03/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	78	IMATINIB	400	258684004	2	Oral	26643006	03/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	03/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	400	258684004	2	Oral	26643006	03/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IMATINIB	400	258684004	2	Oral	26643006	03/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/06/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Osimertinib	80	258684004	2	Oral	26643006	03/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	38	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	04/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ALECTINIB	600	258684004	2	Oral	26643006	04/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/06/2023	RH8
RH8	C349	80463	9		99	Not known	TEPOTINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEPOTINIB	225	258684004	2	Oral	26643006	04/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Fluorouracil + Mitomycin + RT (Bladder)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Fluorouracil + Mitomycin + RT (Bladder)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	18	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	790	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	480	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	33	LENALIDOMIDE	15	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1200	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	30	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	05/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	148	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	16	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	240	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VENETOCLAX	400	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	300	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	90	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C833	96803	9		98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB - EMTANSINE	160	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C833	96803	9		98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	05/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C833	96803	9		98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C833	96803	9		98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	Osimertinib	80	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	AML MAINT MIDOST	2	PATIENT is not taking part in a CLINICAL TRIAL	6	MIDOSTAURIN	50	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	05/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C719		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	EVEROLIMUS SEGA>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	EVEROLIMUS	5	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C459		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	65	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	100	258684004	2	Oral	26643006	05/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	05/06/2023	RH8
RH8	C459		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	360	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	54	BOSUTINIB	500	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	88	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C509		1	Adjuvant Therapy			ALPELIS & FULVES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ALPELISIB	300	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE 90 CYC1	2	PATIENT is not taking part in a CLINICAL TRIAL	104	IMATINIB	400	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IMATINIB	400	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C189				99	Not known	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1950	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CARFILZOMIB	54	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PALBOCICLIB	125	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	05/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	05/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	PONATINIB - C3>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PONATINIB	15	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	30	NIRAPARIB	100	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	180	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	05/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C06X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/06/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	40	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	120	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C61X		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	80	258684004	2	Oral	26643006	05/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL (C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DURVALUMAB	1500	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	29	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	05/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	2	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	05/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	650	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	135	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			SOTORASIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	SOTORASIB	960	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	180	258684004	1	Intravenous	47625008	05/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	49	IBRUTINIB	420	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	36	IBRUTINIB	420	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DASATINIB	20	258684004	2	Oral	26643006	05/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	790	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	790	258684004	1	Intravenous	47625008	06/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	240	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DEXAMETHASONE	10	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	600	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	25	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	120	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	128	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	06/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		9				Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINORELBINE	90	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	100	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	600	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CETUXIMAB	900	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)			Cisplatin + Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)			Cisplatin + Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	89	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C629	90613	1	Adjuvant Therapy	99	Not known	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	1080	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C06		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	400	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	12	258684004	1	Intravenous	47625008	06/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	88	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	180	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	06/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	48	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYD AML/CML 1DAY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	40	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABOZANTINIB	40	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABOZANTINIB	20	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CABOZANTINIB	20	258684004	2	Oral	26643006	06/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	500	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	100	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	330	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PANITUMUMAB	220	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Osimertinib	80	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	VENETOCLAX	200	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	250	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	68	258684004	1	Intravenous	47625008	06/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIMRDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	80	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	24	METFORMIN	850	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	42	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	3.3	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CAR LEN DEX 13>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CARFILZOMIB	54	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NINTEDANIB	200	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	600	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	600	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AVELUMAB	800	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AVELUMAB	800	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AXITINIB	5	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ACALABRUTINIB	100	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C917	98311	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ORAL MTX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	65	METHOTREXATE	10	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IMATINIB	100	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ZANUBRUTINIB	160	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BLEOMYCIN	23750		1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	26	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	80	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	5	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DURVALUMAB	1500	258684004	1	Intravenous	47625008	06/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DURVALUMAB	1500	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PEMBRO CHL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	29	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			LORLATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LORLATINIB	100	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	THALIDOMIDE	100	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	71	IBRUTINIB	140	258684004	2	Oral	26643006	06/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/06/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	06/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	25	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	336	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	164	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	10	258684004	2	Oral	26643006	07/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	5	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1400	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	750	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	900	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1200	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	110	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	07/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1800	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	113	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	240	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	100	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	07/06/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1400	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)			Cisplatin + Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)			Cisplatin + Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	89	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	830	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C49X		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	07/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	240	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	53	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	53	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	40	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q 28D>1	2	PATIENT is not taking part in a CLINICAL TRIAL	80	LENALIDOMIDE	5	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CABOZANTINIB	40	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABEMACICLIB	150	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	07/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	07/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	100	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PALBOCICLIB	100	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	100	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ANASTROZOLE	1	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C911	98233	9		98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	200	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	200	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	36	RIBOCICLIB	400	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	8	ISATUXIMAB	800	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IBRUTINIB	280	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ALECTINIB	600	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	19	METFORMIN	850	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	99	Not known	RAI RDE ARMB CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	RITUXIMAB	600	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1100	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	24	GEMCITABINE	1200	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRAMETINIB	2	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AVELUMAB	800	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AXITINIB	5	258684004	2	Oral	26643006	07/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	MITHRI RUXOL >	1	PATIENT is taking part in a CLINICAL TRIAL	25	RUXOLITINIB	15	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CETUXIMAB	1000	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	Nivolumab	480	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IMATINIB	400	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB - EMTANSINE	360	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB - EMTANSINE	280	258684004	1	Intravenous	47625008	07/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMETREXED	900	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C946	99753	9		98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	20	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	45	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	55	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1950	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DURVALUMAB	1500	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ISATUXIMAB	800	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ISATUXIMAB	900	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	Nivolumab	480	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DAROLUTAMIDE	600	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	29	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	07/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	36	RUXOLITINIB	15	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RUXOLITINIB	15	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	07/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509				99	Not known	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	07/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	5	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	07/06/2023	RH8
RH8	C509				99	Not known	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	80	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB DERUXTECAN	280	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	D479		3	Not Applicable (Primary Treatment)	98	Other	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	2	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	07/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	54	IBRUTINIB	420	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	IBRUTINIB	420	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	71	DASATINIB	100	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	ASCIMINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ASCIMINIB	80	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IBRUTINIB	420	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ERIBULIN	2.38	258684004	1	Intravenous	47625008	07/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	07/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	07/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	28	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB - EMTANSINE	260	258684004	1	Intravenous	47625008	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	500	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	28	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	28	FLUOROURACIL	550	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CETUXIMAB	400	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	28	CETUXIMAB	800	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1500	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	45	LENALIDOMIDE	5	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1600	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	128	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	45	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1450	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	180	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	76	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	08/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	08/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	240	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	100	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	08/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)			Cisplatin + Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VENETOCLAX	400	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C719				99	Not known	Temozolomide + RT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	145	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC>9	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	65	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D761		3	Not Applicable (Primary Treatment)	98	Other	HLH-94 + R D8-28	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	44	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	80	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	53	PALBOCICLIB	100	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PALBOCICLIB	75	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	Osimertinib	80	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Osimertinib	80	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	TRAMETINIB	2	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DABRAFENIB	150	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	BOSUTINIB	500	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	D761		3	Not Applicable (Primary Treatment)	98	Other	HLH-94 + R D8-28	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	240	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA(C1 9)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IXAZOMIB	4	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	41	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	41	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PALBOCICLIB	100	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	38	PALBOCICLIB	125	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PALBOCICLIB	100	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	216	258684004	1	Intravenous	47625008	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	08/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	55	VENETOCLAX	400	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	600	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	600	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	80	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	SACITUZUMAB GOVITECAN	830	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ACALABRUTINIB	100	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CHLORAMBUCIL	12	258684004	2	Oral	26643006	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)	98	Other	NIVO/IPI RCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	85	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA VCD + LEN	1	PATIENT is taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	08/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	88	Nivolumab	480	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)	98	Other	NIVO/IPI RCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	240	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Melphalan oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	MELPHALAN	14	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IMATINIB	400	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C159				99	Not known	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1300	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C159				99	Not known	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	250	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ETOPOSIDE	164	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C66		3	Not Applicable (Primary Treatment)			AVELUMAB UC5-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AVELUMAB	800	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	37	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	55	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	54	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	25	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IXAZOMIB	4	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	600	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABAZITAXEL	48	258684004	1	Intravenous	47625008	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	92	RUXOLITINIB	5	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Trabectedin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRABECTEDIN	2.1	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	800	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	10	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	550	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OXALIPLATIN	100	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	200	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	360	258684004	1	Intravenous	47625008	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	30	NILOTINIB	400	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	26	IBRUTINIB	420	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IBRUTINIB	420	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			TEPOTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEPOTINIB	450	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	102	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	102	ERIBULIN	1.67	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THALIDOMIDE	100	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	08/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	08/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	08/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	88	258684004	1	Intravenous	47625008	08/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	216	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	39	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	350	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	39	FLUOROURACIL	700	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	39	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CETUXIMAB	800	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	39	CETUXIMAB	800	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	800	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	180	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	09/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	500	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	550	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2200	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	315	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	180	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	102	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	09/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	09/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C01X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	28	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	09/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMG>4	1	PATIENT is taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	600	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	80	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	80	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CABOZANTINIB	20	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	52	PALBOCICLIB	100	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	41	PALBOCICLIB	75	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	75	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	47	PALBOCICLIB	75	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PALBOCICLIB	100	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	400	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	09/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	132	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C10X				99	Not known	COMPARE - ARM 5>	1	PATIENT is taking part in a CLINICAL TRIAL	6	DURVALUMAB	1500	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	49	BOSUTINIB	400	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ALECTINIB	600	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IMATINIB	400	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C01X				99	Not known	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C43.9		9		99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1150	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	350	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PANITUMUMAB	180	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PALBOCICLIB	125	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	800	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	400	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	09/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	144	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	09/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO RESECTED >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NIRAPARIB	200	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Olaparib - PS>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Olaparib	300	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C911	98233	9		99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ACALABRUTINIB	100	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		9		98	Other	RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ETOPOSIDE	164	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	97	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	80	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Nivolumab	480	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	09/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	3	Not Applicable (Primary Treatment)	99	Not known	PEMBRO CHL>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C680				99	Not known	XELOX UROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2000	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C680				99	Not known	XELOX UROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	260	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	22	RUXOLITINIB	10	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RUXOLITINIB	15	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		9				CARBO BR CA	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Olaparib	300	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Dabrafenib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DABRAFENIB	50	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	10	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IBRUTINIB	560	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	19	APIXABAN	2.5	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	300	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ERIBULIN	2.02	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	09/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	09/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	8	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PROCARBAZINE	100	258684004	2	Oral	26643006	09/06/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Osimertinib	80	258684004	2	Oral	26643006	10/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	Osimertinib	40	258684004	2	Oral	26643006	10/06/2023	RH8
RH8	C61X		9				ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/06/2023	RH8
RH8	C61X		9				ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	10/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/06/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ETOPOSIDE	164	258684004	1	Intravenous	47625008	10/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DASATINIB	20	258684004	2	Oral	26643006	10/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	46	DASATINIB	40	258684004	2	Oral	26643006	10/06/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	11/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/06/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IMATINIB	400	258684004	2	Oral	26643006	11/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ETOPOSIDE	164	258684004	1	Intravenous	47625008	11/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	11/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	11/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	IBRUTINIB	420	258684004	2	Oral	26643006	11/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	216	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	550	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1200	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	120	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	30	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	900	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	12/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	96	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	12/06/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CARBOPLATIN	700	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin AUC 2 - 5	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	110	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	12/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ BEV CAR TAX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	1000	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ BEV CAR TAX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ BEV CAR TAX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	790	258684004	1	Intravenous	47625008	12/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	12/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Osimertinib	80	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABEMACICLIB	150	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ANASTROZOLE	1	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	100	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ BEV CAR TAX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	VENETOCLAX	100	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	12/06/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	85	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	12/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMETREX LUNG 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMETREX LUNG 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	700	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	43	RIBOCICLIB	400	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	12/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RIBOCICLIB	600	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	400	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	NIRAPARIB	200	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH1 -	1	PATIENT is taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ACALABRUTINIB	100	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ACALABRUTINIB	100	258684004	2	Oral	26643006	12/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ACALABRUTINIB	100	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH1 -	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	19	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH1 -	1	PATIENT is taking part in a CLINICAL TRIAL	1	DAUNORUBICIN	57.5	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C880	97613	9		98	Other	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZANUBRUTINIB	80	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	70	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	70	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C06X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	63	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	12/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	80	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C509				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)			LENVATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENVATINIB - LENVIMA	16	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	10	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	6	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	15	POMALIDOMIDE	3	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	18	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	12/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	36	RUXOLITINIB	5	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	116	RUXOLITINIB	10	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	D45X	99503	9		98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	27	RUXOLITINIB	15	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ISATUXIMAB	900	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APIXABAN	2.5	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	10	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	10	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	10	258684004	2	Oral	26643006	12/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	12/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Erlotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	73	ERLOTINIB	50	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	IBRUTINIB	140	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	100	IBRUTINIB	280	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	IBRUTINIB	420	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Z-Dex.	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IDARUBICIN HYDROCHLORIDE	15	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Z-Dex.	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	10	258684004	2	Oral	26643006	12/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IFOSFAMIDE	2160	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ETOPOSIDE	120	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C833	96803	1	Adjuvant Therapy	98	Other	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C833	96803	1	Adjuvant Therapy	98	Other	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C833	96803	1	Adjuvant Therapy	98	Other	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C833	96803	1	Adjuvant Therapy	98	Other	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	88	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	12/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	630	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	12/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	28	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	28	FLUOROURACIL	800	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	28	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	330	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	270	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	28	CETUXIMAB	1000	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C900		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	116	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	80	LENALIDOMIDE	15	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	13/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	600	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	240	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/06/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	108	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	330	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	180	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	13/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	79	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	40	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	41	PALBOCICLIB	75	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ANASTROZOLE	1	258684004	2	Oral	26643006	13/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABEMACICLIB	150	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABEMACICLIB	100	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Osimertinib	80	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	67	TRAMETINIB	1.5	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	67	DABRAFENIB	100	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	180	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EVEROLIMUS	5	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EXEMESTANE	25	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/06/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	600	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	50	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Nivolumab	480	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	75	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	120	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	400	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C349	80423	9				ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	80	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	80	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	Osimertinib	40	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DURVALUMAB	1500	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	96	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	RUXOLITINIB	25	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Olaparib	300	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Olaparib	300	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	700	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	150	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	35	NILOTINIB	200	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IBRUTINIB	420	258684004	2	Oral	26643006	13/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	13/06/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	13/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IFOSFAMIDE	2160	258684004	1	Intravenous	47625008	13/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ETOPOSIDE	120	258684004	1	Intravenous	47625008	13/06/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	450	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	600	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CETUXIMAB	900	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CETUXIMAB	900	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1450	258684004	2	Oral	26643006	14/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	550	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	83	LENALIDOMIDE	5	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	500	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	15	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1400	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1500	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	45	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	280	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	5600	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	330	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	132	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VENETOCLAX	400	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	56	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	41	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	14/06/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Osimertinib	40	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	56	PANITUMUMAB	500	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PALBOCICLIB	75	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C911	98233	9		98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	200	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	14/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Nivolumab	480	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	99	Not known	RAI RDE ARMB CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	RITUXIMAB	600	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C04X		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PALBOCICLIB	75	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	14/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C64		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	120	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	81	Olaparib	250	258684004	2	Oral	26643006	14/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1000	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	400	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	2	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	10	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2150	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ISATUXIMAB	440	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NINTEDANIB	200	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	5	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C829	96913	9		98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	18	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	14/06/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	BEXAROTENE	225	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	95	AVELUMAB	800	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IXAZOMIB	2.3	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C44X		9		98	Other	Vismodegib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	VISMONDEGIB	150	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C44X		9				Cemiplimab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	14/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	55	NILOTINIB	300	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	83	NILOTINIB	150	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C831	96733	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IBRUTINIB	560	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ERIBULIN	2.38	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IFOSFAMIDE	2160	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ETOPOSIDE	120	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	14/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	14/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	96	258684004	1	Intravenous	47625008	14/06/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	15/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	890	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	5	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	500	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IFOSFAMIDE	5600	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	15/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	15/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	15/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TEMOZOLOMIDE	380	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	50	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENVATINIB - KISPLYX	20	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Osimertinib	80	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DABRAFENIB	150	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRAMETINIB	2	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	200	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	23	RIBOCICLIB	200	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	108	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	600	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	8	ISATUXIMAB	590	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C749		3	Not Applicable (Primary Treatment)			MITOTANE 4.5-9.0	2	PATIENT is not taking part in a CLINICAL TRIAL	36	MITOTANE	1000	258684004	2	Oral	26643006	15/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C749		3	Not Applicable (Primary Treatment)			MITOTANE 4.5-9.0	2	PATIENT is not taking part in a CLINICAL TRIAL	36	MITOTANE	500	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	37	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C189				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRIFLURIDINE/TIPIRACIL	55	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	16	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABOZANTINIB	20	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ABEM & LETROZ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABEMACICLIB	100	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	378	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	15/06/2023	RH8
RH8	C509		9				RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	200	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			R-LENALID-Cyc>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	80	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ACALABRUTINIB	100	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	120	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PEMETREXED	1000	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	15	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	15/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IBRUTINIB	560	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	38	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	DEXAMETHASONE	10	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	45	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	POMALIDOMIDE	1	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2500	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ISATUXIMAB	650	258684004	1	Intravenous	47625008	15/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	APIXABAN	2.5	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	10	IXAZOMIB	4	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	10	APIXABAN	2.5	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	43	RUXOLITINIB	10	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	15/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	700	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	150	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	APIXABAN	2.5	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	41	SUNITINIB	50	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	28	IBRUTINIB	420	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	102	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	POMALIDOMIDE	4	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	102	ERIBULIN	1.67	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	15/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IFOSFAMIDE	2160	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ETOPOSIDE	120	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	50	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINBLASTINE SULFATE	12	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DACARBAZINE	700	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DACARBAZINE	700	258684004	1	Intravenous	47625008	15/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	20000	408102007	1	Intravenous	47625008	15/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	750	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CETUXIMAB	900	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	42	LENALIDOMIDE	15	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	550	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1650	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	800	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2150	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	16/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	9	GEMCITABINE	1100	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	16/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	108	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 150mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	ISATUXIMAB	860	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKY PAC + TRAS MT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKY PAC + TRAS MT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	16/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	300	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	47	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	43	PALBOCICLIB	100	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PALBOCICLIB	125	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABEMACICLIB	100	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABEMACICLIB	150	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABEMACICLIB	100	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	125	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PALBOCICLIB	100	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PALBOCICLIB	100	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	16/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233			98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VENETOCLAX	400	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		9				RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	400	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	400	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ALECTINIB	600	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NIRAPARIB	200	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	34	IMATINIB	400	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRIFLURIDINE/TIPIRACIL	60	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRIFLURIDINE/TIPIRACIL	60	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1650	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C920	98723	9				Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	400	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C920	98723	9				Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	100	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	SACITUZUMAB GOVITECAN	600	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ACALABRUTINIB	100	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	GILTERITINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GILTERITINIB	120	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	360	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1400	258684004	1	Intravenous	47625008	16/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Nivolumab	480	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	10	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	80	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	25	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	5	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	POMALIDOMIDE	4	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	15	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	15	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C911	98233	1	Adjuvant Therapy			Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CHLORAMBUCIL	16	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ISATUXIMAB	700	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APIXABAN	2.5	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IXAZOMIB	4	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IXAZOMIB	3	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IXAZOMIB	4	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APIXABAN	2.5	258684004	2	Oral	26643006	16/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	18	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	16/06/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	5	258684004	2	Oral	26643006	16/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	2.02	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	68	258684004	1	Intravenous	47625008	16/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	17/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	17/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	49	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CABOZANTINIB	20	258684004	2	Oral	26643006	18/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABOZANTINIB	20	258684004	2	Oral	26643006	18/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	400	258684004	2	Oral	26643006	18/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/06/2023	RH8
RH8	C43.9		9		99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TEMOZOLOMIDE	325	258684004	2	Oral	26643006	18/06/2023	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ZANUBRUTINIB	80	258684004	2	Oral	26643006	18/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)			ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZANUBRUTINIB	160	258684004	2	Oral	26643006	18/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	OSIMERT ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Osimertinib	80	258684004	2	Oral	26643006	18/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	5	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	25	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	15	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C80.9				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C80.9				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	240	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	19/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	96	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	19/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	19/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	120	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	19/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DABRAFENIB	100	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRAMETINIB	1	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	225	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACI Z>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	270	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRAMETINIB	2	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DABRAFENIB	150	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IBRUTINIB	420	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C349	80463	9		99	Not known	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ALECTINIB	450	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	68	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	19/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRAST UZUMAB	1200	258684004	5	Subcutaneous	34206005	19/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMID E	500	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMID E	500	258684004	2	Oral	26643006	19/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	12	NINTEDANIB	200	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	RIBOCICLIB	400	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ACALABRUTINIB	100	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	D475		3	Not Applicable (Primary Treatment)	98	Other	IMAT CEL/HES *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IMATINIB	100	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	400	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C06X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	63	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	70	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	70	258684004	1	Intravenous	47625008	19/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CAPECITABINE	2000	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AXITINIB	5	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	68	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	D45	99503			99	Not known	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	18	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	19/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABAZITAXEL	54	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	19/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	10	258684004	2	Oral	26643006	19/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	1.6	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PROCARBAZINE	150	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NILOTINIB	400	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C719		9				PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LOMUSTINE	160	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DEXAMETHASONE	10	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	POMALIDOMIDE	3	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	APIXABAN	2.5	258684004	2	Oral	26643006	19/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	19/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LIPOSOMAL DOXORUBICIN	54	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	600	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	20/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	198	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CETUXIMAB	900	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	600	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	120	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C679		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C679		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	20/06/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	120	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	164	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	370	258684004	2	Oral	26643006	20/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	80	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	80	258684004	2	Oral	26643006	20/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	5	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	500	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	40	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PANITUMUMAB	220	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CARBOPLATIN	560	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	180	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	216	258684004	1	Intravenous	47625008	20/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C509				99	Not known	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	RIBOCICLIB	400	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	200	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	70	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C519		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Nivolumab	480	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	Nivolumab	480	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	20/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	30	NIRAPARIB	100	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AVELUMAB	800	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	AVELUMAB	800	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ACALABRUTINIB	100	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	1100	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	14	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	20/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	20	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	15	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	5	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IXAZOMIB	4	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IXAZOMIB	4	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	5	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	18	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	20/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	46	RUXOLITINIB	10	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS>75>	1	PATIENT is taking part in a CLINICAL TRIAL	12	IXAZOMIB	4	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	20/06/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	378	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	120	258684004	1	Intravenous	47625008	20/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	20/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POMALIDOMIDE	4	258684004	2	Oral	26643006	20/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	20/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TALIMOGENE LAHERPAREPVEC 10*6	2	74964007	5	Subcutaneous	34206005	20/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	550	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	790	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	890	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	198	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	145	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DEXAMETHASONE	20	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	44	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	21/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	5	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1500	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	45	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	750	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1650	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	225	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	225	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C800				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	240	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1800	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	21/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	21/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	148	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C629	90613	1	Adjuvant Therapy	99	Not known	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	1130	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	21/06/2023	RH8
RBZ	C911	98233	9		98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C509		9				Vinorelbine (oral)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	110	258684004	2	Oral	26643006	21/06/2023	RH8
RBZ	C911	98233	9		98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	180	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	21/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	120	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	550	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	64	PALBOCICLIB	100	258684004	2	Oral	26643006	21/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PANITUMUMAB	340	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1100	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Osimertinib	80	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	200	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	8	ISATUXIMAB	800	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	58	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C189				99	Not known	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRIFLURIDINE/TIPIRACIL	70	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	6	POLATUZUMAB VEDOTIN	128	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PACLITAXEL ALBUMIN	160	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	24	GEMCITABINE	1200	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C920	98723	9				Veneto + Azacit	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	21/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	11	NINTEDANIB	200	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	43	RIBOCICLIB	400	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	600	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	99	Not known	RAIN RDE ARMB I	1	PATIENT is taking part in a CLINICAL TRIAL	2	IBRUTINIB	420	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AVELUMAB	800	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENCORAFENIB	300	258684004	2	Oral	26643006	21/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	120	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MATRIX - CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYTARABINE	3600	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CETUXIMAB	1000	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	400	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB - EMTANSINE	240	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	700	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	80	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	POMALIDOMIDE	3	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2750	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	315	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	180	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	378	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ISATUXIMAB	800	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	Nivolumab	480	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	21/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABAZITAXEL	40	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	98	Other	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	21/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	21/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	1800	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	300	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	135	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			Ipilimumab	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	250	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	300	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	61	PAZOPANIB	400	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	21/06/2023	RH8
RH8	C921	98633			99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	73	NILOTINIB	300	258684004	2	Oral	26643006	21/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IBRUTINIB	560	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	30	NILOTINIB	300	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ERIBULIN	1.06	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	21/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	21/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	21/06/2023	RH8
RH8	C31X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Fluorouracil 4 or 5 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C31X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Fluorouracil 4 or 5 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C31X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Fluorouracil 4 or 5 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	6400	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C31X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Fluorouracil 4 or 5 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	22/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	FLUOROURACIL	550	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	CETUXIMAB	800	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1000	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	600	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	30	LENALIDOMIDE	10	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	128	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	400	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C05.1				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	400	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	22/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C05.1				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	240	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	148	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel + Trastuzumab (Load)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel + Trastuzumab (Load)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	22/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	148	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C56X		2	Neoadjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Vinorelbine (oral)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	110	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC>9	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	22/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	120	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	80	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	120	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	Osimertinib	40	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	56	PALBOCICLIB	125	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	790	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PALBOCICLIB	100	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PALBOCICLIB	75	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	22/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	20	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	14	VENETOCLAX	400	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BOSUTINIB	300	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	108	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	51	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	54	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C900	97323	9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	22/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	98	Other	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	37	PALBOCICLIB	75	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	216	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRAMETINIB	2	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C66		3	Not Applicable (Primary Treatment)			AVELUMAB UC5 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AVELUMAB	800	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	80	258684004	1	Intravenous	47625008	22/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CHLORAMBUCIL	16	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IBRUTINIB	560	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			LENV + PEMBR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - LENVIMA	20	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			LENV + PEMBR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZOLIZUMAB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	67	LENALIDOMIDE	15	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	24	CAPECITABINE	2150	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	67	IXAZOMIB	4	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	98	Other	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	550	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OXALIPLATIN	100	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	IBRUTINIB	280	258684004	2	Oral	26643006	22/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NILOTINIB	200	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IBRUTINIB	420	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			CYCLO PO	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	50	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	POMALIDOMIDE	2	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	22/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	22/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	108	258684004	1	Intravenous	47625008	22/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	40	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	40	FLUOROURACIL	700	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	40	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	23/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	40	CETUXIMAB	800	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Load	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Load	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	350	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Load	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CETUXIMAB	800	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	25	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IRINOTECAN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	450	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	225	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C509		9				Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	9	GEMCITABINE	1100	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DOCETAXEL	120	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	1	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	23/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	ISATUXIMAB	860	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	96	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENCORAFENIB	250	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BINIMETINIB	30	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKY PAC + TRAS MT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	23/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	31	CABOZANTINIB	20	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CABOZANTINIB	20	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CABOZANTINIB	40	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	100	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	100	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PALBOCICLIB	75	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	40	TRAMETINIB	1	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	40	DABRAFENIB	75	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	13	VENETOCLAX	400	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	225	258684004	1	Intravenous	47625008	23/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	58	ALECTINIB	600	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	33	IBRUTINIB	280	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	80	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	29	METFORMIN	850	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C900	97323	9		99	Not known	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	100	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	800	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	900	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	RIBOCICLIB	400	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	53	Nivolumab	480	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	45	IBRUTINIB	420	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	SACITUZUMAB GOVITECAN	600	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABOZANTINIB	20	258684004	2	Oral	26643006	23/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C830	96993	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	18	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CHLORAMBUCIL	2	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C509		9				GEMCARBO 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1400	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IMATINIB	400	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	152	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	80	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2450	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	LENALIDOMIDE	25	258684004	2	Oral	26643006	23/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	28	CAPECITABINE	1000	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C44X		9		98	Other	Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	IXAZOMIB	3	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C829	96953	9		98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CABAZITAXEL	44	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RUXOLITINIB	5	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LENVATINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - LENVIMA	24	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	800	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	23/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	135	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	THALIDOMIDE	100	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NILOTINIB	300	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NILOTINIB	200	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C921	98633	9		98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	114	NILOTINIB	150	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	23/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	2.02	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/06/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/06/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	25	IMATINIB	400	258684004	2	Oral	26643006	24/06/2023	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	35	IMATINIB	400	258684004	2	Oral	26643006	24/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	Osimertinib	80	258684004	2	Oral	26643006	25/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/06/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	NIRAPARIB	100	258684004	2	Oral	26643006	25/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	15	258684004	2	Oral	26643006	25/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	APIXABAN	2.5	258684004	2	Oral	26643006	25/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IBRUTINIB	420	258684004	2	Oral	26643006	25/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	360	258684004	1	Intravenous	47625008	25/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	360	258684004	1	Intravenous	47625008	25/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Fluorouracil + Mitomycin + RT (Bladder)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	500	258684004	1	Intravenous	47625008	26/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	480	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	10	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	72	LENALIDOMIDE	5	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	15	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	550	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	900	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	120	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	22	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	26/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	300	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	148	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	96	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	26/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	120	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C01		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	120	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	17	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C679				99	Not known	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C679				99	Not known	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	270	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	450	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	68	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C833	96803	9		98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C833	96803	9		98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	26/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	9		98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C833	96803	9		98	Other	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CABOZANTINIB	20	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Osimertinib	80	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	26/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRAMETINIB	2	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DABRAFENIB	100	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/06/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	26/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1950	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1400	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	26/06/2023	RH8
RH8	C519		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	D591		3	Not Applicable (Primary Treatment)	98	Other	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH1 -	1	PATIENT is taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C917	98311	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ORAL MTX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	66	METHOTREXATE	10	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH1 -	1	PATIENT is taking part in a CLINICAL TRIAL	1	DAUNORUBICIN	57.5	258684004	1	Intravenous	47625008	26/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Melphalan oral	2	PATIENT is not taking part in a CLINICAL TRIAL	4	MELPHALAN	8	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	300	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB - EMTANSINE	160	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C848	97183	9		98	Other	Mogamulizumab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MOGAMULIZUMAB	88	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C06X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	63	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C09X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	70	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/06/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	26/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	86	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	63	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	15	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	120	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2300	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IXAZOMIB	3	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APIXABAN	2.5	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	600	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	51	RUXOLITINIB	10	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	48	RUXOLITINIB	15	258684004	2	Oral	26643006	26/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EVEROLIMUS	5	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	3	ACALABRUTINIB	100	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVALUMAB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DURVALUMAB	600	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	APIXABAN	2.5	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	SUNITINIB	37.5	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IBRUTINIB	420	258684004	2	Oral	26643006	26/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IBRUTINIB	140	258684004	2	Oral	26643006	26/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	630	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MELPHALAN	260	258684004	1	Intravenous	47625008	26/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LIPOSOMAL DOXORUBICIN	36	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	FLUOROURACIL	800	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	240	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	29	CETUXIMAB	1000	258684004	1	Intravenous	47625008	27/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	600	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	96	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	27/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	27/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	28	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	15	258684004	2	Oral	26643006	27/06/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	54	PALBOCICLIB	75	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	Osimertinib	40	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PALBOCICLIB	125	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	330	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	27/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Osimertinib	80	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PALBOCICLIB	125	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PALBOCICLIB	125	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	180	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	68	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IXAZOMIB	2.3	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	27/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	CABOZANTINIB	40	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	CABOZANTINIB	20	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	50	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C519		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TAMOXIFEN	20	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ACALABRUTINIB	100	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C349	80463	9				PEMBRO 428 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	400	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	41	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C541		3	Not Applicable (Primary Treatment)			LENV + PEMBR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - LENVIMA	20	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	4	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			LENV + PEMBR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1050	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	25	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DURVALUMAB	1500	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C44X		9				Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IXAZOMIB	4	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	27/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	27/06/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/06/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	700	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OXALIPLATIN	150	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/06/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	THALIDOMIDE	100	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	27/06/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	27/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	100	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	NILOTINIB	150	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	NILOTINIB	300	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	27/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TALIMOGENE LAHERPAREPVEC 10*6	4	74964007	5	Subcutaneous	34206005	27/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DACARBAZINE	630	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	17500	408102007	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	27/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	28/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	450	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	600	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	500	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	336	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CETUXIMAB	900	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CETUXIMAB	900	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	145	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	10	258684004	2	Oral	26643006	28/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	550	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	76	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	123	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189				99	Not known	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	500	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	200	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	28/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)			Cisplatin + Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	36	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)			Cisplatin + Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	28/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)			Cisplatin + Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	1	PATIENT is taking part in a CLINICAL TRIAL	25	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	42	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	1	PATIENT is taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	52	PALBOCICLIB	75	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	28/06/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1100	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	100	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	38	PALBOCICLIB	100	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	400	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	30	Nivolumab	480	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C921	98633	9		98	Other	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	85	BOSUTINIB	200	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	120	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	29	NIRAPARIB	200	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	1	PATIENT is taking part in a CLINICAL TRIAL	25	APIXABAN	2.5	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189				99	Not known	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C01X				99	Not known	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	350	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PANITUMUMAB	180	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	48	RIBOCICLIB	200	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AVELUMAB	800	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AXITINIB	5	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C911	98233	1	Adjuvant Therapy			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ACALABRUTINIB	100	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMETREXED	900	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	Nivolumab	480	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	9		98	Other	Melphalan oral	2	PATIENT is not taking part in a CLINICAL TRIAL	5	MELPHALAN	16	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IMATINIB	400	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Olaparib	100	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB - EMTANSINE	360	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB - EMTANSINE	280	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	POMALIDOMIDE	2	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	1	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	10	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	10	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	40	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	80	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1000	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	POMALIDOMIDE	4	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1950	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2650	258684004	2	Oral	26643006	28/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	POMALIDOMIDE	2	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	POMALIDOMIDE	4	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ISATUXIMAB	1000	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ISATUXIMAB	440	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ISATUXIMAB	900	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C189				99	Not known	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	Nivolumab	480	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APIXABAN	2.5	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APIXABAN	2.5	258684004	2	Oral	26643006	28/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DAROLUTAMIDE	600	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	26	RUXOLITINIB	10	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	96	AVELUMAB	800	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C509				99	Not known	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	28/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	800	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	28/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509				99	Not known	THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	80	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Olaparib	200	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB DERUXTECAN	280	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	28/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	100	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DASATINIB	100	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C831	96733	1	Adjuvant Therapy			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IBRUTINIB	560	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ERIBULIN	1.06	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	28/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VC-RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VC-RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CYCLOPHOSPHAMIDE	500	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THALIDOMIDE	100	258684004	2	Oral	26643006	28/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	28/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	28/06/2023	RH8
RH8	C859	95913	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C859	95913	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C859	95913	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	165	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	96	258684004	1	Intravenous	47625008	28/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LIPOSOMAL DOXORUBICIN	28	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	400	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CETUXIMAB	800	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CAPECITABINE	1500	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1600	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	128	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	45	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	200	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C20				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	77	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	240	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	100	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	53	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)			Cisplatin + Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	36	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)			Cisplatin + Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	100	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AXITINIB	8	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	75	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	65	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C 19)	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	64	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			HYD AML/CML 1DAY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	64	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	40	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	57	LENALIDOMIDE	5	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	Osimertinib	40	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	75	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PALBOCICLIB	75	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	55	PALBOCICLIB	75	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PALBOCICLIB	100	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABEMACICLIB	100	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	220	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABEMACICLIB	50	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PALBOCICLIB	100	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	50	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C911	98233	9		98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	400	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	250	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EXEMESTANE	25	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	600	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	108	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		9				RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	400	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	8	ISATUXIMAB	590	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	80	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IMATINIB	400	258684004	2	Oral	26643006	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IMATINIB	400	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	42	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	POLATUZUMAB VEDOTIN	152	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	42	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	50	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	1000	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	400	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SACITUZUMAB GOVITECAN	780	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)	98	Other	NIVO/IPI RCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	85	258684004	1	Intravenous	47625008	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64		3	Not Applicable (Primary Treatment)	98	Other	NIVO/IPI RCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	240	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IMATINIB	400	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	Olaparib	100	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C159				99	Not known	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1300	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C159				99	Not known	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	250	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	80	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	80	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	25	258684004	2	Oral	26643006	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ISATUXIMAB	650	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	D475		3	Not Applicable (Primary Treatment)	98	Other	IMAT CEL/HES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	100	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	12	IXAZOMIB	4	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	800	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LENVATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENVATINIB - LENVIMA	14	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DAROLUTAMIDE	600	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	600	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABAZITAXEL	48	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABAZITAXEL	40	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	82	RUXOLITINIB	15	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Olaparib	100	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	700	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	150	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	29/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENVATINIB - KISPLYX	14	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	360	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	92	NILOTINIB	200	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NILOTINIB	400	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	103	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	103	ERIBULIN	1.67	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C349	80463	9				PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PROCARBAZINE	200	258684004	2	Oral	26643006	29/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CHLORAMBUCIL	10	258684004	2	Oral	26643006	29/06/2023	RH8
RH8	C859	95913	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB	700	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	50	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINBLASTINE SULFATE	12	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DACARBAZINE	700	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DACARBAZINE	700	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	20000	408102007	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	750	258684004	1	Intravenous	47625008	29/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	790	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	30/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	240	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	216	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	750	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CETUXIMAB	900	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	650	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2200	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	315	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	560	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	180	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	145	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB-ONTRUZANT	378	258684004	1	Intravenous	47625008	30/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	103	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1500	258684004	1	Intravenous	47625008	30/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C01X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)			Cisplatin + Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	36	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	120	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Vinorelbine (oral)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	90	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	ISATUXIMAB	860	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKY PAC + TRAS MT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	50	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	28	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	30/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	1.4	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYD AML/CML 1DY>	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	600	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	750	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	40	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	560	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PALBOCICLIB	75	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	57	VENETOCLAX	300	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	120	258684004	1	Intravenous	47625008	30/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	TRAMETINIB	2	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DABRAFENIB	150	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	FLAIR - IBR/VEN*	1	PATIENT is taking part in a CLINICAL TRIAL	14	VENETOCLAX	400	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	108	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	30/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1100	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	800	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RIBOCICLIB	600	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	Nivolumab	480	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IBRUTINIB	140	258684004	2	Oral	26643006	30/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C459		3	Not Applicable (Primary Treatment)			NIVO - MESO C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Nivolumab	480	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NIRAPARIB	200	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	120	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APALUTAMIDE	240	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Melphalan oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MELPHALAN	16	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IMATINIB	300	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			AVELUMAB UC5-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AVELUMAB	800	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB DERUXTECAN	320	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	120	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	80	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ISATUXIMAB	700	258684004	1	Intravenous	47625008	30/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	96	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			VTD - RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Olaparib	250	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Olaparib	300	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	300	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	D591		3	Not Applicable (Primary Treatment)	99	Not known	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	30/06/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NILOTINIB	400	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	NILOTINIB	200	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	NILOTINIB	400	258684004	2	Oral	26643006	30/06/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	NILOTINIB	400	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C880	97613	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IBRUTINIB	420	258684004	2	Oral	26643006	30/06/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ACALABRUTINIB	100	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	50	IMATINIB	400	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	39	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	02/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CABOZANTINIB	20	258684004	2	Oral	26643006	02/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	Osimertinib	40	258684004	2	Oral	26643006	02/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Osimertinib	80	258684004	2	Oral	26643006	02/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ALECTINIB	600	258684004	2	Oral	26643006	02/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	02/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	02/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	02/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ACALABRUTINIB	100	258684004	2	Oral	26643006	02/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	700	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	216	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	34	LENALIDOMIDE	15	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	03/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1300	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	96	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	03/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	03/07/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 150mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C679				99	Not known	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VENETOCLAX	400	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	65	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	4000	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	03/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	Osimertinib	80	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	AML MAINT MIDOST	2	PATIENT is not taking part in a CLINICAL TRIAL	7	MIDOSTAURIN	50	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	03/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	03/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	56	VENETOCLAX	400	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	VENETOCLAX	100	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	03/07/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	350	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VENETOCLAX	100	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	55	BOSUTINIB	500	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	110	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	03/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1400	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	240	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	03/07/2023	RH8
RH8	C519		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	31	NIRAPARIB	100	258684004	2	Oral	26643006	03/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	D591		3	Not Applicable (Primary Treatment)	98	Other	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH1 -	1	PATIENT is taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH1 -	1	PATIENT is taking part in a CLINICAL TRIAL	1	DAUNORUBICIN	57.5	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	180	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMETREXED	750	258684004	1	Intravenous	47625008	03/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IMATINIB	400	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IMATINIB	400	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ/BEVA HCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	2900	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C848	97183	9		98	Other	Mogamulizumab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MOGAMULIZUMAB	88	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ/BEVA HCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	480	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	80	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2150	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C509				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	120	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C61X		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	80	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Osimertinib	80	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	20	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	03/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C169		2	Neoadjuvant Therapy			OX/CAP C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	500	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	30	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	03/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	100	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C169		2	Neoadjuvant Therapy			OX/CAP C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	110	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	80	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	20	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	18	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	18	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	0.74	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	0.74	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Crizotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	CRIZOTINIB	250	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	68	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	68	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	50	IBRUTINIB	420	258684004	2	Oral	26643006	03/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	37	IBRUTINIB	420	258684004	2	Oral	26643006	03/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	1	Adjuvant Therapy	98	Other	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C833	96803	1	Adjuvant Therapy	98	Other	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C833	96803	1	Adjuvant Therapy	98	Other	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C833	96803	1	Adjuvant Therapy	98	Other	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	88	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	96	258684004	1	Intravenous	47625008	03/07/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	330	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	270	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DEXAMETHASONE	10	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	600	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	25	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	120	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1500	258684004	1	Intravenous	47625008	04/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CISPLATIN	40	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	550	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C509				99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C259		9				Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	04/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	96	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	300	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	96	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	65	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	04/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENCORAFENIB	200	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	21	BINIMETINIB	30	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	180	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	4000	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	49	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	41	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	500	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	100	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PANITUMUMAB	220	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	04/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	VENETOCLAX	200	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ALPELIS & FULVE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ALPELISIB	300	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Wkly Epirubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	270	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	04/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NINTEDANIB	200	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RIBOCICLIB	600	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	600	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C519		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AVELUMAB	800	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	04/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DACARBAZINE	630	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	480	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	96	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	20	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	04/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C829	96913	1	Adjuvant Therapy	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	30	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	80	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	20	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Olaparib	300	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Olaparib	300	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	18	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	18	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	0.74	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	0.74	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	04/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	68	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	68	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PROCARBAZINE	200	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	53	PAZOPANIB	400	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	72	IBRUTINIB	140	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LOMUSTINE	200	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - KISPLYX	20	258684004	2	Oral	26643006	04/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TALIMOGENE LAHERPAREPVEC 10*8	2	74964007	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	04/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VC-RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	13	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VC-RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	04/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	04/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	500	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CETUXIMAB	600	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	6	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	5	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1500	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	45	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APIXABAN	2.5	258684004	2	Oral	26643006	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	650	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2150	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C20		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	280	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IFOSFAMIDE	5600	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	180	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IDARUBICIN HYDROCHLORIDE	16	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUDARABINE PHOSPHATE	65	258684004	1	Intravenous	47625008	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	1	Adjuvant Therapy	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C920	98723	1	Adjuvant Therapy	98	Other	FLAG + Idarubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	4000	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AVELUMAB	800	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AXITINIB	5	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	36	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	54	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	0.97	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	54	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	40	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61X		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q 28D>1	2	PATIENT is not taking part in a CLINICAL TRIAL	81	LENALIDOMIDE	5	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	550	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	40	Osimertinib	80	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABEMACICLIB	150	258684004	2	Oral	26643006	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PANITUMUMAB	340	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189				99	Not known	PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	135	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C189				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PANITUMUMAB	340	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	100	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRAMETINIB	2	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DABRAFENIB	150	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	37	RIBOCICLIB	400	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	9	ISATUXIMAB	800	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ALECTINIB	600	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	16	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PACLITAXEL ALBUMIN	150	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	23	GEMCITABINE	1200	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	270	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	PONATINIB - C3>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PONATINIB	15	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AVELUMAB	800	258684004	1	Intravenous	47625008	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AXITINIB	5	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	15	HYDROXYCARBAMIDE	300	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APALUTAMIDE	240	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	MITHRI RUXOL >	1	PATIENT is taking part in a CLINICAL TRIAL	26	RUXOLITINIB	15	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO + FULVEST	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CETUXIMAB	1000	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Nivolumab	480	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2000	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	400	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	27	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	33	CAPECITABINE	1300	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	56	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	2150	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	80	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	5	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	180	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ISATUXIMAB	800	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	Nivolumab	480	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	145	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO MSI C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	20	258684004	1	Intravenous	47625008	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	80	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	20	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	18	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	18	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	0.74	258684004	1	Intravenous	47625008	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	0.74	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DEXAMETHASONE	4	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	1800	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	300	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	5	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PEMETREXED	900	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	68	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	68	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	3	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	05/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	46	NILOTINIB	400	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	IBRUTINIB	420	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IBRUTINIB	560	258684004	2	Oral	26643006	05/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IBRUTINIB	420	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DASATINIB	20	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	05/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	05/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	180	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	108	258684004	1	Intravenous	47625008	05/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	890	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	FLUOROURACIL	550	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	CETUXIMAB	800	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	540	258684004	1	Intravenous	47625008	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2150	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1600	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	128	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	45	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	250	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IFOSFAMIDE	5600	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	630	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VENETOCLAX	400	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	108	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	220	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	160	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DARATUMUMAB SC>9	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	45	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CAPECITABINE	1800	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CABOZANTINIB	20	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABOZANTINIB	20	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CABOZANTINIB	40	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	54	PALBOCICLIB	100	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	100	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	225	258684004	1	Intravenous	47625008	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Osimertinib	80	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX-R WK3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	100	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	100	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DABRAFENIB	150	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	TRAMETINIB	2	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	600	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	108	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	FLAIR - IBR/VEN*	1	PATIENT is taking part in a CLINICAL TRIAL	25	VENETOCLAX	400	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TUCATINIB	250	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	BOSUTINIB	500	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			ALPELIS & FULVES	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ALPELISIB	250	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	FLAIR - IBR/VEN*	1	PATIENT is taking part in a CLINICAL TRIAL	25	IBRUTINIB	140	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	34	IMATINIB	400	258684004	2	Oral	26643006	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		99	Not known	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	120	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	16	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C64		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	39	PALBOCICLIB	125	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PALBOCICLIB	100	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	216	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	600	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	57	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	5	FIANLIMAB/CEMIPLIMAB	750	258684004	1	Intravenous	47625008	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	5	FIANLIMAB/CEMIPLIMAB	1950	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ACALABRUTINIB	100	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CHLORAMBUCIL	18	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CHLORAMBUCIL	12	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	5	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	89	Nivolumab	480	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Nivolumab	480	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARB/PAC/NIVO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ZANUBRUTINIB	160	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C349	80463	2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARB/PAC/NIVO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	330	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BINIMETINIB	45	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENCORAFENIB	450	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C349	80463	2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARB/PAC/NIVO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	378	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PEMETREXED	1000	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C349	80463	2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARB/PAC/NIVO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C66		3	Not Applicable (Primary Treatment)			AVELUMAB UC5-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AVELUMAB	800	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	39	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	38	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	56	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	55	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	20	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO*	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DAROLUTAMIDE	600	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DAROLUTAMIDE	600	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DAROLUTAMIDE	600	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	30	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	06/07/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	93	RUXOLITINIB	5	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Trabectedin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRABECTEDIN	1.75	258684004	1	Intravenous	47625008	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			LORLATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LORLATINIB	100	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	164	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	80	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	20	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	550	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	10	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	OXALIPLATIN	100	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			SOTORASIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	SOTORASIB	960	258684004	2	Oral	26643006	06/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	29	SUNITINIB	25	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	31	NILOTINIB	400	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IBRUTINIB	420	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IBRUTINIB	420	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			NIVO SCCA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	280	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	103	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	103	ERIBULIN	1.67	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	06/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	06/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	41	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	350	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	500	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	41	FLUOROURACIL	700	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	41	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CETUXIMAB	800	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CETUXIMAB	900	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	41	CETUXIMAB	800	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C20				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C20				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	700	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	500	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	200	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IFOSFAMIDE	5600	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	113	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	240	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	100	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1500	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C629	90613	1	Adjuvant Therapy	99	Not known	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	820	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	13	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	400	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Bevacizumab 15mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	107	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKY PAC + TRAS MT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKY PAC + TRAS MT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	ISATUXIMAB	860	258684004	1	Intravenous	47625008	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	100	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	120	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Refine L Pemb 6W	1	PATIENT is taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	42	PALBOCICLIB	75	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	53	PALBOCICLIB	100	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PALBOCICLIB	100	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ANASTROZOLE	1	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PALBOCICLIB	100	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	120	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	50	BOSUTINIB	400	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	BOSUTINIB	400	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NIRAPARIB	200	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>*	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C06X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1650	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C34.9		9		99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1150	258684004	2	Oral	26643006	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1100	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PALBOCICLIB	125	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	400	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	216	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	378	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C509		9		98	Other	RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	400	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO RESECTED >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Olaparib - PS>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Olaparib	300	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SACITUZUMAB GOVITECAN	600	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SACITUZUMAB GOVITECAN	780	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	Nivolumab	480	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	400	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	160	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	35	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	98	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	120	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CAPECITABINE	1800	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CAPECITABINE	1450	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CAPECITABINE	1800	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	Nivolumab	480	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	30	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	23	RUXOLITINIB	10	258684004	2	Oral	26643006	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RUXOLITINIB	15	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		9				CARBO BR CA	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	800	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	10	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	135	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Dabrafenib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DABRAFENIB	50	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	ASCIMINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ASCIMINIB	80	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			TEPOTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEPOTINIB	450	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	APIXABAN	2.5	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/07/2023	RH8
RH8	D591		3	Not Applicable (Primary Treatment)	99	Not known	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	46	SUNITINIB	50	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	55	IBRUTINIB	560	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	72	DASATINIB	100	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IBRUTINIB	560	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ERIBULIN	1.94	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	2.02	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	1.94	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PROCARBAZINE	100	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CHLORAMBUCIL	8	258684004	2	Oral	26643006	07/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	07/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	64	258684004	1	Intravenous	47625008	07/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	Osimertinib	80	258684004	2	Oral	26643006	08/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	Osimertinib	80	258684004	2	Oral	26643006	08/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	08/07/2023	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IMATINIB	400	258684004	2	Oral	26643006	08/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			SOTORASIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SOTORASIB	960	258684004	2	Oral	26643006	08/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CABOZANTINIB	20	258684004	2	Oral	26643006	09/07/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CABOZANTINIB	20	258684004	2	Oral	26643006	09/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ACALABRUTINIB	100	258684004	2	Oral	26643006	09/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	46	IBRUTINIB	420	258684004	2	Oral	26643006	09/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	47	DASATINIB	40	258684004	2	Oral	26643006	09/07/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	550	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	120	258684004	1	Intravenous	47625008	10/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1450	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	10/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	96	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	10/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C914	99403	3	Not Applicable (Primary Treatment)	98	Other	Cladribine (subcut) 5 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	500	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C914	99403	3	Not Applicable (Primary Treatment)	98	Other	Cladribine (subcut) 5 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CLADRIBINE	10.8	258684004	5	Subcutaneous	34206005	10/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CETUXIMAB	400	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CARBOPLATIN	700	258684004	1	Intravenous	47625008	10/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	225	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	Osimertinib	80	258684004	2	Oral	26643006	10/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	100	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	VENETOCLAX	100	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	225	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	300	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	200	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	350	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL.	2	PATIENT is not taking part in a CLINICAL TRIAL	101	IBRUTINIB	280	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	120	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	68	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	68	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	100	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	110	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IMATINIB	100	258684004	2	Oral	26643006	10/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	10/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	10/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PALBOCICLIB	125	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	44	RIBOCICLIB	400	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	400	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	RIBOCICLIB	600	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C519		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	70	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	NIRAPARIB	200	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	D591		3	Not Applicable (Primary Treatment)	98	Other	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C64X		1	Adjuvant Therapy	98	Other	PEMBRO ADJ RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C79.5				99	Not known	CAPE + TEMOZOL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APALUTAMIDE	240	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	750	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	336	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C159		9				OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1150	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C159		9				OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CIS 35 WK RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	70	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	E-BEACOP/DAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BLEOMYCIN	23750		1	Intravenous	47625008	10/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	80	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C159		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	650	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	10/07/2023	RH8
RH8	C159		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	135	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CABAZITAXEL	54	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	117	RUXOLITINIB	10	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	37	RUXOLITINIB	5	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	D45X	99503	9		98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	28	RUXOLITINIB	15	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBROLIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	10/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	10	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	10	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C44X				99	Not known	Cemiplimab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	10/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DASATINIB	20	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	IBRUTINIB	420	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Olaparib	300	258684004	2	Oral	26643006	10/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	630	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	10/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	10/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	FLUOROURACIL	800	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C56X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	198	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	30	CETUXIMAB	1000	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	5	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	600	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	81	LENALIDOMIDE	15	258684004	2	Oral	26643006	11/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	5	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	25	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C679		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1500	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C679		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	600	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	450	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	180	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	240	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	11/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINORELBINE	120	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	11/07/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	164	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C914	99403	3	Not Applicable (Primary Treatment)	98	Other	Cladribine (subcut) 5 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C914	99403	3	Not Applicable (Primary Treatment)	98	Other	Cladribine (subcut) 5 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CLADRIBINE	10.8	258684004	5	Subcutaneous	34206005	11/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	96	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	108	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	240	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	80	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	40	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	42	PALBOCICLIB	75	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	11/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABEMACICLIB	150	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ANASTROZOLE	1	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABEMACICLIB	100	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CARBOPLATIN	450	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	75	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	162	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Wkly Epirubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C01X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C349	80423	9				ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C519		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	70	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Nivolumab	480	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ACALABRUTINIB	100	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PALBOCICLIB	75	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	400	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	11/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1000	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	225	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	81	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	80	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	120	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	11/07/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	26	RUXOLITINIB	25	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	11/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	10	258684004	2	Oral	26643006	11/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	700	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OXALIPLATIN	150	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	378	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	120	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	11/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	320	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	36	NILOTINIB	200	258684004	2	Oral	26643006	11/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	630	258684004	1	Intravenous	47625008	11/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	17500	408102007	1	Intravenous	47625008	11/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	550	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	700	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	336	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	12/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	450	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	600	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CETUXIMAB	900	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CETUXIMAB	900	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189				99	Not known	Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1450	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	550	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	84	LENALIDOMIDE	5	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	15	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	12/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	128	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	100	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C914	99403	3	Not Applicable (Primary Treatment)	98	Other	Cladribine (subcut) 5 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1800	258684004	1	Intravenous	47625008	12/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C914	99403	3	Not Applicable (Primary Treatment)	98	Other	Cladribine (subcut) 5 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CLADRIBINE	10.8	258684004	5	Subcutaneous	34206005	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	148	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BEVACIZUMAB - ALYMSYS	450	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	180	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	12	VENETOCLAX	400	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	12/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB - EMTANSINE	240	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R(IVF)-IBRU MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C880	97613	9		98	Other	RAIN RDE DRC CY>	1	PATIENT is taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	42	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	12/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Osimertinib	80	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1100	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PALBOCICLIB	100	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	48	PALBOCICLIB	75	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	200	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	200	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Nivolumab	480	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R(IVF)-IBRU MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IBRUTINIB	560	258684004	2	Oral	26643006	12/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	58	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IMATINIB	300	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C921	98633	9		98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	400	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	43	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PACLITAXEL ALBUMIN	150	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	350	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	12/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PANITUMUMAB	180	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	23	GEMCITABINE	1200	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PALBOCICLIB	75	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	144	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	AVELUMAB	800	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ACALABRUTINIB	100	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	120	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	12/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	82	Olaparib	250	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BCNU/THIOTEPA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C880	97613	9		98	Other	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZANUBRUTINIB	80	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BCNU/THIOTEPA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARMUSTINE	712.8	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	3	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	10	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2750	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C20				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2450	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	10	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ISATUXIMAB	440	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ISATUXIMAB	900	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)			LENVATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENVATINIB - LENVIMA	16	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	12/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVALUMAB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DURVALUMAB	1000	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	BEXAROTENE	225	258684004	2	Oral	26643006	12/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	97	AVELUMAB	800	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Olaparib	200	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	800	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	12/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			Ipilimumab	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	250	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Erlotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	74	ERLOTINIB	50	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	100	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	12/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	320	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	12/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	44	IBRUTINIB	140	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	84	NILOTINIB	150	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	56	NILOTINIB	300	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C831	96733	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IBRUTINIB	560	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	12/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	12/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	12/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	12/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	12/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	12/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	13/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab (1st Course)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	360	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CETUXIMAB	800	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	145	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cytarabine low (10to20mg/m2) IV/SC	2	PATIENT is not taking part in a CLINICAL TRIAL	27	CYTARABINE	20	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	5	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	13/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	2000	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	100	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	220	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	360	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	70	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel + Trastuzumab (Load)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C509				99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel + Trastuzumab (Load)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	120	258684004	1	Intravenous	47625008	13/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C61		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C914	99403	3	Not Applicable (Primary Treatment)	98	Other	Cladribine (subcut) 5 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C914	99403	3	Not Applicable (Primary Treatment)	98	Other	Cladribine (subcut) 5 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CLADRIBINE	10.8	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C61		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	1	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	13/07/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	13/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		2	Neoadjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TEMOZOLOMIDE	380	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	10	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	790	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	330	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	88	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	160	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	13/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	57	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABEMACICLIB	150	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	50	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	57	PANITUMUMAB	500	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Osimertinib	80	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	Osimertinib	40	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	75	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX-R WK4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	200	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	200	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	13/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EVEROLIMUS	5	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			EVERO + EXEMES>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EXEMESTANE	25	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	24	RIBOCICLIB	200	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	200	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	108	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	600	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	9	ISATUXIMAB	590	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	38	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	120	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FXT3-mFOLFOXIRI	1	PATIENT is taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FXT3-mFOLFOXIRI	1	PATIENT is taking part in a CLINICAL TRIAL	1	FLUOROURACIL	6400	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	150	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PALBOCICLIB	75	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ABEM & LETROZ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABEMACICLIB	100	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FXT3-mFOLFOXIRI	1	PATIENT is taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRAMETINIB	2	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DABRAFENIB	150	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	50	RIBOCICLIB	400	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C509		9				RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	200	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ACALABRUTINIB	100	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43		9				PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	120	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IMATINIB	400	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZOLIZUMAB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IBRUTINIB	420	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	34	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	DEXAMETHASONE	10	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	20	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	46	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	POMALIDOMIDE	1	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829	96983	3	Not Applicable (Primary Treatment)			LENALID MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	Osimertinib	40	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ISATUXIMAB	650	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	APIXABAN	2.5	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			LENALID MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	11	APIXABAN	2.5	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS FIT>	1	PATIENT is taking part in a CLINICAL TRIAL	11	IXAZOMIB	4	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	44	RUXOLITINIB	10	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	13/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	29	LENALIDOMIDE	10	258684004	2	Oral	26643006	13/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	700	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	150	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	APIXABAN	2.5	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	320	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IBRUTINIB	420	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	POMALIDOMIDE	4	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	13/07/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	600	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	50	258684004	1	Intravenous	47625008	13/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	12	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	700	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DACARBAZINE	700	258684004	1	Intravenous	47625008	13/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	20000	408102007	1	Intravenous	47625008	13/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	750	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CETUXIMAB	900	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	550	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	43	LENALIDOMIDE	15	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	120	258684004	1	Intravenous	47625008	14/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	550	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	800	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	100	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	172	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	11	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C509		9				Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	10	GEMCITABINE	1100	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	14/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C914	99403	3	Not Applicable (Primary Treatment)	98	Other	Cladribine (subcut) 5 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1500	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C914	99403	3	Not Applicable (Primary Treatment)	98	Other	Cladribine (subcut) 5 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CLADRIBINE	10.8	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	13	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	270	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKY PAC + TRAS MT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	220	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	48	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	14/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	44	PALBOCICLIB	100	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Osimertinib	40	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	125	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABEMACICLIB	100	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABEMACICLIB	100	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PALBOCICLIB	75	258684004	2	Oral	26643006	14/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	100	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PALBOCICLIB	100	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C911	98233			98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VENETOCLAX	400	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	225	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	400	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		9				RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	400	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	2	ISATUXIMAB	780	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C921	98633	9		99	Not known	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BOSUTINIB	200	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	80	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ALECTINIB	600	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NIRAPARIB	200	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRIFLURIDINE/TIPIRACIL	60	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRIFLURIDINE/TIPIRACIL	55	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	14/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	900	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	800	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	200	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SACITUZUMAB GOVITECAN	600	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	GILTERITINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GILTERITINIB	120	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APALUTAMIDE	240	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	120	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	Nivolumab	480	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	160	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	153	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	37	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	40	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	40	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	10	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	25	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1600	258684004	2	Oral	26643006	14/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	5	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2450	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	POMALIDOMIDE	4	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	15	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	15	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C911	98233	1	Adjuvant Therapy			Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CHLORAMBUCIL	16	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	29	CAPECITABINE	1000	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ISATUXIMAB	700	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	APIXABAN	2.5	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IXAZOMIB	4	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IXAZOMIB	3	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IXAZOMIB	4	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APIXABAN	2.5	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	14/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C44X		9		98	Other	Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	D591		3	Not Applicable (Primary Treatment)	99	Not known	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	14/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ERIBULIN	1.94	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	2.02	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	1.94	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	14/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	14/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Osimertinib	80	258684004	2	Oral	26643006	15/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IMATINIB	400	258684004	2	Oral	26643006	15/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CABOZANTINIB	20	258684004	2	Oral	26643006	15/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	50	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IBRUTINIB	420	258684004	2	Oral	26643006	15/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	77	IMATINIB	200	258684004	2	Oral	26643006	16/07/2023	RH8
RH8	C921	98633			99	Not known	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IMATINIB	400	258684004	2	Oral	26643006	16/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/07/2023	RH8
RH8	C34.9		9		99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TEMOZOLOMIDE	325	258684004	2	Oral	26643006	16/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	360	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	216	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	480	258684004	1	Intravenous	47625008	17/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2000	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Arsenic Trioxide (Induction Week)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ARSENIC TRIOXIDE	33	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	5	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	15	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	15	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C189		9		99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C189		9		99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C189		9		99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	650	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	17/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	120	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	360	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	790	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	18	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C679				99	Not known	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	270	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C679				99	Not known	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	80	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CABOZANTINIB	40	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	68	TRAMETINIB	1.5	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	68	DABRAFENIB	100	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRAMETINIB	1	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DABRAFENIB	100	258684004	2	Oral	26643006	17/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C349	80463	9		99	Not known	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ALECTINIB	450	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	17/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	13	NINTEDANIB	200	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	RIBOCICLIB	400	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C519		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	70	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	300	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AXITINIB	5	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	26	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2300	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL (C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DURVALUMAB	1500	258684004	1	Intravenous	47625008	17/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB UC-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	69	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	600	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DAROLUTAMIDE	600	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	17/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	17/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	17/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	4	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	10	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	10	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	17/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	96	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	96	258684004	1	Intravenous	47625008	17/07/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	300	258684004	1	Intravenous	47625008	18/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Arsenic Trioxide (Induction Week)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ARSENIC TRIOXIDE	33	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	600	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	120	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	550	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	240	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	148	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINORELBINE	120	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	18/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TEMOZOLOMIDE	370	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	18/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	18/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	330	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	68	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	240	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	18/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	80	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABOZANTINIB	40	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CABOZANTINIB	20	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	CABOZANTINIB	20	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	5	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	500	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	18/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PANITUMUMAB	220	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PALBOCICLIB	125	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	96	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	18/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	240	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509				99	Not known	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	RIBOCICLIB	400	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	18/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRAMETINIB	2	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	200	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C519		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	70	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	40	Nivolumab	480	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Nivolumab	480	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	31	NIRAPARIB	100	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ACALABRUTINIB	100	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APALUTAMIDE	240	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	400	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C859	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BCNU/THIOTEPA	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	18/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ZANUBRUTINIB	80	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	D473	99623			98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	15	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	21	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	15	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	5	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IXAZOMIB	4	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IXAZOMIB	4	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	18/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	600	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	19	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	18/07/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	47	RUXOLITINIB	10	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	18/07/2023	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	1.6	258684004	1	Intravenous	47625008	18/07/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PROCARBAZINE	150	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	18/07/2023	RH8
RH8	C719				99	Not known	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LOMUSTINE	120	258684004	2	Oral	26643006	18/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	19/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LIPOSOMAL DOXORUBICIN	54	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	300	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DEXAMETHASONE	20	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	5	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	360	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1200	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	19/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX> +	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENCORAFENIB	300	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX> +	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CETUXIMAB	1000	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AVELUMAB	800	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	35	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	40	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	120	258684004	2	Oral	26643006	19/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2000	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	200	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1100	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX-R WK5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	9	ISATUXIMAB	800	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	120	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE 90 CYC1	2	PATIENT is not taking part in a CLINICAL TRIAL	24	IMATINIB	200	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	52	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	19/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Wkly Epirubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	19/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABEMACICLIB	50	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	12	NINTEDANIB	200	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	44	RIBOCICLIB	400	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	270	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RIBOCICLIB	400	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	99	Not known	RAIN RDE ARMB I	1	PATIENT is taking part in a CLINICAL TRIAL	3	IBRUTINIB	420	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	AVELUMAB	800	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ACALABRUTINIB	100	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	120	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			WKLY PAC + CAR	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	300	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB - EMTANSINE	280	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	19/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1000	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	800	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	225	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	165	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	D475		3	Not Applicable (Primary Treatment)	98	Other	IMAT CEL/HES>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IMATINIB	100	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	19/07/2023	RH8
RH8	C04X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	POMALIDOMIDE	3	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1950	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2500	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2650	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	19/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CAPECITABINE	2000	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	180	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ISATUXIMAB	800	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	800	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DAROLUTAMIDE	600	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	19/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Olaparib	200	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	10	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C44X		9		98	Other	Vismodegib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	VISMONDEGIB	150	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB DERUXTECAN	280	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	2	258684004	2	Oral	26643006	19/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	220	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C921	98633			99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	74	NILOTINIB	300	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	28	IBRUTINIB	560	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	19/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	19/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	19/07/2023	RH8
RH8	C859	95913	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C859	95913	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C859	95913	9		98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	19/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	31	FLUOROURACIL	550	258684004	1	Intravenous	47625008	20/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	31	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	336	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	31	CETUXIMAB	800	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	2000	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1600	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	45	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	500	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	70	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1600	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	20/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	20/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	20/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.6	258684004	5	Subcutaneous	34206005	20/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	20/07/2023	RH8
RH8	C11X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	108	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	160	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	80	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	120	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PALBOCICLIB	100	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DABRAFENIB	150	258684004	2	Oral	26643006	20/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRAMETINIB	2	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet CY2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	15	VENETOCLAX	400	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	108	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	20/07/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	120	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C189				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRIFLURIDINE/TIPIRACIL	55	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	43	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	16	258684004	1	Intravenous	47625008	20/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	43	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	38	PALBOCICLIB	75	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	270	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	20/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TC(BREAST) - C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	SACITUZUMAB GOVITECAN	780	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ACALABRUTINIB	100	258684004	2	Oral	26643006	20/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ACALABRUTINIB	100	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	22	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	57	PALBOCICLIB	125	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C269		9		99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	400	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ACALABRUTINIB	100	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	20/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	68	LENALIDOMIDE	15	258684004	2	Oral	26643006	20/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	68	IXAZOMIB	4	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	800	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DAROLUTAMIDE	600	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABAZITAXEL	40	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	20/07/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			NIVO SCCA >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	280	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Olaparib	100	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	550	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	65	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	POLATUZUMAB VEDOTIN	140	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	220	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	20/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	46	IBRUTINIB	280	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	34	NILOTINIB	200	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NILOTINIB	200	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			CYCLO PO	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	50	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	104	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	POMALIDOMIDE	4	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	104	ERIBULIN	1.67	258684004	1	Intravenous	47625008	20/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APIXABAN	2.5	258684004	2	Oral	26643006	20/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	42	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	500	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	21/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	42	FLUOROURACIL	700	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	42	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CETUXIMAB	900	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	42	CETUXIMAB	800	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	20	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	10	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	800	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	25	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	180	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	750	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2200	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	200	258684004	1	Intravenous	47625008	21/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		2	Neoadjuvant Therapy	98	Other	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	315	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB-ONTRUZANT	378	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	104	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	10	GEMCITABINE	1100	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C01X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKY PAC + TRAS MT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	108	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	220	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	600	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	80	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	65	PALBOCICLIB	100	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Osimertinib	80	258684004	2	Oral	26643006	21/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	100	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PALBOCICLIB	75	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	400	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	41	DABRAFENIB	75	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	41	TRAMETINIB	1	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	14	VENETOCLAX	400	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	120	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	59	ALECTINIB	600	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	46	IBRUTINIB	420	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	300	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C01X				99	Not known	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	100	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	378	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	RIBOCICLIB	400	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	54	Nivolumab	480	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	34	IBRUTINIB	280	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Olaparib - PS>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Olaparib	300	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	200	258684004	1	Intravenous	47625008	21/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CHLORAMBUCIL	2	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APALUTAMIDE	240	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	400	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	80	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1800	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	40	LENALIDOMIDE	25	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	Nivolumab	480	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	40	IXAZOMIB	3	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	17	RUXOLITINIB	5	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Olaparib	250	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Olaparib	300	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Olaparib	300	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	21/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	600	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	5	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	135	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	99	Not known	ASCIMINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ASCIMINIB	80	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB DERUXTECAN	320	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	D591		3	Not Applicable (Primary Treatment)	99	Not known	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	2	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	62	PAZOPANIB	400	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	220	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NILOTINIB	300	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C921	98633	9		98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	115	NILOTINIB	150	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	21/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	600	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	21/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	21/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/07/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	80	258684004	2	Oral	26643006	22/07/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	10	258684004	2	Oral	26643006	22/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IXAZOMIB	4	258684004	2	Oral	26643006	22/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	22/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	220	258684004	1	Intravenous	47625008	22/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	22/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINIB RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CABOZANTINIB	20	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Osimertinib	80	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABOZANTINIB	20	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	NIRAPARIB	100	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	LENALIDOMIDE	15	258684004	2	Oral	26643006	23/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	APIXABAN	2.5	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LENVATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - LENVIMA	24	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	23/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	220	258684004	1	Intravenous	47625008	23/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	33	IBRUTINIB	420	258684004	2	Oral	26643006	23/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - VEGZELMA	450	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	216	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	73	LENALIDOMIDE	5	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	550	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	900	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C189		9				Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	120	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C23		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	22	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	24/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	250	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	225	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	100	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	24/07/2023	RH8
RH8	C679				99	Not known	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VENETOCLAX	400	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	220	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	24/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	HYD AML/CML 1DY>	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	700	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	24/07/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	75	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	24/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRAMETINIB	2	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DABRAFENIB	100	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	85	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	24/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	100	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	360	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IMATINIB	400	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	24/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1650	258684004	2	Oral	26643006	24/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1400	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	24/07/2023	RH8
RH8	C519		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	70	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	2000	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	MERCAPTOPURINE	120	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C917	98311	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ORAL MTX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	67	METHOTREXATE	10	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CHLORAMBUCIL	18	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CHLORAMBUCIL	16	258684004	2	Oral	26643006	24/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Melphalan oral	2	PATIENT is not taking part in a CLINICAL TRIAL	5	MELPHALAN	8	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	36	IMATINIB	400	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMETREXED	750	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	87	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2150	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	LENALIDOMIDE	15	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	120	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C169		2	Neoadjuvant Therapy			OX/CAP> C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	500	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C169		2	Neoadjuvant Therapy			OX/CAP> C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	110	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IXAZOMIB	3	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APIXABAN	2.5	258684004	2	Oral	26643006	24/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	52	RUXOLITINIB	10	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	49	RUXOLITINIB	15	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	10	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	APIXABAN	2.5	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBROLIZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	THALIDOMIDE	100	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	24/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	47	IBRUTINIB	140	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IBRUTINIB	420	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ERIBULIN	2.02	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	POMALIDOMIDE	3	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	24/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DACARBAZINE	630	258684004	1	Intravenous	47625008	24/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LIPOSOMAL DOXORUBICIN	36	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	360	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	270	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509				99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C259		9				Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	240	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	100	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	25/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	1	PATIENT is taking part in a CLINICAL TRIAL	2	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	270	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	150	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	180	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	108	258684004	1	Intravenous	47625008	25/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	28	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	600	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LENALIDOMIDE	15	258684004	2	Oral	26643006	25/07/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	55	PALBOCICLIB	75	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	24	PALBOCICLIB	125	258684004	2	Oral	26643006	25/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	300	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	100	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Osimertinib	80	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PALBOCICLIB	125	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PALBOCICLIB	125	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	66	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	108	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TAMOXIFEN	20	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IXAZOMIB	2.3	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IMATINIB	400	258684004	2	Oral	26643006	25/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	55	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C900	97323	9		99	Not known	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C900	97323	9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C189				99	Not known	PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		3	Not Applicable (Primary Treatment)			ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	400	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk) Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	AVELUMAB	800	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.45	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	Nivolumab	480	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	25/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BUSULFAN	30	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C44		3	Not Applicable (Primary Treatment)			AVELUMAB>4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	22	AVELUMAB	800	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	42	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	13	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	4	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	80	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	25	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C509				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	80	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DURVALUMAB	1500	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IXAZOMIB	4	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	BEVACIZUMAB - ALYMSYS	1200	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	600	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVALUMAB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DURVALUMAB	600	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Olaparib	300	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Olaparib	300	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	25/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	700	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	11	OXALIPLATIN	150	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	700	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	5	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	NILOTINIB	300	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	25/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	25/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IFOSFAMIDE	2160	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	120	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	350	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	25/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	630	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	17500	408102007	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	25/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRASTUZUMAB-ONTRUZANT	378	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	600	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CETUXIMAB	900	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	145	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	26/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	10	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	124	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	77	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1500	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CISPLATIN	45	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	650	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1800	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	26/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C900	97323	9		98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	26/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1400	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1200	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	26/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AVELUMAB	800	258684004	1	Intravenous	47625008	26/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AXITINIB	5	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	36	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	58	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	1400	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	0.97	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	43	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CABOZANTINIB	20	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	53	PALBOCICLIB	75	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	58	PANITUMUMAB	500	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	725	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Osimertinib	80	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	39	PALBOCICLIB	100	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	100	258684004	2	Oral	26643006	26/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	400	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	31	Nivolumab	480	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	30	NIRAPARIB	200	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	19	METFORMIN	850	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/07/2023	RH8
RH8	C20		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PAN/IRI/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C04X		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C20		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PAN/IRI/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	26/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PAN/IRI/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	900	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C20		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PAN/IRI/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PANITUMUMAB	600	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	49	RIBOCICLIB	200	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C64		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APALUTAMIDE	240	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	Nivolumab	480	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	300	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Olaparib	100	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	26/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	POMALIDOMIDE	2	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	26/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	2	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	10	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	40	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	80	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	POMALIDOMIDE	2	258684004	2	Oral	26643006	26/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ISATUXIMAB	440	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C44X		9				Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APIXABAN	2.5	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CABAZITAXEL	40	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	27	RUXOLITINIB	10	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C64X				99	Not known	LEN/EVEROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EVEROLIMUS	5	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AVELUMAB	800	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AXITINIB	5	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DEXAMETHASONE	4	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PEMETREXED	900	258684004	1	Intravenous	47625008	26/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	26/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	26/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	26/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	26/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 4	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	26/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	VC-RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	13	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IFOSFAMIDE	2160	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	120	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	165	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	96	258684004	1	Intravenous	47625008	26/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	175	258684004	1	Intravenous	47625008	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	500	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	270	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	DEXAMETHASONE	10	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LENALIDOMIDE	15	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1600	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CISPLATIN	45	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APIXABAN	2.5	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IFOSFAMIDE	5600	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C40X		3	Not Applicable (Primary Treatment)			Etoposide + Ifosfamide (3 days)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB-ONTRUZANT	588	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	78	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1600	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	164	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - VEGZELMA	700	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	164	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	100	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENCORAFENIB	250	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	BINIMETINIB	30	258684004	2	Oral	26643006	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKLY EPIRUBICIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	65	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	65	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO428 6WK C1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	20	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	40	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	58	LENALIDOMIDE	5	258684004	2	Oral	26643006	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	10	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	Osimertinib	40	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PALBOCICLIB	75	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	35	PALBOCICLIB	75	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PALBOCICLIB	100	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	790	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	150	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABEMACICLIB	100	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABEMACICLIB	50	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Osimertinib	80	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PALBOCICLIB	75	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PALBOCICLIB	100	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	9		98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	600	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & EXEMES>2	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EXEMESTANE	25	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	9	ISATUXIMAB	590	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	148	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IMATINIB	400	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	99	Not known	POLATUZ R-BEND.	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	CABOZANTINIB	20	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	CABOZANTINIB	40	258684004	2	Oral	26643006	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829	96903	3	Not Applicable (Primary Treatment)	98	Other	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	400	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	400	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AVELUMAB	800	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AXITINIB	5	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	SACITUZUMAB GOVITECAN	780	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	58	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	6	FIANLIMAB/CEMIPLIMAB	750	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	6	FIANLIMAB/CEMIPLIMAB	1950	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ACALABRUTINIB	100	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ACALABRUTINIB	100	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			REG R3767 CY>1	1	PATIENT is taking part in a CLINICAL TRIAL	6	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	400	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	Olaparib	100	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SACITUZUMAB GOVITECAN	740	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PEMETREXED	1000	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	40	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	27/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1650	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	80	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	40	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ISATUXIMAB	650	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB UC-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DAROLUTAMIDE	600	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DAROLUTAMIDE	600	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	83	RUXOLITINIB	15	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Trabectedin	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRABECTEDIN	1.75	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APALUTAMIDE	240	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	132	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	148	258684004	1	Intravenous	47625008	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	1800	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	300	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	135	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENVATINIB - KISPLYX	20	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	5	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	42	SUNITINIB	50	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	27/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	40	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	27/07/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	93	NILOTINIB	200	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	37	NILOTINIB	200	258684004	2	Oral	26643006	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NILOTINIB	200	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	104	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	104	ERIBULIN	1.67	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINBLASTINE SULFATE	4.8	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CHLORAMBUCIL	10	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PROCARBAZINE	200	258684004	2	Oral	26643006	27/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IFOSFAMIDE	2160	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IE <25	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	120	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	50	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINBLASTINE SULFATE	12	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DACARBAZINE	700	258684004	1	Intravenous	47625008	27/07/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DACARBAZINE	700	258684004	1	Intravenous	47625008	27/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	20000	408102007	1	Intravenous	47625008	27/07/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	480	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2150	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	400	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1800	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	120	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C679		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1300	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	180	258684004	1	Intravenous	47625008	28/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ZOLEDRONIC ACID ADJ	3.3	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	113	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	240	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C61		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	100	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - VEGZELMA	450	258684004	1	Intravenous	47625008	28/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - VEGZELMA	450	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	14	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	ISATUXIMAB	530	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	160	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	220	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ERLOTINIB 2MTH +	2	PATIENT is not taking part in a CLINICAL TRIAL	74	ERLOTINIB	50	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	28/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	99	Not known	HYDROX SCD 1 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	40	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1100	258684004	1	Intravenous	47625008	28/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	100	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	180	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	58	VENETOCLAX	300	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DABRAFENIB	150	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	TRAMETINIB	2	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	2	ISATUXIMAB	780	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IBRUTINIB	140	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	120	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	88	IMATINIB	300	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	28/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1650	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	50	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C189				99	Not known	Regorafenib CRC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	REGORAFENIB	160	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	270	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	NINTEDANIB	200	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	RIBOCICLIB	600	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIVO - MESO C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Nivolumab	480	258684004	1	Intravenous	47625008	28/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259				99	Not known	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	200	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	160	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	SACITUZUMAB GOVITECAN	600	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN	180	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C911	98233	1	Adjuvant Therapy			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ACALABRUTINIB	100	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	28/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	120	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	APALUTAMIDE	240	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD- Cyc 8	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.05	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	400	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	160	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro *	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			AVELUMAB UC5-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	AVELUMAB	800	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	40	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1000	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	120	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	80	258684004	2	Oral	26643006	28/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CAPECITABINE	1800	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CAPECITABINE	1450	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ISATUXIMAB	700	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABAZITAXEL	44	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		9				CARBO BR CA	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	450	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	800	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OXALIPLATIN	135	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	28/07/2023	RH8
RH8	C7A				99	Not known	LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	28/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DASATINIB	100	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	NILOTINIB	400	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C880	97613	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IBRUTINIB	420	258684004	2	Oral	26643006	28/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ERIBULIN	1.94	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ERIBULIN	1.67	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C509		1	Adjuvant Therapy			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ERIBULIN	2.02	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	64	258684004	1	Intravenous	47625008	28/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	Osimertinib	40	258684004	2	Oral	26643006	29/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/07/2023	RH8
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IMATINIB	400	258684004	2	Oral	26643006	29/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	150	258684004	2	Oral	26643006	29/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ALECTINIB	600	258684004	2	Oral	26643006	30/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/07/2023	RH8
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IMATINIB	300	258684004	2	Oral	26643006	30/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LIPOSOMAL DOXORUBICIN	28	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	400	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	35	LENALIDOMIDE	15	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C189		9		99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C189		9		99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	650	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C189		9		99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1450	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	31/07/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	31/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	31/07/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CY-1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	12	VENETOCLAX	400	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	220	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			ENCOR + CETUX> +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENCORAFENIB	225	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			ENCOR + CETUX> +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CETUXIMAB	800	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	31/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	AML MAINT MIDOST	2	PATIENT is not taking part in a CLINICAL TRIAL	8	MIDOSTAURIN	50	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	630	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	31/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Osimertinib	80	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	31/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	300	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	200	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	350	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	270	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VENETOCLAX	100	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	56	BOSUTINIB	500	258684004	2	Oral	26643006	31/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	110	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	100	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	68	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	85	IMATINIB	200	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IMATINIB	400	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	31/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	D473	99623			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	31/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD - Cyc 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	400	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C259		9		1	Curative – aiming to permanently eradicate the disease	GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1400	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	750	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	NIRAPARIB	100	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	D45	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C43		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APALUTAMIDE	240	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	240	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	180	258684004	2	Oral	26643006	31/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL C3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IMATINIB	400	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	51	IMATINIB	400	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C159		9				OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1150	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C159		9				OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	20	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	34	CAPECITABINE	1150	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	80	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C159		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP> C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	650	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C61		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1400	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	120	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C61X		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	80	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C159		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OX/CAP> C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THALIDOMIDE	100	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DURVALUMAB	1500	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	20	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	80	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB UC-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AVELUMAB	800	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA	2	PATIENT is not taking part in a CLINICAL TRIAL	64	LENALIDOMIDE	10	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	31	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	31/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - VEGZELMA	900	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Olaparib	300	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/07/2023	RH8
RH8	C719		9		98	Other	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	31/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C719		9		98	Other	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PROCARBAZINE	200	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	31/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	IBRUTINIB	420	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	51	IBRUTINIB	420	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C719		9		98	Other	PCV - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LOMUSTINE	200	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ERIBULIN	2.02	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Z-DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IDARUBICIN HYDROCHLORIDE	10	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Z-DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	6	258684004	2	Oral	26643006	31/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	135	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	165	258684004	1	Intravenous	47625008	31/07/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	96	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	72	258684004	1	Intravenous	47625008	31/07/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	400	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C679		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C679		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	550	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	180	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	180	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	21	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	01/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINORELBINE	120	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	113	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DOCETAXEL	132	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	1	PATIENT is taking part in a CLINICAL TRIAL	3	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	01/08/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	400	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		9				Vinorelbine (oral)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	90	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	270	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	240	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	150	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	BINIMETINIB	30	258684004	2	Oral	26643006	01/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENCORAFENIB	200	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	1	PATIENT is taking part in a CLINICAL TRIAL	26	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	50	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CABOZANTINIB	20	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	42	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	FLUOROURACIL	500	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	80	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	1	PATIENT is taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	10	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	100	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PANITUMUMAB	220	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACI Z>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CARBOPLATIN	450	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Osimertinib	80	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	57	VENETOCLAX	400	258684004	2	Oral	26643006	01/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	VENETOCLAX	200	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	300	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PACLITAXEL	162	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	400	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	90	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ALPELIS & FULVE>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ALPELISIB	300	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	1	PATIENT is taking part in a CLINICAL TRIAL	26	APIXABAN	2.5	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	350	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	01/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PANITUMUMAB	180	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	270	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RIBOCICLIB	600	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	RIBOCICLIB	600	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ACALABRUTINIB	100	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	20	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	01/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	80	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	80	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	20	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LENVATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENVATINIB - LENVIMA	14	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	650	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	31	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	150	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	10	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	01/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	378	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			THP > (SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	120	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	320	258684004	1	Intravenous	47625008	01/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	73	IBRUTINIB	140	258684004	2	Oral	26643006	01/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			TVEC >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TALIMOGENE LAHERPAREPVEC 10*8	4	74964007	5	Subcutaneous	34206005	01/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - VEGZELMA	550	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	700	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	336	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	02/08/2023	RH8
RBZ	C189						Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C189						Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	500	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C189						Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C189						Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CETUXIMAB	600	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	02/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189						Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1200	258684004	2	Oral	26643006	02/08/2023	RBZ
RBZ	C189						Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	02/08/2023	RBZ
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2200	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1500	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	145	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C23X				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CISPLATIN	45	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	02/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	02/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	02/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C900	97323	9				Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	02/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	9				Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	02/08/2023	RBZ
RBZ	C900	97323	9				Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	02/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	148	258684004	1	Intravenous	47625008	02/08/2023	RH8
RBZ	C04		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	96	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	2	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	02/08/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	98	Other	Methotrexate intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	1	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	02/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETO + RITUX C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	02/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60)3 + 10 + GO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	200	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETO + RITUX C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	300	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	200	258684004	1	Intravenous	47625008	02/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX> +	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CETUXIMAB	1000	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	58	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AVELUMAB	800	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AXITINIB	5	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	02/08/2023	RH8
RBZ	C189						PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C880	97613	9		98	Other	RAI DRC CATCH UP	1	PATIENT is taking part in a CLINICAL TRIAL	7	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	55	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	HYD AML/CML 1DY>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	55	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	02/08/2023	RH8
RBZ	C189						PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C189						PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/08/2023	RBZ
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C61X		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q 28D>1	2	PATIENT is not taking part in a CLINICAL TRIAL	82	LENALIDOMIDE	5	258684004	2	Oral	26643006	02/08/2023	RH8
RBZ	C189						PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C189						PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	550	258684004	1	Intravenous	47625008	02/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189						PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	Osimertinib	80	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABEMACICLIB	150	258684004	2	Oral	26643006	02/08/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	02/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	100	258684004	2	Oral	26643006	02/08/2023	RH8
RBZ	C189						PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PANITUMUMAB	340	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C189						PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PANITUMUMAB	340	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	100	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	84	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRAMETINIB	2	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DABRAFENIB	150	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	38	RIBOCICLIB	400	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	10	ISATUXIMAB	800	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ALECTINIB	600	258684004	2	Oral	26643006	02/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/08/2023	RBZ
RBZ	C900	97323	9				DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	02/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	400	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	02/08/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	450	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	MITHRI RUXOL >>	1	PATIENT is taking part in a CLINICAL TRIAL	27	RUXOLITINIB	15	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO and FULV 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	400	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	270	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	144	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	AVELUMAB	800	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	AXITINIB	5	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	D693		9		1	Curative – aiming to permanently eradicate the disease	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ACALABRUTINIB	100	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	02/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APALUTAMIDE	240	258684004	2	Oral	26643006	02/08/2023	RBZ
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	02/08/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Nivolumab	480	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IMATINIB	400	258684004	2	Oral	26643006	02/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	22	IMATINIB	400	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB - EMTANSINE	240	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2000	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			CAR-CAP-TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	330	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	20	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	28	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	2650	258684004	2	Oral	26643006	02/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1400	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	80	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	28	LENALIDOMIDE	5	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	99	Not known	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Osimertinib	80	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	180	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ISATUXIMAB	800	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	80	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	20	258684004	1	Intravenous	47625008	02/08/2023	RH8
RBZ	C159		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	Nivolumab	480	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CABAZITAXEL	40	258684004	1	Intravenous	47625008	02/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Olaparib	200	258684004	2	Oral	26643006	02/08/2023	RBZ
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	5	258684004	2	Oral	26643006	02/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C254						LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	10	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	02/08/2023	RBZ
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	02/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	320	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	100	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	IBRUTINIB	420	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	47	NILOTINIB	400	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	48	DASATINIB	40	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IBRUTINIB	420	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IBRUTINIB	560	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ERIBULIN	1.06	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	02/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	02/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	02/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	02/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	180	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	150	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	96	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	108	258684004	1	Intravenous	47625008	02/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	96	258684004	1	Intravenous	47625008	02/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			EC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	120	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			EC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	02/08/2023	RBZ
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	FLUOROURACIL	550	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1800	258684004	2	Oral	26643006	03/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CETUXIMAB	800	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	CETUXIMAB	800	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	145	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	03/08/2023	RH8
RBZ	C679		2	Neoadjuvant Therapy			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	500	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	13	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C189						Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1200	258684004	2	Oral	26643006	03/08/2023	RBZ
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C189						Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	220	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day loading dose	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	70	258684004	2	Oral	26643006	03/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509				99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RBZ	C61		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	03/08/2023	RBZ
RBZ	C61		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	164	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RH8	C56X		2	Neoadjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	10	BEVACIZUMAB - ALYMSYS	350	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	7	VENETOCLAX	400	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	12	VENETOCLAX	400	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAZOPANIB - RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	54	PAZOPANIB	400	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKLY EPIRUBICIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	03/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CAPECITABINE	1800	258684004	2	Oral	26643006	03/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	55	PALBOCICLIB	100	258684004	2	Oral	26643006	03/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	03/08/2023	RBZ
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	03/08/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BINIMETINIB	30	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENCORAFENIB	300	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DABRAFENIB	150	258684004	2	Oral	26643006	03/08/2023	RBZ
RBZ	C43		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRAMETINIB	2	258684004	2	Oral	26643006	03/08/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	TRAMETINIB	2	258684004	2	Oral	26643006	03/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	DABRAFENIB	150	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	600	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	108	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	BOSUTINIB	500	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	108	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			TUC CAPE & TRAS>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TUCATINIB	250	258684004	2	Oral	26643006	03/08/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IMATINIB	200	258684004	2	Oral	26643006	03/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	03/08/2023	RBZ
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Wkly Epirubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	16	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	03/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)			CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2150	258684004	2	Oral	26643006	03/08/2023	RBZ
RBZ	C679		9				ATEZOLIZUMAB >>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	40	PALBOCICLIB	125	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PALBOCICLIB	100	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	270	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	600	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	120	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 837 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ACALABRUTINIB	100	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CHLORAMBUCIL	18	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CHLORAMBUCIL	12	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C349	80463	2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARB/PAC/NIVO >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	330	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	90	Nivolumab	480	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Nivolumab	480	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SACITUZUMAB GOVITECAN	740	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C541		3	Not Applicable (Primary Treatment)			LENV + PEMBR>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - LENVIMA	14	258684004	2	Oral	26643006	03/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C541		3	Not Applicable (Primary Treatment)			LENV + PEMBR>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	03/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	20	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	03/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	57	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C189				99	Not known	RALT + OXALI	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	135	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C189				99	Not known	RALT + OXALI	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RALTITREXED	3	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	70	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	80	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C900	97323	9		98	Other	DT-PACE RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	20	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	98	Other	DAROL + ADT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	300	258684004	2	Oral	26643006	03/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	31	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	03/08/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	94	RUXOLITINIB	5	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			NIVO SCCA >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	280	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POLATUZUMAB VEDOTIN	126	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	03/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	03/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	320	258684004	1	Intravenous	47625008	03/08/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	32	NILOTINIB	400	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	28	IBRUTINIB	420	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IBRUTINIB	420	258684004	2	Oral	26643006	03/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - CY1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	03/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - CY1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	03/08/2023	RH8
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINBLASTINE SULFATE	4.8	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	03/08/2023	RBZ
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	600	258684004	1	Intravenous	47625008	03/08/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	43	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	500	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	43	FLUOROURACIL	700	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	43	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CETUXIMAB	900	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	43	CETUXIMAB	800	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	600	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	04/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1400	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	89	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1500	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	200	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	180	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	173	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	04/08/2023	RH8
RH8	C509		9				Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	04/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	04/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	04/08/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1500	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C719				99	Not known	Temozolomide 150mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	180	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	14	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	04/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	270	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	2	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	400	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	ISATUXIMAB	530	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARB + ETOP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	108	258684004	1	Intravenous	47625008	04/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	160	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	800	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMETREXED	900	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	04/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	26	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	41	Osimertinib	80	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	54	PALBOCICLIB	100	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	04/08/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Osimertinib	80	258684004	2	Oral	26643006	04/08/2023	RBZ
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ANASTROZOLE	1	258684004	2	Oral	26643006	04/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PALBOCICLIB	100	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	37	PALBOCICLIB	75	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PALBOCICLIB	100	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	180	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		9		98	Other	RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	400	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PACLITAXEL	270	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	51	BOSUTINIB	400	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	26	BOSUTINIB	400	258684004	2	Oral	26643006	04/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	29	NIRAPARIB	200	258684004	2	Oral	26643006	04/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NIRAPARIB	200	258684004	2	Oral	26643006	04/08/2023	RBZ
RBZ	C911	98233	3	Not Applicable (Primary Treatment)			IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IBRUTINIB	280	258684004	2	Oral	26643006	04/08/2023	RBZ
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	04/08/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRIFLURIDINE/TIPIRACIL	55	258684004	2	Oral	26643006	04/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	04/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZO 4WK URO>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C34.9		9		99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	1300	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PALBOCICLIB	125	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RIBOCICLIB	400	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	378	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	PONATINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PONATINIB	15	258684004	2	Oral	26643006	04/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NIRAPARIB	100	258684004	2	Oral	26643006	04/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	160	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	SACITUZUMAB GOVITECAN	600	258684004	1	Intravenous	47625008	04/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/08/2023	RH8
RBZ	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/08/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/08/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ACALABRUTINIB	100	258684004	2	Oral	26643006	04/08/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	04/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	240	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	160	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	154	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	04/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	38	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	36	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	80	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	57	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	99	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	120	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CAPECITABINE	2450	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	2150	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	30	CAPECITABINE	1000	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C44X		9		98	Other	Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Nivolumab	480	258684004	1	Intravenous	47625008	04/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	98	Other	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	31	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	04/08/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	RUXOLITINIB	10	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RUXOLITINIB	15	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	LENALIDOMIDE	10	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Dabrafenib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DABRAFENIB	50	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	APIXABAN	2.5	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	600	258684004	1	Intravenous	47625008	04/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	56	IBRUTINIB	560	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C921	98633	9		5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NILOTINIB	200	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	2	NILOTINIB	400	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	24	DASATINIB	20	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IBRUTINIB	560	258684004	2	Oral	26643006	04/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ERIBULIN	1.94	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ERIBULIN	1.67	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	04/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CABOZANTINIB	20	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CABOZANTINIB	20	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CABOZANTINIB	40	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Osimertinib	80	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ACALABRUTINIB	100	258684004	2	Oral	26643006	05/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ZANUBRUTINIB	160	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			LORLATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LORLATINIB	100	258684004	2	Oral	26643006	05/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	CABOZANTINIB	20	258684004	2	Oral	26643006	06/08/2023	RH8
RH8	C921	98633	9		98	Other	IMAT RDE 90 CYC1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	200	258684004	2	Oral	26643006	06/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/08/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	06/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	400	258684004	2	Oral	26643006	06/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			TEPOTINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEPOTINIB	450	258684004	2	Oral	26643006	06/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	ASCIMINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ASCIMINIB	80	258684004	2	Oral	26643006	06/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	47	IBRUTINIB	420	258684004	2	Oral	26643006	06/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	73	DASATINIB	100	258684004	2	Oral	26643006	06/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	07/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	216	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	480	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2000	258684004	2	Oral	26643006	07/08/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	900	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CISPLATIN	22	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	07/08/2023	RH8
RBZ	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	07/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	120	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C10X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CARBOPLATIN	700	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	360	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	07/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	220	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/08/2023	RH8
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	07/08/2023	RH8
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/08/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	07/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	07/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PALBOCICLIB	125	258684004	2	Oral	26643006	07/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Osimertinib	80	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	Osimertinib	80	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	100	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	07/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	VENETOCLAX	100	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	07/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	07/08/2023	RBZ
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	102	IBRUTINIB	280	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	22	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	07/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Wkly Epirubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	36	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	07/08/2023	RH8
RBZ	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/08/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PALBOCICLIB	125	258684004	2	Oral	26643006	07/08/2023	RBZ
RBZ	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1400	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	45	RIBOCICLIB	400	258684004	2	Oral	26643006	07/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	400	258684004	2	Oral	26643006	07/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	RIBOCICLIB	600	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C920	98723	9				VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	40	258684004	5	Subcutaneous	34206005	07/08/2023	RH8
RH8	C920	98723	9				VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	100	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	NIRAPARIB	200	258684004	2	Oral	26643006	07/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	07/08/2023	RH8
RBZ	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - VEGZELMA	1200	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RH8	D473	99623	9		98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1780	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	07/08/2023	RH8
RBZ	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APALUTAMIDE	240	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	07/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APALUTAMIDE	240	258684004	2	Oral	26643006	07/08/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	180	258684004	2	Oral	26643006	07/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APALUTAMIDE	240	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	1000	258684004	1	Intravenous	47625008	07/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C269		1	Adjuvant Therapy	99	Not known	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IMATINIB	400	258684004	2	Oral	26643006	07/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB - EMTANSINE	160	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	98	Other	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	07/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ACALABRUTINIB	100	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	07/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	07/08/2023	RH8
RBZ	D473	99623	9				HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	07/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	80	258684004	2	Oral	26643006	07/08/2023	RH8
RBZ	C189						Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1650	258684004	2	Oral	26643006	07/08/2023	RBZ
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DAROLUTAMIDE	600	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DAROLUTAMIDE	600	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	07/08/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	RUXOLITINIB	5	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	118	RUXOLITINIB	10	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	D45X	99503	9		98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	29	RUXOLITINIB	15	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	07/08/2023	RH8
RH8	C900	97323	9		98	Other	PBDA - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	5	ACALABRUTINIB	100	258684004	2	Oral	26643006	07/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	10	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	10	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C900	97323	9		98	Other	PBDA - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Panobinostat	15	258684004	2	Oral	26643006	07/08/2023	RH8
RBZ	C900	97323	1	Adjuvant Therapy			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	10	258684004	2	Oral	26643006	07/08/2023	RBZ
RH8	C900	97323	9		98	Other	PBDA - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	07/08/2023	RH8
RBZ	C97X						LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	07/08/2023	RBZ
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	43	IBRUTINIB	420	258684004	2	Oral	26643006	07/08/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	31	NILOTINIB	300	258684004	2	Oral	26643006	07/08/2023	RH8
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DACARBAZINE	630	258684004	1	Intravenous	47625008	07/08/2023	RBZ
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	700	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	5	258684004	2	Oral	26643006	08/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	82	LENALIDOMIDE	15	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	5	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C679		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1500	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1100	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	30	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APIXABAN	2.5	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1650	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1450	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	240	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C80.9				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ETOPOSIDE	148	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C80.9				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	120	258684004	1	Intravenous	47625008	08/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C259		9				Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1800	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	148	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	79	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	50	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	08/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	08/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	08/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	270	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	150	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	270	258684004	1	Intravenous	47625008	08/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	162	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AVELUMAB	800	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	375	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	08/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	81	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	08/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	08/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	08/08/2023	RBZ
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	08/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	08/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	33	ENZALUTAMIDE	40	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	43	PALBOCICLIB	75	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	08/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	08/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABEMACICLIB	150	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ANASTROZOLE	1	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABEMACICLIB	100	258684004	2	Oral	26643006	08/08/2023	RH8
RBZ	C920	98733	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	08/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	49	PALBOCICLIB	75	258684004	2	Oral	26643006	08/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP>	1	PATIENT is taking part in a CLINICAL TRIAL	6	CARBOPLATIN	400	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	08/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	08/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	08/08/2023	RBZ
RBZ	C920	98733	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	VENETOCLAX	100	258684004	2	Oral	26643006	08/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	08/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	08/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	08/08/2023	RBZ
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CABOZANTINIB	20	258684004	2	Oral	26643006	08/08/2023	RBZ
RH8	C499		3	Not Applicable (Primary Treatment)			TRABECTEDIN 4WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRABECTEDIN	3	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NINTEDANIB	200	258684004	2	Oral	26643006	08/08/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Nivolumab	480	258684004	1	Intravenous	47625008	08/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ALECTINIB	600	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO*	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/08/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	75	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IMATINIB	400	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C349	80423	9				ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	164	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	27	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	08/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	82	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	80	258684004	2	Oral	26643006	08/08/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	100	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	120	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	08/08/2023	RH8
RBZ	C900	97323	9				CAR LEN DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	08/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	600	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DAROLUTAMIDE	600	258684004	2	Oral	26643006	08/08/2023	RH8
RBZ	C900	97323	9				CAR LEN DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	25	258684004	2	Oral	26643006	08/08/2023	RBZ
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	08/08/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	27	RUXOLITINIB	25	258684004	2	Oral	26643006	08/08/2023	RH8
RBZ	C900	97323	9				CAR LEN DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARFILZOMIB	32	258684004	1	Intravenous	47625008	08/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	132	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C44		3	Not Applicable (Primary Treatment)			AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	23	AVELUMAB	800	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RBZ	C900	97323	9				CAR LEN DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	08/08/2023	RBZ
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	10	258684004	2	Oral	26643006	08/08/2023	RH8
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	650	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	375	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	08/08/2023	RH8
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	100	258684004	1	Intravenous	47625008	08/08/2023	RBZ
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	240	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	08/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	37	NILOTINIB	200	258684004	2	Oral	26643006	08/08/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	630	258684004	1	Intravenous	47625008	08/08/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	17500	408102007	1	Intravenous	47625008	08/08/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BENDAMUSTINE HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	28	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	600	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	09/08/2023	RH8
RBZ	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	560	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	300	258684004	1	Intravenous	47625008	09/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CETUXIMAB	900	258684004	1	Intravenous	47625008	09/08/2023	RH8
RBZ	C189						Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RBZ	C189						Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1450	258684004	2	Oral	26643006	09/08/2023	RBZ
RH8	C900	97323	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	85	LENALIDOMIDE	5	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	15	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2200	258684004	1	Intravenous	47625008	09/08/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	650	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RBZ	C189						Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1300	258684004	2	Oral	26643006	09/08/2023	RBZ
RBZ	C189						Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	09/08/2023	RH8
RBZ	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	09/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	120	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RBZ	C900	97323	9				Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	09/08/2023	RBZ
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1400	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1000	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	1	PATIENT is taking part in a CLINICAL TRIAL	4	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	09/08/2023	RH8
RH8	C21X				99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	14	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	400	258684004	2	Oral	26643006	09/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	180	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETO + RITUX C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	300	258684004	2	Oral	26643006	09/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	AVELUMAB	800	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	09/08/2023	RH8
RBZ	C20		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB - EMTANSINE	280	258684004	1	Intravenous	47625008	09/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	46	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMG>4	1	PATIENT is taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	22	ENZALUTAMIDE	80	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	43	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/08/2023	RH8
RBZ	C20		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	900	258684004	1	Intravenous	47625008	09/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C20		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	2000	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	09/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	09/08/2023	RH8
RBZ	C20		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PANITUMUMAB	600	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	200	258684004	1	Intravenous	47625008	09/08/2023	RH8
RBZ	C920	98733	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	09/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	09/08/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Nivolumab	480	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	NIRAPARIB	200	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IMATINIB	200	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	200	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE 90 CYC1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IMATINIB	400	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	44	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	09/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	09/08/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Regorafenib CRC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	REGORAFENIB	160	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	200	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PALBOCICLIB	75	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	144	258684004	1	Intravenous	47625008	09/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	200	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C920	98723	9				VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	40	258684004	5	Subcutaneous	34206005	09/08/2023	RH8
RH8	C920	98723	9				VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	300	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	D693		9		1	Curative – aiming to permanently eradicate the disease	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ACALABRUTINIB	100	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APALUTAMIDE	240	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	120	258684004	2	Oral	26643006	09/08/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			DURVALUMAB> +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DURVALUMAB	1000	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	480	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	83	Olaparib	250	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1000	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	164	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB DERUXTECAN	260	258684004	1	Intravenous	47625008	09/08/2023	RH8
RBZ	C509						MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	09/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	D473	99623			99	Not known	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	09/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	4	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	10	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU-ECHO	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DEXAMETHASONE	2	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL 6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	56	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2500	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2650	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CAPECITABINE	2000	258684004	2	Oral	26643006	09/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL 6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DAROLUTAMIDE	600	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	10	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	630	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	150	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ISATUXIMAB	440	258684004	1	Intravenous	47625008	09/08/2023	RH8
RBZ	C44		3	Not Applicable (Primary Treatment)			Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C900	97323	1	Adjuvant Therapy			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ISATUXIMAB	900	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	145	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			DOCE/DAROL 6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	800	258684004	1	Intravenous	47625008	09/08/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			PEMBROLIZ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	09/08/2023	RH8
RBZ	C900	97323	9				CAR LEN DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARFILZOMIB	32	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C848	97183	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	35	BEXAROTENE	225	258684004	2	Oral	26643006	09/08/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AVELUMAB	800	258684004	1	Intravenous	47625008	09/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Olaparib	200	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	750	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	09/08/2023	RH8
RBZ	C259						LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	09/08/2023	RBZ
RBZ	C252						LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	12	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	09/08/2023	RBZ
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	SUNITINIB	37.5	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	09/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	09/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	57	NILOTINIB	300	258684004	2	Oral	26643006	09/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Dasatinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	DASATINIB	20	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C831	96733	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IBRUTINIB	560	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ERIBULIN	1.06	258684004	1	Intravenous	47625008	09/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	THALIDOMIDE	100	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	09/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	09/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	09/08/2023	RH8
RBZ	C159		2	Neoadjuvant Therapy			FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RBZ	C159		2	Neoadjuvant Therapy			FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	165	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RBZ	C159		2	Neoadjuvant Therapy			FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	96	258684004	1	Intravenous	47625008	09/08/2023	RBZ
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	336	258684004	1	Intravenous	47625008	10/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189						Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RBZ	C189						Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RBZ	C189						Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	800	258684004	2	Oral	26643006	10/08/2023	RBZ
RBZ	C189						Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CAPECITABINE	1500	258684004	2	Oral	26643006	10/08/2023	RBZ
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Cytarabine low (10to20mg/m2) IV/SC	2	PATIENT is not taking part in a CLINICAL TRIAL	28	CYTARABINE	20	258684004	5	Subcutaneous	34206005	10/08/2023	RBZ
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	26	LENALIDOMIDE	5	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1400	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1600	258684004	1	Intravenous	47625008	10/08/2023	RH8
RBZ	C679		2	Neoadjuvant Therapy			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	89	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CISPLATIN	45	258684004	1	Intravenous	47625008	10/08/2023	RH8
RBZ	C679		2	Neoadjuvant Therapy			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	128	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RBZ	C20						Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RBZ	C20						Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	4	258684004	2	Oral	26643006	10/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C20						Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	10/08/2023	RBZ
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	500	258684004	1	Intravenous	47625008	10/08/2023	RH8
RBZ	C20						Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C349	80463	2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C349	80463	2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	80	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	250	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	164	258684004	1	Intravenous	47625008	10/08/2023	RH8
RBZ	C61		2	Neoadjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	10/08/2023	RBZ
RBZ	C61		2	Neoadjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	120	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1200	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	330	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	10/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PAC 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FT3-mFOLFOXIRI>1	1	PATIENT is taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENVATINIB - KISPLYX	14	258684004	2	Oral	26643006	10/08/2023	RH8
RBZ	C880	97613	3	Not Applicable (Primary Treatment)			DRC CATCH UP RIT	2	PATIENT is not taking part in a CLINICAL TRIAL	8	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FT3-mFOLFOXIRI>1	1	PATIENT is taking part in a CLINICAL TRIAL	2	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABEMACICLIB	150	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	10/08/2023	RH8
RBZ	C920	98733	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	100	258684004	2	Oral	26643006	10/08/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	125	258684004	2	Oral	26643006	10/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PALBOCICLIB	75	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FT3-mFOLFOXIRI>1	1	PATIENT is taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIMRDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	200	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIMRDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	150	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO and FULVON	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	200	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	108	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C509		9				RIBO and FULVON	2	PATIENT is not taking part in a CLINICAL TRIAL	14	RIBOCICLIB	600	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	10	ISATUXIMAB	590	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIMRDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	50	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIMRDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	58	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	26	METFORMIN	850	258684004	2	Oral	26643006	10/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	39	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	44	BEVACIZUMAB - ALYMSYS	1300	258684004	1	Intravenous	47625008	10/08/2023	RH8
RBZ	C829	96953	3	Not Applicable (Primary Treatment)			R-LENALID -Cyc1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEV HCC +	2	PATIENT is not taking part in a CLINICAL TRIAL	44	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	10/08/2023	RH8
RBZ	C829	96953	3	Not Applicable (Primary Treatment)			R-LENALID -Cyc1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	20	258684004	2	Oral	26643006	10/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			ABEM & LETROZ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABEMACICLIB	100	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PALBOCICLIB	75	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	51	RIBOCICLIB	400	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	25	RIBOCICLIB	200	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C920	98723	9				VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	40	258684004	5	Subcutaneous	34206005	10/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	200	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C920	98723	9				VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	100	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	120	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	SACITUZUMAB GOVITECAN	780	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	D473	99623	9		98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	16	HYDROXYCARBAMIDE	300	258684004	2	Oral	26643006	10/08/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/08/2023	RH8
RBZ	C911	98233	9				ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ACALABRUTINIB	100	258684004	2	Oral	26643006	10/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	120	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PALBOCICLIB	125	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	10/08/2023	RH8
RBZ	C679		9				AVELUMAB UC +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	164	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	10/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IBRUTINIB	560	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	1	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	DEXAMETHASONE	10	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	POMALIDOMIDE	1	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	10/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	10/08/2023	RBZ
RBZ	C189						Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2150	258684004	2	Oral	26643006	10/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ISATUXIMAB	650	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	APIXABAN	2.5	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	800	258684004	1	Intravenous	47625008	10/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	10/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	10/08/2023	RBZ
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DAROLUTAMIDE	600	258684004	2	Oral	26643006	10/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DAROLUTAMIDE	600	258684004	2	Oral	26643006	10/08/2023	RBZ
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	45	RUXOLITINIB	10	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	10/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	148	258684004	1	Intravenous	47625008	10/08/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Olaparib	100	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	10	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	LENALIDOMIDE	10	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	30	LENALIDOMIDE	10	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	700	258684004	1	Intravenous	47625008	10/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	150	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	25	APIXABAN	2.5	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sorafenib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SORAFENIB	400	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	10/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	105	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	POMALIDOMIDE	4	258684004	2	Oral	26643006	10/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	105	ERIBULIN	1.67	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C349	80463	9				PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	10/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	10/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - VEGZELMA	400	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	216	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CETUXIMAB	900	258684004	1	Intravenous	47625008	11/08/2023	RH8
RBZ	C20						Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RBZ	C20						Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	11/08/2023	RBZ
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	400	258684004	1	Intravenous	47625008	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	44	LENALIDOMIDE	15	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	800	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1400	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	120	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	180	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	128	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB-ONTRUZANT	378	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	105	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1500	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	120	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C910	98353	3	Not Applicable (Primary Treatment)	98	Other	Methotrexate intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	2	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	11/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	270	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	TEMOZOLOMIDE	380	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	250	258684004	2	Oral	26643006	11/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - VEGZELMA	400	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	2000	258684004	1	Intravenous	47625008	11/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2200	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	400	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKY PAC + TRAS MT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	66	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	ISATUXIMAB	530	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	200	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	160	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	132	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	50	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	38	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	49	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	1.4	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	750	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	38	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	80	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	99	Not known	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	29	ENZALUTAMIDE	120	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	10	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Osimertinib	80	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	45	PALBOCICLIB	100	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	43	PALBOCICLIB	75	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	AZACITIDINE	140	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABEMACICLIB	100	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABEMACICLIB	100	258684004	2	Oral	26643006	11/08/2023	RH8
RBZ	C499		3	Not Applicable (Primary Treatment)			GEM/DOC STS 2ND>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1100	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RBZ	C920	98733	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	11/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	125	258684004	2	Oral	26643006	11/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PALBOCICLIB	75	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	32	PALBOCICLIB	100	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		9				PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PALBOCICLIB	100	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	180	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C911	98233			98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	11	VENETOCLAX	400	258684004	2	Oral	26643006	11/08/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPILIMRDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	175	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	11/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	11/08/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			RIBO and FULVON	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RIBOCICLIB	200	258684004	2	Oral	26643006	11/08/2023	RBZ
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		9				RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RIBOCICLIB	400	258684004	2	Oral	26643006	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	3	ISATUXIMAB	780	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	IBRUTINIB - CLL.	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IBRUTINIB	280	258684004	2	Oral	26643006	11/08/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	58	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Nivolumab	480	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	40	ALECTINIB	600	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IMATINIB	400	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	200	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Wkly Epirubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	3	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C80.9				99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	11/08/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Osimertinib	80	258684004	2	Oral	26643006	11/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Pac Alb CarboHP	1	PATIENT is taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	300	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRAMETINIB	2	258684004	2	Oral	26643006	11/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RH8	C920	98723	9				VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	40	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Olaparib - PS>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Olaparib	300	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	160	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	11/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL ALBUMIN	180	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ACALABRUTINIB	100	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	99	Not known	GILTERITINIB>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GILTERITINIB	120	258684004	2	Oral	26643006	11/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			ATEZO/NAB PAC>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APALUTAMIDE	240	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APALUTAMIDE	120	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	APALUTAMIDE	120	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	Nivolumab	480	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	160	258684004	1	Intravenous	47625008	11/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	11/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMB ADJ MAIN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C880	97613	9		98	Other	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZANUBRUTINIB	80	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BINIMETINIB	45	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENCORAFENIB	450	258684004	2	Oral	26643006	11/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	400	258684004	2	Oral	26643006	11/08/2023	RBZ
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	164	258684004	1	Intravenous	47625008	11/08/2023	RH8
RBZ	C679		3	Not Applicable (Primary Treatment)			AVELUMAB UC5-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AVELUMAB	800	258684004	1	Intravenous	47625008	11/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	40	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	DEXAMETHASONE	20	258684004	2	Oral	26643006	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	40	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	10	258684004	2	Oral	26643006	11/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	40	258684004	2	Oral	26643006	11/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	80	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	80	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	25	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	5	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1300	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1800	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	LENALIDOMIDE	5	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	POMALIDOMIDE	4	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	15	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	15	258684004	2	Oral	26643006	11/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	11/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	25	258684004	2	Oral	26643006	11/08/2023	RBZ
RH8	C911	98233	1	Adjuvant Therapy			Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CHLORAMBUCIL	16	258684004	2	Oral	26643006	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	11/08/2023	RBZ
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ISATUXIMAB	700	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IXAZOMIB	4	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	APIXABAN	2.5	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IXAZOMIB	2.3	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	2.5	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IXAZOMIB	3	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IXAZOMIB	4	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	9		98	Other	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APIXABAN	2.5	258684004	2	Oral	26643006	11/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IXAZOMIB	4	258684004	2	Oral	26643006	11/08/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BEVACIZUMAB - ALYMSYS	700	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - ALYMSYS	900	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)			LENVATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENVATINIB - LENVIMA	16	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CABAZITAXEL	40	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Olaparib	300	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Olaparib	300	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Olaparib	250	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POLATUZUMAB VEDOTIN	140	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	FLUOROURACIL	800	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	600	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OXALIPLATIN	135	258684004	1	Intravenous	47625008	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB DERUXTECAN	320	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	POLATUZUMAB VEDOTIN	160	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	2	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Erlotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	75	ERLOTINIB	50	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	11/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			CYCLO PO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	50	258684004	2	Oral	26643006	11/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	4.8	258684004	1	Intravenous	47625008	11/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CHLORAMBUCIL	8	258684004	2	Oral	26643006	11/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PROCARBAZINE	100	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	11/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	11/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	100	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	37	Osimertinib	40	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IMATINIB	400	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	C41X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CE<25 (PT SP)	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ETOPOSIDE	164	258684004	1	Intravenous	47625008	12/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	51	ENZALUTAMIDE	160	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OSIMERT ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	Osimertinib	40	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	45	IBRUTINIB	140	258684004	2	Oral	26643006	12/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	30	IBRUTINIB	420	258684004	2	Oral	26643006	12/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	13/08/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Osimertinib	40	258684004	2	Oral	26643006	13/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IMATINIB	200	258684004	2	Oral	26643006	13/08/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	13/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	13/08/2023	RH8
RH8	C34.9		9		99	Not known	CAPE + TEMOZOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TEMOZOLOMIDE	330	258684004	2	Oral	26643006	13/08/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	240	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	240	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Arsenic Trioxide (Induction Week)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ARSENIC TRIOXIDE	27	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	15	258684004	2	Oral	26643006	14/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	14/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	15	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	15	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	20	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	THALIDOMIDE	50	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	14/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	APIXABAN	2.5	258684004	2	Oral	26643006	14/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	14/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	56	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	80	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	14/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Vinorelbine (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C189		9		99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C189		9		99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	650	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C189		9		99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C189		9		99	Not known	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CETUXIMAB	800	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	220	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	14/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	80	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	120	258684004	2	Oral	26643006	14/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Osimertinib	80	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	14/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	400	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	69	TRAMETINIB	1.5	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	69	DABRAFENIB	100	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DABRAFENIB	100	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRAMETINIB	1	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	14/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	400	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	300	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	120	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C349	80463	9		99	Not known	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ALECTINIB	450	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPILIM RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	90	258684004	1	Intravenous	47625008	14/08/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)			IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IBRUTINIB	420	258684004	2	Oral	26643006	14/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C459		9				NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	360	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	14/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Wkly Epirubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	36	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	D45X	99503			99	Not known	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CABOZANTINIB	20	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1650	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	270	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRAMETINIB	2	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	14	NINTEDANIB	200	258684004	2	Oral	26643006	14/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ 2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RIBOCICLIB	600	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C920	98723	9				VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	40	258684004	5	Subcutaneous	34206005	14/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BOSUTINIB	300	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C844	97023	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	14	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C64X		1	Adjuvant Therapy	98	Other	PEMBRO ADJ RCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	14/08/2023	RH8
RBZ	C911	98233	9				ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ACALABRUTINIB	100	258684004	2	Oral	26643006	14/08/2023	RBZ
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	D473	99623			99	Not known	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/08/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	14/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DURVALUMAB	1500	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	14/08/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	14/08/2023	RH8
RBZ	C848	97183	3	Not Applicable (Primary Treatment)			BEXAROTENE>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEXAROTENE	300	258684004	2	Oral	26643006	14/08/2023	RBZ
RH8	C900	97323	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	10	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	LENALIDOMIDE	10	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C900	97323	9		98	Other	PBDA - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	14/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			Ipilimumab	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	250	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	10	258684004	2	Oral	26643006	14/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ERIBULIN	2.02	258684004	1	Intravenous	47625008	14/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	2.02	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	96	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C349	80423	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAV	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	14/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	600	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	15	CETUXIMAB	900	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	15/08/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1100	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RBZ	C679		1	Adjuvant Therapy			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	15/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	79	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	145	258684004	1	Intravenous	47625008	15/08/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	30	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RBZ	C679		1	Adjuvant Therapy			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	128	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	15/08/2023	RH8
RBZ	C509						Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	15/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	15/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	15/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	15/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	15/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	15/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	15/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	FLUOROURACIL	800	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	31	CETUXIMAB	1000	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TEMOZOLOMIDE	370	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	220	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	270	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	15/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	220	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	240	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	150	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	15/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	15/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	28	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	600	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	15/08/2023	RBZ
RH8	C349	80463	9				PEMBRO428 6WK C1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	80	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	500	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	15/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/08/2023	RBZ
RBZ	C946	99893	3	Not Applicable (Primary Treatment)			LENALID 5Q RDE>1	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	5	258684004	2	Oral	26643006	15/08/2023	RBZ
RH8	C509		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PALBOCICLIB	125	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	300	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PANITUMUMAB	220	258684004	1	Intravenous	47625008	15/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	15/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	15/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	15/08/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	TRAMETINIB	2	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DABRAFENIB	150	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	108	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	15/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	15/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	15/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	15/08/2023	RBZ
RH8	C349	80463			99	Not known	Refine L 12W C1	1	PATIENT is taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATEZ MAIN SC +	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	15/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	700	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RH8	C509				99	Not known	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	RIBOCICLIB	400	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	108	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RIBOCICLIB	200	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C920	98723	9				VEN /LD CYT C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	40	258684004	5	Subcutaneous	34206005	15/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	41	Nivolumab	480	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	32	NIRAPARIB	100	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	99	Not known	RAIN RDE ARMB I	1	PATIENT is taking part in a CLINICAL TRIAL	4	IBRUTINIB	420	258684004	2	Oral	26643006	15/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APALUTAMIDE	240	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APALUTAMIDE	240	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENCORAFENIB	450	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BINIMETINIB	45	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	43	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	15/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	16	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	22	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	15/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	25	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	LENALIDOMIDE	15	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C169		2	Neoadjuvant Therapy			OX/CAP> C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	500	258684004	2	Oral	26643006	15/08/2023	RH8
RBZ	C509						Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	15/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	22	LENALIDOMIDE	5	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C169		2	Neoadjuvant Therapy			OX/CAP> C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	80	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	IXAZOMIB	4	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	IXAZOMIB	4	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BEVACIZUMAB - VEGZELMA	1300	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BEVACIZUMAB - VEGZELMA	1200	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DAROLUTAMIDE	600	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	20	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	15/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	48	RUXOLITINIB	10	258684004	2	Oral	26643006	15/08/2023	RH8
RBZ	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	15/08/2023	RBZ
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	15/08/2023	RH8
RBZ	C900	97323	9				CAR LEN DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARFILZOMIB	44	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	Olaparib	300	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Olaparib	300	258684004	2	Oral	26643006	15/08/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	15/08/2023	RH8
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	700	258684004	1	Intravenous	47625008	15/08/2023	RH8
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	800	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	12	OXALIPLATIN	150	258684004	1	Intravenous	47625008	15/08/2023	RH8
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	165	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			SOTORASIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	SOTORASIB	960	258684004	2	Oral	26643006	15/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	200	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	40	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	450	258684004	1	Intravenous	47625008	15/08/2023	RH8
RBZ	C859	95913	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RBZ	C859	95913	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RBZ	C859	95913	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	15/08/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	15/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	15/08/2023	RH8
RBZ	C189						Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	TRASTUZUMAB-ONTRUZANT	378	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1800	258684004	2	Oral	26643006	16/08/2023	RH8
RBZ	C189						Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	500	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RBZ	C189						Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	400	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	216	258684004	1	Intravenous	47625008	16/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C159		3	Not Applicable (Primary Treatment)			Cape + Cisplatin + Trastuzumab Main	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CISPLATIN	145	258684004	1	Intravenous	47625008	16/08/2023	RH8
RBZ	C189						Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CETUXIMAB	600	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LENALIDOMIDE	5	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1800	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	250	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	16/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	2000	258684004	1	Intravenous	47625008	16/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	120	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	700	258684004	1	Intravenous	47625008	16/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C61X				99	Not known	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CETUXIMAB	1100	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C61X		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	148	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1450	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)	99	Not known	MITOMYCIN + CAPECITABINE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	MITOMYCIN	20	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C719				99	Not known	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	300	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C719		9				Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	350	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	16/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	AVELUMAB	800	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	55	258684004	1	Intravenous	47625008	16/08/2023	RH8
RBZ	C189						PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	500	258684004	1	Intravenous	47625008	16/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	0.98	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	800	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	36	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	16/08/2023	RH8
RBZ	C189						PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RBZ	C189						PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/08/2023	RBZ
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	120	258684004	2	Oral	26643006	16/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/08/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)			CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CABOZANTINIB	40	258684004	2	Oral	26643006	16/08/2023	RH8
RBZ	C189						PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	550	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RBZ	C189						PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RBZ	C189						PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	16/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	100	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	100	258684004	2	Oral	26643006	16/08/2023	RH8
RBZ	C189						PAN/FOLFIRINOX >1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PANITUMUMAB	340	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RBZ	C189						PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PANITUMUMAB	340	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	10	ISATUXIMAB	800	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	23	METFORMIN	850	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/08/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ENGOT PEMBRO 6W	1	PATIENT is taking part in a CLINICAL TRIAL	17	PEMBROLIZUMAB/PLACEBO	400	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	16/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	FLUOROURACIL	350	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PANITUMUMAB	180	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	13	NINTEDANIB	200	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	45	RIBOCICLIB	400	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	270	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	144	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	D693		9		1	Curative – aiming to permanently eradicate the disease	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	14	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ACALABRUTINIB	100	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENCORAFENIB	300	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	120	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CETUXIMAB	1000	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	480	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/08/2023	RH8
RBZ	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO MAIN SC	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	22	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	22	258684004	1	Intravenous	47625008	16/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	16/08/2023	RBZ
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	0.74	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	0.74	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	36	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	POMALIDOMIDE	3	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	180	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ISATUXIMAB	800	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	96	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	96	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	16/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	10	CABAZITAXEL	40	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	16/08/2023	RH8
RH8	C44X		9				Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	4	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/08/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DEXAMETHASONE	4	258684004	2	Oral	26643006	16/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	LENALIDOMIDE	10	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	700	258684004	1	Intravenous	47625008	16/08/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PEMETREXED	900	258684004	1	Intravenous	47625008	16/08/2023	RBZ
RBZ	C179						LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	16/08/2023	RBZ
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	209	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	16/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633			99	Not known	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	75	NILOTINIB	300	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IBRUTINIB	560	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			SOTORASIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	SOTORASIB	960	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	16/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	16/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	16/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	16/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	55	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINBLASTINE SULFATE	13	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DACARBAZINE	790	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	180	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	135	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	OXALIPLATIN	150	258684004	1	Intravenous	47625008	16/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	21250	408102007	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	88	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	108	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	80	258684004	1	Intravenous	47625008	16/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	33	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LIPOSOMAL DOXORUBICIN	46	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	33	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	33	FLUOROURACIL	550	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	360	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	12	CETUXIMAB	800	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	33	CETUXIMAB	800	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1400	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	GEMCITABINE	1600	258684004	1	Intravenous	47625008	17/08/2023	RH8
RBZ	C679		2	Neoadjuvant Therapy			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	17/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C679		2	Neoadjuvant Therapy			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	113	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CISPLATIN	45	258684004	1	Intravenous	47625008	17/08/2023	RH8
RBZ	C679		2	Neoadjuvant Therapy			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	500	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	14	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C20X		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	250	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	79	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	15	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C349	80463	2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINORELBINE	80	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1600	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	17/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	164	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	132	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	240	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	132	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C52X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1200	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C719		9				Temozolomide + RT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	150	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	17/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	10	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CABOZANTINIB	20	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	80	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CABOZANTINIB	40	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	CABOZANTINIB	20	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	120	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	58	PALBOCICLIB	125	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	790	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP A 100>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	180	258684004	1	Intravenous	47625008	17/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PALBOCICLIB	100	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DABRAFENIB	150	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DABRAF AND TRAM>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRAMETINIB	2	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	120	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	16	VENETOCLAX	400	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	108	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	148	258684004	1	Intravenous	47625008	17/08/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	480	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	18	METFORMIN	850	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	FLAIR - IBRUT MA	1	PATIENT is taking part in a CLINICAL TRIAL	21	IBRUTINIB	420	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	54	IMATINIB	400	258684004	2	Oral	26643006	17/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			Wkly Epirubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	17/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C829	96953	3	Not Applicable (Primary Treatment)			R-LENALID -Cyc1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	16	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/08/2023	RH8
RBZ	C64		1	Adjuvant Therapy			PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	39	PALBOCICLIB	75	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	270	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL	300	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	216	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	Nivolumab	480	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	120	258684004	1	Intravenous	47625008	17/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	SACITUZUMAB GOVITECAN	780	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SACITUZUMAB GOVITECAN	740	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ATTEND MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	59	ATEZOLIZUMAB/PLACEBO	1200	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CHLORAMBUCIL	22	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	APALUTAMIDE	240	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	400	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ACALABRUTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ACALABRUTINIB	100	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C880	97613	9		5	Palliative – aiming to delay tumour progression	ZANUBRUTINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ZANUBRUTINIB	80	258684004	2	Oral	26643006	17/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PEMETREXED	1000	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)			R-IBRUT MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IBRUTINIB	560	258684004	2	Oral	26643006	17/08/2023	RH8
RBZ	C66		3	Not Applicable (Primary Treatment)			AVELUMAB UC5-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	AVELUMAB	800	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)			Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BUSULFAN	2	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	22	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	22	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	41	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	0.74	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	0.74	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	17/08/2023	RH8
RBZ	C61		9				DOCE/DAROL 6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	17/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	69	LENALIDOMIDE	15	258684004	2	Oral	26643006	17/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2150	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	17/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CAPECITABINE	1000	258684004	2	Oral	26643006	17/08/2023	RBZ
RBZ	C61		9				DOCE/DAROL 6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DAROLUTAMIDE	600	258684004	2	Oral	26643006	17/08/2023	RBZ
RH8	C848	97183	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	96	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C833	97353	3	Not Applicable (Primary Treatment)	98	Other	DA-EPOCH C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	96	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			NIVO SCCA >>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	280	258684004	1	Intravenous	47625008	17/08/2023	RH8
RBZ	C61		9				DOCE/DAROL 6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	148	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	69	IXAZOMIB	4	258684004	2	Oral	26643006	17/08/2023	RH8
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	POMALIDOMIDE	2	258684004	2	Oral	26643006	17/08/2023	RH8
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	17/08/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DAROLUTAMIDE	600	258684004	2	Oral	26643006	17/08/2023	RBZ
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	13	RUXOLITINIB	15	258684004	2	Oral	26643006	17/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	17/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ISATUXIMAB	600	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ISA/POM/DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	R-DHAP>RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYTARABINE	4000	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			Dabrafenib	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DABRAFENIB	150	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	D479		3	Not Applicable (Primary Treatment)	98	Other	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C629	90613	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	17/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	47	IBRUTINIB	280	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	35	NILOTINIB	200	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	7	NILOTINIB	200	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	105	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	17/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	105	ERIBULIN	1.67	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	17/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	17/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	44	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	350	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	FLUOROURACIL	500	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	44	FLUOROURACIL	700	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	44	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + Oxaliplatin + MdG Maint	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CETUXIMAB	800	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	18	CETUXIMAB	900	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	44	CETUXIMAB	800	258684004	1	Intravenous	47625008	18/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	480	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	2150	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Arsenic Trioxide (Induction Week)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ARSENIC TRIOXIDE	27	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C900	97323	9		99	Not known	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C900	97323	9		99	Not known	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	20	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	19	LENALIDOMIDE	25	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C900	97323	9		99	Not known	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C900	97323	9		99	Not known	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	600	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1500	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1800	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	200	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	250	258684004	1	Intravenous	47625008	18/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	18/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	18/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	14	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	18/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	1.8	258684004	5	Subcutaneous	34206005	18/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	18/08/2023	RBZ
RH8	C259		1	Adjuvant Therapy	98	Other	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1500	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	99	Not known	Methotrexate intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	3	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	18/08/2023	RH8
RH8	C719				99	Not known	Temozolomide 150mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEMOZOLOMIDE	285	258684004	2	Oral	26643006	18/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BEVACIZUMAB - VEGZELMA	450	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - VEGZELMA	450	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	15	BEVACIZUMAB - VEGZELMA	500	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Bevacizumab 15mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	108	BEVACIZUMAB - VEGZELMA	1200	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	160	258684004	1	Intravenous	47625008	18/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			WKY PAC + TRAS MT>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	66	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA CY1	1	PATIENT is taking part in a CLINICAL TRIAL	1	ISATUXIMAB	530	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	180	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE - ARMJ>4	1	PATIENT is taking part in a CLINICAL TRIAL	29	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	28	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	CABOZANTINIB	20	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/08/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	66	PALBOCICLIB	100	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	100	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	30	PALBOCICLIB	75	258684004	2	Oral	26643006	18/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	162	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	15	VENETOCLAX	400	258684004	2	Oral	26643006	18/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	18/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	18/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	60	ALECTINIB	600	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB - CLL-	2	PATIENT is not taking part in a CLINICAL TRIAL	35	IBRUTINIB	280	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X		1	Adjuvant Therapy	99	Not known	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	20	METFORMIN	850	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	200	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Wkly Epirubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	18/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	60	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	65	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C06X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C02X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	1650	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PALBOCICLIB	100	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PACLITAXEL	378	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	19	RIBOCICLIB	400	258684004	2	Oral	26643006	18/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO SKIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	55	Nivolumab	480	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	47	IBRUTINIB	420	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Olaparib - PS>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Olaparib	300	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ACALABRUTINIB	100	258684004	2	Oral	26643006	18/08/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RBZ	C43		1	Adjuvant Therapy			PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RBZ	C43		1	Adjuvant Therapy			PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APALUTAMIDE	240	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C34.9		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	EVEROLIMUS NET	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EVEROLIMUS	10	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	UKALL 14 PH2 -	1	PATIENT is taking part in a CLINICAL TRIAL	2	CYTARABINE	140	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	200	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	1100	258684004	1	Intravenous	47625008	18/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	18/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	D475		3	Not Applicable (Primary Treatment)			IMAT CEL/HES>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IMATINIB	100	258684004	2	Oral	26643006	18/08/2023	RBZ
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	31	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	18/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1500	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	80	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	80	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	14	CAPECITABINE	1450	258684004	2	Oral	26643006	18/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	POMALIDOMIDE	2	258684004	2	Oral	26643006	18/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	41	LENALIDOMIDE	25	258684004	2	Oral	26643006	18/08/2023	RH8
RBZ	C61		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	18/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ISATUXIMAB	900	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RH8	C541		3	Not Applicable (Primary Treatment)			NIVO MSI>C19	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Nivolumab	480	258684004	1	Intravenous	47625008	18/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APIXABAN	2.5	258684004	2	Oral	26643006	18/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	41	IXAZOMIB	3	258684004	2	Oral	26643006	18/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	18/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	18/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			EC - Pembro	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	2	258684004	2	Oral	26643006	18/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	600	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C829	96953	9		98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	98	Other	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	RUXOLITINIB	5	258684004	2	Oral	26643006	18/08/2023	RH8
RBZ	C946	99893	3	Not Applicable (Primary Treatment)			Azacitidine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	18/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	164	258684004	1	Intravenous	47625008	18/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Olaparib	300	258684004	2	Oral	26643006	18/08/2023	RBZ
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	1800	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	300	258684004	1	Intravenous	47625008	18/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	5	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	100	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C44X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cemiplimab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	110	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	POLATUZUMAB VEDOTIN	200	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	600	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C24.1		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	IRINOMDG>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENALIDOMIDE	15	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Sunitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	47	SUNITINIB	50	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	9	NILOTINIB	300	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C921	98633	9		98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	116	NILOTINIB	150	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			CYCLO PO	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	50	258684004	2	Oral	26643006	18/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ERIBULIN	1.94	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ERIBULIN	1.67	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	15	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	18/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	4.8	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHLVPP	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THALIDOMIDE	100	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	1.15	258684004	5	Subcutaneous	34206005	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	18/08/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	18/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	18/08/2023	RH8
RH8	C833	96803	9		1	Curative – aiming to permanently eradicate the disease	RCEOP	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	64	258684004	1	Intravenous	47625008	18/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	18/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	19/08/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ACALABRUTINIB	100	258684004	2	Oral	26643006	19/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ACALABRUTINIB	100	258684004	2	Oral	26643006	19/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	13	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	19/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	80	258684004	2	Oral	26643006	19/08/2023	RH8
RBZ	C900	97323	9				LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	10	258684004	2	Oral	26643006	19/08/2023	RBZ
RBZ	C900	97323	9				LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IXAZOMIB	4	258684004	2	Oral	26643006	19/08/2023	RBZ
RBZ	C349	80463	9				LORLATINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LORLATINIB	100	258684004	2	Oral	26643006	19/08/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	48	IBRUTINIB	140	258684004	2	Oral	26643006	19/08/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			ERLOTINIB 2MTH +	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ERLOTINIB	150	258684004	2	Oral	26643006	20/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	20/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Osimertinib	80	258684004	2	Oral	26643006	20/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	20/08/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	NIRAPARIB	100	258684004	2	Oral	26643006	20/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IMATINIB	400	258684004	2	Oral	26643006	20/08/2023	RH8
RH8	D475		3	Not Applicable (Primary Treatment)	98	Other	IMAT CEL/HES>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	100	258684004	2	Oral	26643006	20/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	11	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	20/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	20/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	LENALIDOMIDE	15	258684004	2	Oral	26643006	20/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	28	APIXABAN	2.5	258684004	2	Oral	26643006	20/08/2023	RH8
RBZ	C921	98633	3	Not Applicable (Primary Treatment)			ASCIMINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ASCIMINIB	80	258684004	2	Oral	26643006	20/08/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	63	PAZOPANIB	400	258684004	2	Oral	26643006	20/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	34	IBRUTINIB	420	258684004	2	Oral	26643006	20/08/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			Pazopanib	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PAZOPANIB	600	258684004	2	Oral	26643006	20/08/2023	RBZ
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	21/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	300	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	180	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Arsenic Trioxide (Induction Week)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ARSENIC TRIOXIDE	27	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	74	LENALIDOMIDE	5	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2200	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1450	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	315	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	21/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	96	258684004	1	Intravenous	47625008	21/08/2023	RH8
RBZ	C349	80463	9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	4	258684004	2	Oral	26643006	21/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	1	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	21/08/2023	RH8
RBZ	C349	80463	9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	560	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RBZ	C349	80463	9				Carboplatin + Pemetrexed	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	1000	258684004	1	Intravenous	47625008	21/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - VEGZELMA	450	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RH8	C499		3	Not Applicable (Primary Treatment)			Doxorubicin 75mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	220	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	21/08/2023	RH8
RBZ	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RBZ	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	150	258684004	2	Oral	26643006	21/08/2023	RBZ
RBZ	C880	97613	3	Not Applicable (Primary Treatment)			DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IPILIMUMAB	300	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	Nivolumab	100	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVEL >4 +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AXITINIB	6	258684004	2	Oral	26643006	21/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	150	258684004	2	Oral	26643006	21/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	21/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VENETOCLAX	400	258684004	2	Oral	26643006	21/08/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	350	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	225	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IPILIMUMAB	200	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	21/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	100	258684004	2	Oral	26643006	21/08/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	110	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	68	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C509				99	Not known	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	21/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	21/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		1	Adjuvant Therapy			ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/08/2023	RH8
RBZ	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RBZ	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1300	258684004	2	Oral	26643006	21/08/2023	RBZ
RBZ	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	165	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	RIBOCICLIB	400	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	22	RIBOCICLIB	400	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BOSUTINIB	400	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL ALBUMIN BOUND	250	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO*	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	21/08/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C917	98311	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ORAL MTX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	68	METHOTREXATE	10	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)			R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CHLORAMBUCIL	16	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GEMCIT/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2000	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	630	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	APALUTAMIDE	240	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APALUTAMIDE	240	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM CAR TAXOL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	270	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Melphalan oral	2	PATIENT is not taking part in a CLINICAL TRIAL	6	MELPHALAN	8	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AVELUMAB UC +	2	PATIENT is not taking part in a CLINICAL TRIAL	4	AVELUMAB	800	258684004	1	Intravenous	47625008	21/08/2023	RH8
RBZ	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - VEGZELMA	1300	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RBZ	C227						ATEZ/BEVA HCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - VEGZELMA	1200	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/08/2023	RH8
RBZ	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	21/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C227						ATEZ/BEVA HCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RBZ	C159		9				OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1150	258684004	2	Oral	26643006	21/08/2023	RBZ
RBZ	C159		9				OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	250	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	DEXAMETHASONE	5	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	88	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C900	97323	9		99	Not known	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	LENALIDOMIDE	15	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ENZALUTAMIDE	160	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C44X				99	Not known	Cemiplimab>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	53	RUXOLITINIB	10	258684004	2	Oral	26643006	21/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	50	RUXOLITINIB	15	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	10	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C900	97323	9		98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	APIXABAN	2.5	258684004	2	Oral	26643006	21/08/2023	RH8
RBZ	C911	98233	3	Not Applicable (Primary Treatment)			Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IBRUTINIB	420	258684004	2	Oral	26643006	21/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POMALIDOMIDE	3	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ERIBULIN	2.02	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	21/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	2.02	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	21/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	21/08/2023	RH8
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINBLASTINE SULFATE	11	258684004	1	Intravenous	47625008	21/08/2023	RBZ
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DACARBAZINE	630	258684004	1	Intravenous	47625008	21/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C859	95913	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LIPOSOMAL DOXORUBICIN	36	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	360	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin + Liposomal Doxorubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	300	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	270	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	7.5	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1500	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C679		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	22/08/2023	RH8
RBZ	C679		1	Adjuvant Therapy			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Paclitaxel (weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	108	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C679		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CISPLATIN	113	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	APIXABAN	2.5	258684004	2	Oral	26643006	22/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C20X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	550	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2000	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1800	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	180	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RBZ	C259		9				Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1800	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	22/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	22/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DOCETAXEL	132	258684004	1	Intravenous	47625008	22/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BEVACIZUMAB - VEGZELMA	350	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	240	258684004	1	Intravenous	47625008	22/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	240	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	22/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	162	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	150	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	22/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	HYD AML/CML 1DY>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTINRDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CABOZANTINIB	20	258684004	2	Oral	26643006	22/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	56	PALBOCICLIB	75	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	25	PALBOCICLIB	125	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABEMACICLIB	150	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	100	258684004	2	Oral	26643006	22/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PALBOCICLIB	125	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PALBOCICLIB	125	258684004	2	Oral	26643006	22/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	22/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IMATINIB	400	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IMATINIB	400	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C900	97323	9		99	Not known	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RH8	C900	97323	9		98	Other	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Wkly Epirubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	36	258684004	1	Intravenous	47625008	22/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	7	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	22/08/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABOZANTINIB	40	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CABOZANTINIB	20	258684004	2	Oral	26643006	22/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			CAPE ADJ BREAST	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	1950	258684004	2	Oral	26643006	22/08/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	14	PALBOCICLIB	75	258684004	2	Oral	26643006	22/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	10	RIBOCICLIB	400	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	BOSUTINIB - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	13	BOSUTINIB	500	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	480	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVO MAIN 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Nivolumab	480	258684004	1	Intravenous	47625008	22/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C865	97053	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C865	97053	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C865	97053	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C911	98233	9		98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ACALABRUTINIB	100	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)			ATEZO 4WK URO>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APALUTAMIDE	240	258684004	2	Oral	26643006	22/08/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	Nivolumab	480	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	70	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			LENV + PEMBR>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENVATINIB - LENVIMA	14	258684004	2	Oral	26643006	22/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	2260	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			LENV + PEMBR>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PROCARBAZINE	200	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	400	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BUSULFAN	2	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	14	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	DEXAMETHASONE	4	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ENZALUTAMIDE	80	258684004	2	Oral	26643006	22/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	25	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	80	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	120	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DURVALUMAB	1500	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	IXAZOMIB	4	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C900	97323	9		5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	APIXABAN	2.5	258684004	2	Oral	26643006	22/08/2023	RH8
RBZ	C900	97323	9				CAR LEN DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARFILZOMIB	44	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			DURVALUMAB>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DURVALUMAB	600	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RBZ	C44		3	Not Applicable (Primary Treatment)			AVELUMAB>4-	2	PATIENT is not taking part in a CLINICAL TRIAL	24	AVELUMAB	800	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	22/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	10	258684004	2	Oral	26643006	22/08/2023	RH8
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	650	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	375	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	2250	258684004	1	Intravenous	47625008	22/08/2023	RH8
RBZ	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	100	258684004	1	Intravenous	47625008	22/08/2023	RBZ
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			NIV FOLFOX	2	PATIENT is not taking part in a CLINICAL TRIAL	3	Nivolumab	240	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	THALIDOMIDE	100	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	22/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	46	NILOTINIB	300	258684004	2	Oral	26643006	22/08/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINBLASTINE SULFATE	10	258684004	1	Intravenous	47625008	22/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DACARBAZINE	630	258684004	1	Intravenous	47625008	22/08/2023	RH8
RH8	C812	96523	9		1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	17500	408102007	1	Intravenous	47625008	22/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - VEGZELMA	700	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BEVACIZUMAB - VEGZELMA	550	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	790	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	700	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	300	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	336	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	600	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	17	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CETUXIMAB	900	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	23/08/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	23/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C189						Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1650	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1200	258684004	2	Oral	26643006	23/08/2023	RBZ
RBZ	C189						Capecitabine (14 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	9	CAPECITABINE	1300	258684004	2	Oral	26643006	23/08/2023	RBZ
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	DEXAMETHASONE	10	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	125	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	78	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	15	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2200	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	145	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1800	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	650	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	23/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		1	Adjuvant Therapy	99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	225	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	113	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C169		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	10	TRASTUZUMAB-ONTRUZANT	504	258684004	1	Intravenous	47625008	23/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	17	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	120	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C900	97323	9				Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	23/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	Gemcitabine + Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	148	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	3	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	23/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	1	PATIENT is taking part in a CLINICAL TRIAL	5	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	23/08/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	7	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	23/08/2023	RH8
RBZ	C911	98233	9				Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	23/08/2023	RBZ
RH8	C509		9				Vinorelbine (oral)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINORELBINE	90	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C911	98233	9				Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VENETOCLAX	400	258684004	2	Oral	26643006	23/08/2023	RBZ
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	200	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C880	97613	9		98	Other	DRC-DEX RIT + CYC	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	220	258684004	1	Intravenous	47625008	23/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	23/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	23/08/2023	RH8
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	59	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C20		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	23/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	3	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	23/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A RCHOP ARMA	1	PATIENT is taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C20		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	900	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C20		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/08/2023	RBZ
RBZ	C61		9				ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/08/2023	RBZ
RBZ	C189		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	59	PANITUMUMAB	500	258684004	1	Intravenous	47625008	23/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C20		3	Not Applicable (Primary Treatment)			PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PANITUMUMAB	600	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PALBOCICLIB	100	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	40	PALBOCICLIB	100	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	23/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	50	RIBOCICLIB	200	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C509				99	Not known	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RIBOCICLIB	400	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	32	Nivolumab	480	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB> - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	31	NIRAPARIB	100	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C900	97323	9				DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	17	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/08/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	200	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	23/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	300	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)			TRIFLURID/TIPIR	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRIFLURIDINE/TIPIRACIL	60	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	23/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	6	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	23/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			Pac Alb CarboHP	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	450	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AVELUMAB	800	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL >4-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	AXITINIB	5	258684004	2	Oral	26643006	23/08/2023	RBZ
RH8	D693		9		1	Curative – aiming to permanently eradicate the disease	RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	23/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAYS	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAN/OX/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	750	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAN/OX/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAN/OX/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PANITUMUMAB	440	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PAN/OX/MDG 2WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	23/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	5	APALUTAMIDE	240	258684004	2	Oral	26643006	23/08/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	23/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	17	APALUTAMIDE	240	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	36	Nivolumab	480	258684004	1	Intravenous	47625008	23/08/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	Nivolumab	480	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	37	IMATINIB	400	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	27	IMATINIB	400	258684004	2	Oral	26643006	23/08/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Olaparib	100	258684004	2	Oral	26643006	23/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB - EMTANSINE	240	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	POM/DEX>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	15	POMALIDOMIDE	2	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	400	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C812	96523	9		98	Other	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	18	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C812	96523	9		98	Other	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	2560	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	3	IXAZOMIB/PLACEBO	4	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	10	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	10	258684004	2	Oral	26643006	23/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ENZALUTAMIDE	80	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	13	ENZALUTAMIDE	40	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CAPECITABINE	2650	258684004	2	Oral	26643006	23/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	POMALIDOMIDE	2	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	POMALIDOMIDE	4	258684004	2	Oral	26643006	23/08/2023	RBZ
RH8	C20X		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2000	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	3	LENALIDOMIDE	10	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C259		1	Adjuvant Therapy	99	Not known	mFOLFIRINOX>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	150	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ISATUXIMAB	440	258684004	1	Intravenous	47625008	23/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ISATUXIMAB	1000	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RH8	C812	96523	9		98	Other	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	108	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C900	97323	9		98	Other	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	18	APIXABAN	2.5	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AVELUMAB	800	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	APIXABAN	5	258684004	2	Oral	26643006	23/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C64		3	Not Applicable (Primary Treatment)			AXIT + AVEL>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	AXITINIB	5	258684004	2	Oral	26643006	23/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - ALYMSYS	1100	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DAROL + ADT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	300	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABAZITAXEL	54	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	RUX COMP PV	2	PATIENT is not taking part in a CLINICAL TRIAL	28	RUXOLITINIB	10	258684004	2	Oral	26643006	23/08/2023	RH8
RBZ	D471	99613	3	Not Applicable (Primary Treatment)			Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RUXOLITINIB	15	258684004	2	Oral	26643006	23/08/2023	RBZ
RBZ	C900	97323	9				CAR LEN DEX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARFILZOMIB	44	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Olaparib	200	258684004	2	Oral	26643006	23/08/2023	RBZ
RH8	C44X		9		98	Other	Vismodegib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	VISMONDEGIB	150	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	23/08/2023	RH8
RH8	C05.1				99	Not known	TOPO (PO)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TOPOTECAN	5	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	23/08/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ERIBULIN	1.06	258684004	1	Intravenous	47625008	23/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	23/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	23/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	23/08/2023	RH8
RBZ	C159		2	Neoadjuvant Therapy			FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	7	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C159		2	Neoadjuvant Therapy			FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	7	OXALIPLATIN	100	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RBZ	C159		2	Neoadjuvant Therapy			FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	7	DOCETAXEL	96	258684004	1	Intravenous	47625008	23/08/2023	RBZ
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BENDAMUSTINE HYDROCHLORIDE	157.5	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BEVACIZUMAB - VEGZELMA	350	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Bendamustine + Rituximab(Sub Courses)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	270	258684004	1	Intravenous	47625008	24/08/2023	RH8
RBZ	C56		1	Adjuvant Therapy			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	24/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	400	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C20X				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1500	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine low (10to20mg/m2) IV/SC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	20	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	1000	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C189				99	Not known	Fluorouricil + Folonic Acid (MdG)	2	PATIENT is not taking part in a CLINICAL TRIAL	12	FLUOROURACIL	5650	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C679				99	Not known	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1600	258684004	1	Intravenous	47625008	24/08/2023	RH8
RBZ	C679		2	Neoadjuvant Therapy			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	360	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VINORELBINE	70	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	8	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	9	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/08/2023	RBZ
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1600	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	24/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C61		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	24/08/2023	RBZ
RBZ	C04		3	Not Applicable (Primary Treatment)			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	88	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RBZ	C61		1	Adjuvant Therapy			Docetaxel 75mg/m2 (21 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	120	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RH8	C910	98363	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Methotrexate intrathecal	2	PATIENT is not taking part in a CLINICAL TRIAL	5	METHOTREXATE	12.5	258684004	3	Intrathecal	72607000	24/08/2023	RH8
RH8	C829	96913	3	Not Applicable (Primary Treatment)	98	Other	Rituximab (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB	1400	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BEVACIZUMAB - VEGZELMA	700	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BEVACIZUMAB - VEGZELMA	350	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	12	BEVACIZUMAB - VEGZELMA	700	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	500	258684004	1	Intravenous	47625008	24/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	500	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Obin + Venet Cy3-6	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VENETOCLAX	400	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC) +	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	108	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZO CARBO + ETOP	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	180	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	160	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PERTUZUMAB/TRASTUZUMAB	1800	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	DRC CATCH UP RIT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	66	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	66	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/08/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO428 6WK C1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	20	258684004	2	Oral	26643006	24/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	40	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	34	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	28	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CABOZANTINIB	20	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	22	PALBOCICLIB	75	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	12	PALBOCICLIB	75	258684004	2	Oral	26643006	24/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ABEMACICLIB	100	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ABEMACICLIB	150	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	890	258684004	1	Intravenous	47625008	24/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	36	PALBOCICLIB	75	258684004	2	Oral	26643006	24/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	Osimertinib	80	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	42	TRAMETINIB	1	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	42	DABRAFENIB	75	258684004	2	Oral	26643006	24/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RH8	C911	98233	9		98	Other	VENETOCLAX MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	VENETOCLAX	400	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	75	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	108	258684004	1	Intravenous	47625008	24/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	600	258684004	2	Oral	26643006	24/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	10	ISATUXIMAB	590	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	3	ISATUXIMAB	780	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBOHP(SC)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	164	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	360	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE 90 CYC1	2	PATIENT is not taking part in a CLINICAL TRIAL	25	IMATINIB	300	258684004	2	Oral	26643006	24/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	29	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	24/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/08/2023	RBZ
RBZ	C829	96953	3	Not Applicable (Primary Treatment)			R-LENALID -Cyc1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	24/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	24/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C23		3	Not Applicable (Primary Treatment)			CAPE ADJ CHOLAN	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	2150	258684004	2	Oral	26643006	24/08/2023	RBZ
RH8	C189				99	Not known	RALT + OXALI >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RALTITREXED	4.25	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C189				99	Not known	RALT + OXALI >1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	24/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	400	258684004	2	Oral	26643006	24/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	11	RIBOCICLIB	400	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	AXIT + AVE >4>>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	AXITINIB	5	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	SACITUZUMAB GOVITECAN	740	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	24/08/2023	RH8
RBZ	D693		9				RITUX 100 WKLY	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	24/08/2023	RH8
RBZ	C43		9				PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RH8	C946	99893	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENALID 5Q RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	59	LENALIDOMIDE	5	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C830	96993	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CHLORAMBUCIL	18	258684004	2	Oral	26643006	24/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAPARIB Main>	2	PATIENT is not taking part in a CLINICAL TRIAL	16	Olaparib	100	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	24/08/2023	RH8
RBZ	C679		9				ATEZOLIZUMAB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RBZ	C189		9				ENCOR + CETUX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENCORAFENIB	300	258684004	2	Oral	26643006	24/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RIBOCICLIB	600	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	400	258684004	1	Intravenous	47625008	24/08/2023	RH8
RBZ	C189		9				ENCOR + CETUX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CETUXIMAB	900	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RBZ	C679		9				AVELUMAB UC 5	2	PATIENT is not taking part in a CLINICAL TRIAL	5	AVELUMAB	800	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RBZ	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	24/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	40	258684004	2	Oral	26643006	24/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			DOCE/DAROL 6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	2	Oral	26643006	24/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C189				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1650	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	80	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ENZALUTAMIDE	160	258684004	2	Oral	26643006	24/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			DOCE/DAROL 6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DAROLUTAMIDE	600	258684004	2	Oral	26643006	24/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ISATUXIMAB	650	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	113	258684004	1	Intravenous	47625008	24/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			DOCE/DAROL 6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DOCETAXEL	132	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	84	RUXOLITINIB	15	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C499		3	Not Applicable (Primary Treatment)			Trabectedin	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRABECTEDIN	1.75	258684004	1	Intravenous	47625008	24/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	24/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	POLATUZUMAB VEDOTIN	128	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	2	Oral	26643006	24/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	800	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAROLUTAMIDE	600	258684004	2	Oral	26643006	24/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	5	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	700	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	165	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	150	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	24/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	38	NILOTINIB	200	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	94	NILOTINIB	200	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	NILOTINIB	200	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			TEPOTINIB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TEPOTINIB	450	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	1	258684004	1	Intravenous	47625008	24/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C829	96983	3	Not Applicable (Primary Treatment)			CVP R	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	600	258684004	1	Intravenous	47625008	24/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	24/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	24/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	890	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	240	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C189		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	11	CETUXIMAB	900	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	400	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	10	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	800	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	GEMCITABINE	1400	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	120	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Oxaliplatin + Modified de Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	9	OXALIPLATIN	180	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	1800	258684004	1	Intravenous	47625008	25/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CISPLATIN	89	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	45	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1250	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	1	FLUOROURACIL	800	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C20						Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1650	258684004	2	Oral	26643006	25/08/2023	RBZ
RH8	C189		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	165	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C15.9				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	630	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C20						Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	225	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C15.9				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ETOPOSIDE	180	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	41	TRASTUZUMAB-ONTRUZANT	651	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C509		9				Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	25/08/2023	RBZ
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	15	BEVACIZUMAB - VEGZELMA	500	258684004	1	Intravenous	47625008	25/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab 7.5mg/kg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	BEVACIZUMAB - ALYMSYS	500	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	560	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	200	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	160	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	EPIRUBICIN HYDROCHLORIDE	130	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	240	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	180	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	144	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			WKLY EPIRUBICIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	40	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ATEZ BEV CAR TAX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BEVACIZUMAB - VEGZELMA	700	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	BEVACIZUMAB - VEGZELMA	1100	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	3	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	25/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C833	96803	3	Not Applicable (Primary Treatment)			CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1400	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEM ECHO/ECG	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	40	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ATEZ ADJ NSCLC>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ATEZ BEV CAR TAX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ABEMACICLIB	150	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ABEM + LETR ADJ>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ABEMACICLIB	100	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C189				99	Not known	Regorafenib CRC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	REGORAFENIB	120	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ATEZ BEV CAR TAX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	450	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	Osimertinib	80	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PALBOCICLIB	100	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	59	VENETOCLAX	300	258684004	2	Oral	26643006	25/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	120	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	IPILIMUMAB	85	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ATEZ BEV CAR TAX	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	300	258684004	1	Intravenous	47625008	25/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C539		3	Not Applicable (Primary Treatment)			CAR/PAC/BEVACIZ>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	PACLITAXEL	270	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	25/08/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	TRAMETINIB	2	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DABRAFENIB	150	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	120	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		9				Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C459		3	Not Applicable (Primary Treatment)			NIV/IPI MESO Cy1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	Nivolumab	360	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	140	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	200	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Wkly Epirubicin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	EPIRUBICIN HYDROCHLORIDE	36	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL ALBUMIN BOUND	160	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	EPIRUBICIN HYDROCHLORIDE	160	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C189				99	Not known	TRIFLURID/TIPI>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRIFLURIDINE/TIPIRACIL	55	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	900	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	25/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		2	Neoadjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	13	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C10		3	Not Applicable (Primary Treatment)			PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	2	258684004	2	Oral	26643006	25/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C259				99	Not known	GEMCIT/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	162	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			NINTEDANIB MONO	2	PATIENT is not taking part in a CLINICAL TRIAL	6	NINTEDANIB	200	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RIBOCICLIB	600	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IBRUTINIB-CLL>.	2	PATIENT is not taking part in a CLINICAL TRIAL	23	IBRUTINIB	140	258684004	2	Oral	26643006	25/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C459		3	Not Applicable (Primary Treatment)			NIVO - MESO C19	2	PATIENT is not taking part in a CLINICAL TRIAL	13	Nivolumab	480	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL ALBUMIN BOUND	160	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ACALABRUTINIB	100	258684004	2	Oral	26643006	25/08/2023	RH8
RBZ	C43		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RBZ	C43		1	Adjuvant Therapy			PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C911	98233	1	Adjuvant Therapy			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ACALABRUTINIB	100	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	APALUTAMIDE	120	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	9	APALUTAMIDE	240	258684004	2	Oral	26643006	25/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	APALUTAMIDE	240	258684004	2	Oral	26643006	25/08/2023	RBZ
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C269		3	Not Applicable (Primary Treatment)			Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	300	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL ALBUMIN BOUND	170	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			ATEZO MAINTEN	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ATEZOLIZUMAB	1680	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	900	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMB + PEME 1	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMETREXED	800	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	D475		3	Not Applicable (Primary Treatment)	98	Other	IMAT CEL/HES>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IMATINIB	100	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	39	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	155	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/08/2023	RH8
RH8	C509		9				MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	25/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	40	258684004	2	Oral	26643006	25/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	94	DEXAMETHASONE	10	258684004	2	Oral	26643006	25/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	120	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ENZALUTAMIDE	80	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	25/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	94	LENALIDOMIDE	15	258684004	2	Oral	26643006	25/08/2023	RBZ
RH8	C509		9				Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	31	CAPECITABINE	1000	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C900	97323	9		99	Not known	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ISATUXIMAB	700	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	94	APIXABAN	2.5	258684004	2	Oral	26643006	25/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	94	IXAZOMIB	4	258684004	2	Oral	26643006	25/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cabazitaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CABAZITAXEL	40	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C44X		9		98	Other	Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	10	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	600	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	725	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C259				99	Not known	Folfirinox	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	135	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CARBO/PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	378	258684004	1	Intravenous	47625008	25/08/2023	RH8
RBZ	C172						LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LANREOTIDE	90	258684004	5	Subcutaneous	34206005	25/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C179						LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	25/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RBZ	C509		1	Adjuvant Therapy			ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	25/08/2023	RBZ
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	25	NILOTINIB	400	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C880	97613	9		98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IBRUTINIB	420	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	GDP (RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	GDP (RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	GEMCITABINE	2200	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	GDP (RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	164	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ERIBULIN	1.94	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ERIBULIN	1.67	258684004	1	Intravenous	47625008	25/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	25/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	1.15	258684004	5	Subcutaneous	34206005	25/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	25/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	25/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	25/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	THALIDOMIDE	50	258684004	2	Oral	26643006	25/08/2023	RBZ
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	25/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	3	258684004	5	Subcutaneous	34206005	25/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	APIXABAN	2.5	258684004	2	Oral	26643006	25/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	39	ENZALUTAMIDE	160	258684004	2	Oral	26643006	26/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LENALIDOMIDE	15	258684004	2	Oral	26643006	26/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	40	Osimertinib	40	258684004	2	Oral	26643006	26/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Osimertinib	80	258684004	2	Oral	26643006	26/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>(C 19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IXAZOMIB	2.3	258684004	2	Oral	26643006	26/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IMATINIB	400	258684004	2	Oral	26643006	26/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	CABOZANTINIB	20	258684004	2	Oral	26643006	26/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANT - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	33	CABOZANTINIB	40	258684004	2	Oral	26643006	26/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	14	ACALABRUTINIB	100	258684004	2	Oral	26643006	26/08/2023	RH8
RH8	C269		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	7	IMATINIB	400	258684004	2	Oral	26643006	26/08/2023	RH8
RH8	D45X	99503	1	Adjuvant Therapy			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	26/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	42	Osimertinib	80	258684004	2	Oral	26643006	27/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	31	ALECTINIB	600	258684004	2	Oral	26643006	27/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	27/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	6	IMATINIB	400	258684004	2	Oral	26643006	27/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	27/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	27/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	CTD Attenuated (Thalidomide 50mg)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C719		1	Adjuvant Therapy	98	Other	Temozolomide 200mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	TEMOZOLOMIDE	400	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/08/2023	RBZ
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	AML MAINT MIDOST	2	PATIENT is not taking part in a CLINICAL TRIAL	9	MIDOSTAURIN	50	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	28/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	57	BOSUTINIB	500	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEMBRO 531 6WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	28/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			NIRAPARIB 1st >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	NIRAPARIB	100	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 1 DAY-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	2000	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	28/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	80	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	LEN/DEX/IXA>	2	PATIENT is not taking part in a CLINICAL TRIAL	65	LENALIDOMIDE	10	258684004	2	Oral	26643006	28/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/08/2023	RBZ
RBZ	C61		3	Not Applicable (Primary Treatment)			Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ENZALUTAMIDE	160	258684004	2	Oral	26643006	28/08/2023	RBZ
RH8	C189		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1950	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C61X		9				Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	80	258684004	2	Oral	26643006	28/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DAROLUTAMIDE	600	258684004	2	Oral	26643006	28/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	148	258684004	1	Intravenous	47625008	28/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	39	IBRUTINIB	420	258684004	2	Oral	26643006	28/08/2023	RH8
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	400	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RBZ	C56		3	Not Applicable (Primary Treatment)			Bevacizumab + Carbo + Pacliaxel(mEOC)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	180	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	600	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	700	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin + Paclitaxel (3 weekly)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	300	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	16	CETUXIMAB	900	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	5	IRINOTECAN HYDROCHLORIDE	480	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	440	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CAPECITABINE	2000	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C189				99	Not known	Capecitabine (21 day) + Irinotecan	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C924	98663	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Arsenic Trioxide (Induction Week)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ARSENIC TRIOXIDE	27	258684004	1	Intravenous	47625008	29/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	LENALIDOMIDE	10	258684004	2	Oral	26643006	29/08/2023	RH8
RBZ	C900	97323	2	Neoadjuvant Therapy			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	24	LENALIDOMIDE	20	258684004	2	Oral	26643006	29/08/2023	RBZ
RH8	C679		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	4	GEMCITABINE	1500	258684004	1	Intravenous	47625008	29/08/2023	RH8
RBZ	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1100	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)			Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CISPLATIN	30	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C900	97323	9		98	Other	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	13	APIXABAN	2.5	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1650	258684004	2	Oral	26643006	29/08/2023	RH8
RBZ	C189		1	Adjuvant Therapy			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	1300	258684004	2	Oral	26643006	29/08/2023	RBZ
RH8	C189		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	225	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C80.9				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	29/08/2023	RH8
RBZ	C189		1	Adjuvant Therapy			Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	180	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C80.9				99	Not known	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	220	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	16	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RBZ	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1600	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	148	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	79	258684004	1	Intravenous	47625008	29/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Etoposide (3 day)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ETOPOSIDE	50	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	500	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	360	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C541		3	Not Applicable (Primary Treatment)			Carboplatin AUC 6 - 10	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	500	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C66X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	400	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	240	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	EPIRUBICIN HYDROCHLORIDE	150	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1000	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	EC POST CARB + PAC	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	2	258684004	2	Oral	26643006	29/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	1	PATIENT is taking part in a CLINICAL TRIAL	27	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	90	258684004	1	Intravenous	47625008	29/08/2023	RH8
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			WKLY EPIRUBICIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	45	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	29/08/2023	RH8
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	51	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	30	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERON>(C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	17	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	29/08/2023	RH8
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	29/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/08/2023	RH8
RBZ	C833	96803	9				CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1600	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	43	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	27	ENZALUTAMIDE	80	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	1	PATIENT is taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	10	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	20	PALBOCICLIB	100	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	160	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	200	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	890	258684004	1	Intravenous	47625008	29/08/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	29/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	180	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CARBOPLATIN	240	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	90	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carb/Tax/RT-60Gy	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	72	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	D(sc)VD-Cycs 4-7	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	58	VENETOCLAX	400	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	VENETOCLAX MAIN>	2	PATIENT is not taking part in a CLINICAL TRIAL	19	VENETOCLAX	200	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PACLITAXEL	132	258684004	1	Intravenous	47625008	29/08/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	VENETOCLAX	100	258684004	2	Oral	26643006	29/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			CARBO PAC + PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	132	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	99	Not known	NEO TCARBHP(SC)>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOCETAXEL	164	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	25	METFORMIN	850	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	IMAT RDE90 CYC>1	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IMATINIB	200	258684004	2	Oral	26643006	29/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	2	Neoadjuvant Therapy	98	Other	Muk9 mainSCdar>1	1	PATIENT is taking part in a CLINICAL TRIAL	27	APIXABAN	2.5	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	56	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	30	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	23	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NEO AD PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RBZ	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BEVACIZUMAB - VEGZELMA	1200	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/08/2023	RH8
RBZ	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PACLITAXEL ALBUMIN	170	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C64X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			PEM MAIN 200 +	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	29/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	20	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RBZ	C189						PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RBZ	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC>>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	560	258684004	1	Intravenous	47625008	29/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	630	258684004	1	Intravenous	47625008	29/08/2023	RH8
RBZ	C259		9				GEMCIT/ABRAXANE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	GEMCITABINE	1400	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C349	80463	3	Not Applicable (Primary Treatment)			CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMETREXED	1000	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	16	RIBOCICLIB	600	258684004	2	Oral	26643006	29/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Paclitax 14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	336	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C539		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CISPLATIN	70	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	SACITUZUMAB GOVITECAN	550	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C911	98233	9		98	Other	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	100	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ACALABRUTINIB	100	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	10	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			PEMBRO 366 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	10	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C911	98233	9		98	Other	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CHLORAMBUCIL	18	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	APALUTAMIDE	240	258684004	2	Oral	26643006	29/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	Nivolumab	480	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C269		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IMATINIB	300	258684004	2	Oral	26643006	29/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB - EMTANSINE	160	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RBZ	C509		2	Neoadjuvant Therapy			NEO AD PHESGO	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/08/2023	RBZ
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	E-BEACOPP RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	20000		1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	28	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	12	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	10	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	16	ENZALUTAMIDE	80	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	160	258684004	2	Oral	26643006	29/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C23		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3500	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RBZ	C23		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	100	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C499		3	Not Applicable (Primary Treatment)			PAC 80 ANGIO	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	120	258684004	1	Intravenous	47625008	29/08/2023	RH8
RBZ	C349	80463	3	Not Applicable (Primary Treatment)			DOCET/NINTED	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOCETAXEL	132	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	2	Oral	26643006	29/08/2023	RH8
RBZ	C812	96523	3	Not Applicable (Primary Treatment)			PEMBRO CHL>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	29/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DAROLUTAMIDE	600	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C829	96953	3	Not Applicable (Primary Treatment)	98	Other	OBIN + CVP>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C829	96913	1	Adjuvant Therapy	98	Other	OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	11	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	132	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	29/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	REM A ARMB	1	PATIENT is taking part in a CLINICAL TRIAL	6	ACALABRUTINIB	100	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	LENALIDOMIDE	10	258684004	2	Oral	26643006	29/08/2023	RH8
RBZ	C787						LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	29/08/2023	RBZ
RBZ	C900	97323	9				D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	29/08/2023	RBZ
RH8	D693		9		98	Other	Rituximab	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	29/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	29/08/2023	RH8
RBZ	C900	97323	9				D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	20	258684004	2	Oral	26643006	29/08/2023	RBZ
RH8	C900	97323	9		98	Other	D-VTD 5-6	2	PATIENT is not taking part in a CLINICAL TRIAL	5	BORTEZOMIB	2.5	258684004	5	Subcutaneous	34206005	29/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	74	IBRUTINIB	140	258684004	2	Oral	26643006	29/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab (Kadcyla?) (Maintenance)	2	PATIENT is not taking part in a CLINICAL TRIAL	29	TRASTUZUMAB - EMTANSINE	220	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	FLUOROURACIL	800	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	30/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	700	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	32	CETUXIMAB	1000	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C20X		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CETUXIMAB	1100	258684004	1	Intravenous	47625008	30/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	9	LENALIDOMIDE	5	258684004	2	Oral	26643006	30/08/2023	RBZ
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2200	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C679		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IRINOTECAN HYDROCHLORIDE	330	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	5000	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189		9		1	Curative – aiming to permanently eradicate the disease	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	16	FLUOROURACIL	900	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	900	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	250	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Cisplatin + Fluorouracil (3 wk)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	FLUOROURACIL	2500	258684004	1	Intravenous	47625008	30/08/2023	RH8
RBZ	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB-ONTRUZANT	441	258684004	1	Intravenous	47625008	30/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	22	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	30/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			Liposomal Doxorubicin 50mg/m2	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LIPOSOMAL DOXORUBICIN	76	258684004	1	Intravenous	47625008	30/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C259		1	Adjuvant Therapy			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	2000	258684004	1	Intravenous	47625008	30/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			Paclitaxel 80mg/m2 day 1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	120	258684004	1	Intravenous	47625008	30/08/2023	RBZ
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	900	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	VENETO + RITUX C>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VENETOCLAX	400	258684004	2	Oral	26643006	30/08/2023	RH8
RBZ	C509		1	Adjuvant Therapy			WKY PAC + TRAS AD>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PACLITAXEL	144	258684004	1	Intravenous	47625008	30/08/2023	RBZ
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CARBO PAC + PEMB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	220	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOXORUBICIN HYDROCHLORIDE	80	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	IRINOTECAN HYDROCHLORIDE	220	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	56	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	21	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	12	ABIRATERONE ACETATE	500	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	VINCRISTINE SULFATE	2	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	CHOP R - 21 days	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CYCLOPHOSPHAMIDE	1200	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	56	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X		9				ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	11	DEXAMETHASONE	40	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	FLUOROURACIL	500	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	2	LENALIDOMIDE	10	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	7	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	30/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ABEM + LET ADJ>>	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ABEMACICLIB	150	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C20X				99	Not known	PAN/IRI/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	21	PANITUMUMAB	220	258684004	1	Intravenous	47625008	30/08/2023	RH8
RBZ	C920	98743	3	Not Applicable (Primary Treatment)			Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	AZACITIDINE	150	258684004	5	Subcutaneous	34206005	30/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	19	PALBOCICLIB	100	258684004	2	Oral	26643006	30/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		1	Adjuvant Therapy			TRAS SC MAIN-ADJ	2	PATIENT is not taking part in a CLINICAL TRIAL	13	TRASTUZUMAB	600	258684004	5	Subcutaneous	34206005	30/08/2023	RBZ
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	30/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	3	RIBOCICLIB	400	258684004	2	Oral	26643006	30/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PACLITAXEL	144	258684004	1	Intravenous	47625008	30/08/2023	RBZ
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	TRAMETINIB	2	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DABRAFENIB	150	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >3	2	PATIENT is not taking part in a CLINICAL TRIAL	4	RIBOCICLIB	400	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C509		9				RIBO and FULV ON	2	PATIENT is not taking part in a CLINICAL TRIAL	39	RIBOCICLIB	400	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	2	ISATUXIMAB	530	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C900	97323	9		98	Other	RADA ISAT CY2-12	1	PATIENT is taking part in a CLINICAL TRIAL	11	ISATUXIMAB	800	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC MAIN <<	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Nivolumab	480	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			ALECTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ALECTINIB	600	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ALPELIS & FULVE>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ALPELISIB	300	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	STAMPEDE-ARMK>4	1	PATIENT is taking part in a CLINICAL TRIAL	20	METFORMIN	850	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	RADA LEN + ISA >	1	PATIENT is taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	30/08/2023	RH8
RBZ	C900	97323	3	Not Applicable (Primary Treatment)			DARATUMUMAB >25	2	PATIENT is not taking part in a CLINICAL TRIAL	11	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	30/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1100	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C04X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	99	Not known	EC(90)-14 day>1	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	2	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C01X				99	Not known	PEMBRO H + N +	2	PATIENT is not taking part in a CLINICAL TRIAL	16	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PEMB 6WK COLREC	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	FLUOROURACIL	2000	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	FLUOROURACIL	350	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CAPECITABINE	1150	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEM-OXCAP B 80>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	150	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			PAN/OX/MDG 2WK>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	PANITUMUMAB	180	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			PAC WKLY (3WKS)	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PACLITAXEL	144	258684004	1	Intravenous	47625008	30/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	19	TRAMETINIB	2	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET	2	PATIENT is not taking part in a CLINICAL TRIAL	19	DABRAFENIB	100	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL ALBUMIN BOUND	180	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C911	98233	9		98	Other	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	1	RITUXIMAB - RIXATHON	600	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	6	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	8	ACALABRUTINIB	100	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ATEZO/PAC ALB>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	19	APALUTAMIDE	240	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	30/08/2023	RH8
RBZ	C61		3	Not Applicable (Primary Treatment)			APALUTAMIDE >1	2	PATIENT is not taking part in a CLINICAL TRIAL	15	APALUTAMIDE	240	258684004	2	Oral	26643006	30/08/2023	RBZ
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	MITHRI RUXOL >	1	PATIENT is taking part in a CLINICAL TRIAL	28	RUXOLITINIB	15	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENCOR + CETUX>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	CETUXIMAB	1000	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	7	Nivolumab	480	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C159		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	NIVO - AD OES>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	480	258684004	1	Intravenous	47625008	30/08/2023	RH8
RBZ	C64		3	Not Applicable (Primary Treatment)			NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Nivolumab	480	258684004	1	Intravenous	47625008	30/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C921	98633	3	Not Applicable (Primary Treatment)	98	Other	Imatinib 400mg	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IMATINIB	400	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C509		2	Neoadjuvant Therapy	99	Not known	KADCYLA ADJ>1	2	PATIENT is not taking part in a CLINICAL TRIAL	6	TRASTUZUMAB - EMTANSINE	280	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	D473	99623	1	Adjuvant Therapy			HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	1000	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	OX/CAP> A 100	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OXALIPLATIN	225	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	23	BINIMETINIB	30	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENCORAFENIB	100	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Busulfan Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	25	BUSULFAN	30	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	ADJ PHESGO -	2	PATIENT is not taking part in a CLINICAL TRIAL	18	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/08/2023	RH8
RBZ	C509						MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	9	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	30/08/2023	RBZ
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	6	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	3	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	5	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	30/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	29	IXAZOMIB/PLACEBO	3	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			PEMBRO MAINT	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	26	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1400	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C20X		9		99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	1300	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ENZALUTAMIDE	80	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ENZALUTAMIDE	160	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	FLUOROURACIL	4450	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CAPECITABINE	650	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CAPECITABINE	2000	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	FITNESS MAIN	1	PATIENT is taking part in a CLINICAL TRIAL	29	LENALIDOMIDE	5	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C541		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	CAR/PACLITAX	2	PATIENT is not taking part in a CLINICAL TRIAL	6	CARBOPLATIN	630	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			OX/CAP> C 60	2	PATIENT is not taking part in a CLINICAL TRIAL	2	OXALIPLATIN	150	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C23X		3	Not Applicable (Primary Treatment)			FOLFOX - RDE	2	PATIENT is not taking part in a CLINICAL TRIAL	8	OXALIPLATIN	180	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C349	80463	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	DURVAL (C19)	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DURVALUMAB	1500	258684004	1	Intravenous	47625008	30/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	ISA/POM/DEX>	2	PATIENT is not taking part in a CLINICAL TRIAL	20	ISATUXIMAB	800	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C812	96523	9		98	Other	E-BEACOP/DAC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	20000		1	Intravenous	47625008	30/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - VEGZELMA	800	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Abiraterone	2	PATIENT is not taking part in a CLINICAL TRIAL	6	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DAROLUTAMIDE	600	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	220	258684004	1	Intravenous	47625008	30/08/2023	RH8
RBZ	C44		3	Not Applicable (Primary Treatment)			Cemiplimab>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	CEMIPLIMAB	350	258684004	1	Intravenous	47625008	30/08/2023	RBZ
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DOCETAXEL	148	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Olaparib	100	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C900	97323	1	Adjuvant Therapy	98	Other	LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	23	LENALIDOMIDE	5	258684004	2	Oral	26643006	30/08/2023	RH8
RBZ	C254						LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	11	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	30/08/2023	RBZ
RBZ	C259						LANREOTIDE	2	PATIENT is not taking part in a CLINICAL TRIAL	7	LANREOTIDE	120	258684004	5	Subcutaneous	34206005	30/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	TRASTUZUMAB DERUXTECAN	260	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C509		9				ENHERTU -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB DERUXTECAN	400	258684004	1	Intravenous	47625008	30/08/2023	RH8
RBZ	C509		2	Neoadjuvant Therapy			ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	3.3	258684004	1	Intravenous	47625008	30/08/2023	RBZ

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RBZ	C509		2	Neoadjuvant Therapy			ZOLE ACID	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	30/08/2023	RBZ
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			ENHERTU >	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DEXAMETHASONE	2	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C509		9				ENHERTU -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C509		9				ENHERTU -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	30/08/2023	RH8
RH8	C629	90803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	BEP 5 Day	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BLEOMYCIN	30000	408102007	1	Intravenous	47625008	30/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	52	IBRUTINIB	420	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	48	NILOTINIB	400	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	46	IBRUTINIB	420	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	3	IBRUTINIB	560	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	19	IBRUTINIB	420	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C509				99	Not known	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ERIBULIN	1.06	258684004	1	Intravenous	47625008	30/08/2023	RH8
RBZ	C509		3	Not Applicable (Primary Treatment)			Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	1	ERIBULIN	2.38	258684004	1	Intravenous	47625008	30/08/2023	RBZ
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	30/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	40	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	THALIDOMIDE	100	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	30/08/2023	RH8
RH8	C900	97323	9		98	Other	D-VTD*	2	PATIENT is not taking part in a CLINICAL TRIAL	2	APIXABAN	2.5	258684004	2	Oral	26643006	30/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DOXORUBICIN HYDROCHLORIDE	55	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	VINBLASTINE SULFATE	13	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DACARBAZINE	790	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	OXALIPLATIN	135	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C812	96523	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	ABVD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BLEOMYCIN	21250	408102007	1	Intravenous	47625008	30/08/2023	RH8
RH8	C159		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	80	258684004	1	Intravenous	47625008	30/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	IRINOTECAN HYDROCHLORIDE	360	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189		9		99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	IRINOTECAN HYDROCHLORIDE	300	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	34	IRINOTECAN HYDROCHLORIDE	240	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189		9		99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189		9		99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	FLUOROURACIL	650	258684004	1	Intravenous	47625008	31/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	34	FLUOROURACIL	3150	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	34	FLUOROURACIL	550	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189				99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	13	CETUXIMAB	800	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189		9		99	Not known	Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CETUXIMAB	800	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)			Cetuximab + FOLFIRI cycle 2 onwards	2	PATIENT is not taking part in a CLINICAL TRIAL	34	CETUXIMAB	800	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)			Cytarabine low (10to20mg/m2) IV/SC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	20	258684004	5	Subcutaneous	34206005	31/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Lenalidomide 25mg (Cycle 1 to 25)	2	PATIENT is not taking part in a CLINICAL TRIAL	27	LENALIDOMIDE	5	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	GEMCITABINE	1400	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C679		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Cisplatin + Gemcitabine (D 1 & 8)	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CISPLATIN	89	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	500	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189				99	Not known	Irinotecan + Modified De Gramont	2	PATIENT is not taking part in a CLINICAL TRIAL	15	FLUOROURACIL	2800	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CARBOPLATIN	500	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	500	258684004	1	Intravenous	47625008	31/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C189				99	Not known	Capecitabine + Oxaliplatin 21day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	OXALIPLATIN	280	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ETOPOSIDE	220	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Etoposide IV 3 day	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ETOPOSIDE	200	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C159		3	Not Applicable (Primary Treatment)			Trastuzumab 21 day maintenance	2	PATIENT is not taking part in a CLINICAL TRIAL	1	TRASTUZUMAB-ONTRUZANT	378	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C349	80463	2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CARBOPLATIN	450	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C349	80463	2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Carboplatin + Vinorelbine Oral	2	PATIENT is not taking part in a CLINICAL TRIAL	2	VINORELBINE	80	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C259		3	Not Applicable (Primary Treatment)			Gemcitabine 1000mg/m2 D1 8 15	2	PATIENT is not taking part in a CLINICAL TRIAL	5	GEMCITABINE	1600	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	31/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	99	Not known	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	2	BORTEZOMIB	2.75	258684004	5	Subcutaneous	34206005	31/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Bortezomib + Cyclophos + Dex	2	PATIENT is not taking part in a CLINICAL TRIAL	8	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	31/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Cyclophosphamide + Docetaxel	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DOCETAXEL	164	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	300	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C349	80423	3	Not Applicable (Primary Treatment)			ATEZ CARB + ETOP> +	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ETOPOSIDE	108	258684004	1	Intravenous	47625008	31/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C56X		3	Not Applicable (Primary Treatment)			GemCarbo Days 1 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	1600	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)	99	Not known	Obin + Venet C7-12	2	PATIENT is not taking part in a CLINICAL TRIAL	8	VENETOCLAX	400	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CARBOPLATIN	160	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BINIMETINIB	30	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			ENCOR + BINIM C>2	2	PATIENT is not taking part in a CLINICAL TRIAL	3	ENCORAFENIB	300	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	WKLY CARBO + PACL	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PACLITAXEL	132	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/08/2023	RH8
RH8	C189		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Irinotecan 14day	2	PATIENT is not taking part in a CLINICAL TRIAL	11	IRINOTECAN HYDROCHLORIDE	270	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)			ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	7	ABIRATERONE ACETATE	1000	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	D57X		3	Not Applicable (Primary Treatment)	98	Other	HYDROX SCD 7 DY-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	1000	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ABIRATERONE CY>1	2	PATIENT is not taking part in a CLINICAL TRIAL	32	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	DEXAMETHASONE	20	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	9	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	24	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	CABOZANTIN RDE >	2	PATIENT is not taking part in a CLINICAL TRIAL	17	CABOZANTINIB	20	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	4	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	ENZALUTAMIDE(C19	2	PATIENT is not taking part in a CLINICAL TRIAL	44	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	Muk9 mainSCdar>1	2	PATIENT is not taking part in a CLINICAL TRIAL	18	LENALIDOMIDE	10	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PALBO & LETROZ>2	2	PATIENT is not taking part in a CLINICAL TRIAL	56	PALBOCICLIB	100	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C349	80463	3	Not Applicable (Primary Treatment)			OSIMERTINIB C19>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Osimertinib	80	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C920	98723	9				Veneto + Azacit>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	AZACITIDINE	160	258684004	5	Subcutaneous	34206005	31/08/2023	RH8
RH8	C900	97323	9		99	Not known	D(sc)VD(wk)Cy2/ 3	2	PATIENT is not taking part in a CLINICAL TRIAL	3	BORTEZOMIB	2	258684004	5	Subcutaneous	34206005	31/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	IPILIMUMAB	150	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			Paclitaxel 7 day	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL	108	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	DABRAFENIB	150	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			DABRAF + TRAMET>	2	PATIENT is not taking part in a CLINICAL TRIAL	34	TRAMETINIB	2	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	38	BOSUTINIB	500	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C921	98633	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	BOSUTINIB - RDE>	2	PATIENT is not taking part in a CLINICAL TRIAL	52	BOSUTINIB	400	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C43X		3	Not Applicable (Primary Treatment)			NIVOL/IPIL RDE -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	Nivolumab	50	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	BENDAMUSTINE HYDROCHLORIDE	197.5	258684004	1	Intravenous	47625008	31/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		9				ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	5	PACLITAXEL ALBUMIN BOUND	120	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	45	BEVACIZUMAB - VEGZELMA	1300	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ZOLEDRONIC ACID ADJ	4	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	ZOLE ACID HER -	2	PATIENT is not taking part in a CLINICAL TRIAL	2	ZOLEDRONIC ACID ADJ	3.5	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	D45X	99503	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	8	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 7 DAYS-	2	PATIENT is not taking part in a CLINICAL TRIAL	9	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C64X		1	Adjuvant Therapy	3	Palliative – aiming to relieve and/or control malignancy related symptoms	PEMBRO ADJ RCC>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMBROLIZUMAB	200	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C829	96903	3	Not Applicable (Primary Treatment)	99	Not known	OBIN + BENDA >1	2	PATIENT is not taking part in a CLINICAL TRIAL	4	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			ATEZ/BEVA HCC -	2	PATIENT is not taking part in a CLINICAL TRIAL	45	ATEZOLIZUMAB	1200	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		9				ATEZO/PAC ALB>*	2	PATIENT is not taking part in a CLINICAL TRIAL	5	ATEZOLIZUMAB	840	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	CARBOPLATIN	400	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	41	PALBOCICLIB	125	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C509		9				PALBO & FULV >2	2	PATIENT is not taking part in a CLINICAL TRIAL	29	PALBOCICLIB	100	258684004	2	Oral	26643006	31/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C349	80463	9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	CAR PEM PEMBRO>	2	PATIENT is not taking part in a CLINICAL TRIAL	3	PEMETREXED	750	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			RIBO & LETROZ >	2	PATIENT is not taking part in a CLINICAL TRIAL	12	RIBOCICLIB	600	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	SACITUZUMAB GOVITECAN	780	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	5	RITUXIMAB - RIXATHON	700	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C227		3	Not Applicable (Primary Treatment)			LENVATINIB HCC	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - LENVIMA	12	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C43X		1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	PEMBRO 553 6WK	2	PATIENT is not taking part in a CLINICAL TRIAL	4	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			SACITUZ GOVIT>	2	PATIENT is not taking part in a CLINICAL TRIAL	8	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C911	98233	3	Not Applicable (Primary Treatment)			ACALABRUTINIB >	2	PATIENT is not taking part in a CLINICAL TRIAL	35	ACALABRUTINIB	100	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C831	96733	3	Not Applicable (Primary Treatment)	99	Not known	R Chlorambucil	2	PATIENT is not taking part in a CLINICAL TRIAL	5	CHLORAMBUCIL	18	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	91	Nivolumab	480	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C64X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	NIVO RCC 4WK>>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	Nivolumab	480	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	EPIRUBICIN HYDROCHLORIDE	180	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 3/4 -	2	PATIENT is not taking part in a CLINICAL TRIAL	1	HYDROXYCARBAMIDE	1500	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYCLOPHOSPHAMIDE	1300	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60) 3 + 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		1	Adjuvant Therapy	98	Other	EC(90)-14 day	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	2	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60) 3 + 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DAUNORUBICIN	110	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C920	98733	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(60) 3 + 10	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CYTARABINE	180	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)			MET PHESGO >	2	PATIENT is not taking part in a CLINICAL TRIAL	33	PERTUZUMAB/TRASTUZUMAB	1200	258684004	5	Subcutaneous	34206005	31/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)	98	Other	HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	4	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	D473	99623	3	Not Applicable (Primary Treatment)			HYDROXY 5/2-	2	PATIENT is not taking part in a CLINICAL TRIAL	2	HYDROXYCARBAMIDE	500	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	37	DEXAMETHASONE	0.5	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	15	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	58	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	18	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	37	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X		9		3	Palliative – aiming to relieve and/or control malignancy related symptoms	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	23	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C20X				99	Not known	Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	4	CAPECITABINE	2650	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	10	ENZALUTAMIDE	40	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C61X				99	Not known	Enzalutamide	2	PATIENT is not taking part in a CLINICAL TRIAL	11	ENZALUTAMIDE	160	258684004	2	Oral	26643006	31/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C61X		3	Not Applicable (Primary Treatment)	98	Other	DAROL + ADT>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAROLUTAMIDE	300	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C509		1	Adjuvant Therapy			Capecitabine	2	PATIENT is not taking part in a CLINICAL TRIAL	1	CAPECITABINE	2000	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	R-GDP(RDE) >	2	PATIENT is not taking part in a CLINICAL TRIAL	3	GEMCITABINE	2000	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	BEVACIZUMAB - VEGZELMA	800	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C73X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LENVATINIB>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	LENVATINIB - LENVIMA	14	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DEXAMETHASONE	4	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DEXAMETHASONE	8	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DAUNORUBICIN	130	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DAROLUTAMIDE	600	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C829	96983	3	Not Applicable (Primary Treatment)			OBIN MAINT>	2	PATIENT is not taking part in a CLINICAL TRIAL	12	OBINUTUZUMAB	1000	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	D471	99613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ruxolitinib	2	PATIENT is not taking part in a CLINICAL TRIAL	95	RUXOLITINIB	5	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C920	98723	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	DA(50)3 + 8	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYTARABINE	220	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C61X				99	Not known	DOCE/DAROL>	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	148	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C21X		3	Not Applicable (Primary Treatment)			NIVO SCCA >	2	PATIENT is not taking part in a CLINICAL TRIAL	5	Nivolumab	280	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C56X		3	Not Applicable (Primary Treatment)			OLAP/BEVA>>	2	PATIENT is not taking part in a CLINICAL TRIAL	6	Olaparib	100	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	DOXORUBICIN HYDROCHLORIDE	100	258684004	1	Intravenous	47625008	31/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	RITUXIMAB - RIXATHON	800	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	POLATUZUMAB VEDOTIN	152	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C833	96803	3	Not Applicable (Primary Treatment)	1	Curative – aiming to permanently eradicate the disease	POLA-RCHP>	2	PATIENT is not taking part in a CLINICAL TRIAL	2	CYCLOPHOSPHAMIDE	1500	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)			LENA MONO>	2	PATIENT is not taking part in a CLINICAL TRIAL	14	LENALIDOMIDE	10	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C921	98633	1	Adjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	Nilotinib	2	PATIENT is not taking part in a CLINICAL TRIAL	33	NILOTINIB	400	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	5	Palliative – aiming to delay tumour progression	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	29	IBRUTINIB	420	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C880	97613	3	Not Applicable (Primary Treatment)	98	Other	Ibrutinib	2	PATIENT is not taking part in a CLINICAL TRIAL	16	IBRUTINIB	420	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	LENVATINIB - KISPLYX	10	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	105	DEXAMETHASONE	8	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C64X		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	LEN/PEMB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	PEMBROLIZUMAB	400	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C509		3	Not Applicable (Primary Treatment)	3	Palliative – aiming to relieve and/or control malignancy related symptoms	Eribulin	2	PATIENT is not taking part in a CLINICAL TRIAL	105	ERIBULIN	1.67	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C44X		9				AVELUMAB	2	PATIENT is not taking part in a CLINICAL TRIAL	1	AVELUMAB	800	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DARATUMUMAB SC (HYALURONIDASE)	1800	258684004	5	Subcutaneous	34206005	31/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	DEXAMETHASONE	40	258684004	2	Oral	26643006	31/08/2023	RH8
RH8	C900	97323	3	Not Applicable (Primary Treatment)	98	Other	D-VTD	2	PATIENT is not taking part in a CLINICAL TRIAL	1	BORTEZOMIB	2.25	258684004	5	Subcutaneous	34206005	31/08/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	FLUOROURACIL	3950	258684004	1	Intravenous	47625008	31/08/2023	RH8

Organisation Identifier (Code Of Provider)	Primary Diagnosis	Morphology ICD-O	Adjunctive Therapy	Adjunctive Therapy Definition	Intent Of Treatment	Intent Of Treatment Definition	Regimen	Clinical Trial	Clinical Trial Definition	Cycle Number	Drug Name	Actual Dose Per Administration	Unit Of Measurement (SNOMED CT DM + D)	SACT Administration Route	SACT Administration Route Definition	Route Of Administration (SNOMED CT DM + D)	Administration Date	Organisation Identifier Of SACT Administration
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	OXALIPLATIN	100	258684004	1	Intravenous	47625008	31/08/2023	RH8
RH8	C169		2	Neoadjuvant Therapy	1	Curative – aiming to permanently eradicate the disease	FLOT	2	PATIENT is not taking part in a CLINICAL TRIAL	5	DOCETAXEL	72	258684004	1	Intravenous	47625008	31/08/2023	RH8